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Abstract 
Successful pregnancy requires tight regulation of two important processes: spiral 
artery remodelling and invasion of uterine tissue by placental extravillous trophoblast 
(EVT); disruption of these processes occurs in pregnancy complications such as 
sporadic miscarriage (SM). Maternal factors, including cytokines and growth factors, 
may play a role in regulating these fundamental events. The biological function of 
interleukins (IL)-6 and -8 in other physiological processes suggest that these cytokines 
maybe important mediators in uteroplacental tissues in early pregnancy.  
The aim of this study was to investigate intrauterine IL-6, IL-8 and their receptors at 
the fetal-maternal interface in early pregnancy; specifically, to investigate their role in 
regulation of EVT invasion and spiral artery remodelling events and determine whether 
levels of cytokines are altered in SM.  
IL-6, IL-8 and their receptors were localised in placental bed in the first half of 
pregnancy by immunohistochemistry. CD56+, CD14+, CD10+ and CD8+ cells were 
isolated from 8-10 and 12-14 weeks gestational age decidua using positive 
immunomagnetic separation and secretion of IL-6 and IL-8 was measured and 
compared by ELISA. All decidual cell types investigated secreted both IL-6 and IL-8. 
Decidual CD14+ cells were the most abundant source of both cytokines. Secretion of IL-
6 by CD10+ cells (P=0.005) and IL-8 by CD56+ cells (P=0.02) was higher at 12-14 weeks 
compared with 8-10 weeks GA. Compared with healthy pregnant decidua, secretion of 
IL-6 and IL-8 protein by both CD14+ (IL-6 P=0.05; IL-8 P<0.0001) and CD56+ cells ( IL-6 
P=0.02; IL-8 P=0.003) was reduced in SM (≤12+6 weeks gestation). 
The functional role of these cytokines in early pregnancy was assessed with invasion 
assays and a chorionic plate artery (CpA) model of artery remodelling. IL-6 did not 
stimulate EVT invasion in vitro but did cause phosphorylation of kinase proteins 
involved in trophoblast cell signalling and reduced EVT secretion of RANTES. IL-6 and 
IL-8 both contributed to misalignment of VSMC in CpA (P=0.04; P=0.001 respectively) 
and IL-6 increased the separation of CpA VSMC layers alone (P=0.02) and combined to 
its receptor sIL-6Rα (P=0.001). CD56+ and CD14+ leucocytes were observed in the walls 
of spiral arteries in the first half of pregnancy with CD14+ cells producing increased 
Ang-2 (P=0.002) and decreased Ang-1 at 12-14 weeks compared with 8-10 weeks GA 
(P=0.03). 
Production of IL-6 and IL-8 within the placental bed in early pregnancy and reduced 
levels in SM, together with their effects on EVT and VSMCs suggests a possible 
involvement in controlling trophoblast function and contribution in regulating spiral 
artery remodelling events.    
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1. Introduction 
1.1 Overview of normal placental development 
1.1.1 Implantation 
Successful implantation depends on an ideal environment in the maternal 
endometrium  reviewed by Loke et al., (1995). The endometrium achieves this by 
undergoing rapid, spontaneous changes during the luteal phase of the menstrual cycle, 
resulting in a decidualised endometrial stroma that provides the optimal environment 
for embryo implantation. This is a dynamic process involving a complex network of 
coordinating events regulated by autocrine, paracrine and endocrine factors, although 
the molecular interactions are not fully understood. Existing data derived from knock 
out animal studies have provided some insight of the physiological functions essential 
for embryo implantation; however, in vivo implantation studies in humans are not 
possible, resulting in a relative lack of understanding of defective implantation in 
humans.  
Successful oocyte fertilisation ceases the menstrual cycle. The uterus becomes 
sensitive to implantation by the initial secretion of progesterone from the ovaries; 
known as the receptive phase, this allows the endometrium to decidualise and is 
characterised by smooth projections of uterine epithelium named pinopodes. Even if 
fertilisation is successful, implantation and successful pregnancy is not guaranteed; the 
maternal tissues and newly formed conceptus require a symbiotic chemical balance of 
growth factors, hormones and immunomodulators for implantation to occur. During 
this time the cells of the zygote undergo a series of mitotic cellular divisions resulting 
in the blastocyst, with successful implantation occurring approximately 6-7 days after 
fertilisation.    
After fertilisation (between 3-6 days post fertilisation) the conceptus begins to 
undergo a series of cell divisions first reaching the morula (16-cell stage) then dividing 
into a 32-cell blastocyst consisting of two different cell populations: apical cells and 
basal cells. Following successful attachment of the blastocyst to the receptive 
endometrium, placentation is initiated. The surrounding hull of apical cells of the 
blastocyst contains an inner cell mass of basal cells that rapidly begin to proliferate and 
differentiate into an embryo and the amnion (Vitiello and Patrizio, 2007) , while the 
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outer apical cells of the trophectoderm eventually give rise to the chorion. The 
blastocyst then attaches to the uterine endometrium by the embryonic pole (Boyd, 
1970). Implantation involves attachment of the apical plasma membranes of the 
trophoblast cells to the apical plasma membranes of uterine epithelia (Aplin, 1991) and 
the blastocyst invades the uterine epithelium and implants into the endometrial 
stroma (Figure 1.1). During this time at day 8 post conception (the prelacunar stage; 
Figures 1.1a and 1.1b) trophoblast cells of the embryonic pole begin to proliferate and 
differentiate into two distinctive inner and outers layer of trophoblast cell populations 
encasing the developing mass of embryonic cells and amnion, termed embryoblast 
(Heuser, 1941). The outer layer of trophoblast cells fuse together to form a 
multinucleated trophoblast population which is in direct contact with the maternal 
tissues, known as syncytiotrophoblast cells, and the inner layer which consists of a 
proliferating mass of trophoblast cells known as cytotrophoblast cells, which are 
temporarily mononuclear (Figure 1.1) and contribute to other trophoblast populations 
(which will be discussed later in this chapter). Between 8-12 days after fertilisation 
small vacuoles known as lacunae begin to form in the syncytium (the lacunar stage; 
Figure 1.1c); these continue to enlarge to form a network bathed in maternal blood, 
which will eventually form the intervillous space. At day 12 post conception the 
blastocyst is fully embedded into the maternal endometrium and the uteroplacental 
circulation is established (Figures 1.1c and 1.1d).     
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Figure 1.1 Blastocyst implantation and early placental development 
Simplified drawings showing blastocyst implantation and early placental development: a and b: 
prelacunar stages; c: lacunar stage (formation of lacunae); d: formation of early intervillous 
space. Maternal tissues are in shown in red and fetal tissues are in blue. Key: E: endometrial 
epithelium; EB: embryoblast; CT: cytotrophoblast; ST: syncytiotrophoblast; EM: embryonic 
mesenchyme; CP: chorionic plate; T: primary villi; L: maternal blood lacunae; TS: trophoblast 
shell; EV: endometrial vessel; D: decidua; G: trophoblast giant cell. Image source: modified 
from (Kaufmann, 1992). 
1.1.2 Development of placenta 
The placenta is an important organ that maintains and protects the developing fetus. It 
plays a number of critical roles, from nutrient exchange and waste secretion to 
sequestering the developing fetus from dangerous pathogens and the maternal 
immune system. In addition, the placenta serves as an active endocrine hub producing 
and secreting growth factors, cytokines and hormones essential for a successful 
pregnancy.  
1.1.2.1 Chorionic villi 
Formation of the chorionic villi and the fetal circulation is evident from 3 weeks after 
fertilisation, developing from the trophoblastic shell. The chorionic plate becomes the 
4 
 
definitive placenta (Figure 1.1d). The chorionic villi arise from the chorionic plate and 
are either free floating in the intervillous space or become anchored to the maternal 
decidua.   
After 4 weeks the basic structure of the placenta is formed. The human placenta is a 
disc like structure comprising many tree like projections resulting in a branching 
system of chorionic villi, which increases from 20 weeks of gestation (Boyd, 1970)  
Chorionic villi are in contact with maternal blood and develop into a mass of tissue that 
makes up the mature placenta, with the fetal circulation extending within the villous 
stromal mesenchyme. New villous branches bud from existing chorionic villi, ensuring 
a maximum surface area in contact with maternal blood for absorption of nutrients, 
exchange of gases and waste secretion. Thus the chorionic villi are the main functional 
units of the placenta. Mature chorionic villi consist of a mesenchymal core embedded 
with fetal capillaries and the two layers of trophoblast cells; the mononucleated 
cytotrophoblast cells which are encased by mutlinucleated syncytiotrophoblast cells 
(Figure 1.2).   
Placental macrophages known as Hofbauer cells were first identified more than 150 
years ago (Kastschenko, 1885) as large ovoid cells with abundant cytoplasm that are 
present in the chorionic villous core of the placenta from at least 8 weeks gestation 
until term (Boyd, 1970). They appear in the placental villi prior to the establishment of 
fetal circulation, suggesting that they are derived from mesenchymal stem cells in early 
pregnancy; evidence indicates that they have an M2 type phenotype (Joerink et al., 
2011). Despite numerous investigations, the function of Hofbauer cells remains largely 
unknown but a role protecting the fetus against immune attack has been proposed 
(Uren and Boyle, 1990, Castellucci et al., 2000). Immunohistochemical studies of first 
trimester placentas demonstrating close contact with endothelial progenitor cells and 
placental vessels have led to suggestions of a role in early placental vasculogenesis 
rather than an immunological role (Seval et al., 2007). This also relates to previous 
studies revealing that placental macrophages express high levels of VEGF-A (Sharkey et 
al., 1993).  
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1.1.2.2 Villous trophoblast cells 
Following successful implantation the cytotrophoblast cells differentiate into villous 
cytotrophoblast cells (vCTB). The vCTB cells fuse to form the multinuclear 
syncytiotrophoblast layer which covers the floating chorionic villi in the intervillous 
space where the villi are bathed in maternal blood allowing sufficient nutrient and gas 
exchange for the developing fetus (Ferretti et al., 2007). The syncytiotrophoblast cell 
layer is also involved in the maintenance of pregnancy by releasing factors that 
increase progesterone levels such as human chorionic gonadotrophin (hCG) and 
human placental lactogen (hPL) (Vitiello and Patrizio, 2007). Cytotrophoblast cells form 
columns covered by a syncytiotrophoblast cell layer and they begin to proliferate. As 
the cells proliferate they break through the syncytiotrophoblast layer and the 
cytotrophoblast columns extend from the tips of floating chorionic villi and eventually 
attach to the maternal decidua, anchoring the chorionic villi to the uterine tissues.   
1.1.2.3 Non-villous trophoblast cells 
During the third month of pregnancy in parts of the established placenta the chorionic 
villi on the anembryonic pole of the conceptus regress thus allowing the definitive 
placenta to develop which is bathed in maternal blood. The non-villous areas of the 
outer placenta are comprised of non-villous cytotrophoblast cells which are a 
heterogeneous population (Bulmer and Johnson, 1985) and exist as a multilayered 
epithelium in direct contact with maternal stroma -that do not invade the adjacent 
decidua. This is termed the chorion laeve contrasting with the chorion frondosum of 
the villous placenta. The role of the non-villous cytotrophoblast cells within the 
chorion laeve remains unclear.      
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Figure 1.2 Fetal placental circulation and a representative drawing of a chorionic villous 
A: Representative drawing of a mature chorionic villus showing the fetal placental circulation; 
B: The dotted line shows the position of a representative drawing of a cross section through a 
chorionic villus at approximately 10 weeks gestational age; C: Cross section through a chorionic 
villus at full term (Modified from (Gude et al., 2004)). 
1.1.3 Extravillous trophoblast cells  
Upon attachment and anchorage of chorionic villi to the decidua, the anchored villous 
cytotrophoblast cells form columns and begin to differentiate from a proliferative 
phenotype into a distinct invasive phenotype known as extravillous trophoblast (EVT) 
cells (Fitzgerald et al., 2008). The two trophoblast subtypes can be distinguished by 
phenotypic differences in their expression of various cell adhesion molecules (CAM), 
MHC antigens and secretion of growth factors (Norwitz et al., 2001). The 
cytotrophoblast cell columns that protrude from the villi spread laterally to form the 
cytotrophoblast shell from which invading EVT arise (Kurman et al., 1984, Loke et al., 
1995) . 
1.1.3.1 EVT invasion 
Classical histological methods used on placental bed biopsies between 8-18 weeks 
gestational age taken from pregnant hysterectomy samples have been the most 
influential early studies on trophobast invasion (Pijnenborg et al., 1980, Pijnenborg et 
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al., 1982, Pijnenborg et al., 1983). EVT from the cytotrophoblast shell invade the 
uterine decidua and myometrium and fuse to form multinucleated giant cells. These 
studies provide evidence that the process of EVT invasion occurs from week 8 of 
gestation right through to 18 weeks gestation, and this has been confirmed by spiral 
artery Doppler studies (Matijevic et al., 1995). 
The invading EVT infiltrate the maternal uterine tissues by two separate pathways; the 
interstitial route associated with active degradation of the extracellular matrix by 
secretion of matrix metalloproteinases (MMPs), thereby allowing interstitial EVT (iEVT) 
cells to migrate through the decidua to the inner myometrium (Lash et al., 2005); and 
the route taken by a subtype of EVT known as endovascular EVT (eEVT) which 
accumulate to form plugs within the lumen of the spiral artery and which, in early 
pregnancy, plug the outlet of the spiral arteries (SpA) into the intervillous space (Figure 
1.3).  
EVT which have been observed aligning adjacent to SpAs have been termed 
perivascular EVT and EVT cells present embedded in the walls of spiral arteries have 
been termed intramural EVT. These cells can be distinguished as they differ in 
morphology to iEVT, adopting a more dendritic spindle shape compared with the 
rounded interstitial EVT cell (Kurman et al., 1984).   
The origin of eEVT has been debated with disagreement regarding whether this EVT 
subpopulation has a route of invasion which originates from interstitial invasion, or 
whether they invade by a separate pathway altogether and represent a distinct EVT 
population. It has been suggested that eEVT originate from invading iEVT which 
penetrate the SpA vessel wall from the outside, rather than by retrograde migration 
intraluminally (Kaufmann et al., 2003). However, in a recent review (Pijnenborg et al., 
2011) emphasised that intraluminal trophoblast cells that have been identified in SpA 
cross sections are cytotrophoblastic in origin (Boyd, 1970) indicating an endovascular 
pathway, although Pijnenborg et al. (2011) suggested that there is a possibility that 
eEVT are derived from both intraluminal trophoblast and iEVT; perivascular EVT 
clusters have been observed close to decidual SpA indicating the possibility of 
transmural trophoblast migration, whereas the sparse dispersion of EVT and reduced 
concentration of EVT near SpAs within myometrium suggests that interstitial EVT may 
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be responsible for eEVT at deeper levels (Pijnenborg et al., 2006a). Phenotypic 
differences between eEVT and iEVT, such as the expression of NCAM (CD56) by eEVT 
(Burrows et al., 1994) also provide evidence for the argument that eEVT are a distinct 
trophoblast population differing from iEVT. In support of an interstitial route for 
endovascular trophoblast invasion is that fusion of iEVT into multinucleate trophoblast 
giant cells in the decidua may result in iEVT losing their invasive phenotype and 
therefore are unable to penetrate the walls of SpAs; this has been considered as a 
mechanism for inhibiting eEVT invasion and the presence of large clusters of 
trophoblast giant cells which have been observed in pre-eclampsia, may equate to the 
shallow invasion observed in these pregnancies (Stanek and Biesiada, 2012). 
Recently a potential new subtype of EVT cell has been hypothesised as an alternative 
route to the wider known routes of trophoblast invasion; named as endoglandular EVT 
invasion (Moser et al., 2010). In this study EVT was detected in uterine glands using 
confrontation co-culture assays, suggesting that the glandular lumina are able to open 
up into the intervillous space to provide key growth factors for the developing embryo 
prior to the establishment of maternal blood flow into the intervillous space.  
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Figure 1.3 Schematic representation of trophoblast invasion   
Schematic representation of interstitial and endovascular trophoblast invasion in human 
pregnancy before week 6 of gestation (A) and after week 20 of normal gestation (B). Blue: fetal 
tissues. Red: maternal tissues. ps: zone of placental separation, where the basal plate (decidua 
basalis above, attached to the placenta) separates from the placental bed (remaining in the 
uterus after delivery) (Image taken from (Kaufmann et al., 2003)).  
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1.1.3.2 Waves of invasion 
Waves of invasion refer predominantly to endovascular trophoblast invasion. There is 
debate as to whether endovascular EVT invasion through the decidua into the 
myometrium is an ongoing process or as to whether it occurs in two separate waves; 
with wave one occurring in the first trimester up to 8-10 weeks gestation and wave 
two occurring in the first half of the second trimester from 14-18 weeks gestation with 
a break in between wave one and wave two during which there is no significant 
additional trophoblast invasion. 
Evidence supporting the two wave concept using complete hysterectomy samples of 
known gestational age showed that the earliest gestation that decidual spiral arteries 
were completely filled with eEVT was at 10 weeks gestation whereas the earliest 
observation of eEVT infiltrating inner myometrial SpAs was observed after 14 weeks 
gestation(Pijnenborg et al., 1983) suggesting a temporary break between the two 
waves of EVT invasion – the mechanisms that would underlie such a two wave process 
of invasion are not known. 
1.1.3.4 Trophoblast differentiation 
As mentioned previously, during placental development, the cytotrophoblast stem 
cells in the chorionic villi differentiate into two distinct trophoblast populations; 
syncytiotrophoblast and extravillous trophoblast. The syncytiotrophoblast remain 
epithelial whilst the extravillous trophoblast acquires a distinct phenotype, losing 
epithelial markers such as α-integrin 6 but retaining cytokeratins (reviewed by (Vicovac 
and Aplin, 1996)) and up regulating α5β1 and α1β1 integrins (Damsky et al., 1994).   
Human trophoblast differentiation has been difficult to explore in vivo undoubtedly 
because of the difficulty and ethical issues around obtaining normal pregnancy tissue. 
Furthermore, the human placenta has a highly specific structure rendering laboratory 
animal studies of limited value. Therefore, in vitro studies have been necessary to 
investigate trophoblast differentiation. Differentiation from proliferative CTB into 
invasive iEVT is thought to be influenced by a variety of factors including extra cellular 
matrix contact and maternal endometrial components. In recent years it has come to 
light that oxygen tension has an important effect on the placental and embryonic 
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development. In vitro studies have shown that physiological factors such as hypoxic 
conditions can trigger cytotrophoblast cells of the placenta to proliferate and form 
cytotrophoblast cell columns; as the extravillous trophoblast cells encounter increasing 
oxygen levels in the maternal uterine decidua they are stimulated to differentiate into 
an invasive phenotype (Genbacev et al., 1997). 
During the first 10-12 weeks of gestation the endovascular EVT plug the outflow of the 
uterine spiral arteries, preventing maternal blood flow entering the intervillous space 
and therefore creating a physiological hypoxic environment (Hustin and Schaaps, 
1987). The low partial oxygen pressure is thought to be the driving force for substantial 
development of the early placenta and is thus crucial for fetal development. Rodesch 
et al. (1992) observed a significantly lower level of oxygen tension between the 
placenta (17.9 mmHg) and the endometrium (39.6mmHg) at 8-10 weeks gestation 
which balanced out at 12-13 weeks gestation due to loosening of the luminal 
trophoblast plug, thus allowing flow of maternal blood into the intervillous space. 
Overall it is believed that plugging of the mouths of spiral arteries by endovascular 
trophoblast cells is responsible for creating this hypoxic state. However, the 
phenotypic shift from proliferative trophoblast to invasive trophoblast requires a high 
oxygen state raising the question of how the endovascular trophoblast cells invade the 
arteries primarily? Pijnenborg et al. (2006a) have suggested that blastocyst 
implantation is associated with temporary high oxygen concentrations allowing 
invasion of EVT which is then followed by lower concentrations due to the sealing of 
the outflow of arteries protecting the feto-placental unit from oxidative stress. 
Although oxygen gradients are believed to play a role in controlling the invasive 
potential of EVT, it is not clear why the EVT target the uterine spiral arteries rather 
than the uterine veins (Pijnenborg et al., 1980). Reports have suggested that venous 
endothelial cells express an ephrin protein named EPHB4 which may act to repel 
invading trophoblast (Red-Horse et al., 2005). In addition it has also been suggested 
that chemoattractants produced by the vascular smooth muscle cells of the spiral 
arteries may play a role in recruiting the endovascular trophoblast to their lumen 
(Whitley and Cartwright, 2009). At the end of the first trimester, from 10-12 weeks 
gestational age onwards, the maternal-placental circulation is established and the 
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invasive endovascular EVT proceed to migrate in a retrograde direction down the spiral 
arteries into the myometrial artery segments (James et al., 2006). 
1.2 Maternal-fetal interface 
1.2.1 The placental bed 
Maternal fetal contact is initiated at the time of implantation of the blastocyst into the 
uterine epithelium and the placental bed is formed (Figure 1.3B). Underlying the 
attached placenta is the uterine wall which includes the cytotrophoblast shell, the 
decidualised endometrium and inner third of the myometrium. The placental bed is 
characterised microscopically by the presence of EVT in both decidual and myometrial 
stroma and SpAs.  
Spiral arteries run perpendicular to the basal plate of the maternal fetal interface.  The 
placental bed contains approximately 150 spiral arteries providing channels for 
sufficient blood flow to the intervillous space.   
1.2.1.1 Decidua and Decidualisation 
Successful pregnancy requires a highly receptive endometrium during the implantation 
window which involves a symbiotic signalling process between the blastocyst and the 
mother (Aplin, 2000). Decidualisation of the endometrium regulates placentation and 
provides maternal immune tolerance against fetal antigens, thus preventing rejection 
of the developing fetus (Pijnenborg, 2002, Salker et al., 2010).  Throughout each 
menstrual cycle the endometrium prepares itself for the chance of an implanting 
blastocyst before fertilisation of the oocyte has occurred. The endometrium undergoes 
rapid changes of remodelling during the mid-secretory phase of the menstrual cycle in 
a process known as decidualisation, providing an optimal environment for embryo 
implantation. If fertilisation does not occur the endometrium will shed during a 
process known as menstruation. However, if fertilisation of the oocyte  does occur, 
rising levels of progesterone trigger the endometrium to undergo further 
decidualisation (Schindler, 1997) and the levels of progesterone remain high during 
pregnancy to maintain the decidua. Decidualisation (governed by oestrogen and 
progesterone), involves the extensive proliferation and differentiation of fibroblast 
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cells into enlarged glycogen filled-endometrial stromal cells characteristic of the 
decidua (Kurita et al., 2001).  
The decidua consists of three anatomical regions in relation to their positions to the 
site of implantation. At approximately 8-10 weeks gestation the decidua that 
encapsulates the developing fetus is termed decidua capsularis. The decidua parietalis 
lines the entire body of the pregnant uterus and the decidua basalis is the maternal 
aspect underlying the placenta that is located between the chorionic sac and 
myometrium (Figure 1.4A). After week 12 of gestation the decidua capsularis comes 
into contact with the decidua parietalis and these start to fuse together until the 
uterine cavity is gradually obliterated (Figure 1.4B).  
Functional roles for the decidua have been suggested; these include providing a source 
of growth factors and cytokines to regulate trophoblast invasion (Brosens et al., 2002); 
reviewed in section 1.1.5), to facilitate the exchange of nutrients to the developing 
fetus as well as protecting the fetus from the maternal immune system (Croy et al., 
2002).  
 
Figure 1.4 Areas of decidua in the developing stages of first half of pregnancy 
Areas of the decidua in relationship to the developing fetus and progressive obliteration of the 
uterine cavity. A: 6-8weeks gestation; B: 16 weeks gestation. Image taken from Langman’s 
Medical Embryology (2004). 
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1.2.2 Establishment of uteroplacental circulation 
Invasion of EVT through the decidua, myometrium and uterine spiral arteries is 
essential for successful human pregnancy. Invasion of EVT into the spiral arteries is 
required to establish a low-pressure, continuous flow of blood supply to the 
intervillous space, providing nutrients for the developing fetus. 
 1.2.2.1 Spiral artery remodelling 
Spiral arteries begin to develop from endometrial radial arteries in the secretory phase 
of the menstrual cycle (Figure 1.5), when progesterone levels are increased (Ferenczy 
et al., 1979). In the non-pregnant uterus the spiral arteries consist of thick muscular 
walls with a well defined elastic lamina, which is lost as the artery penetrates the 
endometrium (Robertson and Manning, 1974). During the menstrual cycle, if 
implantation of the blastocyst into the endometrium does not occur, the spiral arteries 
regress and are lost during menstruation. However, if implantation does occur then 
spiral arterioles and arteries develop further and supply the placenta and fetus with 
the required nutrients vital for development. 
The spiral arteries and arterioles achieve this by undergoing extensive remodelling into 
highly dilated structures that lack muscle and elastic (Pijnenborg et al., 2006b). During 
early pregnancy the spiral arteries responses include vessel dilation, loss of vascular 
smooth muscle cell (VSMC) arrangement and vacuolation of the media (Craven et al., 
1998). The arteries are termed ‘spiral’ because they are highly coiled, narrow, 
muscular structures (Figure 1.5). The coiling increases their surface area to achieve 
maximum blood flow (a 3-4 fold increase) for the demands of exchanging respiratory 
gases and nutrients from mother to fetus. Thus, the purpose of the remodelling of the 
coiled vessels is to ensure that an adequate volume of blood at a low pressure enters 
the intervillous space (Harris and Aplin, 2007). The process of spiral artery remodelling 
is a reversible one where the musculo-elastic structure of the vessels, consisting of 
VSMCs, elastic and extracellular matrix are displaced with fibrinoid material containing 
intramural trophoblast cells, resulting in large, dilated low resistance vessels 
(Pijnenborg et al., 1980). Figure 1.6 illustrates the various stages of spiral artery 
remodelling. Another characteristic of spiral arteries undergoing transformation is 
endothelial cell swelling and the displacement of SpA endothelium by eEVT cells. 
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Complete re-endothelialisation of the spiral arteries has been reported at term (Khong 
et al., 1992), although it is disputed to what extent SpAs lose their endothelial cell 
lining at earlier stages of pregnancy and it is likely that endothelial cells and eEVT cells 
coexist in a spatial and temporal manner.  
Early spiral artery remodelling changes are associated with interstitial EVT in decidua 
where they begin to disrupt the media; VSMCs start to separate and become 
hypertrophic, suggesting that interstitial EVT are ‘priming’ the SpA for endovascular 
trophoblast invasion. In addition there is now recent evidence to support trophoblast-
independent spiral artery remodelling by decidual cells before trophoblast invasion 
into the maternal tissues occurs (Smith et al., 2009). By 10 weeks of gestation eEVT has 
caused severe disruption to the artery media (Pijnenborg et al., 1983); the vascular 
walls of decidual spiral arteries have completely diminished; the arteries have lost the 
internal elastic lamina, and their walls are then replaced by deposition of fibrinoid 
material which maintains the integrity of the vessel. The intramural trophoblast cells in 
the walls of the spiral arteries are embedded in amorphous fibrinoid material and 
ultrastructural observations suggest that this fibrinoid is derived from degenerative 
trophoblast cells, maternal serum leakage and elastic lamina residue (De Wolf et al., 
1973). 
1.2.2.2 Origin of intramural EVT 
The initial view of the origin of intramural EVT was that this trophoblast population 
derived from the lumen of SpA and therefore, are endovascular in origin, as they 
become embedded in the vessel walls (Brosens et al., 1967). This was supported by 
observations of trophoblast cells located in the intima rather than the media of 
myometrial spiral arteries at 16-22 weeks of gestation (De Wolf et al., 1980). However, 
conflicting evidence from immunohistochemical studies has demonstrated that 
intramural EVT lack expression of human chorionic gonadotrophin (hCG) in common 
with the interstitial EVT population, but contrasting the endovascular EVT population 
(Kurman et al., 1984).      
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Figure 1.5 Vascular anatomy of a pregnant uterus 
Image taken from Brosens et al. (1967). 
1.2.3 Control of trophoblast invasion 
The invasive nature of interstitial EVT occurs through proteolytic action. This is 
achieved by their ability to secrete a class of zinc-dependent endopeptidases known as 
matrix metalloproteinases (MMPs), cathepsins and urokinase-type plasminogen 
activators (uPA) (Bischof et al., 2000). Degradation of the extracellular matrix allows 
movement of the EVT between the decidual and myometrial compartments. EVT cells 
share some characteristics with malignant cells; their ability to migrate and invade 
tissue and their capacity to sequester themselves from the host’s immune system 
(Ferretti et al., 2007). However, in contrast to the uncontrolled invasion of malignant 
cells, the invasion of EVT cells through uterine tissues is a tightly controlled process 
limited both to spatially (localised to the decidua and inner third of the myometrium) 
and developmentally (invasion ceases during the second trimester of pregnancy) 
(Meisser et al., 1999). Disruptions in this tightly controlled environment can lead to 
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placental deficiencies which affect the maternal vascular homeostasis resulting in 
pregnancy complications such as early miscarriage, pre-eclampsia, intrauterine growth 
restriction and placenta accreta. Despite the importance of trophoblast invasion in 
pregnancy very little is understood about the factors that control this process, 
although decidual factors are likely to play an important role. Several growth factors 
and cytokines, some secreted by trophoblast themselves, are believed to  be 
responsible for regulating this process by modulating protease activity, disrupting cell 
adhesion and inducing cell apoptosis (Lash et al., 2005), thereby affecting trophoblast 
migration, proliferation and differentiation into an non-invasive phenotype (Fitzgerald 
et al., 2008) so that trophoblast invasion ceases in the inner third of the myometrium.  
1.2.4 Control of spiral artery remodelling 
Remodelling of the decidual segments of spiral arteries is generally complete by 10-12 
weeks’ gestation and continues in the myometrial segments up until around week 20-
22 of gestation (Pijnenborg et al., 2006b). Spiral artery remodelling is crucial for a 
successful pregnancy: failure of spiral artery remodelling has been implicated in the 
pathogenesis of pre-eclampsia (Pijnenborg et al., 1991), intrauterine growth restriction 
(Khong et al., 1986), second trimester miscarriage (Khong et al., 1987, Ball et al., 
2006a) and preterm delivery (Kim et al., 2003). Despite its importance in early 
pregnancy, the molecular mechanisms that are involved in spiral artery remodelling 
remain unclear. Lack of appropriate physiological and pathological models hinders 
studies. A number of possible mechanisms such as cellular migration, 
dedifferentiation, macrophage phagocytosis and apoptosis may be responsible for 
vascular smooth muscle displacement. It is likely that several of these mechanisms 
work together in a co-ordinated fashion to regulate the process of spiral artery 
remodelling.  
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Figure 1.6 The different stages of uterine spiral artery remodelling 
The arteries begin to develop in the secretory phase of the menstrual cycle in non-pregnant 
endometrium. The earliest stage in vascular remodelling during pregnancy (stage 1) shows 
endothelial vacuolation and slight swelling of the VSMCs. Interstitial trophoblast then begins to 
invade the surrounding stromal tissue which is associated with further disorganisation of the 
VSMC layer (stage 2). Only in stage 3 does the endovascular trophoblast appear leading to 
intramural trophoblast becoming embedded within a fibrinoid layer, replacing the VSMCs 
(stage 4). In the final stage of spiral artery remodelling the endothelium has re-generated 
(Pijnenborg et al., 2006b). 
1.2.4.1 Fate of SpA VSMCs 
There are numerous ways in which both endovascular and interstitial trophoblast may 
influence spiral artery remodelling. Interstitial trophoblast is likely to influence the 
behaviour of the VSMCs; it has been observed that invasion of interstitial trophoblast 
through the extracellular matrix of the decidua liberates growth factors that could 
influence vessel wall structure as well as facilitating transit of the endovascular 
trophoblast along the arteries (Harris and Aplin, 2007). Endothelial changes are likely 
to be influenced by the endovascular trophoblast which transiently replaces the 
endothelial cells lining the spiral arteries.  The loss of endothelial cell adherence may 
lead to anoikis which in turn affects the composition of the ECM which could affect the 
differentiation state of the VSMC (Whitley and Cartwright, 2009). The close 
relationship between the endothelial cells and the VSMCs is essential for maintaining 
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the integrity of the vasculature and disruptions in this relationship are thought to be 
the likely cause of remodelling in the spiral arteries (Whitley and Cartwright, 2009). 
There have also been observations of vascular smooth muscle cell reorganisation 
occurring in the presence of intramural trophoblast where fibrinoid displaces the 
muscle of the vessel wall (Kam et al., 1999). Recent in vitro data suggest that the 
trophoblast is responsible for SpA VSMC apoptosis (Cartwright et al., 2007, Smith et al., 
2009) although VSMC apoptosis is rarely detected in vivo in the placental bed (Bulmer 
et al., 2012). However, the limitation in assessment of apoptosis is that it is a transient 
process with cell loss and evidence may therefore be difficult to detect. The 
contribution of apoptosis to loss of spiral artery smooth muscle remains a cause for 
debate. Migration and de-differentiation of VSMCs have both been suggested as well 
as apoptosis (Bulmer et al., 2012). 
1.2.4.2 Factors responsible for SpA remodelling 
Although it has been suggested that interstitial and endovascular EVT are responsible 
for complete spiral artery remodelling, others have suggested that the arterial 
modifications are initiated in a maternal response to pregnancy prior to trophoblast 
invasion along the lumen of the spiral artery vessels (Craven et al., 1998). This 
maternal response of arterial modification has been termed trophoblast-independent 
remodelling and appears to be a decidual component that is independent of 
trophoblast.  This tophoblast-independent phase occurs in the early stages of 
pregnancy, with trophoblast-dependent spiral artery remodelling starting at 
approximately 6-8 weeks of gestation (Pijnenborg et al., 2006b) (Figure 1.7).  
Histological evidence shows that in the absence of EVT the vessels are surrounded by a 
cell type within decidua termed uterine natural killer (uNK) cells (Bulmer et al., 1991) 
which are described in further detail in section 1.4.2.  There is speculation that the 
secretion of growth factors such as vascular endothelial growth factor (VEGF)-C and 
transforming growth factor-beta1 (TGF-β1) by uNK cells initiate the decidual-
associated remodelling in preparation for trophoblast infiltration to allow the final 
stages of transformation to take place (Lash et al., 2006c).   
Craven et al. (1998) have demonstrated changes in spiral artery vessel structure in the 
absence of trophoblast. The initial changes included swelling and vacuolation of the 
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medial smooth muscle cells, increased vascular permeability and increased endothelial 
cell activation leading to vessel dilation (Figure 1.6, Stage 1). It also has been 
documented that progesterone may have an indirect effect on vascular remodelling by 
its effects on recruitment of cells such as lymphocytes, macrophages and uNK cells to 
the endometrium associated with the ability to up-regulate stromal cell chemokine 
expression (Sentman et al., 2004). In agreement with data that uNK cells play an 
important role in early events of spiral artery remodelling, evidence from transgenic 
mice deficient in uNK cells has shown failure of decidual artery remodelling and 
implantation site abnormalities (Ashkar et al., 2000). It has also been reported that in 
human placental bed biopsies uNK cells are localised in association with vessels 
undergoing remodelling (Bulmer and Lash, 2005). These data and the observation that 
uNK cells diminish in number after 20 weeks’ gestation when SpA changes are almost 
complete provides support for the suggestion that these cells play a role in the spiral 
artery remodelling process can be made. However, the confinement of uNK cells to the 
endometrium needs to be considered since trophoblast invasion and spiral artery 
remodelling extend through to the inner third of the myometrium where uNK cells are 
not a prominent feature; this may reflect a role for these cells in early SpA vascular 
changes and priming of SpA VSMCs for the later trophoblast-dependent alterations 
which mediate transformation of myometrial segments of spiral arteries.    
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Figure 1.7 Process of decidual spiral artery remodelling 
Representation of process of decidual artery remodelling. An un-remodelled artery has intact 
endothelium and a VSMC cell layer making it a low flow, high resistant vessel.  During 
pregnancy the spiral arteries undergo remodelling initially brought about by maternal immune 
cells and completed by invading EVT. VSMC layers and endothelium are lost and are replaced 
with embedded intramural trophoblast and fibrinoid material, changing the integrity of the 
vessel and thereby creating a high flow, low resistant vessel. Endothelial displacement is 
transient and is replaced by the third trimester. Image taken from Cartwright et al. (2010). 
1.2.5 Aberrant trophoblast invasion and deficient spiral artery 
remodelling 
Spiral artery remodelling plays an important role in the establishment and 
maintenance of successful pregnancy and understanding the mechanisms which 
control this process may improve understanding of important pregnancy complications 
which are associated with aberrant trophoblast invasion.    
These processes involve a complex network of molecular and cellular interactions 
which at each stage could be compromised leading to pregnancy complications and 
disorders. Several pregnancy disorders including recurrent and spontaneous 
miscarriage, pre-eclampsia, premterm labour and intrauterine growth restriction have 
22 
 
been associated with aberrant trophoblast invasion and/or deficient spiral artery 
remodelling.   
Recurrent miscarriage (RM) is defined as three or more consecutive pregnancy losses 
before 20 weeks gestation (Wilcox et al., 1988) and affects approximately 1 in 300 
women. Known causes of 20-50% of RM cases are associated with infection, endocrine 
disturbances, endometrial defects and abnormal embryo karyotype (Li et al., 2002). 
Although the causes of the remaining 50% of RM cases are unknown, there is a 
majority of evidence suggesting an immune involvement (reviewed by Laird et al. 
(2003) and Bansal (2010)). Women suffering RM have displayed higher uterine blood 
flow resistance compared with healthy successful pregnancies indicating insufficient 
establishment of the uteroplacental circulation, which may be the result of aberrant 
trophoblast invasion due to defective immune tolerance mechanisms (Habara et al., 
2002). Decreased levels of EVT HLA-G expression has been identified in RM (Emmer et 
al., 2002) suggesting a down regulation of uNK cell ‘self’ recognition causing a 
detrimental anti-fetal immune response by production of pro-inflammatory Th1 type 
cytokines. It has been proposed that an imbalance in Th1/Th2 reactivity in RM 
influences immunisation of paternal antigens (Szpakowski et al., 2000) and recently 
increased numbers of Th17 cells in both decidual tissues and maternal blood with 
increased levels of IL-17 in peripheral blood have been implicated in women suffering 
RM suggesting that Th17 cells destroy the conceptus by mediating maternal immune 
tolerance (Liu et al., 2011). A reduction in placental VEGF has also been observed in 
women suffering RM which could prevent the maturation of blood vessels, therefore 
affecting uteroplacental circulation and preventing a viable pregnancy (Vuorela et al., 
2000). Recent reports identify specific paternal genetic patterns in HLA-C expression 
and maternal NK recognition which has been associated with increased risk of RM, 
indicating that successful placentation relies on a coordinated balance of NK inhibition 
and activation of trophoblast through HLA-C recognition (Hiby et al., 2008).                  
Pre-eclampsia is a disease which is characterised by gestational hypertension and 
proteinuria, which has serious health consequences for both mother and baby; it is a 
major cause of maternal mortality and morbidity (Barton et al., 2001) and can cause 
fetal mortality (Sibai et al., 1995). Although pre-eclampsia is often not evident until the 
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third trimester, the disease is established during the first half of pregnancy during 
stages of trophoblast invasion and spiral artery remodelling. In the initial stages of the 
disease defective spiral artery remodelling is caused by shallow eEVT invasion in 
decidual spiral artery segments and a lack of invasion into the myometrium in early 
second trimester, meaning that myometrial spiral arteries do not undergo 
physiological change or remodelling, suggesting that the ‘second wave’ of trophoblast 
invasion does not occur (Brosens et al., 1972, Pijnenborg et al., 1991). Observations of 
term placental bed biopsies revealed a higher proportion of un-remodelled SpAs in pre 
eclamptic patients compared with normal pregnancies (Kim et al., 2003), providing 
evidence that impaired SpA remodelling is either a causative factor or an effect of the 
disease. A lack of spiral artery remodelling may be due to delayed endovascular 
trophoblast invasion; eEVT was detected in the lumen of third trimester decidual spiral 
arteries in patients with pre-eclampsia, while an absence of intraluminal eEVT is 
apparent in normal pregnancies beyond the second trimester (Khong et al., 1986).  
Progression of the disease is characterised by endothelial cell dysfunction with 
deficient production of nitric oxide (Roberts and Lain, 2002) causing vasoconstriction 
and reducing the flow of blood into the intervillous space, increasing oxidative stress to 
the placenta, resulting in uteroplacental ischemia. Placental ischemia has been 
suggested to evoke an inflammatory response by the release of many cytokines and 
growth factors from the placenta and further affect endothelial fuction. Secretion of 
placental TNF-α and circulating levels of VEGF agonist (sFlt1) have been associated 
with endothelial dysfunction in pre-eclampsia (Maynard et al., 2003, Hung et al., 2004).       
Fetal intrauterine growth restriction (IUGR) is a major cause of fetal morbidity and 
mortality; 50% of stillbirths at term are associated with IUGR (Froen et al., 2004). IUGR 
is defined as a failure of the fetus to reach its genetically predetermined growth 
potential and is characterised by abnormal fetal weight, size, and symmetry. As well as 
genetic predisposition, optimal fetal growth is also dependent on a regulated 
combination of maternal, fetal, placental and external factors (such as maternal 
smoking, consumption of alcohol and use of recreational drugs during pregnancy). 
Irregularities of such factors contribute to uteroplacental dysfunction which is the 
most common cause of IUGR (Baschat et al., 2000). Placental dysfunction is likely to 
24 
 
occur in the first trimester of pregnancy which suggests defective trophoblast 
adherence and invasion, therefore affecting SpA changes; such changes have been 
histologically observed in the placental bed in IUGR (Hustin et al., 1983). Such 
insufficiencies of uterplacental perfusion impinge on nutrient transfer to the fetus 
(Baschat and Hecher, 2004) and the condition may manifest early in pregnancy.              
Pregnancy disorders such as RM, pre-eclampsia and IUGR are multifactorial but some 
studies indicate an association with restricted eEVT invasion and failure of SpA 
remodelling and that pregnancy outcome is directly linked with the timing and extent 
of these processes. Therefore, investigation into the regulation of these processes at 
the maternal fetal-interface in early pregnancy will likely provide insight into a better 
understanding in the mechanisms involved in pregnancy pathology.        
1.3 Immunology of normal pregnancy 
1.3.1 Immunological paradox of pregnancy 
The fetus can be considered to be semi-allogenic to the mother due to contribution of 
human leucocyte antigen (HLA) genes from each parent. Fetal tissue expressing 
paternal alloantigens would be expected to stimulate a maternal T-cell immune 
response; however, a detrimental T-cell response is not initiated and the fetus escapes 
rejection. This unique process which allows a genetically and immunologically foreign 
entity to survive and evade the maternal immune system is described as the 
immunological paradox of pregnancy (Billingham et al., 1953, Damber et al., 1977).    
In 1953 comparisons were proposed between allografts in organ transplantation and 
the fetus; however, it was highlighted that pregnancy contradicted the immunology 
concept of allogeneic rejection (Billingham et al., 1953). The fetus, like the allograft is 
non-self; it is semiallogeneic but despite this the fetus is able to survive, whereas an 
allogeneic allograft is rejected. Explanations proposed in early studies were that the 
maternal immune response was suppressed during pregnancy, that the fetus did not 
express mature antigens and that the placenta served as an immune barrier between 
mother and fetus by lacking major histocompatibility complex (MHC) gene 
products/antigens. However, later studies revealed that the fetus is in fact 
immunogenic and does evoke a maternal immune response; this was demonstrated in 
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studies in mouse (Hoskin and Murgita, 1989), proving that the fetus expresses mature 
antigens and that the mother is immunologically aware of the pregnancy. Beer and 
Billingham (1971) proposed five concepts to explain this immunological paradox: 
1) Fetal and maternal blood circulations are separate. 
2) The uterus is an immunological privileged site. 
3) An immunological barrier exists at the maternal-fetal interface – paternal 
alloantigens are not expressed or are sequestered. 
4) Decidual inhibition of alloreactivity. 
5) Production of immunosuppressive factors by the fetus and mother.  
Recent studies have proved or refuted some of these hypotheses; evidence of an anti-
inflammatory and immunosuppressive response at the maternal-fetal interface has 
been reported. However, contrary to this is evidence that direct contact between fetal 
cells and maternal cells is associated with immune recognition, providing evidence that 
the developing fetus and the mother have an interactive relationship.  
1.3.2 Trophoblast major histocompatibility complex (MHC) expression 
During normal pregnancy chorionic villi become bathed in maternal blood and cells 
from the placenta invade the maternal uterine tissues. To avoid a hostile immune 
response from the mother, the placenta ensures a safe immunological barrier from 
maternal immune attack. Trophoblast cells are the first lineage derived from the 
developing embryo. They are extraembryonic in nature containing unmethylated DNA 
(Ohgane et al., 2002), express retroviral proteins (Mi et al., 2000) and have a genetic 
contribution from the father and thus are semi-allogenic to the mother. However, 
human villous trophoblast cells do not express either usual class I or class II MHC 
antigens (Faulk and Temple, 1976, Sunderland et al., 1981) suggesting that these cells 
are sequestered when encountered by maternal blood permitting survival of the 
developing fetus. Extravillous trophoblast cells are not confined to the chorionic villi, 
obviously since they are extravillous and are able to invade the maternal tissues 
without evoking an immune attack. Villous stromal cells do express MHC antigens so 
the lack of exposure to blood in the intervillous space relies on the intact 
syncytiotrophoblast cell layer, once syncytiotrophoblast layer is broken, the villous 
stroma is exposed to maternal immune cells in the intervillous space.   
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EVT cells do not express the highly polymorphic HLA class I molecules HLA-A and HLA-B 
but they do express the less polymorphic HLA-C (Moffett-King, 2002) and unusual non-
classical truncated class I MHC molecules, HLA-E and HLA-G (Hunt et al., 1988, King et 
al., 2000a), which are invariant and show limited polymorphism (Carosella, 2000).  
HLA-G expression is almost entirely specific to EVT cells and due to its limited 
polymorphism; it is unlikely to be recognised by the adaptive maternal immune 
system. However, HLA-G recognition is specific to maternal NK leucocytes through 
killer inhibitory receptor (KIR) expression and this recognition prevents EVT cytotoxity 
from NK cells. Complete lack of MHC class I molecules would expose the EVT to cell 
lysis (Hunt et al., 2000, Fournel et al., 2000) and also further down regulates a 
maternal T cell cytotoxic response to the placental cells (Bainbridge et al., 2000). 
HLA-G expression is essential for successful pregnancy outcome (Fuzzi et al., 2002) 
decreased EVT HLA-G expression has been implicated in miscarriage (Emmer et al., 
2002) and the presence of a number of rare HLA-G isoforms have been detected in 
women suffering from recurrent miscarriage (van der Ven et al., 2000, Aldrich et al., 
2000, Pfeiffer et al., 2001). The functions of HLA-G remain unclear but aside from 
protection against maternal leucocytes, other roles of HLA-G have been proposed such 
as promoting uNK cell proliferation and interferon (IFN)-γ production (van der Meer et 
al., 2004) suggesting a regulatory role in EVT invasion (Lash et al., 2006b) and 
modification of the maternal immune response by suppressing allogeneic lymphocyte 
proliferation (Apps et al., 2007).    
1.3.3 Th1/Th2 paradigm  
CD4+ Helper T lymphocytes (Th) contribute towards immunity as well as producing 
cytokines. They are classified into different functional subsets; Th1 and Th2. In the 
normal immune system there is a balance between in Th1/Th2 responses. A Th1 
response produces cytokines such as IFN-γ, TNF-α, and interleukin (IL)-2 which 
promote cell mediated immunity and this response will predominate over Th2, 
whereas a Th2 response provides humoral immunity by the production of IL-4, IL-5, IL-
9, IL10 and IL-13.  Another CD4+ T lymphocyte subpopulation has also been identified 
that do not secrete either Th1 or Th2 type cytokines but produce TGF-β and IL-10 
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which down regulates the effects of Th1 cells; this population of cells has been named 
Th3 (Borish and Steinke, 2003).         
Wegmann et al. (1993) proposed that during pregnancy a Th2 response prevails, 
whereas a Th1 response is detrimental to pregnancy and many studies, particularly in 
mouse pregnancy, have provided evidence of this. TNF-α serum levels are elevated in 
pre-term labour and pre-eclampsia (Casey et al., 1989). TNF-α is considered to be 
harmful for pregnancy; increased levels are associated with embryonic demise in 
mouse studies (Clark et al., 2004) and TNF-α affects feto-placental development by 
inhibiting trophoblast invasion (Bauer et al., 2004, Huber et al., 2006, Otun et al., 
2011). Lash et al. (2006b) have also demonstrated the inhibitory effects of IFN-γ on 
EVT invasion by apoptosis and decreased protease activity. The Th1-type immunity was 
considered to be incompatible for successful human pregnancy (Raghupathy, 1997), 
favouring Wegmann’s hypothesis. Th1 cytokine dominance has been reported in RM 
compared with normal pregnancies (Raghupathy et al., 2000), although this has been 
disputed by (Bates et al., 2002) who reported a Th2 shift in RM. Challenging the 
concept of a Th2 bias in normal pregnancy are data proving that IFN-γ is essential for 
successful pregnancy outcome as it is pivotal in SpA remodelling (Ashkar et al., 2000, 
Croy et al., 2003, Murphy et al., 2009, Robson et al., 2012). Furthermore a study using 
a Th2 knockout (IL-4, IL-5, IL-9 and IL-13 ko) mouse showed normal reproductive 
outcome (Fallon et al., 2002). Additional cytokines such as IL-15 and IL-18 have been 
observed at the maternal-fetal interface (Chaouat et al., 2002, Murphy et al., 2009) 
that are not classed Th1 nor Th2 type cytokines, again challenging the paradigm and 
adding to its complexity.     
These data, combined with many studies investigating the Th1/Th2 paradigm, suggest 
that the immune responses at the maternal-fetal interface is a complex one, which 
may be time specific, dynamic and continuous rather than focusing on maternal 
tolerance alone.  
1.3.4 Cytokines in normal pregnancy 
Human endometrium produces a wide variety of pro-inflammatory cytokines 
throughout the proliferative and secretory phases of the menstrual cycle (Tabibzadeh, 
1991). These cytokines are believed to play a significant role in the modulation of the 
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uterine environment preparing the uterus for implantation of the developing 
conceptus and formation of a functional placenta for the establishment of pregnancy.  
Prevention of maternal rejection of the fetus requires a regulated environment which 
occurs primarily at the maternal-fetal interface and within the uterine tissues. In 
normal systems naive CD4+ T-cells are the major producers of cytokines and are 
divided into three subsets Th1, Th2 and Th3 (see section 1.3.3). However, a plethora of 
Th1 and Th2 cytokines are produced by trophoblast cells, maternal T lymphocytes, 
stromal cells, epithelial cells, uNK cells, macrophages and other maternal leucocytes, 
localised at the maternal-fetal interface (Vince and Johnson, 2000) and maintenance 
and development of the fetal-placental unit may be dependent on these cytokines. 
The presence of these cytokines at the maternal-fetal interface influence the local 
environment by regulating processes such as implantation, placental development, 
cytotrophoblast proliferation, angiogenesis, EVT invasion, SpA remodelling, cellular 
growth and apoptosis (Piccinni et al., 2000, Drake et al., 2001, Dimitriadis et al., 2005, 
Lash et al., 2006c, Murphy et al., 2009). However, this is a complex area of research 
due to the pleiotrophy and redundancy of the cytokine network and a wide range of 
results have been reported; some known functions of specific cytokines are 
summarised below in sections 1.3.4.1 and 1.3.4.2.       
1.3.4.1 Cytokines and implantation 
It is likely that a complex mix of cytokines in the endometrium is involved in blastocyst 
implantation. Studies have focused on IL-1 and receptors for IL-1 have been reported 
to be distributed throughout the human endometrium and are present at the 
maternal-fetal interface, suggesting a role in the implantation of the blastocyst (Simon 
et al., 1998). Cytokines may increase the receptivity of the endometrium allowing 
communication with the developing embryo. Gp130 cytokines, including IL-6 and 
leukaemia inhibitory factor (LIF), play important roles in implantation; LIF knockout 
mice failed to initiate decidualisation and therefore failed to support implantation; LIF-
/- mice injected with exogenous LIF rescued implantation (Stewart et al., 1992). Laird et 
al. (1997) have linked successful implantation with LIF in humans. Women with 
unexplained infertility produced lower levels of endometrial LIF in the luteal phase of 
the menstrual cycle compared with controls and this has subsequently been confirmed 
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(Ledee-Bataille et al., 2002). IL-6 deficient mice have shown reduced fertility and 
reduced numbers of viable implantation sites (Robertson, 2000).Together with LIF, IL-6 
and IL-1, IL-11 has also been suggested to be important in pregnancy; in vitro studies 
have shown that IL-11 stimulates decidualisation of human endometrial stromal cells 
(Dimitriadis et al., 2002) and primary decidual cells in vitro secrete IL-11 and regulate 
trophoblast invasion (von Rango et al., 2004). Impaired synthesis of endometrial 
epithelial IL-11 has also been implicated in women suffering recurrent miscarriage 
(Linjawi et al., 2004) providing further evidence for the importance of this cytokine in 
early pregnancy. 
There are many other factors alongside gp130 cytokines that are involved in 
implantation such as progesterone, a variety of chemokines and other cytokines such 
as TNF-α, TGF-β1 and IL-15 (Dimitriadis et al., 2005), indicating the complexity of this 
event with multiple contributors to the processes involved.  
1.3.4.2 Cytokines and trophoblast invasion 
The mechanisms that control EVT invasion in early pregnancy remains widely 
misunderstood although it is likely that several cytokines and growth factors derived 
from the decidua and trophoblasts themselves are involved (Meisser et al., 1999, 
Bischof et al., 2000, Lala and Chakraborty, 2003, Lash et al., 2006c, Naruse et al., 2010). 
Moreover various decidual cells, such as uNK cells, decidualised endometrial stromal 
cells and macrophages secrete both inhibitory and stimulating factors that may control 
EVT invasion (outlined in Figure 1.8; Knofler and Pollheimer (2012)). TNF-α and IFN-γ 
are cytokines which are associated with the inhibition of trophoblast invasion by 
triggering cell death and also inhibiting protease enzymes (Ho et al., 1999, Knofler et 
al., 2000, Lash et al., 2006b, Otun et al., 2011). TGF-β1, 2 and 3 have been reported to 
inhibit trophoblast invasiveness by reducing trophoblast protease activity (Lash et al., 
2005). There is also evidence indicating that a Th2 type response prevents trophoblast 
apoptosis (Aschkenazi et al., 2002) suggesting that Th2 cytokines may stimulate 
invasion; this coincides with studies of IL-6 (Jovanovic and Vicovac, 2009, Dubinsky et 
al., 2010), IL-8 (Hanna et al., 2006, De Oliveira et al., 2010), IL-11 (Paiva et al., 2007) 
and IL-1β (Gonzalez et al., 2011, Prutsch et al., 2012), all of which have been reported 
to stimulate trophoblast invasion.   
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This area has remained inconclusive and many reports are contradictory. This may be 
an effect of studying cytokines in isolation. Furthermore the source of trophoblast cells 
and the cell lines used in these studies have varied, thus adding to the difficulty of 
elucidating the mechanisms that are involved in the control of trophoblast invasion.  
        
Figure 1.8 Inhibitory and stimulating factors influencing trophoblast invasion 
Summary of inhibitory and stimulating factors secreted by predominant cells of the decidua; 
uNK cells, decidual stromal cells and macrophages which influence trophoblast invasive 
behaviour. Image from Knofler and Pollheimer (2012).   
 
1.4 Decidual cell populations 
1.4.1 Leucocyte populations and distribution 
The human endometrium is a complex mucosal tissue and has a unique immune cell 
component (Eriksson et al., 2004). This component prepares the maternal 
environment to adapt to the implanting fetus by providing immune surveillance 
against invading pathogens and regulating immune responses to the semi-allogeneic 
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fetus. This balance of immune regulation is necessary for successful pregnancy and is 
controlled by an intrauterine leucocyte population which differs from peripheral blood 
leucocyte populations adding to the immune paradigm.  
Maternal leucocytes are an important component of the endometrium. They are 
present during the proliferative phase and early secretory phase of the menstrual cycle 
but increase in number substantially at the time of expected implantation and 
continue to rise in early pregnancy (Bulmer et al., 1991), accounting for approximately 
30-40% of the stromal cells within the decidualised endometrium lining the uterus 
during pregnancy. Three major decidual leucocyte populations have been identified in 
pregnancy; uterine natural killer cells, macrophages and T lymphocytes (Bulmer et al., 
1991); dendritic cells are less abundant (Gardner and Moffett, 2003) with NKT cells 
(Tsuda et al., 2001) and T regulatory cells (Heikkinen et al., 2004) accounting for a 
small subset of the decidual leucocyte population but with equal functional 
importance. All of these endometrial leucocytes are present at the implantation site 
where they encounter the invading trophoblast. In contrast B lymphocytes are rare in 
the decidua throughout pregnancy.  
The explanation for the increasing numbers of leucocytes around the time of expected 
implantation (mid secretory phase) in a fertilised cycle still remains unknown. 
Suggestions for this increase include hormonal fluctuations, differentiation of 
precursor cells and proliferation of existing leucocytes or leucocyte recruitment from 
other sites. There has been extensive investigation of the role of endometrial 
leucocytes in pregnancy ranging from immune tolerance to regulation of trophoblast 
invasion and spiral artery remodelling. Uterine natural killer cells and macrophages 
have been implicated in pregnancy disorders such as pre-eclampsia, fetal growth 
restriction and recurrent abortion suggesting that these leucocytes have an important 
role in normal pregnancy.  
1.4.2 Uterine natural killer cells 
Human uterine natural killer (uNK) cells are the most prominent leucocyte population 
within early pregnant decidua and they rapidly increase in number during the first 
trimester of pregnancy, accounting for over 70% of the decidual stromal leucocyte 
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population during the first half of pregnancy with uNK cell numbers decreasing after 
week 20 of gestation (Bulmer et al., 1991). 
1.4.2.1 Phenotypic features of uterine natural killer cells 
Human natural killer (NK) cells originate from stem cell haematopoietic precursors 
(Colucci et al., 2003). Distinct lineages of NK cells arise depending on their location; in 
tissues, lymphoid and non-lymphoid organs and peripheral blood where they may 
differ in phenotype and function. 
Uterine natural killer cells have been classified as a ‘natural killer’ cell subtype due to 
their cytoplasmic granules similar to that of the large granular lymphocyte appearance 
of peripheral blood (PB) NK cells. They were first recognised in the 1920s (Bulmer and 
Lash, 2005) and further characterised in non-pregnant and pregnant endometrium 
using phloxine tartrazine staining of cytoplasmic granules (Hamperl and Hellweg, 
1958). The majority of NK cells are characterised by their expression of CD56 cell 
membrane protein and the lack of CD3 expression and uterine natural killer cells are 
now characterised by their CD56 expression. Bulmer et al. (1991) quantified the 
numbers of phloxine tartrazine granulated cells and CD56+ cells in non-pregnant and 
early pregnant endometrium and the results were comparable. This major subset of 
NK cells in the uterus predominantly have the phenotype CD56bright  CD16negative, similar 
to an NK cell phenotype observed in the gastrointestinal  tract and secondary lymph 
nodes (Drayton et al., 2006, Sentman et al., 2007), whereas over 90% of the peripheral 
blood NK cell population are CD56dim  CD16positive, the remaining 10% being CD56bright 
CD16dim (Cooper et al., 2001). In contrast with uNK cells, which have cytoplasmic 
granules, peripheral blood CD56bright CD16dim NK cells are usually agranular. The CD56 
antigen expressed on human NK cells is an isoform of the human neural cell adhesion 
molecule with an unknown function, but the CD56dim NK cell population is highly 
cytotoxic while the CD56positive population are strong producers of cytokines (Cooper et 
al., 2001, Szekeres-Bartho, 2008). Uterine NK cells express a variety of other cell 
surface markers that reflect their unique phenotypic and functional properties (Cooper 
et al., 2001); these are summarised in Table 1.1. The CD16 cell surface molecule is a 
low affinity FcγR, which binds to antibody coated targets resulting in a signal for 
cellular cytotoxicity (Cooper et al., 2001). CD16 along with other cell surface molecules 
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gives rise to the antibody dependent cytotoxic potential of NK cells, whereas the 
release of perforin (Rukavina et al., 1995) and granulysin (Nakashima et al., 2008) by 
uNK cells is associated with cell mediated killing, although this NK cell mediated 
apoptosis has never been observed in normal human decidua unless activated in vitro 
with IL-2 or IL-15 (Verma et al., 2000, Kopcow et al., 2005). Unlike peripheral blood NK 
cells, uNK cells lack expression of CD16, the consequence of this difference affects the 
functional antibody dependent cytotoxity of these cells and uNK cells. Furthermore, 
uNK cells have lower cytotoxic activity than PBNK cells despite their content of perforin 
(Kopcow et al., 2005).  
CD9 and KIRs (killer immunoglobulin-like receptors) are other cell surface markers used 
to distinguish between CD56bright PBNK cells and uNK cells as these markers are more 
widely expressed on the latter, along with CD9 expression (Eriksson et al., 2004). CD9 is 
believed to be involved in various cellular and physiological functions such as cellular 
migration and invasion (Boucheix and Rubinstein, 2001). The expression of cell surface 
receptors by uNK cells may also modulate the maternal immune response at the time 
of implantation and placentation; they are able to recognise the unusual trophoblast 
MHC class I ligands, such as HLA-C, HLA-G and HLA-E and reproductive success may 
primarily depend on this allorecognition (King et al., 1996a, Koopman et al., 2003). KIR 
expression by uNK cells is highly variable and allows for recognition with polymorphic 
HLA-C ligands expressed by EVT (Sharkey et al., 2008). The EVT HLA-E ligand is 
recognised by uNK cells through the lectin-like inhibitory receptor CD94/NKG2A (King 
et al., 2000b). There is evidence that HLA-G binds to uNK cells by KIR2DL4 receptor, but 
expression of this receptor by uNK cells is debated (Apps et al., 2008) and it is likely 
that trophoblast HLA-G binds to LILR (leucocyte immunoglobulin-like receptors) which 
is expressed by decidual macrophages (discussed further in section 1.4.3) and is only 
present on a minority of uNK cells (Apps et al., 2007). Uterine natural killer cells are 
also able to recognise HLA-C expressed by extravillous trophoblast. Each individual 
pregnancy is characterised by specific combinations of uNK cell KIRs and EVT HLA-C 
variants; although complex, particular combinations such as maternal KIR AA and fetal 
HLA-C2 are over represented in pre-eclampsia, intrauterine growth restriction and 
recurrent miscarriage (Hiby et al., 2010), highlighting that the interaction between EVT 
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HLA-C and uNK KIRS governs the maternal-fetal immune response and therefore 
appears to be crucial for reproductive success.            
Expressing this mix of highly variable KIRs and the activating receptors NKp30, NKp44, 
NKG2D, uNK cells remain tolerant towards trophoblast cells and have been suggested 
to be cytokine producers at the fetal-maternal interface (Kopcow et al., 2005).   
Table 1.1 Phenotypic differences and similarities of NK cell surface markers 
Phenotypic differences and similarities of expression of cell surface markers by PBNK 
(peripheral blood NK) and uNK (uterine NK) cells. Table modified from Kalkunte et al. (2008); (+ 
presence; - absence; +/- variable expression). 
 
1.4.2.2 uNK cell localisation and distribution  
Uterine NK cells are found in abundance in both decidua basalis and decidua parietalis; 
they are not a prominent feature in the human myometrium and therefore should 
perhaps be termed ‘endometrial’ rather than ‘uterine’ (Bulmer and Lash, 2005) . 
During the first trimester of pregnancy the uNK cells are in close association with fetal 
trophoblast cells (King et al., 1996a), but the presence of uNK cells in endometrium 
does not depend on the presence of trophoblast and they are also present throughout 
the menstrual cycle in non-pregnant endometrium (Bulmer and Lash, 2005), albeit in 
small numbers in proliferative and early secretory phases (Loke et al., 1995). Uterine 
natural killer cells are also prominent in decidualised endometrium in ectopic 
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pregnancy where trophoblast is absent (Laskarin et al., 2010) as well as pseudo 
decidualised endometrium under the influence of progesterone (Le Bouteiller and 
Piccinni, 2008). Oestrogen and progesterone are thought to play a role in regulating 
the proliferation and recruitment of uNK cells  (Bulmer and Lash, 2005) and uNK cells 
are particularly prominent in progesterone treated endometrium. However, uNK cells 
themselves lack expression of the progesterone receptor suggesting that their function 
is not directly altered by the hormone  (King et al., 1996b) but uNK cells do express ER-
β1 and Gh receptor proteins indicating that oestrogen and glutocorticoids may up-
regulate gene transcription in uNK cells  (Henderson et al., 2003). Progesterone plays a 
role in up-regulating the release of various factors from surrounding stromal cells, such 
as endometrial derived IL-15 and prolactin (Kao et al., 2002, Mirkin et al., 2005), all of 
which may influence uNK cell differentiation, function and proliferation (Bulmer and 
Lash, 2005). The co-localisation of decidualised endometrial stromal cells with uNK 
cells is striking and uNK cells are also seen in areas of ectopic decidua; this relationship 
may suggest a fundamental role for decidual stromal cells in the differentiation of uNK 
cells (Kitaya et al., 2000, Dunn et al., 2002). If pregnancy does not occur, uNK cell 
numbers begin to diminish during menstruation providing further evidence of direct or 
indirect hormonal influence on the evolution of these cells. During early pregnancy 
uNK cells accumulate around invading EVT and remodelling SpAs (Bulmer et al., 1991, 
Smith et al., 2009) and contribute to the majority of decidual leucocytes into the early 
second trimester (Williams et al., 2009b). Their numbers progressively dwindle in the 
second trimester and lower numbers of CD56+ cells are observed in term deciduas 
(Williams et al., 2009b). This spatial and temporal distribution has led to the suggestion 
that uNK cells play a role in trophoblast invasion and SpA remodelling.      
 1.4.2.3 uNK cell function during pregnancy 
The role of uNK cells during early pregnancy remains unclear but their importance in 
placentation has been demonstrated in both mouse and humans (Manaster and 
Mandelboim, 2010). This has led to investigation and focus on uNK secreted cytokines 
and growth factors that may influence EVT invasion. More recently it has been 
proposed uNK cells may be involved in the early stages of spiral artery remodelling due 
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to the fact that uNK cells are present in maximum numbers at the time of spiral artery 
remodelling and reduce in number in the second half of pregnancy (Smith et al., 2009).  
Uterine NK cells produce a significant number of cytokines, chemokines and angiogenic 
growth factors including IL-10, IL-1β, TGF-β1, INF-γ, GM-CSF, LIF and TNF-α (Rieger et 
al., 2001, von Rango et al., 2003) with production of some cytokines increasing with 
gestational age (Lash et al., 2010b). 
The cytokines produced by uNK cells have been proposed to regulate EVT invasion in 
early pregnancy. There is evidence that the uNK cell derived cytokines including TNF-α, 
TGF-β1 and IFN-γ all inhibit trophoblast invasion in vitro (Lash et al., 2005, Lash et al., 
2006b, Otun et al., 2011). However, other studies have reported stimulation of 
trophoblast invasion with uNK cell supernatants (Hanna et al., 2006, Lash et al., 
2010a), although gestational age differences have been reported (Lash et al., 2010b). A 
recent study by (De Oliveira et al., 2010) demonstrated that IL-8 secreted by uNK cells 
increased the invasiveness of EVT using placental explants. These are but a few of the 
many studies that have investigated the effects of various cytokines and chemokines 
that are known to be produced by uNK cells on trophoblast invasion, with 
contradictory reports. This is likely to be explained by the complexity of the cytokine 
milieu in vivo, the different tissues used and their gestational age, as it has been 
demonstrated that uNK cell cytokine secretion differs with gestational age (Naruse et 
al., 2010, Lash et al., 2010c). Recent co-culture studies with isolated uNK cells and EVT 
from the same patient also had an effect on the cytokine secretion profile of uNK cells 
(Lash et al., 2011); secretion of several cytokines and growth factors was reduced 
when uNK cells and EVT were in direct contact, suggesting a regulatory mechanism for 
cytokine secretion in the placental bed.      
The role of uNK cells in SpA remodelling has been suggested by numerous 
immunohistochemical studies; Lash et al. (2006c) have demonstrated that human uNK 
cells isolated from first trimester decidua are a prominent source of a range of 
angiogenic growth factors which reduce with increasing gestational age. Reduced 
numbers of uNK cells in third trimester pregnant decidua have been associated with 
pre-eclampsia and intrauterine growth restriction (Williams et al., 2009a), suggesting a 
role for these cells in SpA remodelling. Craven et al. (1998) proposed that early initial 
37 
 
changes in SpA remodelling occur prior to invading trophoblast and it has recently 
been reported that uNK cells have a possible involvement in mediating the effects of 
early ‘trophoblast-independent’ SpA remodelling (Pijnenborg et al., 2006b, Smith et al., 
2009, Fraser et al., 2012, Robson et al., 2012, Wallace et al., 2012). Robson et al. (2012) 
reported evidence of VSMC disruption when chorionic plate arteries from term 
placentas and myometrial arteries from non-pregnant hysterectomy specimens were 
treated with uNK cell supernatants from pregnancies at 8-10 weeks gestation. 
Disruptions in VSMC integrity was observed when both CpA and non-pregnant 
myometrial SpA vessels were treated with Ang-1, Ang-2, IFN-γ and VEGF-C – all of 
which are growth factors produced by uNK cells (Lash et al., 2006c), and the addition 
of Ang-2 inhibitor also abrogated the effects of uNK cell supernatants on VSMC 
disorganisation in CpA. Altered levels of extra cellular matrix components of the vessel 
walls were also observed when treated with uNK cell supernatants in both vessel 
models suggesting that these cells may initiate the early stages of SpA trophoblast 
independent remodelling by the action of MMPs and via the secretion of Ang-2. Other 
studies suggest that the early vascular changes in SpAs are initiated by uNK cells 
through apoptotic mechanisms (Harris et al., 2007, Keogh et al., 2007, Smith et al., 
2009, Fraser et al., 2012).         
Studies investigating murine pregnancies have also implicated uNK cells in SpA 
remodelling. This was first demonstrated in the Tgε26 strain of mouse that lacks NK 
cells; they display abnormal vasculature and irregular decidual organisation along with 
a small placenta (Guimond et al., 1997). Uterine NK cell derived cytokines, such as 
interferon-γ (IFN-γ), have been suggested to be important in SpA remodelling. IFN-γ in 
mouse models modulates vascular modification and decidual integrity (Ashkar et al., 
2000), but in humans it has been observed that uNK-cell derived IFN-γ is secreted at  
low levels (Lash et al., 2006b, Marzusch et al., 1997) and it has little effect on VSMC 
organisation of non-pregnant myometrial arteries in vitro but does alter VSMC 
organisation of chorionic plate arteries (Robson et al., 2012); it is likely that angiogenic 
growth factors play a more substantial role. Together with murine studies and 
investigation with human pregnancies, there is accumulating evidence that uNK cells 
are a major source of decidual cytokines, which could be involved in the processes of 
early pregnancy and now numerous studies are focusing on this aspect of their biology.            
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1.4.2 Decidual T lymphocytes 
Approximately 10% of the endometrial stromal leucocyte population comprises CD3+ T 
lymphocytes in early pregnancy (Bulmer et al., 1991). CD3+ T lymphocytes have been 
subjected to relatively little research compared with uNK cells and 
decidual/endometrial macrophages. Endometrial CD3+ T lymphocytes are 
predominantly CD8+ unlike the peripheral blood population where CD3+ CD4+ T cells 
are more abundant (3:1 ratio) (Bulmer et al., 1991).  
Endometrial T lymphocytes numbers do not alter greatly during the menstrual cycle 
and pregnancy, leading to the suggestion that these cells do not have a key role in the 
establishment and maintenance of pregnancy but rather play an important role in 
providing immune protection against external pathogens (Vassiliadou and Bulmer, 
1996). Murine studies have shown that decidual CD8+ T lymphocytes exert 
immunosuppressive activity by a reduction in cytotoxic activity (Nagarkatti and Clark, 
1983, Thomas and Erickson, 1986). However,  Scaife et al. (2006) demonstrated that 
decidual CD8+ T lymphocytes isolated from early pregnancy are capable of cytolysis and 
evoke a Th1 cytokine response, releasing high levels of IFN-γ.         
Decidual T lymphocytes have been reported to express markers such as HLA-DR, CD38 
and CD49a unlike peripheral blood T lymphocytes (Geiselhart et al., 1995) and decidual 
CD8+ T lymphocytes have been reported to stimulate trophoblast invasion in vitro 
(Scaife et al., 2006), suggesting that these cells may have an important role in 
trophoblast function and normal placental development. 
CD4+ T cells are a minor component of the decidual leucocoyte population and 
immunohistochemical studies have been difficult to identify these cells in the 
endometrium due to macrophage expression of CD4. To date there have been no 
specific functional studies of CD4+ T cells in the endometrium or decidua.  
1.4.2.1 Natural killer T cells 
Human natural killer T (NKT) cells have been identified in early pregnant decidua 
(Tsuda et al., 2001). NKT cells are characterised by the expression of either a non-
variant or invariant T cell receptor, CD161 (C-type lectin) and CD56. NKT cells are 
present at the maternal-fetal interface during pregnancy and the proportion of non-
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variant NKT cells are higher in pregnant decidua compared with NKT cells in peripheral 
blood of the same patients (Tsuda et al., 2001, Boyson et al., 2002, Uemura et al., 
2008).  
Peripheral blood NKT cells are potent anti-tumour effector cells (Ohkawa et al., 2001). 
Unlike uNK cells NKT cells lack expression of KIR CD94/NKG2A and their suggested role 
in pregnancy is to produce cytokines. NKT cells have been reported to produce large 
amounts of IL-4 and IFN-γ (Bendelac, 1997, Tsuda et al., 2001); cytokines that have 
been implicated in pregnancy. Although NKT cells do not express KIRs that enable 
them to recognise MHC class I molecules, recognition of trophoblast may be achieved 
through presentation of glycolipids on CD1d receptor expressed by trophoblast cells 
(Bendelac et al., 2007, Uemura et al., 2008). Numbers of CD3+CD56+ cells dwindle in 
decidua at term compared with numbers in first trimester decidua (Williams et al., 
2009b) and this observation together with reports of reduced CD3+CD56+ cell numbers 
in recurrent miscarriage (Yamamoto et al., 1999), suggests a role for these cells in early 
pregnancy processes.      
1.4.2.2 Regulatory T lymphocytes 
Regulatory T lymphocytes (T reg cells) are a highly heterogeneous T cell population and 
play an important role in suppressing the peripheral T cell response. CD4+CD25+ T reg 
cells are the most widely studied T reg population. T reg cells are present at the 
maternal-fetal interface and 10-15% of decidual CD4+ T lymphocytes are CD4+CD25+ T 
reg cells (Heikkinen et al., 2004). Yang et al. (2009) reported an increase of CD25 bright 
cells in the decidual CD4+ T cell population compared with the peripheral CD4+ T cell 
population, suggesting a role for these cells in maternal tolerance to fetal alloantigens. 
Nevertheless, the activation of regulatory T cells and induction of tolerance in 
pregnancy remains unclear, although reduced numbers of CD4+CD25+ T reg cells have 
been associated with sporadic miscarriage (Sasaki et al., 2004), recurrent miscarriage 
(Yang et al., 2009) and pre-eclampsia (Sasaki et al., 2007). 
1.4.3 Decidual macrophages 
Macrophages have the ability to alter their antigen presenting status in response to 
the microenvironment, thereby altering their function allowing them to participate in a 
40 
 
wide range of biological processes including metabolism, vascular remodelling and 
tissue homeostasis (Gordon, 2007). 
Decidual macrophages are the second most abundant leucocyte population and 
account for approximately 20-25% of all decidual leucocytes in early pregnancy 
(Bulmer et al., 1988) and are present at the implantation site (Loke and King, 2000). 
Macrophages are potent antigen presenting cells (APCs) and are more abundant APCs 
than dendritic cells. They have been characterised in the endometrium and decidua by 
immunodetection of CD14 cell surface protein and CD68 lysosomal protein 
(CD14+/CD68+). Despite some similarities with peripheral blood monocytes, evidence 
regarding the origin of decidual macrophages is lacking. However, increasing evidence 
suggests that decidual macrophages originate from a myeloid lineage and have a 
plasticity which allows them to alter their phenotype by functional differentiation to 
adapt to the local microenvironment of the human decidua.       
Histological studies have provided circumstantial evidence that uNK cells along with 
other leucocytes wirthin the decidua, including decidual macrophages, initiate spiral 
artery remodelling prior to the invasion of extravillous trophoblast cells (Smith et al., 
2009). Decidual leucocytes including decidual macrophages are producers of varied 
amounts of growth factors, cytokines and proteases which may contribute to vessel 
remodelling (Plaisier et al., 2009). 
Decidual macrophages highly express the MHC class II human leucocyte antigen HLA-
DR, allowing antigen presentation to decidual T cells, contributing to maternal-fetal 
tolerance (Figure 1.9). This allows the invading trophoblast to interact with 
macrophages in the decidua through a variety of receptor- ligand pairs, thereby 
activating macrophages in the decidua (Vince and Johnson, 2000, Renaud and Graham, 
2008). Leucocyte immunoglobulin-like receptor (LILR) expression has been detected on 
decidual macrophages (Apps et al., 2007). LILR is a ligand for non-classical HLA-G 
expressed on EVT; therefore, invasive trophoblast may modulate the function of 
decidual macrophages or vice versa (Figure 1.9). Decidual macrophages are thought to 
be incapable of differentiating into dendritic cells, but during early pregnancy a 
subpopulation of CD14+/HLA-DR+ cells express the immature dendritic cell marker 
41 
 
CD209 (DC-SIGN) (Kammerer et al., 2003) suggesting that these cells have the ability to 
differentiate into mature (CD83+) dendritic cells.  
Decidual macrophages also have an important immunoregulatory role preventing 
aggressive immune inflammatory responses, thus resulting in a tolerant immune 
environment that supports placentation, implantation, efficient trophoblast invasion 
and vascular remodelling (Seavey and Mosmann, 2008). Classic macrophages secrete 
high amounts of Th1 pro-inflammatory cytokines; TNF-α and IL-12 have been classified 
as M1 pro-inflammatory macrophages, whereas macrophages which respond to Th2 
cytokines such as IL-4 and IL-13 possess an immunosuppressive phenotype and are 
therefore termed activated macrophages or M2 macrophages. Decidual macrophages 
have been suggested to have an immunosuppressive role by the secretion of 
prostaglandins and cytokines such as IL-10 and IL-1 (Goerdt and Orfanos, 1999). 
Lidstrom et al. (2003), using an enzyme-linked immunosorbent spot-forming cell assay 
(ELISPOT), demonstrated that decidual macrophages are potent producers of IL-10 
which is an immunosuppressive cytokine indicating that macrophages could potentially 
regulate functions such as trophoblast invasion in early pregnancy (Renaud and 
Graham, 2008). In keeping with this, gene expression profiles from microarrays have 
demonstrated that decidual macrophages contain up-regulated transcripts encoding 
genes for immunosuppressive and tissue remodelling proteins compared with 
peripheral blood macrophages (Gustafsson et al., 2008). In addition to production of 
immunosuppressive cytokines, cell lines expressing the trophoblast HLA-G homodimer 
induce decidual macrophages to secrete large amounts of pro-inflammatory cytokines 
IL-6 and IL-8 (Li et al., 2009). It has been suggested that infection during pregnancy 
may cause aberrant macrophage activation, leading to switching from M2 polarisation 
(immunosuppressive) to M1 (pro-inflammatory) phenotype, with an increase in pro-
inflammatory cytokine secretion; this would initially serve as a defence mechanism 
against invading pathogens but could in turn affect angiogenesis, trophoblast function 
and placental apoptosis resulting in a variety of pregnancy disorders (Renaud and 
Graham, 2008). 
Macrophages are also capable of phagocytosis and decidual macrophages express 
specific phagocytic receptors which are able to bind with extracellular matrix products 
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(Repnik et al., 2008); high numbers of CD14+ cells have been identified in proximity to 
spiral arteries suggesting phagocytosis and apoptotic cell clearance (Abrahams et al., 
2004a). Furthermore, recent data demonstrates the identification of two unique 
human decidual macrophage populations; CD11cHI and CD11cLO both with pro- and 
anti-inflammatory functions (Houser et al., 2011) suggesting that these cells have the 
ability to facilitate immune responses and tissue remodelling events by the secretion 
of proteases and cytokines playing an important role at the maternal-fetal interface.  
Macrophage derived TNF-α has been shown to restrict trophoblast invasiveness 
through inducing apoptosis and increased macrophage derived TNF-α levels have been 
associated with pregnancies complicated by pre-eclampsia, intrauterine growth 
restriction and early onset spontaneous abortion (Reister et al., 2001).  However, 
overall there are few reports on decidual macrophage cytokine secretion and relatively 
little attention has focused on macrophage function in normal pregnancies, although 
various model systems have been used to characterise phenotype.  
Despite the limited understanding of decidual leucocytes it appears that they are 
associated with one another and the factors they produce are likely to work together 
to provide an environment which is conducive for successful pregnancy. Hence, studies 
of isolated single leucocyte populations in vitro may not reflect the in vivo situation 
where interactions between the various cell types are likely.  
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Figure 1.9 Molecular interactions of a decidual macrophage 
Molecular interactions of decidual macrophages with cells of the decidua (Nagamatsu and 
Schust, 2010). 
1.4.4 Decidual dendritic cells 
Decidual dendritic cells account for 1-2% of the leucocyte population in early human 
pregnancy with numbers remaining constant throughout gestation. Dendritic cells are 
a unique cell population which induce primary immune responses. Following 
menstruation when oestrogen levels are highest, oestrogen stimulates the 
differentiation and maturation of dendritic cells to express costimulatory molecules 
including CD83 and CD86 and high levels of MHC class II (Paharkova-Vatchkova et al., 
2004). Both immature (CD83-/CD209+) and mature dendritic cells have been identified 
in uterine tissues by expression of CD83 (Kammerer et al., 2000), suggesting that the 
presence of immature cells mediate tolerance to the developing fetus, whereas the 
mature dendritic cells protect the maternal-fetal interface from invading pathogens.  
Collins et al. (2009) recently presented evidence from studies in mouse agreeing with 
this; that the decidual environment prevents dendritic cell surveillance at the 
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maternal- fetal interface and that dendritic cell trafficking to the uterine lymph nodes 
from decidua is minimal; decidual factors play a role in sequestering the migratory 
capacity of mature dendritic cells whilst retaining the DC responsiveness to antigens. 
Kammerer et al. (2003) reported similar findings from isolated human decidual 
dendritic cells; these cells were unable to stimulate naïve T cells after antigen binding. 
The entrapment of decidual dendritic cells in the human endometrium remains to be 
understood and therefore migration and activation of T cell responses may contribute 
to pathological pregnancy. Uterine dendritic cells also secrete growth factors such as 
VEGF-A and TGF-β1 (Plaks et al., 2008) but they have no effect on trophoblast invasion 
(Huang et al., 2008), suggesting that their importance is for preparing the 
endometrium for embryo implantation. Decidual dendritic cells have been proposed to 
induce tolerance under normal physiological conditions acting as ‘gatekeepers’ of 
uterine immune environment (Blois et al., 2004). 
Limited investigation of pathological pregnancies suggests that the function of these 
cells is in immunomodulatory control during pregnancy. Huang et al. (2008) reported 
infiltration of both CD83+ mature and CD209+ immature dendritic cells in decidua from 
women suffering pre-eclampsia suggesting that they may play a role in the 
pathogenesis of the disease; whether this is cause or effect is unclear.           
1.4.5 Decidual stromal cells 
Decidual stromal cells (DSCs) are the major component of the human decidua (Bulmer 
et al., 1995). Endometrial stromal cells are mainly comprised of fibroblast cells which 
are believed to originate from mesenchymal cells. Decidualisation of the endometrial 
stromal fibroblast cells is triggered by progesterone (Brosens et al., 2002, Gellersen 
and Brosens, 2003) and decidual stromal cells are considered to have a nutritional and 
endocrine function during pregnancy (Riddick and Kusmik, 1977). However, increasing 
evidence has demonstrated that decidual stromal cells orchestrate leucocyte 
differentiation, trafficking and recruitment into the endometrium during early 
pregnancy (Robertson et al., 2002). Hess et al. (2007) have also demonstrated that 
since EVT invade through the decidua, DSC are in close proximity to trophoblast cells in 
vivo, and these cells respond to trophoblast secreted products in vitro, enriching the 
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implantation site with cytokines and chemokines. DSCs can be identified within the 
decidua by their expression of CD10 and CD13 (Garcia-Pacheco et al., 2001).  
The relevance of decidual stromal cells in pregnancy is that they exert immune 
functions and assist the immunomodulation of decidual factors ensuring a healthy 
environment for the developing fetus and these cells also produce a wide array of 
cytokines that may regulate EVT invasion and spiral artery remodelling. 
1.4.6 Decidual epithelial cells 
The human endometrium consists of glandular and surface epithelial cells. As well as 
the endometrial stroma, the glandular epithelium undergoes proliferation, 
differentiation and shedding throughout the menstrual cycle (Tabibzadeh, 1991). 
However, the functional role of glands post implantation has been sparsely studied. 
There is increasing evidence that endometrial epithelial cells are important functional 
cells during the first trimester of pregnancy. Uterine glandular epithelial cells are 
present and highly active at 6 weeks of pregnancy, secreting carbohydrates, sugars and 
lipids providing a source of essential nutrients at the maternal fetal interface to drive 
the many processes (Hempstock et al., 2004). A variety of growth factors and cytokines 
have also been identified in glandular secretions including VEGF, LIF and epidermal 
growth factor (EGF) receptors for which are expressed by villous and extravillous 
trophoblast cells (Burton et al., 2007), suggesting that these secretory factors 
produced by decidual glands play roles in placental morphogenesis, trophoblast 
invasion and modulate immune responses at the maternal-fetal interface during the 
first trimester of pregnancy.  
1.5 Interleukin-6 
1.5.1 The role of IL-6 
IL-6 is a small pleiotrophic cytokine which is an important mediator in acute-phase 
responses to injury and infection. IL-6 is part of the IL-6 family of cytokines which also 
includes LIF, IL-11, oncostatin M (OSM), ciliary neutrophic factor and cardiotrophin-1, 
all sharing the gp130 receptor subunit and involved in activation of target genes 
involved in cellular differentiation, proliferation, apoptosis and cell survival. This 
common signalling element results in overlapping functions of between these proteins.  
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IL-6 has pro and anti-inflammatory properties resulting in a wide array of functions 
besides host defence; IL-6 also has important roles in haematopoiesis, lipid 
metabolism and embryonic development. IL-6 is involved in the pathophysiology of 
many processes resulting in osteoporosis, rheumatoid arthritis and contributes to 
oncogenesis in many cancers. IL-6 has been reported to be expressed in a variety of 
malignant tumours (Kanazawa et al., 2007) and has been reported to increase the 
invasive potential of head and neck squamous cell carcinomas in vitro (Nishino et al., 
1998) as well as reports of inducing morphological changes in a pleomorphic malignant 
fibrous histiocytoma cell line (Nakanishi et al., 2004). Walter et al. (2009) recently 
demonstrated that IL-6 secretion from adipose stromal cells in the breast promotes 
the migration and invasion breast tumour cells in vitro. 
IL-6 is secreted by a range of cell types such as monocytes, lymphocytes and 
fibroblasts. 
1.5.2 IL-6 cell signalling 
1.5.2.1 IL-6 receptors 
IL-6 achieves its biological effects by binding to plasma membrane receptor complexes 
consisting of an 80kDa protein IL-6Rα (gp80; CD126) and the common 130kDa signal 
transducing receptor protein gp130 (CD130).   
Gp130 is ubiquitously expressed on a wide assortment of cells in the body, whereas 
distribution of membrane IL-6Rα is limited and is only expressed on a relatively small 
number of cell types such as hepatocytes, neutrophils and monocytes, indicating that 
the physiological effects of IL-6 may depend on the soluble form of the receptor sIL-
6Rα, therefore allowing IL-6 to elicit its effects on a wide variety of cells. In vivo 
experiments have revealed sIL-6Rα is generated either by proteolysis of the membrane 
form of the receptor or as a result of alternatively spliced mRNA (Knupfer and Preiss, 
2008). This soluble receptor - cytokine complex acts agonistically rather than 
antagonistically (Ancey et al., 2003) which is in constrast with most cytokine/soluble 
receptor systems where cytokine binding to the plasma membrane is prevented having 
an antagonistic effect. The soluble form of IL-6Rα is a 50-55k Da binding protein that 
binds IL-6 ligands with similar affinity to the membrane bound recpetor. Once IL-6 is 
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bound to sIL-6Rα, the protein-receptor complex is recognised by and associates with a 
homerdimeric transmembrane gp130 receptor which then initiates an intracellular 
response through activation of tyrosine kinases on the cytoplasmic tail of the receptor 
(Murakami et al., 1993). Some people view this complex of IL-6 and soluble IL-Rα as a 
cytokine complex rather than a receptor complex. This allows cells such as embryonic 
stem cells, neural cells, smooth muscle cells and endothelial cells which express gp130 
but lack transmembrane IL-6R to respond to IL-6, widening the repertoire of cell types 
that are responsive to this cytokine giving IL-6 the potential to have a spectrum of 
functions such as pro and anti inflammatory activites and aberrant activity in disease 
states.  
1.5.2.2 STAT3, SOCS, MAPKs 
It has been established that most cytokines mediate their effects through two main 
signal transducing pathways; the signal tranducers and activators of transcription 
(STAT) pathway and the mitogen activated protein kinase (MAPK) pathway (Fitzgerald 
et al., 2005). Extensive studies have highlighted a pivotal role of STATs in IL-6 cytokine 
signalling, IL-6 type cytokines including IL-6 utilising the STAT pathway to mediate their 
effects (Fitzgerald et al., 2008). The STAT family is comprised of seven transcript 
variants; STAT1, 2, 3, 4, 5a, 5b and STAT6 and transient association with cytokine 
receptors causes their activation. STAT1 and STAT3 are potently activated by the 
gp130 receptor complexes of all the IL-6 type cytokines (Heinrich et al., 1998). IL-6 
initiates its effects by binding to its receptor system on target cells which causes the 
gp130 receptors to aggregate. Dimerisation of gp130 leads to the juxtaposition of the 
Janus kinases (Jaks) (Fitzgerald et al., 2005), allowing the Jaks to cross-phosporylate 
one another leading to the phosphorylation of docking sites of the SH2 tyrosine 
phosphatase domain and STATs (Kang and Kang, 2008). The STATs then dissociate from 
the ligand where they form homo and heterodimers with other phosphorylated STATs. 
Activated STATs then translocate into the nucleus where they specifically bind to 
promoter regions of the DNA and upregulate the transcription of several genes which 
are involved in proliferation and cell differentiation (Corvinus et al., 2003, Fitzgerald et 
al., 2005) (Figure 1.10). This includes the upregulation of suppressors of cytokine 
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signalling (SOCS) which in an inhibitory feedback system stalls the transduction of the 
signal (Heinrich et al., 2003, Fitzgerald et al., 2005) (Figure 1.10).  
A high degree of STAT3 activity is associated with malignancy of cells and can be 
activated through IL-6 ligand binding (Corvinus et al., 2003). The phosphorylation of 
STAT3 induced by IL-6 binding also leads to the activation of genes involved in chronic 
inflammation associated with arthiritis (Kishimoto, 2006). STAT3 deficient mice have 
demonstrated embryonic lethality: the embryos successfully implant but rapidly die 
due to placental defects (Takeda et al., 1997). STAT3 splice variants (STAT3α and β) 
have been observed in first trimester trophoblast cells with expression lost at term 
(Corvinus et al., 2003). This adds to the proposition for a role for STAT3, via cytokine 
signalling, in trophoblast invasiveness.  
 
 
Figure 1.10 Representative diagram of IL-6 cell signalling pathways 
Representation of the different pathways by which IL-6 can signal and stimulate differing 
cellular cascades. Activation of the Jak-STAT pathway by cytokine (IL-6) binding to its receptor 
(IL-6Rα and gp130). Cytokine-induced receptor aggregation leads to Janus kinase (Jak) 
phosphorylation and activation. Tyrosine residues within the cytoplasmic tail of the cytokine 
receptor are subsequently phosphorylated by the Jaks, providing docking sites for SH2 domain-
containing signalling proteins including STATs. Tyrosine-phosphorylated STATs translocate to 
the nucleus where they bind to promoter regions of their respective target genes, including 
genes involved in acute phase protein synthesis, cell growth, cell differentiation and 
proliferation and the up-regulation of SOCS, creating a feedback regulatory system to dampen 
down the cytokine response. Adapted from (Heinrich et al., 2003). 
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Dimerisation of IL-6 gp130 complex also induces the MAPK cascade. MAPKs also play 
an important part in cellular migration and invasion (Pollheimer and Knofler, 2005). 
The activation of MAPKs includes activation of extracellular-regulated kinases (ERKs). 
The phosphorylation of ERK 1 and ERK 2 have been shown to increase cell growth and 
migration of the human trophoblast cell line, HTR-8/SVneo (Pollheimer and Knofler, 
2005). In accordance with this, stimulated (phosphorylated) ERK 1 and ERK 2 have 
been detected in EVT of human placentae but only up to 12 weeks gestation (Kita et 
al., 2003), suggesting that ERK signalling plays a crucial role during early pregnancy.   
1.5.3 IL-6 in pregnancy 
IL-6 is present in human endometrium throughout the menstrual cycle as well as in 
early pregnancy decidua. IL-6 is secreted by various cell types during pregnancy, but 
production by specific decidual cells remain to be investigated. Aforementioned 
previously there appears to be a delicate balance between a Th1 and a Th2 immune 
response during the implantation window up to placental vascularisation (Chaouat et 
al., 2002, Chaouat et al., 2003, Chaouat et al., 2004). It has also been reported that EVT 
cells express IL-6, and it has been suggested this cytokine can influence trophoblast 
invasion by up-regulating MMPs (Salamonsen et al., 2007). Recent studies have 
localised IL-6 protein and IL-6 mRNA within mid-secretory phase endometrium, along 
with immunohistochemical evidence of IL-6 receptors (Tabibzadeh et al., 1995). 
Jauniaux et al. (1996) have demonstrated IL-6 expression in both syncytiotrophoblast 
and EVT from explanted placental villi and in various other cell types within decidual 
tissue using immunohistochemistry. Meisser et al. (1999) found that IL-6 induced 
trophoblast MMP-2 and MMP-9 activation, which are important mediators in 
trophoblast invasion, but IL-6 did not induce MMP synthesis. In addition, IL-6 deficient 
mice have shown a 48% reduction in implantation sites which has been linked to 
decreased fertility (Robertson, 2000) and IL-6 deficient mice displayed an increased 
rate of mid-gestation miscarriage, although the mice were still fertile (Kopf et al., 
1994). The overall evidence from these studies therefore, suggests a role for IL-6 in 
successful early pregnancy, potentially being involved in regulating trophoblast 
invasion.  
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It has been suggested that IL-6 may contribute to trophoblast growth and placental 
development by stimulation of trophoblast derived human chorionic gonadotrophin 
(hCG) (Nishino et al., 1990), which is essential for the maintenance of pregnancy. Both 
endogenous IL-6 and exogenous IL-6 have been reported to increase migration and the 
invasive potential of the EVT cell line HTR-8/SVneo due to the up-regulation of the 
trophoblast integrin receptors α1, α5 and β5 (Jovanovic and Vicovac, 2009), receptors 
which bind to components within the extracellular matrix. Arimoto-Ishida et al. (2009) 
have demonstrated that up-regulation of α5-integrin under hypoxic conditions 
increased the invasiveness and migration of placental villous explants cells and BeWo 
cells (trophoblast-derived cell line). However, these are cell line data and may vary 
from isolated primary cells which have yet to be studied. Despite extensive 
documentation of the presence of IL-6 in implantation, little is known about the effects 
of this cytokine and how it mediates signalling in the trophoblast. Various reports exist 
on specific cell lines but the overall picture of IL-6 production and function in 
uteroplacental tissues is still unclear. 
The effect of decidual IL-6 on uterine vascular remodelling has not been investigated. 
However, in different tissues IL-6 has been shown to be a potent pro-angiogenic 
cytokine during tumour progression and promotes vasculogenesis in murine brain 
development (Fee et al., 2000). Yao et al. (2007) have demonstrated the effect of IL-6 
on the stimulation of human cerebral smooth muscle and endothelial cell proliferation 
and migration and Fan et al. (2008) have provided more recent evidence that cellular 
signalling cascades from blood derived endothelial cells are activated by IL-6 in vitro 
resulting in proliferation, migration and matrigel tubule formation.   
1.5.3.1 IL-6 in pathological pregnancies 
Although IL-6 has been widely associated with studies involving the progression of 
malignant tumours and is known to have an effect on the invasiveness of neoplastic 
cells, there is limited information on its role in normal pregnancy. Elevated levels of 
plasma IL-6 have been detected in women suffering from pre-eclampsia (Greer et al., 
1994, Vince et al., 1995, Madazli et al., 2003, Freeman et al., 2004) and decidual cells 
have been suggested to account for increasing plasma levels of IL-6 (Lockwood et al., 
2008). In addition, a recent study has demonstrated an increase in serum IL-6 levels in 
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women with symptoms of threatened pre-term delivery (Sorokin et al., 2010) 
indicating that the cause may be due to an immunological effect. 
 
1.6 Interleukin-8 
1.6.1 Role of IL-8 
Interleukin-8 (IL-8) is classified as a pro-inflammatory multifunctional CXC chemokine, 
alternatively known as CXCL8. Chemokines are a large superfamily of structurally and 
functionally related cytokines with chemotactic activity targeted at leucocytes. The IL-8 
gene encodes a 99 amino acid protein with a 77-72aa signalling component and 
expression of this gene is primarily regulated by nuclear factor (NF)-κB. However, a 
number of stimuli, including inflammatory signals (TNF-α and IL-1β) and a variety of 
steroid hormones, also up regulate expression of IL-8 (Brat et al., 2005). IL-8 is best 
characterised as a neutrophil chemoattractant at sites of inflammation and has the 
ability to cause de-granulation of neutrophils and invasion of tissues (Matsushima et 
al., 1988). In contrast to inflamed tissues, the level of IL-8 is relatively low in normal 
tissues. IL-8 also plays a chemotactic role for neoplastic cells. Chemotaxis occurs along 
a chemokine concentration gradient and changes in the morphology of leucocytes can 
be observed following chemokine binding (Dimitriadis et al., 2005). The biological 
activity of chemokines can be enhanced by MMPs, many of which are secreted by 
leucocytes following chemokine binding resulting in a positive feedback mechanism 
and thereby up-regulating the action of chemokines themselves.  
1.6.2 IL-8 cell signalling 
1.6.2.1 CXCR1 and CXCR2 
The biological effects of IL-8 are mediated through the binding of two membrane 
bound G protein-coupled receptors, CXCR1 and CXCR2 (Holmes et al., 1991). These 
receptors are around 40KDa in size and share structural similarities but mediate 
different functional responses (Holmes et al., 1991, Rosenkilde and Schwartz, 2004). 
The structural similarity between the two receptors suggests that they arose from 
genetic duplication. Ligand binding to the receptors elicits a ligand induced 
conformational change resulting in coupling of the heterotrimeric G proteins (Gαβγ) 
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with the carboxy terminus of the 7 transmembrane receptor, which in turn activates 
the Gα subunit to dissociate from the Gβγ subunit. The signal is transduced mainly 
through Gαi which causes the rapid mobilisation of intracellular calcium inducing the 
chemotactic response and there is evidence that released βγ activates PI3Kγ pathways, 
inducing cellular migration (Arai et al., 1997, Neptune and Bourne, 1997). Depending 
on the Gα isoforms, the alpha subunit can mediate intracellular signalling indirectly by 
acting on effector molecules (Figure 1.11) or directly by regulating ion channel or 
kinase function (Figure 1.11). Because of the promiscuity of G-protein coupled 
receptors (GPCRs), activation of CXCR1 and CXCR2 induces diverse signalling pathways 
(Figure 1.11) resulting in a wide range of functions. Both CXCR1 and CXCR2 bind IL-8 
with high affinity, but CXCR1 is only activated in response to binding with IL-8 and 
granulocyte chemotactic protein-2(GCP-2), whereas great promiscuity is found with 
CXCR2, which can be activated by a variety of CXC chemokines (Brat et al., 2005), 
increasing the redundancy of this receptor. CXCR1 and CXCR2 expression has been 
characterised on many cell types other than leucocytes including neurons, epithelial 
cells, endothelial cells, smooth muscle cells and stromal cells indicating that receptor 
activation by IL-8 binding is not solely responsible for leucocyte trafficking but has 
different functions including degranulation, angiogenesis, gene transcription and 
apoptosis (Thelen, 2001). IL-8 signalling stimulates the phosphorylation of Akt kinase 
(Figure 1.11) which is an important kinase with established roles in the modulation of 
cell migration and angiogenesis. The angiogenic effects of IL-8 are mediated primarily 
through CXCR2 binding; this is evident from human herpes virus-8 (HHV8) which 
expresses a mutated form of CXCR2 with absent CXCR1, resulting in highly vascularised 
tumours in the host (Rosenkilde et al., 1999).   
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Figure 1.11 Representative diagram of IL-8 cell signalling pathways 
Diagram showing the range of characterised IL-8 cell signalling pathways. Solid lines represent 
positive regulation by IL-8; dashed lines represent acknowledged pathways through which IL-8 
mediates transcription factors. IL-8 signalling also activates Src and FAK which are non receptor 
tyrosine kinases (Waugh and Wilson, 2008). 
1.6.2.2 Aminopeptidase N 
The biological function of IL-8 is mediated through transmembrane G-protein coupled 
receptors that transmit a signal resulting in a cellular response (outlined in section 
1.6.2.1).  
Aminopeptidase N, alternatively known as CD13 is a Zn2+ dependent ectopeptidase 
membrane glycoprotein with a molecular weight of 150kDa (Hooper, 1994). It is a 
ubiquitously expressed broad functional protease that hydrolyses small peptides and 
preferentially cleaves neutral amino acids, removing N-terminus amino acids from 
their substrates. Ectoenzymes including aminopeptidase N have been recognised as 
moonlighting proteins due to their multifunctional capabilities (Jeffery, 2003). It has 
been proposed that an additional functional role of CD13 as well as its enzymatic 
activity is signal transduction in monocytes (Santos et al., 2000); CD13 does not contain 
a signalling motif due to its short cytoplasmic tail, but it is believed to associate with an 
auxiliary molecule giving the protein signalling capacity. Reports have demonstrated 
that cross-linking of CD13 in monocytes mediates the migration and aggregation of 
monocytes (Mina-Osorio et al., 2006) and induces the MAPK pathway leading to the 
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influx of calcium effecting cytokine secretion and cellular adhesion; one such 
chemokine is IL-8 (Santos et al., 2000), further suggesting involvement of mechanisms 
other than  enzyme activity. CD13 has been linked with the inactivation of IL-8 by 
degradation (Kanayama et al., 1995), along with degradation of CXCL11 (Proost et al., 
2007) and causes down regulation of CXCR4 and inhibition of CXCL12 mediated 
migration in embryonic kidney cells (Wulfaenger et al., 2008) suggesting a regulatory 
role in inflammation, cell proliferation and invasion.  
CD13 is expressed on the surface of many different cell types including macrophages, 
granulocytes, endothelial cells, synaptic membranes of the CNS, epithelial cells in 
kidney and intestines as well as a number of tumours (Look et al., 1989). CD13 has also 
been identified on placental villi, endometrial stromal cells and decidual stromal cells 
during the first trimester of pregnancy (Imai et al., 1992, Seli et al., 2001) and 
expression may be regulated by oestrogen (Seli et al., 2001), suggesting that CD13 may 
play an important role in the modulation of peptide metabolism to aid successful 
implantation and maintenance of pregnancy.  
CD13 along with the other IL-8 receptors has not yet been studied in early pregnancy 
and the physiological roles of these enzymes and signalling components remains to be 
clarified. However, research to date suggests that these receptors may control the 
bioavailabilty of IL-8 and thereby contribute to the regulation of angiogenesis and 
leucocyte migration in pregnancy. Individual chemokine processing is complex due to 
redundancy of receptor binding and studies on IL-8 have mainly focused in 
endometriosis, chorioamnionitis, cervical ripening and parturition.   
1.6.3 IL-8 in inflammation and angiogenesis 
The chemokine system provides regulation and control of homeostatic leucocyte 
movement and inflammation. By their regulation of leucocyte activation, trafficking 
and differentiation, chemokines including IL-8 play a central role in immune defence. 
In addition IL-8 plays a role in other cellular functions (Section 1.5.2.1) including 
angiogenesis. Angiogenesis is described as the neo-formation of blood vessels and is 
essential for embryonic development, wound healing, inflammation and tumour 
growth. In 1992 IL-8 was the first angiogenic chemokine to be discovered (Koch et al., 
1992) and there is increasing evidence of the potency of IL-8 angiogenic properties; IL-
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8 signalling has been associated with the regulation of endothelial permeability by 
stimulating the phosphorylation of VEGFR-2 in endothelial cells by interaction with 
both CXCR1 and CXCR2 receptors (Petreaca et al., 2007). More recently it has been 
reported that IL-8 up regulates VEGF mRNA and protein levels in vascular endothelial 
cells by association of IL-8 with CXCR2; this further stimulates VEGFR-2 in an autocrine 
manner (Martin et al., 2009) inducing cellular proliferation, survival and migration of 
vascular endothelial cells. These reports highlight the potential importance of IL-8 in 
angiogenesis and raise the possibility of a role for IL-8 for the remodelling events in the 
uterine vasculature in normal pregnancy. In pathophysiology IL-8 is also important for 
tumour formation and growth, and many in vitro studies with cancer cell lines and in 
vivo studies with solid cancers have demonstrated that expression of IL-8 corresponds 
to the angiogenic and tumourgenic potential and hence the progression of cancers 
(Waugh and Wilson, 2008). To coincide with this hypothesis, there is evidence that IL-8 
secretion is associated with glioma formation and malignant progression through the 
establishment of new blood vessels (Brat et al., 2005). Therefore, although the focus of 
investigating IL-8 has focused on its role in inflammation and chemotaxis, it is possible 
that the angiogenic effect of IL-8 is crucial in normal pregnancy.  
1.6.4 IL-8 in pregnancy 
The human endometrium is rich in a wide range of chemokines, including IL-8 which 
potentially regulates endometrial angiogenesis and leucocyte trafficking. 
Immunohistochemical studies have demonstrated expression of IL-8 on glandular 
epithelium during the menstrual cycle (Arici et al., 1993). With regard to early 
pregnancy, the recruitment and activation of macrophages and uNK cells are tightly 
regulated at implantation and this is likely to be achieved by the action of chemokines 
(Dimitriadis et al., 2005), although there is no direct evidence for IL-8 involvement. 
Uterine natural killer cells are themselves a major producer of IL-8 (Saito et al., 1994, 
De Oliveira et al., 2010). There are reports describing expression of IL-8 in the 
pregnany endometrium and IL-8 is likely to be involved in leucocyte trafficking to the 
spiral arteries during the first trimester of pregnancy (Hornung et al., 1997, Jones et al., 
2004). IL-8 has been shown to be produced by cells of the placenta, including 
trophoblast, placental macrophages and fibroblasts, and it has been suggested that IL-
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8 mediates the recruitment and accumulation of neutrophils at the maternal-fetal 
interface as a defence mechanism against invading bacteria (Shimoya et al., 1999). 
Although both IL-8 mRNA and protein have been identified in human gestational 
tissues and placenta little is known about its secretion and function in first trimester 
pregnancy, an area requiring exploration. We do know, however, that IL-8 contributes 
to uNK cell stimulation of trophoblast invasion (Hanna et al., 2006, De Oliveira et al., 
2010). 
1.6.4.1 IL-8 and pathological pregnancy  
As mentioned in previous sections IL-8 plays an important part in inflammation, cell 
migration and tumourgenesis by the establishment of new blood vessels but the 
exploration of IL-8 involvement in spiral artery remodelling and trophoblast invasion 
has been sparsely studied and altered levels of uterine IL-8 may contribute to impaired 
remodelling and EVT invasion which are processes associated with preeclampsia and 
IUGR.  
Several studies have associated IL-8 with preeclampsia; significantly elevated levels of 
plasma IL-8 have been observed in preeclamptic subjects compared with healthy 
pregnant and non pregnant subjects (Sharma et al., 2007), indicating that 
inflammation and endothelial dysfunction associated with IL-8 may contribute to the 
pathogenesis of preeclampsia. However, in vitro studies have demonstrated little 
alteration in endothelial gene expression in HUVECS after treatment with plasma from 
preeclamptic patients with only mild induction of IL-8 (Donker et al., 2005), suggesting 
that other factors are involved in endothelial dysfunction in preeclampsia. However, 
levels of IL-8 may be an effect of these alterations and not a cause.  
1.7 Miscarriage 
1.7.1 Prevalence of sporadic miscarriage 
Miscarriage is the commonest gynaecological emergency (70000-90000 per year in 
England and Wales) (Everett, 1997)and has huge financial and personal implications. 
The vast majority of miscarriages occur in healthy women during the first trimester of 
pregnancy. Between 11 and 20% of all clinically recognised pregnancies are lost before 
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the 20th week of gestation. Most miscarriages are sporadic, that is they are non-
recurring.  
Approximately 50% of miscarriages are associated with chromosomal abnormalities 
(aneuploidy) (Jauniaux and Hustin, 1992). However, the cause in the remaining 50% is 
unknown and the mechanisms involved in sporadic first trimester miscarriages are 
poorly understood (Hustin et al., 1996).  
Approximately 70% of early miscarriages have been associated with premature and 
continuous intervillous blood flow, evidence arising from flow patterns using gray scale 
Doppler. This was linked to oxidative stress in villous trophoblast, an effect of a thin 
and disrupted trophoblast shell (Jauniaux et al., 1994, Jauniaux et al., 2000). There is 
also evidence suggesting that deficient trophoblast invasion may be linked with first 
trimester miscarriage; using a morphological method (Hustin et al., 1990) 
demonstrated reduced trophoblast invasion in early aneuploid miscarriages. It was this 
observation that led to the suggestion that trophoblast invasion and spiral artery 
remodelling are primarily reduced in miscarriage, although reports are inconsistent.  
Ball et al. (2006b) assessed trophoblast subpopulations and spiral artery 
transformation in placental bed biopsies from sporadic miscarriage cases (n=73) 
compared with controls (n=179), using an immunohistochemical approach. In contrast 
to Hustin et al. (1990) there was no evidence of failure of trophoblast invasion and 
abnormal spiral artery remodelling in the decidua or myometrium in early (≤12+6 
weeks gestational age) miscarriage, suggesting that these processes do not have a 
pivotal role in the pathogenesis of early miscarriage. The varying results between the 
different studies may be due to the tissue sampled; the abnormalities in early 
miscarriages were detected in studies generally using aspirated gestational sacs which 
include cytotrophoblast cell columns and the cytotrophoblast shell (Hustin et al., 
1990); whereas, placental bed biopsies extend deeper into the uterine wall (Ball et al., 
2006b). However, reduced trophoblast invasion and spiral artery remodelling in late 
(≥13 weeks gestational age) miscarriage was observed (Ball et al., 2006a).        
Increased production of Th1 type cytokines by peripheral blood monocytes, such as 
IFN-γ and TNF-α have been implicated in sporadic miscarriage (Zenclussen et al., 2001), 
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suggesting that an imbalance of the Th1:Th2 ratio may be detrimental to pregnancy. 
Although a later study involving mice, reported a reduction in IL-12 from decidual 
monocytes in SM compared with healthy pregnancy controls (Zenclussen et al., 2002), 
contradicting the Th1 hypothesis as a cause of SM.   
1.7.2 IL-8 and IL-6 in sporadic miscarriage 
There have been very few reports of IL-8 and IL-6 in miscarriage and results have been 
variable. Madhappan et al. (2003) reported significantly higher IL-8 levels in products 
of conception from women with two or more miscarriages (n=7) compared with 
women with normal pregnancy (n=4) or first miscarriage (n=12). Increased IL-8 levels in 
uterine cervical samples have also been associated with women suffering first 
trimester miscarriage compared with controls (Radulovic et al., 2010).  
Jasper et al. (2007) reported reduced endometrial IL-6 mRNA expression in 
endometrial biopsies collected during the mid-secretory phase of the menstrual cycle 
from a group of women experiencing unexplained recurrent miscarriage (n=9) 
compared to women classified with proven fertility (n=12). In contrast, studies in 
mouse have demonstrated that increased levels of IL-6 at the maternal-fetal interface 
were associated with fetal loss (Zenclussen et al., 2003) and more recent data has 
demonstrated increased levels of serum IL-6 and IL-8 with women with second 
trimester abortion compared with levels from first trimester abortion (Galazios et al., 
2011).  
If IL-8 and IL-6 play a role in spiral artery remodelling, increased levels of IL-8 and IL-6 
and loss of normal regulation of these cytokines in early normal pregnancy could lead 
to excessive and inappropriately early spiral artery remodelling, also leading to 
premature movement of the endovascular EVT plugs that sit in the mouths of the 
spiral arteries, hence resulting in premature blood flow into the intervillous space and 
oxidative stress to villous trophoblast. However, these cytokines may also affect the 
invasive potential of EVT and development of the placenta. Observations using 
immunohistochemistry and confocal laser microscopy show a significant increase in 
the translocation of NF-κB in chorionic villi and decidual tissues, with greater 
expression by decidual stromal cells, glandular epithelial cells and vessel endothelial 
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cells from women suffering sporadic miscarriage compared with viable pregnancies 
(Wang et al., 2010). These data suggest that an increase in pro-inflammatory cytokines 
such as IL-8 and IL-6, could possibly lead to the demise of pregnancy suggesting that 
the balance of cytokines relies on stringent regulation for pregnancy success. 
Therefore, IL-6 and IL-8 may play important roles in early pregnancy by establishing the 
necessary changes in the uterus. The few studies that are reported suggest that IL-6 
and IL-8 may be altered in miscarriage but the receptor and signalling status of these 
cytokines have not been previously investigated in miscarriage.  
Due to the pleiotrophy of IL-6 and its prevalent effect on invasion and growth of 
tumours and cancers decribed in section 1.5.1, its effect on the growth of 
hematopoietic precursor cells and its capability of inducing inflammation by 
upregulating acute phase reaction proteins and reducing inflammation by inhibiting 
neutrophil activation, along with receptor expression in glands of the endometrium 
and with altered levels in pregnancy pathology has led to the investigation of this 
cytokine in this study. Similarly the pro-angiogenic effects of IL-8 (described in section 
1.6.3) and altered levels in miscarriage suggest that this cytokine could potentially play 
a role in early pregnancy processes and therefore has also been investigated in this 
study.    
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1.8 Hypotheses and aims 
1.8.1 Hypotheses 
The hypotheses to be tested were:- 
1) IL-6, IL-8 and their receptors are expressed by cells in the placental bed in the 
first half of human pregnancy. 
2) IL-6 stimulates EVT cell invasion in the first half of pregnancy. 
3) Maternal leucocytes in decidualised human endometrium migrate towards and 
invade the VSMC wall of spiral arteries. 
4) Maternal leucocytes release pro angiogenic growth factors which affect the 
integrity of vessel contributing to spiral artery remodelling at both 8-10 and 12-
14 weeks gestation. 
5) IL-6 and IL-8 have a crucial role in the control of spiral artery remodelling by 
disrputing the VSMC wall. 
6) Decidual IL-6 and IL-8 levels are increased in sporadic miscarriage and 
dysregulation of their expression contributes to the pathophysiology of early 
sporadic miscarriage.    
1.8.2 Aims  
IL-6 and IL-8 may play a role in regulating the fundamental processes involved in the 
first half of pregnancy to ensure a successful outcome; therefore altered expression 
could be related to pregnancy complications, including early sporadic miscarriage. The 
aim of this study is to assess the roles of IL-6 and IL-8 in the first half of normal human 
pregnancy. This will clarify the specific role of these cytokines during pregnancy and 
improve understanding of how they affect the early processes both in normal and 
miscarried specimens. Subsequent to this an insight into the causes of sporadic 
miscarriage may become apparent and enhance our understanding of the 
pathogenesis, which in turn may lead to targeted therapies.  
Specific aims:     
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1. To confirm the production and localisation of IL-6 and IL-8 and their receptors 
in normal pregnant decidua from 8-20 weeks gestation in vivo using 
immunohistochemistry. 
2. To determine expression levels of these cytokines in decidual cell populations 
in vitro including uNK cells, macrophages, T cells, and decidual stromal cells. 
3. To determine the effect of IL-6 on EVT invasion in vitro using primary cell 
isolates/ placental explants and an EVT- like cell line. 
4. To explore the effects of IL-6 in EVT cell signalling pathways as a mechanism for 
biological activity. 
5. To determine the effects of IL-6 and IL-8 on vascular smooth muscle cells by 
immunohistochemistry and by using a chorionic plate artery vessel model. 
6. To confirm and compare the expression and localisation of IL-6, IL-8 and their 
receptors in samples obtained from karyotyped miscarriages up to 20 weeks 
gestation. 
 
 
Chapter 2 
Materials and Methods 
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2 Materials and Methods 
2.1 Tissues 
All tissue specimens were obtained from surgical procedure, the nursing staff would 
then inform the laboratory for the samples to be collected fresh from theatre following 
extraction. Following surgical removal, tissue specimens were transferred to the 
laboratory all within a maximum of ten minutes and were immediately prepared for 
cell isolation, tissue preservation or experimental assays outlined in this chapter. 
2.1.1 Normal early human pregnancy decidua  
Normal pregnancy decidua was obtained from women undergoing elective surgical 
termination of pregnancy (TOP) at the Royal Victory Infirmary, Newcastle upon Tyne. 
Gestational age (GA) was determined by ultrasound measurement of fetal crown rump 
length (CRL) or biparietal diameter immediately prior to the procedure; specimens 
were taken at 7-14 weeks gestation. Following surgery aspirated tissue was collected 
into a sterile container and transported to the laboratory where under sterile 
conditions, within a class II laminar flow cabinet (Envair, Rossendale, UK) decidual 
tissue was identified macroscopically by its thick ‘pink like’ appearance and separated 
from the remaining products of conception. Decidual tissue was then washed several 
times in sterile phosphate buffered saline (pH7.4) (PBS; see Appendix) to remove 
excess blood and roughly chopped into 1-2 mm3 pieces using two sterile scalpel blades. 
Chopped tissue was transferred into a sterile universal tube for cell 
fractionation/isolation (section 2.3) 
2.1.2 Normal early pregnancy placenta 
Normal pregnancy placenta was obtained from women (7-14 weeks GA) following 
surgical TOP (section 2.1.1). Placental tissue was identified by its branching villous 
appearance and separated from the aspirated products. The tissue was washed in 
sterile PBS several times to remove excess blood. Terminal chorionic villous tips 
(0.5mm3) of the placenta were dissected using a sterile scalpel blade and suspended in 
either 20ml Hanks balanced salt solution for EVT isolation and culture (section 2.4.5) or 
10ml sterile PBS for placental explant culture (section 2.4.6).   
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2.1.3 Placental bed biopsies 
Placental bed biopsies (6-20 weeks GA) were taken transcervically under ultrasound 
guidance in women undergoing surgical TOP (section 2.1.1) as described previously 
(Robson et al., 2002). Biopsies were immediately transferred into a sterile container 
following surgical removal and transported to the laboratory where biopsies were 
either immediately snap frozen (section 2.1.8.1) or fixed in 10% neutral buffered 
formalin (section 2.1.8.2) for immunohistochemistry.  
2.1.4 Sporadic miscarriage decidua 
Decidua from sporadic miscarriage (6-20 weeks GA; calculated from last menstrual 
period (LMP)) was obtained from women admitted to the Royal Victory Infirmary, 
Newcastle upon Tyne, for evacuation of retained products of conception (ERPC). 
Diagnosis of ‘missed abortion’ was made on the basis of an identifiable fetal pole and 
the absence of fetal heart motion in all cases.  
Patients who had suffered a miscarriage were divided into two different age 
categories: ‘early’ (≤12+6 weeks gestation) and ‘late’ (≥ 13 weeks gestational age). 
Decidual tissue was subjected to enzymatic disaggregation (section 2.3.1) and CD56+ 
and CD14+ cells were isolated using MidiMACS (section 2.3.2 and 2.3.4), cultured for 24 
hours after which cell supernatants were collected (section 2.3.2.2) and stored at -80°C 
until required.  
2.1.5 Sporadic miscarriage placental bed biopsies 
Placental bed biopsies were obtained from women undergoing ERPC (section 2.1.5) 
using the same technique as in section 2.1.3. Samples from patients who had suffered 
a miscarriage were divided into two different age categories: ‘early’ (≤12+6 weeks 
gestation) and ‘late’ (≥ 13 weeks of gestation). Biopsies were either immediately snap 
frozen (section 2.1.8.1) for immunohistochemical analysis. These samples were 
collected as part of a previous morphological and immunohistochemical study of the 
placental bed in miscarriage (Ball et al., 2006a, Ball et al., 2006b).  
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2.1.6 Term placenta from Caesarean section 
Term placenta (37-42weeks gestation) was collected from women undergoing elective 
Caesarean section at the Royal Victoria Infirmary, Newcastle upon Tyne. Following 
Caesarean section the placenta was transported to the laboratory and in a sterile class 
II laminutear flow cabinet (Envair, UK) was used for dissection of chorionic plate 
arteries (CpA). 
2.1.6.1 Dissection of chorionic plate arteries (CpA) 
Chorionic plate artery vessels were identified macroscopically by their white, thick, 
overlapping appearance on the fetal side of the term placenta. They were carefully 
removed from the placenta using forceps and scissors and immediately placed into a 
petri dish containing ice cold sterile PBS (pH 7.4). Connective tissue and blood were 
removed using a sterile scalpel blade and the arteries were chopped into 3mm intact 
rings and placed in sterile PBS until required.  
2.1.7 Ethical approval and informed consent 
Each patient agreeing to donate their tissue for research gave informed written 
consent. Consent was obtained by a team of Research Nurses. Collection of fresh 
samples was approved by the County Durham and Tees Valley Research ethics 
Committee. Collection of archival miscarriage samples was approved by the Joint 
Committee of Newcastle and Tyneside Health Authority and Newcastle University; 
these samples were incorporated into the Uteroplacental Biobank which was approved 
by Newcastle 1 Research Ethics Committee.     
2.1.8 Tissue preservation 
2.1.8.1 Freezing of tissue samples 
Tissue to be frozen (placental bed biopsies, decidua, placenta or CpA segments) was 
placed onto a small piece of filter paper. A metal beaker containing isopentane (BDH 
Laboratory supplies, Poole, UK) was lowered into a flask containing liquid nitrogen. The 
metal beaker was removed from the liquid nitrogen after 1-2 minutes and the tissue 
on the filter paper was lowered into the cooled isopentane using forceps. To ensure 
that the tissue was frozen it was left in the isopentane for approximately 3-4 minutes 
65 
 
and was then placed into labelled freezing bags or a labelled cryotube (Corning, High 
Wycombe, UK) and stored at -80°C until use. 
2.1.8.2 Preparation of frozen tissue sections 
Serial tissue sections (5µm thick) were cut at -30°C using an automated cryostat 
(Reichert-Jung, 2700-Frigocut). The sections were applied onto 
aminopropyltriethoxysilane (APES) coated glass slides and allowed to air dry overnight 
at room temperature. APES coating aids the adherence of the tissue to the slide. 
Following overnight adherence the slides were fixed in acetone for 10 minutes at room 
temperature allowed to air dry and then wrapped in aluminium foil and stored at -20°C 
until use.     
2.1.8.3 Preparation of formalin fixed paraffin embedded (FFPE) tissue sections and 
processing     
Following tissue collection, placental bed biopsies, pieces of decidua, placenta and CpA 
segments were immediately fixed in 10% neutral buffered formalin (aqueous 
formaldehyde). Formalin fixes and preserves the tissue by forming cross-links between 
primary amino groups in proteins with other nitrogen atoms in proteins or DNA, 
delaying the effects of the cell cycle. Tissue was kept in formalin for a minimum of 24 
hours and then embedded in hot paraffin wax. Once cooled serial 3µm sections were 
cut from the paraffin block, mounted onto APES treated glass slides, air dried in an 
oven at 150°C and stored in the laboratory at room temperature until required.      
2.1.8.4 Haematoxylin and Eosin (H&E) staining  
The haematoxylin and eosin (H&E) staining procedure was standard for the initial 
assessment of frozen and FFPE tissue, cell smears (2.4.2) and invasion assays (2.6.4). 
Frozen sections were brought to room temperature and rehydrated in TBS (pH7.6). 
FFPE tissue sections were dewaxed in xylene and rehydrated through descending 
concentrations of alcohol (99%, 95%, 70%, water) and then placed into TBS. Sections 
were stained in fresh Mayer’s haematoxylin (see Appendix) for 1 minute to stain the 
cell nuclei blue and the slides were then washed in running tap water before being 
immersed into Scott’s tap water substitute (see Appendix) for a further minute to 
develop the blue staining. The slides were then rinsed again in running tap water, 
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placed into eosin (see Appendix) for 1 minute to stain the cell cytoplasm pink and 
further washed in running tap water. Sections were dehydrated through ascending 
alcohol concentrations (70%, 95%, 99%) and cleared in xylene. The slides were 
mounted using glass coverslips and DPX mounting agent (Distryrene 80, dibutyl 
phthalate and xylene) (BDH).     
2.2 Immunohistochemistry 
Immunohistochemistry was performed on frozen (2.1.8.2) and FFPE tissue sections 
(2.1.8.3) using the avidin-biotin peroxidase complex (ABC) method (Hsu et al., 1981) 
with a mouse or rabbit Vectastain Elite Kit (Vector Laboratories Ltd, Peterborough, 
UK). Positive and negative controls were included in each staining run for each 
individual antibody. Positive controls included tissue from tonsil, small intestine, 
stomach and breast depending on the primary antibody being used. Negative controls 
were performed by omitting the primary antibody and replacing it with non-immune 
serum. 
2.2.1 Avidin-biotin complex (ABC) method 
FFPE tissue sections (section 2.1.8.3) were dewaxed in xylene, rehydrated though 
descending graded alcohols to running water as for the H&E stain (section 2.1.8.4). The 
sections were then immersed into a 1.5% hydrogen peroxide solution (H2O2) (Sigma) in 
distilled water for 10 minutes in order to block endogenous peroxidase activity. FFPE 
sections were rinsed in water and subjected to pre-treatment to aid antigen retrieval 
after the formalin fixation process; the type of pre-treatment was dependant on 
antibody used (see experimental design sections in results chapters for specific 
antibodies and their pre-treatments). The pre-treated slides were then placed into TBS 
(pH7.6) for 5 minutes at room temperature ready for immunostaining.    
Pre-treatments were used for antigen retrieval. The majority of antibodies used 
required heat induced pre-treatment in citrate buffer pH 6.0 using a pressure cooker 
or microwave. Enzyme induced retrieval was used using trypsin working solution (see 
Appendix).  
Acetone fixed frozen tissue sections were removed from -20°C and brought to room 
temperature. The tissue sections were outlined on glass slides using a wax 
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hydrophobic pen and immersed into TBS (pH7.6) for 5 minutes prior to 
immunostaining. Frozen tissue sections require no pre-treatment. The antibodies used 
for frozen tissue are listed in specific results chapters. 
Immunolabelling was carried out using the avidin-biotin complex (ABC) method 
(Vectorstain Laboratories Ltd) and the reaction is outlined in Figure 2.1. In this method, 
an unlabelled primary antibody is recognised by a biotinylated secondary antibody, 
which then binds to a avidin-biotin enzyme molecule complex. Substrate is added and 
is converted from a colourless product into a coloured reaction product which is 
detectable in the tissue biopsy using light microscopy. 
Non specific reactivity in tissue sections was first blocked by overlaying the sections 
with blocking serum (see Appendix) and incubating in a humid chamber for 10 minutes 
at room temperature. Following blocking the serum was tipped off and appropriately 
diluted primary antibody was added. The incubation period and temperature was 
dependant on the antibody used. After primary antibody incubation sections were 
immersed into TBS (pH7.6) and washed on a rocking platform for 2 x 5 minutes. 
Secondary antibody (see Appendix) was then added to the sections and incubated at 
room temperature for 30 minutes. The sections were washed again in TBS (pH7.6) for 
2 x 5 minutes, incubated in tertiary antibody (see Appendix) for 30 minutes at room 
temperature followed by 2 x 5 minute washes in TBS (pH7.6). The reaction was then 
developed using DAB (see Appendix) for 2-3 minutes or until the reaction gave a brown 
product. The sections were rinsed in tap water and counterstained in Mayer’s 
haematoxylin for 1 minute, further blued in Scott’s tap water and dehydrated though 
ascending alcohol concentrations to be cleared in xylene. Slides were mounted using 
DPX synthetic mounting agent.   
2.2.2 ImmPRESS™ Kit 
The universal ImmPRESS™ kit (Vector Laboratories) was used for some antibodies to 
improve detection and reduce background staining. The reagents of the detection kit 
are biotin and avidin free (Figure 2.1A but without avidin-biotin complex). Secondary 
antibody is conjugated with a unique micro polymer containing active peroxidase 
enzyme and is reacted with peroxidase substrate for colour development, allowing 
sensitive and discrete antigen localisation. 
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Tissue sections were subjected to blocking in diluted normal horse blocking serum 
from the ImmPRESS™ kit for 20 minutes before being incubated with primary antibody 
then washed in TBS (pH7.6) for 2 x 5 minutes. Sections were then incubated with 
ImmPRESS™ reagent for 30 minutes, washed again in TBS (pH7.6) for 2 x 5 minutes and 
the reaction was developed using DAB peroxidase substrate (section 2.2.1). Sections 
were then lightly counterstained with Mayer’s haematoxylin and mounted using DPX 
mountant (section 2.2.1).   
2.2.3 Double immunohistochemical labelling 
Double labelling allows the detection of two antigens expressed by the same cell, with 
the display of two separate chromogens for identification. This double labelling 
technique was performed on decidual CD14+ cell smears following isolation by 
MidiMACS positive immunomagnetic selection (section 2.3.4). The cells were initially 
labelled with a primary mAb during the MidiMACS protocol using anti-CD14 IgG 
conjugated microbeads and this was further developed in the cell smears using the 
ABC Vectastain Elite kit (section 2.2.1) which was developed using either Vector 
NovaRed (see Appendix) or DAB (see Appendix). Following the ABC method the cells 
were double labelled with a second primary mAb for 30 minutes; detection of the 
second antigen was performed using the alkaline phosphatase anti-alkaline 
phosphatase method (APPAP; section 2.2.3.1).     
2.2.3.1 Alkaline phosphatase anti-alkaline phosphatase (APAAP) method 
The APAAP method was devised by Cordell et al. (1984) and further developed by 
Hohmann et al. (1988). After terminating the enzyme reaction of the ABC method 
(section 2.2.1) by washing in tap water for 5 minutes the sections were then washed in 
TBS (pH7.6) and normal rabbit blocking serum (taken from Vectastain Elite goat IgG 
ABC kit) was added to the sections for 10 minutes to block non-specific binding and 
then replaced with second primary mAb diluted in TBS (pH7.6) for 30 minutes. Sections 
were washed in TBS (pH7.6) for 2 x 5 minutes and then incubated with secondary 
rabbit anti-mouse IgG antibody (see Appendix) for 30 minutes. The slides were washed 
in TBS (pH7.6) 2 x 5 minutes and then incubated in APAAP tertiary antibody (see 
Appendix) for 30 minutes. The slides were then washed in TBS (pH7.6) 2 x 5 minutes 
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and the reaction was developed using the alkaline phosphatase substrate kit III (see 
Appendix). The incubation proceeded in the dark at room temperature for 
approximately 20 minutes (development of the colour reaction was assessed 
microscopically). The reaction was stopped by washing the slides in running tap water. 
These sections were not subjected to any counterstain and they were not dehydrated 
as the alkaline phosphatase substrate is soluble in alcohol. Therefore, the sections 
were mounted using a permanent aqueous mounting medium (DAKO; S1964) and 
allowed to air dry overnight at room temperature.    
2.2.4 Optimisation of antibodies 
All primary antibodies were optimised before use. They were optimised using the 
recommended positive control tissue along with the tissue of interest with a number 
of different dilutions and pre-treatments (for FFPE sections). The pre-treatment and 
dilution for the given antibody that resulted in the strongest reactivity with reduced 
background staining was selected for use in the staining run. 
2.2.5 Quantification of immunohistochemistry   
All immunostained sections were blinded independently before assessment. 
Immunohistochemistry was quantified using a quick score method. The proportion of 
positive staining was measured using a 4 point scale; 1=<25%, 2=25-50%, 3=51-75% 
and 4=>75% and the intensity of positive staining was given a score of 1 - 3, with 1 
being weak and 3 being strong immunoreactivity. To give a total score the intensity 
score was multiplied by the proportion score and added together to give a maximum 
of 12 (for example: if 40% of the cells were positively stained and the staining intensity 
was strong then this would have been giving a score of 2 x 3 = 6). Other examples 
include: 100% weak = 4 x 1 = 4; 100% strong = 4 x 3 = 12 and for variable staining: 40% 
weak and 60% strong = 2 x 1 + 3 x 3 = 2 + 9 = 11. The sections were then un-blinded 
following assessment.  
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Figure 2.1 Schematic representation of immunohistochemical labelling 
A) Single labelling with avidin-biotin complex (ABC) method; B) Double labelling combining the 
ABC and the Alkaline Phosphatase anti-Alkaline Phosphatase (APAAP) method. (Own diagram). 
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2.3 Tissue culture 
2.3.1 Enzymatic disaggregation 
A digest medium containing 1mgml-1 of collagenase type II and 0.1mgml-1 DNase type 
IV in incomplete RPMI 1640 medium was added to the chopped decidual tissue 
(section 2.1) and incubated for 40 minutes at room temperature with constant 
agitation. Following digestion disaggregated cells were removed, passed through a 
40µm nylon cell strainer (BD Biosciences) and centrifuged at 300G for 5 minutes to 
pellet cells and aid the removal of any residual enzymes. The cell pellet was then 
resuspended in 1ml of complete RPMI 1640 culture medium (see Appendix). The 
remaining decidual tissue was subjected to a second 40 minute digest as above and 
the resulting cell suspension was pooled with the previous cell suspension. 
The resuspended cells were added to a plastic T75cm3 culture flask containing 20ml 
complete RPMI 1640 culture medium and incubated overnight at 37°C, 5% CO2, in air 
to allow the adherence and therefore, removal of fibroblasts, epithelial cells, 
macrophages and decidual stromal cells, resulting in a cell suspension rich in 
leucocytes as they do not adhere to plastic (Oliver et al., 1999). The following day, the 
non-adherent cells were transferred from the flask into a sterile universal tube and the 
flask was rinsed in sterile PBS (pH7.4). The non-adherent cells were then centrifuged at 
300G for 5 minutes and resuspended in complete RPMI 1640 culture medium to give a 
total concentration of 1x106cells ml-1. 1x 105 cells (100µl) were plated out into wells of 
a plastic U bottomed 96 well culture plate and these were labelled ‘total decidual 
fraction’.       
2.3.2 Isolation of CD56+, CD8+ and CD10+ cells by MidiMACS 
The remaining cell suspension (section 2.3.1) was centrifuged at 300G for 5 minutes 
and the cell pellet resuspended and incubated with either primary anti-CD56 (Coulter, 
High Wycombe, UK), anti-CD8 (DAKO) or anti-CD10 (Leica) monoclonal antibodies 
diluted 1:25 with incomplete RPMI 1640 culture medium for 30 minutes on an ice 
block. The antibody was then washed from the cells by addition of 20ml of ice cold 
sterile PBS (pH7.4) and centrifuged at 300G for 5 minutes. The cells were then 
incubated with MACS indirect goat anti-mouse IgG microbeads diluted 1:4 in ice cold 
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MidiMACS buffer (see Appendix) for 15 minutes. 800µl ice cold MidiMACS buffer was 
then added to the cells to give a total of 1ml. MidiMACS columns (Miltenyi) were 
prepared by placing the column in a magnetic field using a MACS separator and rinsing 
500µl of ice cold MACS buffer through the column. The 1ml cell suspension was then 
applied to the column, the unlabelled cells washed through the column and collected 
as waste. The column was washed with 3x 500µl MACS buffer and the effluent 
collected. The column was removed from the separator and placed into a collection 
tube. Using the plunger provided, 1ml of MACS buffer was immediately flushed 
through the column to remove the magnetically labelled cells. The eluted cells were 
centrifuged at 300G for 5 minutes, the cell supernatant was removed and the pellet 
was resuspended in complete RPMI 1640 culture medium to give a total of 
1x106cellsml-1.   
2.3.2.1 Preparation of CD56+, CD8+ and CD10+ cells for PCR 
Following the MidiMACS cell separation technique (section 2.3.2) the resuspended 
cells were collected into labelled eppendorf tubes and microcentrifuged at 14.1rcf 
(relative centrifugal force) for 60 seconds. The supernatant was then removed and the 
cells were stored at -80°C until required.   
2.3.2.2 Preparation of CD56+, CD8+ and CD10+ cell culture supernatants 
Following the MidiMACS cell separation technique (section 2.3.2) the cells in 
suspension were seeded at 1 x 105 cells/well (100µl) into a 96 well culture plate and 
incubated at 37°C, 5% CO2 in air for 24 hours. Following incubation the cell 
supernatants were collected in sterile eppendorf tubes and microcentrifuged at 14.1rcf 
for 60 seconds. The supernatant was collected into 100µl aliquots, placed into labelled 
freezer bags and stored at-80°C until required; the cell pellet was discarded. 
2.3.2.3 Cell counting  
Cells counts were performed using a haemocytometer and a light microscope 
magnification x200. 10µl cell suspension was applied to the counting grid of the 
haemocytometer and the cells counted. Cells in the outer 4 squares and the centre 
square of the grid were counted and the cell concentration was determined using the 
formula:  
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Cell concentration ml-1 = number of cells in 5 squares   x 106 
                                                                20  
If there were few cells present (<1 cell per square), all 25 squares of the grid were 
counted and the cell concentration was calculated using the following formula: 
Cell concentration ml-1 = total number of cells in 25 squares x 104    
2.3.3 Preparation of cell smears 
2.3.3.1 Cell viability and purity 
Cell purity was assessed following MidiMACS positive immunomagnetic selection. Cell 
smears were prepared on APES-coated glass slides and left to air dry overnight at room 
temperature. Smears were then fixed in acetone for 10 minutes and immersed into 
TBS (pH7.6) for 5 minutes. The cell smears were then treated with secondary antibody 
from the Vectastain Elite ABC kit (section 2.2.1). After washing in TBS, cell smears 
incubated with tertiary antibody, washed again in TBS and the reaction was developed 
with DAB. The smears were counterstained with Mayer’s haematoxylin, dehydrated, 
cleared in xylene and mounted with DPX synthetic resin for assessment of cell purity. 
Cells that had been positivity selected by MidiMACS were positively stained as brown 
cells (see Figure 2.2). The purity of the isolated cell populations were assessed 
microscopically in every 5th sample used; the population was considered ‘pure’ when 
purity was >95%.    
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Figure 2.2 Purity examination of CD56+ stained cells 
Image of CD56+ stained cells which have been isolated by MidiMACS from first trimester 
decidua with a cell purity of >95% x200 magnification. 
 
Cell viability was measured using Trypan blue (Sigma). Trypan blue is a stain which 
cannot be absorbed by healthy viable cells. Dead or damaged cells can readily absorb 
the stain and the cells appear blue when viewed with a microscope, allowing the dead 
cells to be counted. Cell viability was checked following cell isolation and cell culture 
for every 5th sample collected; the sample was discarded if viability and purity was too 
low. In sterile conditions, at T=0, 10µl suspended cells were added to 5µl Trypan blue 
and incubated for 5 minutes at room temperature. The cells were then smeared onto a 
glass slide and microscopically assessed. Samples were used for cell culture if the 
viability was >80%. After 24 hours of culture, once the cell supernatant was harvested, 
the remaining cells were tested for their viability by the addition of Trypan blue to the 
culture plate wells and assessed microscopically. Again the supernatants were deemed 
usable if the cell viability was >80%.     
2.3.4 Isolation of CD14+ cells by MidiMACS 
After enzymatic disaggregation of first trimester decidual tissue and miscarriage 
decidua, the cell suspension of was added to a T75 culture flask containing complete 
RPMI 1640 medium and incubated at 37°C, 5% CO2 in air overnight. Following 
incubation cells remaining in the media suspension were discarded or used for CD56, 
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CD8 and CD10 cell isolation (see section 2.3.2). Cells that had adhered to the plastic 
base of the culture flask were then removed using a cell scraper and sterile PBS 
(pH7.4). The scraped cells were collected into a 50ml conical tube and centrifuged at 
300G for 5 minutes. The cells were resuspended in complete RPMI medium to give a 
cell concentration of 1x106cells ml-1 (total adherent fraction). These cells were plated 
into wells (2 x 105cells per well) of a plastic 48 well culture plate. The remaining 
suspension was centrifuged for a second time at 300G for 5 minutes. The cell pellet 
was resuspended in 80µl MidiMACS buffer (see Appendix) and 20µl CD14 conjugated 
anti-goat IgG beads (Miltenyi Biotech) and incubated at 4°C for 15 minutes. Following 
incubation, the magnetically labelled CD14+ cells were washed in 2mls MidiMACS 
buffer and centrifuged at 300G for 5 minutes. 500µl MidiMACS buffer was then added 
to the cell pellet and flushed through the prepared magnetic column (section 2.3.2). 
The eluted cells were centrifuged at 300G for 5 minutes and the cell pellet was 
resuspended in 1ml CD14+ complete medium (see Appendix) to give a total of 1 x 106 
cells ml-1. The cells were seeded at 2 x 105 cells/well (200µl) into a 48 well culture plate 
and incubated at 37°C, 5% CO2 in air for 24 hours; the supernatants were then 
collected and stored at -80°C (section 2.3.2.2).        
2.3.5 Isolation of EVT from first trimester placenta 
Placental samples from 7-14 weeks gestation were collected and prepared for isolation 
of EVT (2.1.2). EVT cells were isolated from placenta using a modification of the 
method described byTarrade et al. (2001), (Naruse et al., 2010). Briefly, placental 
chorionic villi were washed thoroughly in Hanks Balanced Salt Solution (HBSS, Mg/Ca 
free) to remove excess red blood cells. The chorionic villi were dissected from the 
placental membrane, minced to 0.5mm3 and then enzymatically digested at 37°C using 
a digest media containing 0.025% trypsin (Roche Diagnostics Ltd, Burgess Hill, UK), 
0.5mg DNase I and HBSS for 30 minutes without agitation. Supernatant containing a 
single cell suspension was removed and the remaining chorionic villi were subjected to 
a second 30 minute digestion. The single cell suspensions were mixed with 1ml FCS to 
inhibit any residual enzymes and centrifuged at 300G for 5 minutes. The cell pellet was 
then resuspended in incomplete DMEM:F12 (see Appendix). The cell suspensions were 
combined and layered onto a percoll gradient (10-55% percoll; diluted in HBSS) and 
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centrifuged (1200G, 30 minutes, no brake).The  EVT cell layer (35-40% percoll) was 
removed, diluted in excess medium and centrifuged at 300G for 5 minutes. The cell 
pellet was resuspended in complete DMEM:F12 (see Appendix). The isolated EVT cells 
were cultured on 10µl/well of growth factor reduced Matrigel®(Becton Dickinson, 
Franklin Lakes, US) in a 24 well culture plate and placed overnight in an incubator set 
at 37°C, 5% CO2 in air.       
2.3.5.1 Preparation of whole cell lysates and EVT cell supernatants 
Following overnight incubation EVT cells were washed in sterile PBS (pH7.4) to remove 
dead floating cells and fresh complete DMEM:F12 medium was added to the wells. The 
cells were then returned back to the incubator for 2-3 hours. Cells were treated with 
complete DMEM:F12 medium +/- 10ngml-1 IL-6 (Peprotech EC, London, UK) and 
returned to the incubator for 24 hours. Following incubation the conditioned medium 
was collected, micro centrifuged at 14.1 rcf for 60 seconds and the supernatants were 
collected and the cell pellets discarded. The cell supernatants were stored at -80°C 
until required. The adhered EVT cells were either lysed using 50mM HEPES protein 
extraction buffer containing 1% protease inhibitor cocktail (see Appendix) and a cell 
scraper or subjected to RNA extraction using the TRIZOL method (section 2.9.1). Cells 
were collected into an eppendorf tube and placed on a rocker at 4°C for 30 minutes. 
Cells were then micro centrifuged at 14.1 rcf for 5 minutes and supernatants were 
collected and stored at -80°C for future use.    
2.3.6 Preparation of placental explants 
Placental samples from 8-10 weeks gestation were used for preparing placental 
explants (section 2.1.2). Following sample collection placental tissue was prepared as 
previously described (Lash et al., 2006a). Briefly, the placental tissue was washed in 
sterile PBS (pH 7.4) to remove excess blood. Chorionic villous tips were dissected into 
0.5mm3 segments immersed in PBS (pH7.4) and centrifuged at 300G for 5 minutes. 
Tissue was resuspended in complete DMEM:F12 culture medium such that 15µl 
explant suspension contained 10mg tissue. 
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2.3.7 Chorionic plate artery culture   
Following dissection of chorionic plate arteries (CpA) from term placenta (section 
2.1.5.1), segments were either immediately snap frozen in liquid nitrogen (section 
2.1.8.1)  and stored at -80°C or fixed in formalin for embedding in paraffin (section 
2.1.8.3); these tissues were labelled T=0. The remaining CpA segments were used for 
culture. The segments were placed into a 48 well culture plate containing complete 
RPMI 1640 culture medium (see Appendix) +/- 1 or 10ng ml-1 IL-6 or IL-8 (both 
Miltenyi), 5ng ml-1 sIL-6Rα (Miltenyi) and 10ng ml-1 IL-6 combined with 5ng ml-1 sIL-
6Rα. Each experimental condition was performed in triplicate. The CpA segments were 
incubated at 37°C, 5% CO2 in air for a total of 5 days; medium was changed every other 
day. Following 5 days incubation one segment per treatment was formalin fixed and 
the remaining 2 segments were snap frozen and stored at -80°C until required. Tissue 
that was fixed in formalin was paraffin embedded, processed into tissue sections 
(section 2.1.8.3) and immunostained using the ABC method (section 2.2.1) for VSMC 
differentiation markers (Myosin heavy chain, HCaldesmon, Calponin and α-smooth 
muscle actin), endothelial cells (CD31), proliferative cells (Ki67) and apoptotic cells 
(cleaved caspase 3). Tissue sections were also prepared from frozen tissue samples for 
immunohistochemistry (section 2.1.8.1) to investigate expression of IL-6 and IL-8 
receptors on the VSMCs of CpAs. All antibodies used are listed in Chapter 5 Table 5.1. 
2.4 Cell lines 
2.4.1 HTR-8/SVneo cells 
HTR-8/SVneo cells are a homogeneous human trophoblast cell line derived from first 
trimester trophoblast cells transfected with Simian virus 40 large T antigen (Graham et 
al., 1993). HTR-8/SVneo cells were kindly provided by Professor C.H. Graham, Queen’s 
University, Kingston, Ontario, Canada. Cells were maintained at 37°C, 5% CO2 in air in 
complete RPMI 1640 medium (see Appendix) and passages 10-50 were used for 
experiments. HTR-8/SVneo cells have been reported to be integrin α6 negative, but 
positive for integrin α1, cytokeratin 7 and HLA-G when grown on Matrigel® (Lash et al., 
2005); this is similar to the phenotype of EVT. HTR-8/SVneo cells were grown to 100% 
confluence, trypsinised using 5mls trypsin/EDTA and resuspended in complete RPMI 
1640 culture medium ready for use or to be frozen down and stored in liquid nitrogen.  
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2.4.2 Cryopreservation of cells  
To preserve confluent HTR-8/SVneo cells, cells were trypsinised using Trypsin/EDTA 
and resuspended in 1ml complete RPMI 1640 culture medium which was then added 
to a cryovial containing 1ml DMSO freezing mix (see Appendix). The tube was slowly 
frozen in a vessel containing liquid nitrogen approximately at -210°C prior to storage in 
liquid nitrogen until further use. 
2.5 Invasion assays 
2.5.1 Matrigel® coating of cell culture membrane inserts 
Tissue culture well membrane inserts with a pore size of 8.0µm (24 well format, 
Becton Dickinson, US) that sit into a 24 well culture plate were coated with 10µl chilled 
(4°C) growth factor reduced Matrigel® (Becton Dickinson, Oxford, UK). Coated inserts 
were then incubated at 37°C for at least 30 minutes to allow proteins in the Matrigel® 
to self assemble producing a thin film which the cells can attach to for cell culture. 
Matrigel® is a gelatinous protein mixture that resembles the extracellular environment 
found in tissues; it is liquid at 4°C but solid at 37°C.   
2.5.2 Volume of tissue/number of cells per insert 
Once the placental explants were prepared (see section 2.3.6). 15µl placental explant 
tissue (~10mg) was gently plated onto the Matrigel® coated membrane inserts. 400µl 
complete DMEM:F12 culture medium was added to the lower chamber and then 
incubated at 37°C overnight to allow adherence of the explants to the Matrigel®. The 
next morning (day 1) the medium was removed and 600µl fresh complete DMEM:F12 
culture medium (see Appendix) was added to the lower chambers and 200µl of the 
treatment solution was added to the upper chamber of the corresponding well inserts 
(section 2.5.3). The tissue was then incubated at 37°C, 5% CO2, in air for 6 days. 
Invasion assays were performed in duplicate for each sample and repeated on 5 
separate occasions with 5 different placental explants (Figure 2.3). 
HTR-8/SVneo cells were grown to 100% confluence and prepared for the invasion 
assay (see section 2.4.1). 1x105 cells were added to each of the coated membrane 
inserts. 800µl complete RPMI 1640 culture medium was added to the lower chambers 
and 200µl of the treatment solution (section 2.5.3) was added to the upper chamber of 
79 
 
the well inserts. The cells were then incubated for 48 hours at 37°C, 5% CO2, in air. 
Each invasion assay was performed in triplicate and the assay was repeated on 3 
separate occasions (Figure 2.3). 
 
Figure 2.3 Diagrammatic representation of Matrigel® invasion assay 
Trophoblast cells degrade the Matrigel® and migrate through to the underside of the pore 
membrane insert allowing invaded cells to be counted.   
2.5.3 Concentration and type of treatments 
The treatments added to both the placental explants and HTR-8/SVneo cells for the 
invasion assay were: 
1. 1ng ml-1or 10ng ml-1 human recombinant IL-6 (Peprotech EC, London, UK) 
2. 20ng ml-1 human recombinant sIL-6Rα (Peprotech EC, London, UK)  
3.  20ng ml-1 sIL-6Rα combined with 10ngml-1 IL-6 
4. Medium control containing 10nM acetic acid (IL-6 and sIL-6Rα were 
reconstituted in acetic acid).  
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In addition placental explants were also treated with 1µgml-1 anti-human polyclonal IL-
6 (Peprotech EC, London, UK) to inhibit any endogenous IL-6 that may be produced by 
the explants themselves and to see whether this abrogated the effect of EVT invasion. 
2.5.4 Counting of H&E stained cells on chamber inserts  
Following either 6 days or 48 hours incubation the tissue or cell supernatants were 
removed. The Matrigel® was removed and the upper side of the membrane inserts 
was cleaned with a cotton wool bud. For assessment of the number of invaded cells, 
the membrane filters were initially fixed in 99% alcohol for 5 minutes at room 
temperature and then stained with H&E (section 2.1.7.3). Since the membrane filters 
are plastic they were not cleared in xylene. The bottom of the filters was then cut away 
from the plastic and mounted onto untreated glass slides using DPX synthetic 
mounting resin (Raymond A. Lamb Ltd, London, UK). Each slide was blinded and the 
number of cells in the whole insert was counted using a microscope at x400 
magnification (Figure 2.4). The mean of the duplicates or triplicates was calculated and 
then were normalised to the appropriate control values for each sample in order to 
facilitate comparison between experiments.  
 
Figure 2.4 H&E stained invaded EVT through 8µm pore membrane filter insert 
An H&E stained 8.0µm membrane pore insert illustrating the invaded extravillous trophoblast 
cells from a placental explant. The whole insert was counted. 
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2.6 Kinase phospho-array 
The human kinase phospho array (R&D Systems Inc, UK) is a kit designed to detect the 
phosphorylation of 46 proteins involved in cell signalling and was used for comparison 
of cell lystates from untreated and treated cells. 
2.6.1 Preparation of EVT cell lysates 
Both isolated EVT from placenta at 7-14 weeks gestation (section 2.3.5) and 100% 
confluent HTR-8/SVneo cells (section 2.4.1) were grown on growth factor reduced 
Matrigel® (Becton Dickinson) overnight and then either treated with either 10ng ml-1 
human recombinant IL-6 (Peprotech, EC, London, UK) or treated with 10nM acetic acid 
medium (control) for 10 minutes at 37°C, 5% CO2 in air. The cells were then lysed to 
prepare whole cell lysates using the lysis buffer provided. A BioRad DC total protein 
assay (see section 2.11.2) was then performed to determine the protein concentration 
of the cellular extracts (100µg-500µg protein required for the assay). EVT cell lysates 
were pooled to give a total protein concentration of 250µg for each experiment. 300µg 
total protein concentration was used for each HTR-8/SVneo profile experiment. 
Following the protein assay, cellular extracts were stored at -80°C until required. The 
experiment was repeated on 3 separate occasions for both cell types.   
2.6.2 Array protocol 
Before the array was carried out all of the reagents, including the cellular extracts, 
were brought to room temperature. The array protocol was followed according to 
manufacturer’s instructions (Human Phospho-Kinase Array Kit, R&D systems, Inc. 
Minneapolis, US). The nitrocellulose membranes were then developed using 
chemiluminescence (Thermo Scientific, Rockford, USA) according to the 
manufacturer’s instructions and exposed by X-ray KODAK film (Sigma) for 10 minutes.    
2.6.3 Quantification of results using Adobe Photoshop™ 
The array signals from the X-ray film (Figure 2.5) were scanned and the images were 
analysed using Adobe Photoshop™ software package. The images were quantified by 
using a mean spot pixel density counting method for each kinase signalling protein and 
values were exported to Microsoft Excel for analysis. Corresponding signals were 
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compared to determine the relative change in phosphorylated kinase proteins 
between untreated and treated cells and between samples. Data from the array were 
normalised to control values to facilitate comparison between each experiment (n=3 in 
both EVT and HTR-8/SVneo cell lysates). 
 
Figure 2.5 Representative phospho-array x-ray blot 
Representative phospho-array x-ray blot after treatment with EVT cell lysates. The dots 
represent 46 kinase phosphorylation sites on nitrocellulose. A signal produced at each capture 
spot corresponds to the level of bound phosphorylated protein. Red circles highlight subtle 
differences in signal intensities between untreated and treated cells.   
 
2.7 FASTQuant® multiplex cytokine array 
The FASTQuant® array was used for the quantification of proteins secreted by first 
trimester EVT cells (Whatman).  
2.7.1 Assay protocol 
Three separate FASTQuant® kits were used; Human Th1/Th2, Human angiogenesis and 
Human II (see Appendix for types of proteins detected for each kit and solutions used). 
Each slide in the FASTQuant® kit contained 16 nitrocellulose arrays with the anti-
cytokine monoclonal antibodies arrayed in triplicate.  The assays were performed 
according to the manufacturer’s instructions. Briefly, the prepared EVT cell 
supernatants (section 2.3.5.1) were removed from the -80°C freezer and allowed to 
defrost on ice. Whilst defrosting 70µl of 1x blocking solution (see Appendix) was added 
to each well and incubated for 15 minutes on an oribital shaker at room temperature. 
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Samples were then diluted 1:2 in diluent (see Appendix) and 70µl of each EVT cell 
supernatant was applied to the slides along with an 8 point standard curve (made by 
serial dilutions) after removing the blocking buffer. Samples and standards were 
incubated overnight on an oribital shaker with the FAST frame sealed in a plastic bag 
with a wet paper towel to prevent the FAST slides from drying out. Following overnight 
incubation, the samples were removed and the slides were washed by adding 90µl of 
1x washing buffer (see Appendix) to each well and this wash step was repeated 5 
times.70µl of biotinylated detection antibody cocktail (see Appendix) was then added 
to each well and incubated for 1 hour on an orbital shaker at room temperature. The 
wash step was then repeated and 70µl of streptavidin fluorescently tagged with Cy5 
(see Appendix) (allowing visual detection of protein for quantification) was added to 
each well, the FAST plate was then covered in foil and incubated for 45 minutes on an 
orbital shaker at room temperature. The slides were then washed in dH20 for 5 
minutes and allowed to air dry before scanning.  
2.7.2 Analysis of array raw data 
2.7.2.1 Gene array vision 
The labelled slides were visualised using an Axon GenePix® 4000B Microarray scanner 
and the images were transferred to Gene Array Vision software where the fluorescent 
images could be quantified. Data were exported to Excel for analysis.   
2.8 Laser capture micro dissection of placental bed biopsies 
Laser Capture Microdissection (LCM) is a method for obtaining individual homogenous 
cell populations, cell aggregates and morphological structures from heterogeneous 
samples such as tissue sections. Once the cells are captured they can be used for real-
time RT-PCR and mRNA expression profiling.  
Frozen tissue sections of placental bed biopsies were prepared (section 2.1.8.1 and 
2.1.8.2) but the tissue sections required for LCM were stored at -80°C rather than -
20°C and sections were placed onto polyethylene naphthalate (PEN) membrane glass 
slides (Leica Microsystems, Newcastle, UK) . In this study the LCM staining kit was used 
(Ambion). Tissue sections were removed from -80°C and immediately immersed into a 
chamber containing 95% ethanol for 30-40 seconds then the slides were transferred to 
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75% ethanol for 20-40 seconds and to 50% ethanol for 25 seconds before the addition 
of 300µl of cresyl violet staining solution (a basic stain that binds to negatively charged 
nucleic acids) directly to the tissue section. The tissue was stained for 1 minute and the 
cresyl violet solution was then drained away and the slides were incubated with fresh 
50% ethanol for 30 seconds followed by 75% for 30 seconds then 95% ethanol for 30 
seconds. The slides were then immersed in 100% ethanol for 40 seconds then added to 
another chamber containing 100% fresh ethanol for a further 40 seconds. The slides 
were rinsed in xylene and then placed in a staining chamber of fresh xylene for 5 
minutes. The slides were then air dried at room temperature to allow the evaporation 
of xylene before microdissection.     
Microdissection was performed using Leica Laser Microdissection Microscope. The 
laser used is a UV laser of 337 nm wavelength. The movement during cutting is done 
by the optics, while the stage remains stationary. The region of interest can be marked 
on the monitor and is cut out by PC control. An eppendorf tube is placed beneath the 
stage to capture the sample as it is cut away. The collected sample of interest is then 
subjected to RNA extraction (section 2.9.1). 
2.9 RT-PCR  
2.9.1 Total RNA extraction from cells and LCM samples  
Total RNA was extracted from total decidual, leucocyte and EVT cell isolates (section 
2.3.5.1) using the TRIZOL method (TRIZOL, Sigma). The protocol was followed 
according to the manufacturer’s instructions. Briefly, 500µl TRI® reagent was added to 
isolated cells. The cells were removed using a cell scraper/pipette tip and the contents 
were added into 0.5ml eppendorf tubes. The transferred contents were then 
incubated at room temperature for 5 minutes. 100µl chloroform (Sigma) was added to 
each tube, which was inverted ~20 times and then incubated at room temperature for 
5 minutes before being micro-centrifuged at maximum speed (14rcf) for 15 minutes. 
The colourless aqueous phase was collected into clean tubes containing 250µl 
isopropanol and incubated at -20°C for 1 hour. Following incubation the tubes were 
micro-centrifuged at maximum speed for 5 minutes, after which the supernatant was 
removed and the RNA pellet was washed in 500µl 75% ethanol (1500µl 100% ethanol 
in 500µl water). The tubes were then micro-centrifuged again for 5 minutes and the 
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RNA pellet allowed to dry at room temperature. Once the pellets were dry they were 
resuspended in 50µl nuclease free water and stored at -80°C prior to cDNA conversion 
(section 2.9.2)   
RNA was extracted from tissue collected by laser capture microdissection using Micro 
RNeasy or RNAqueous-Micro kit (Ambion)  
The method used followed the manufacturer’s instructions Ambion:  
RNAqueous®-Micro Kit; RNA Isolation Procedure from LCM Samples 
1. Drop sample into 100 μL Lysis Solution and incubate for 30 minute at 42°C 
Using sharp forceps peel off the thermoplastic film containing the captured cells and 
drop it into a 0.5 mL microcentrifuge tube containing 100 μL of Lysis Solution. Make 
sure that the sample is completely immersed in Lysis Solution. 
a. Incubate the sample for 30 minute at 42°C. 
b. Vortex briefly to mix. Briefly centrifuge to collect the fluid at the bottom of the tube. 
 
2. Prewet the filter with 30 μL of Lysis Solution for ≥5 minute 
a. Pre wet the Micro Filter Cartridge Assembly by applying 30 μL of Lysis Solution to the 
center of the filter and allow it to soak while performing the next two steps. 
b. After completing steps 3 and 4 below, or after 5 minute, centrifuge the pre wetted 
filter for ~30 seconds at top speed to remove liquid. 
 
3. Add 3 μL of LCM Additive to the lysate and mix 
a. Add 3 μL of the LCM Additive to the lysate and mix well by briefly vortexing. 
b. Briefly centrifuge to collect the fluid at the bottom of the tube. 
 
4. Add 100% ethanol to recover either only large RNA species or all RNA 
The amount of ethanol added to the lysate mixture determines what size of RNA will 
be captured on the filter. Instructions are provided below for recovering only RNA 
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species larger than ~75 nt, or for recovering both large and small RNA species, 
including tRNAs and microRNAs. 
• To recover only large RNA species: 
Add 0.5 volumes (52 μL) of 100% ethanol to the lysate mixture, and mix by pipetting up 
and down or by gently vortexing. 
• To recover large and small RNA species: 
Add 1.25 volumes (129 μL) of 100% ethanol to the lysate mixture, and mix by pipetting 
up and down or by gently vortexing. (Yields of total RNA using this method may vary 
from those obtained using the above method.) 
 
5. Pass the lysate mixture through a prepared Micro Filter Cartridge Assembly 
Be sure to remove the Lysis Solution used to prewet the filter by centrifugation (step 
2.b) before applying the lysate mixture. 
a. Load the entire lysate/ethanol mixture onto the prepared Micro Filter Cartridge 
Assembly and close the cap. 
b. Centrifuge for 1 minute at 10,000 x g to bind the RNA to the filter. 
6. Wash with180 μL of Wash Solution 1 
a. Add 180 μL of Wash Solution 1 (working solution mixed with ethanol) to the filter 
and close the cap. 
b. Centrifuge for 1 minute at 10,000 x g to pass the solution through the filter. 
 
7. Wash the filter with 2 x 180 μL Wash Solution 2/3 
a. Open the Micro Filter Cartridge, add 180 μL of Wash Solution 2/3 (working solution 
mixed with ethanol) to the filter and close the cap. 
b. Centrifuge for ~30 seconds to pass the solution through the filter. 
c. Repeat with a second 180 μL aliquot of Wash Solution 2/3. 
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8. Discard the flow-through and centrifuge the filter for 1 minute 
a. Open the Micro Filter Cartridge assembly, remove the filter cartridge from the 
Collection Tube, and pour out the flow-through. 
b. Replace the Micro Filter Cartridge into the same Collection Tube, close the cap, and 
centrifuge the assembly for 1 minute to remove residual fluid and dry the filter. 
9. Elute the RNA in 2 x 8–10 μL of Elution Solution 
a. Label a Micro Elution Tube (1.5 mL tubes provided with the kit) and transfer the 
Micro Filter Cartridge into it. 
b. Apply 8–10 μL of Elution Solution, preheated to 95°C, to the centre of the filter. c. 
Close the cap and store the assembly for 5 minute at room temperature. 
d. Centrifuge the assembly for 1 minute to elute the RNA from the filter. 
Tension from the hinge of the Micro Elution Tube can occasionally cause the cap to 
pop off during the elution spin. To minimize the chance of this happening, bend the 
cap hinge back and forth several times, then press the cap securely onto the Micro 
Filter Cartridge. 
e. Repeat steps b–d with a second 8–10 μL of preheated Elution 
Solution and collect the eluate in the same Micro Elution Tube. 
2.9.2 cDNA conversion 
The quantity of extracted RNA was assessed using a nanodrop machine (ND-1000 V3, 
Labtech Int, UK). 300-500ng extracted RNA was reverse transcribed using Superscript 
III (InVitrogen Ltd, UK) according to the manufacturer’s instructions. Briefly, 2µl dNTP 
(10mM) and Oligo(DTs)12-18 (0,5µgµl
-1) were added to the extracted RNA and topped 
up with 13µl nuclease free water. The reaction tubes were placed in a PCR thermo 
cycler (Eppendorf) and run at 65°C for 5minutes then cooled to 4°C. Meanwhile a 
master mix consisting of 5x RT buffer, 0.1M DTT, RNase OUT and Superscript III (all 
Invitrogen) with 4:1:1:1 ratio, respectively, was prepared. 7µl master mix was then 
added to the reaction tubes and run on the PCR machine at 50°C for 30-60 minutes. 
The reaction was terminated at 70°C for 15 minutes and the cDNA was stored at -20°C 
before PCR amplification (section 2.9.3).   
88 
 
2.9.3 Standard Reverse Transcriptase Polymerase Chain Reaction (RT-
PCR) amplification  
RT-PCR was carried out in 0.2ml thin walled PCR tubes using 2μl DNA, 0.5µl 10mM  
dNTPs consisting of; dATP, dTTP, dGTP, dCTP (Invitrogen), 0.2µl 1x Taq polymerase, 
2.5µl 25mM MgCl2, 2.5µl 10x Buffer IV (all from Invitrogen), 0.25µl 20μM forward 
primer, 0.25µl 20μM reverse primer and 17.8µl sterile filtered distilled water. A 
negative control containing sterile filtered water was included to ensure that the 
reaction mixture was not contaminated with another source of DNA. In addition to 
this, a positive control was used to ensure that all the reagents were still working 
appropriately. A thermo cycler (Eppendorf) was used and the steps of the PCR 
amplification are outlined below (Table 2.1). 
 
Table 2.1 Conditions of a standard PCR reaction 
2.9.3.1 Agarose gel electrophoresis 
The standard concentration of agarose was 2% in 1x Tris-acetate-EDTA (TAE) buffer 
(see Appendix) (2 grams agarose to 100mls 1x TAE buffer) and 0.1% (10µl) ethidium 
bromide. The agarose was boiled in a microwave for 3 x 1 minute to ensure that the 
agarose was fully dissolved. The solution was cooled with cold running tap water for 
1 95oC – 1 minute Denaturation of cDNA 
2 95oC – 30 seconds Denaturation of cDNA 
3 62oC – 30 seconds Annealing of primers (IL-6, 
GAPDH) 
4 72oC – 1 minute Elongation 
5 72oC – 3 minutes Denaturation 
6 4 oC  Temperature required to 
prevent degradation of PCR 
products prior to storage at -
20°C 
Cycles 
(steps 2-4) 
39 Repetition of cycles 
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around 2 minutes to allow the temperature to cool to 55-65°C and then ethidium 
bromide was added. When cooled the solution was slowly poured into a gel tank 
containing a 14 well comb (which allowed 13 samples plus the 1Kb ladder to be run) 
and this was left to set for approximately 40 minutes. When solidified the comb was 
carefully removed and the gel fully immersed in 1x TAE buffer.  The samples were 
prepared by adding 4μl PCR product to 1μl 5x DNA loading buffer and loading 4μl into 
the wells of the gel. A 1kb DNA ladder (InVitrogen) was also loaded onto the gel to 
analyse the size of DNA samples. Electrophoresis was performed at 100v for 
approximately 30 minutes allowing the fragments to completely separate. On 
completion, the agarose gel was immersed in Ethidium Bromide (1μg/ml) diluted in 
H2O for 20 minutes. The DNA bands were visualised by placing the gel into a UV 
transluminator and the image was captured using Alpha Imager software. 
2.9.4 Real time RT-PCR 
A 20µl reaction mix was used; each sample contained 3µl cDNA, 10µl ABI Taqman 
Master Mix (Applied Biosystems, US) 1µl primer/probe (Table 2.2 outlines the different 
primers used) and 6µl nuclease free water. GAPDH primer was used as a reference and 
cDNA negative and positive controls (in house decidua control RNA) were included in 
each run. Real time RT-PCR was performed using an ABI7000 (Applied Biosystems) PCR 
machine and probes labelled with the fluorophore 6-FAM and quencher TAMRA. The 
reaction was performed in triplicate.     
 
Table 2.2 Primers used for real time RT-PCR 
Table showing real time primers used with assay ID and size of gene product. All primers were 
pre-designed by Applied Biosystems- TaqMan® Gene Expression Assays on Demand.   
Primers Assay ID Amplicon length 
GAPDH Hs99999905_m1 122 bp 
Gp130 Hs00174360_m1 72 bp 
IL-6R Hs01075667_m1 111 bp 
CXCR2 Hs01011557_m1 91 bp 
TIMP-1 Hs00171558_m1 104 bp 
IL-1β Hs01555410_m1 91 bp 
RANTES Hs00174575_m1 63 bp 
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2.9.5 Analysis of data 
The amount of fluorescence being emitted increases exponentially in the PCR reaction, 
therefore the amount of cDNA doubles with every cycle of PCR. The number of cycles 
in which the gene is amplified is called the cycle number. If a gene requires a high 
number of cycles before amplification (increasing fluorescence) is detected there is 
less expression of this gene within the cells. The number of cycles of gene amplification 
is shown on the x-axis of the graph and the arbitrary fluorescence units are shown on 
the y-axis, this graph is produced by the ABI7000 software. The amplification of a gene 
eventually plateaus, therefore the cycle number at which the increase in fluorescence 
is exponential (linear) is the threshold and a horizontal line is placed onto the graph. 
The point at which the fluorescence crosses the threshold is called the cycle number 
threshold (Ct).    
The data produced from the RT-PCR reactions in this study were exported to Microsoft 
Excel and the Delta-Delta Ct values were calculated from cycle number of the gene of 
interest compared with the housekeeping gene cycle number.  Delta-Delta Ct method 
is an approximate method of gene quantification. The difference between the Ct value 
of GAPDH gene and Ct value of the gene of interest was calculated, this is Delta Ct: 
ΔCt= [Gene of interest Ct value – Reference gene (GAPDH) Ct value] 
In this study IL-6, IL-8 and GAPDH gene expression by the decidual leucocytes were 
quantified in relation to CD8+ T cell expression levels, therefore gene expression in 
CD8+ T cells was used as a control. 
The difference between the Delta Ct value of each gene from each cell population with 
the Delta Ct value of gene expression from CD8+ T cells is the Delta-Delta Ct value: 
ΔΔCt= [Gene ΔCt - Control gene ΔCt] 
The fold change of Delta-Delta Ct of IL-6 and IL-8 gene expression in deciual CD10+, 
CD14+ and CD56+ cell populations were then calculated in reference to gene 
expression levels in the decidual CD8+ T cells. 
The Delta-Delta Ct method was also used when comparing IL-6 treated EVT cells with 
untreated EVT when investigating whether IL-6 altered the gene expression profiles of 
growth factors produced by EVT (Chapter 4).      
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2.10 Enzyme-linked immunosorbent assay (ELISA) 
2.10.1 Sandwich ELISA protocol 
To detect and quantify the levels of secreted IL-6 and IL-8 from decidual cell 
supernatants at 8-10 weeks and 12-14 weeks gestation and from normal pregnancy 
and evacuated products of conception following spontaneous miscarriage (section 
2.3.2.2), sandwich ELISAs were performed (Figure 2.6). Isolated decidual CD14+ cell 
supernatants taken at 8-10 weeks and 12-14 weeks gestation were also measured for 
the presence of VEGF-C, ANG-1, TGF-β1 and PlGF (see section 2.10.1.1).  
All ELISAs performed in this study were carried out using 96-well microplates (R&D 
Systems Ltd, UK). All reagents used were supplied by either Peprotech Ltd or R&D 
Systems unless otherwise stated. Initially capture antibody was diluted to a working 
concentration in PBS (pH 7.4) and 100µl of working capture antibody solution was 
coated onto the wells of the microplates, the plates were sealed using adhesive strips 
and capture antibody was incubated overnight at room temperature.  Following 
overnight incubation any non-bound antibody was washed and aspirated by using a 
wash buffer (0.05% Tween 20 in PBS pH 7.4); this wash/aspiration step was further 
repeated for 3 times. The microplates were then blocked by adding 300µl of block 
buffer per well (1% BSA (Sigma) in PBS) and incubated at room temperature for 1 hour.  
The wash/aspiration step was repeated as previously mentioned for a total of 3 times. 
A stock standard solution was diluted to a working concentration in reagent dileunt 
(sections 2.10.1.1 and 2.10.1.2) and serial dilutions were made to make an 8-point 
standard curve. Samples were also diluted in reagent dileunt. 100µl of standards and 
samples were added to corresponding wells and incubated for 2 hours at room 
temperature. The wash/aspiration step was again repeated 3 times. 100µl of detection 
antibody was then applied to the wells and was incubated for a further 2 hours at 
room temperature. Following incubation the wash step was again repeated. See 
section 2.10.1.1 for R&D detection method and section 2.10.1.2 for Peprotech Ltd 
detection method.           
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Figure 2.6 Schematic representation of a Sandwich ELISA 
Image modified from ThermoScientific illustrating the mechanism of the sandwich ELISA.  
2.10.1.1 Duoset R&D systems 
The detection of IL-8, VEGF-C, ANG-1, TGF-β1 and PlGF were determined using human 
DuoSet® ELISA development kits (R&D systems, UK) and the protocol was performed 
according to the manufacturer’s instructions. Samples were diluted 1:2 in reagent 
diluent (0.1% BSA (sigma), 0.05% Tween 20in TBS pH 7.4 sterile filtered). The 
streptavidin-HRP conjugate was diluted to 1:200 in reagent diluent; 100µl was added 
to each well and incubated for 20 minutes in the dark at room temperature. Following 
incubation the plate was washed and aspirated x 3 (as described in section 2.10.1) 
before addition of 100µl substrate solution (1:1 ratio of solution A and solution B) per 
well which was incubated for a further 20 minutes in the dark at room temperature. 
50µl of STOP solution (2N H2SO4) was then added to each well until colour developed. 
Colour development was measured using an ELISA plate reader and the optical density 
was determined using Softmax pro with a wavelength setting of 450nm corrected at 
540nm. The concentration of IL-8, VEGF-C, ANG-1, TGF-β1 and PLGF were determined 
with reference to an 8-point standard curve with top standard concentrations of 
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2000pg ml-1, 6000pg ml -1, 10000pg ml-1, 2000pg ml-1, 2000pg ml-1 respectively. All 
samples were run in duplicate and the mean value of the duplicates was used in the 
analysis. 
2.10.1.2 Peprotech Ltd 
The detection of IL-6 was determined using a human IL-6 ELISA development kit 
(Peprotech EC Ltd, UK) and the protocol performed according to the manufacturer’s 
instructions. Samples were diluted 1:2 in diluents buffer (0.05% Tween 20, 0.1% BSA in 
PBS, sterile filtered). The avidin-HRP enzyme conjugate was diluted to 1:2000 in diluent 
buffer and 100µl was added to each well and incubated for 30 minutes in the dark at 
room temperature. Following incubation 100µl of 2,2'-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid) (ABTS) substrate solution (Sigma) was added to 
each well and was incubated at room temperature until colour developed. Colour 
development was measured using an ELISA plate reader (photospectrometer) and the 
optical density was determined using Softmax pro with a wavelength setting of 405-
650nm. The concentration of IL-6 was determined with reference to an 8-point 
standard curve with a top standard concentration of 2000pg ml-1. All samples were run 
in duplicate with the mean value of the duplicates was used in the analysis. 
2.11 Western Blotting 
IL-6 receptor expression was investigated by Western blot analysis.  
2.11.1 Protein extraction 
Protein was obtained from whole cell lysates of isolated EVT cells (section 2.3.5.1) and 
confluent HTR-8/SVneo cells (section 2.4.1).  
2.11.2 Protein quantification 
20µg protein was determined with BioRad DC protein assay which was followed 
according to the manufacturer’s instructions:  
1. Prepare working reagent A- 20µl of reagent S to 1ml reagent A. 
2. Prepare serial dilutions of protein standards from 1.4mgml-1 of BSA (Sigma) 
to 0.2mg ml-1 in lysis buffer for standard curve.  
3. Pipette 5µl/well of standards and samples into a 96 well plate in duplicate. 
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4. Add 25µl of working reagent A followed by 200µl of reagent B. 
5. After 15 minutes the absorbance can be read at 750nm. 
The protein concentration of samples was determined from the standard curve. 
 
2.11.3 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
For details of all buffers and gels see Appendix. 
Gel preparation: The glass plate sandwich (BioRad assembly card) was assembled 
before adding separation gel. The separation gel was filled up to 1cm below from the 
top of the glass slide (for comb) and overlaid with isopropanol. The gel was allowed to 
polymerise for 45 minutes before pouring off the isopropanol and topped the set 
separating gel with the stacking gel and inserted the combs.  The stacking gel was 
incubated for 45 minutes and the combs were removed, leaving behind wells in the 
gel. The size of gel was determined for each specific protein investigated (see Appendix 
and result chapters for more details).  
5µl of protein loading buffer was added to 20µl cell lysates and heated at 95°C for 5 
minutes. The reduced samples were loaded into the wells (total volume 25µl per well) 
along with 10µl protein marker ladder (Invitrogen) into  an electrode tank filled with 1x 
electrode buffer and set to 100V and run until dye position has reached the bottom of 
the gel (1-2hours). Following electrophoresis, the gel slides were removed from the 
chamber, the stacking gel was removed and was allowed to equilibrate in cold transfer 
buffer for 5 minutes. The immunobilon P membranes (Millipore, Bedford, MA) were 
soaked in methanol for 15 minutes and then allowed to equilibrate in transfer buffer. 
The sponge and filter papers on plastic binders were prepared and immersed in 
transfer buffer before adding the gels and membranes. The plastic binders were closed 
and placed into an electrode tank filled with cold transfer buffer and blotted for 2 
hours at 100V. Following blotting the membranes were removed and blocked in 5% 
milk in TBS-T at 4°C overnight ready for probing with antibody (section 2.11.4).           
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2.11.4 Immunodetection 
After overnight incubation the membrane blots were removed from the blocking 
solution and washed in TBS-T (TBS-0.05%Tween20). The primary antibody (for list of 
specific antibodies and dilutions see experimental design in results chapters) was 
diluted in milk blocking solution. The membrane blot was then incubated in primary 
antibody for 1-2 hours depending on the antibody (see individual chapters), on a 
shaker at room temperature. The membrane blot was then washed in TBS-T for 3 x 5 
minutes before addition of secondary antibody which was incubated for 1-2 hours at 
room temperature. The membrane blot was washed for a further 3 x 5 minutes before 
ECL detection (section 2.11.5).  
2.11.5 Chemical detection of protein and developing signal 
All antibodies were subsequently developed using chemiluminscence (Thermo 
Scientific, Rockford, USA) according to the manufacturer’s instructions and recorded 
by X-ray Kodak Scientific Imaging film (Sigma Chemical Co.).    
2.12 Statistical analysis of results 
Data are presented as the mean ± SEM. Data were statistically analysed using the 
commercial software package, StatView (Abacus Concepts Inc., Berkley, US). 
Differences were considered statistically significant at P< 0.05. 
2.12.1 Student’s t-test 
Student’s t-test was performed in order to compare two sets of continuous data with 
normal distribution. 
2.12.2 One-way ANOVA test 
To analyse the mean of two or more sets of samples a one way analysis of variance 
(ANOVA) followed by Fisher’s post hoc analysis was used. 
2.12.3 Non-parametric tests 
For data that was found to have an irregular distribution (not normal) a non 
parametric test was performed. Mann Whitney U tests were applied for skewed data.   
 
 
Chapter 3 
Expression of interleukins-6 and -8, and their receptors in 
placental bed in early human pregnancy and miscarriage 
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3. Expression of IL-6 and IL-8 and their receptors in placental 
bed in early human pregnancy and miscarriage 
3.1 Introduction 
Cytokines are regulatory proteins that play a dominant role in immune responses. 
Although Th2 cytokines are abundant systemically, the role of these cytokines in early 
pregnancy is not well understood, although Th2 cytokines in general have been 
suggested to play an important role in development of successful pregnancy. However 
evidence suggests that Th1 inflammatory response cytokines are important proteins 
for successful pregnancy. 
T-cells were originally hypothesised to be the main source of these cytokines in 
pregnancy (Piccinni, 2005) but this cell type exists as a minor leucocyte population in 
human decidua. The focus has been shifted onto uterine natural killer cells and uterine 
macrophages as being a rich source of cytokines.    
The suggested roles of IL-6 and IL-8 during early human pregnancy have been reviewed 
in Chapter 1. They are thought to be important functional mediators during pregnancy 
but only a small number of studies have investigated these cytokines in early 
pregnancy and pregnancy complications. Although both cytokines have been 
implicated in pregnancy disorders, the production and source of these cytokines within 
uteroplacental tissues has not previously been thoroughly investigated. Studies to date 
have mainly focused on the effect of IL-6 and IL-8 in endometriosis (Ulukus et al., 2005, 
Luk et al., 2005), chorioamnionitis (Arntzen et al., 1998), cervical ripening and 
parturition (Robertson et al., 2010, Prins et al., 2012) but detailed examination of 
localisation and gestational age variation in normal pregnancy has not been 
performed.  
Bowen et al. (2002) reviewed the production of cytokines in placenta and placental 
tissues and most cytokines have been localised to these tissues during normal 
pregnancy indicating proposed roles for cytokines in pregnancy. Placental tissue such 
as chorionic villi and trophoblast cells have been reported to produce IL-6 (Kauma et 
al., 1993) and IL-8 and its receptors have been localised to cells of the placenta (Saito 
et al., 1994, Dame and Juul, 2000). Despite these investigations in placenta, the 
production levels of IL-6 and IL-8 from specific decidual leucocytes, localisation and 
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distribution within the placental bed and decidual tissues in pregnancy remain limited 
and changes within protein levels at different gestations also remains to be 
investigated.   
In the decidua uterine natural killer cells are a rich source of many different cytokines 
and growth factors including TNF-α, IL-10, IL-1β, LIF, GM-CSF and IFN-γ (Lash et al., 
2006c). The functional role of these cytokines in pregnancy has been sparingly 
investigated and results suggest a potential role in regulating trophoblast invasion and 
the control of vascular remodelling but a function for uNK cells and the cytokines they 
secrete still remains unknown. IL-6 production by these cells has not yet been 
investigated in great detail.  
Previous work in our laboratory had focused on the localisation of IL-8 in placental bed 
and its production by uNK cells and CD8+ T cells (Figure 3.1) (De Oliveira et al., 2010). 
The main reason for the study was to investigate the role of IL-8 on EVT invasion and 
IL-8 receptors (CXCR1 and CXCR2) were localised to EVT cells in placental bed (Figure 
3.2). This study extends the investigation to include IL-8 production by other cell types 
of the placental bed and the localisation of IL-8 receptors elsewhere in the placental 
bed, especially focusing on receptor expression by SpAs. Aminopeptidase-N (CD13; see 
Chapter 1) relating to IL-8 signalling has also been investigated in this study. 
The roles of IL-6 and IL-8 in early pregnancy remain largely understood but altered 
serum levels of pro inflammatory cytokines including IL-6 and IL-8 have been 
associated with first trimester sporadic miscarriage (Galazios et al., 2011, Calleja-Agius 
et al., 2012) and although altered levels of these cytokines and their receptors in 
specific pregnant tissues have not been investigated, these data suggest a possible 
importance for these cytokines in normal early pregnancy processes; their roles in 
angiogenesis, cell invasion and inflammation in other tissues and disease states 
suggest a potential role in regulating spiral artery remodelling and regulating 
trophoblast invasion.     
In order to understand the potential role of IL-6 and IL-8 in pregnancy and 
reproductive complications, a detailed understanding of the production and function 
of these cytokines in normal pregnancy is essential. This chapter presents data on 
production and localisation of IL-6 and IL-6 receptor expression and further 
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investigates IL-8 and IL-8 receptor expression in normal early pregnancy as a basis for 
study of their function.  
 
Figure 3.1 
Immunohistochemistry of 
IL-8 staining on CD56+ and 
CD8+ cells in first trimester 
placental bed biopsies 
Representative 
immunohistochemistry 
demonstrating CD56+ cells 
(top) and CD8+cells (centre) 
within FFPE placental bed 
biopsies of first trimester 
pregnancy. Double 
immunostaining for CD56+ 
cells (Purple) also shows IL-
8 expression (brown). 
Representative 
immunostaining for CD8= 
cells (centre) and a serial 
section demonstrates 
positive immunostaining for 
IL-8 in proximity to CD8+ T 
cells. Original magnification 
x400. 
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Figure 3.2 
Immunohistochemistry of 
IL-8 receptor staining 
(CXCR1 and CXCR2) by EVT 
cells in first trimester 
placental bed biopsies 
Representative 
immunohistochemistry 
demonstrating cytokeratin-
7 immunopositive cells 
which identifies EVT in FFPE 
placental bed biopsies of 
first trimester pregnancy. 
Serial sections 
immunostained for IL-8 
receptors (CXCR1 and 
CXCR2) show positive 
staining by EVT cells, 
confirming the expression 
of IL-8 receptors by 
trophoblast cells. Positive 
immunostaining of both 
receptors are evident on 
endovascular, intramural 
and interstitial EVT. PAS 
staining highlights fibrinoid 
deposition in remodelled 
SpA. Original magnification 
x400. 
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3.2 Aims and Hypotheses 
3.2.1 Hypotheses 
1. IL-6 and IL-8 are produced by decidual cells within the placental bed in early 
human pregnancy 
2. Uterine natural killer cells, uterine macrophages and T cells are all sources IL-6 
and IL-8 in early human pregnancy with increased expression levels at 12-14 
weeks gestation compared with 8-10 weeks gestation.  
3. Uterine natural killer cells are the major producer of both IL-6 and IL-8 within 
the placental bed in the first half of pregnancy.  
4. IL-6 and IL-8 receptors are expressed by cells within the placental bed in early 
human pregnancy 
5. Levels of IL-6 and IL-8 are increased in sporadic miscarriage. 
3.2.2 Aims 
1) Investigate the localisation of IL6, IL-8 and their receptors; IL-6Rα, gp130, 
CXCR1,CXCR2 using immunohistochemistry and laser capture microdissection 
2) Measure IL-6 and IL-8 protein production from isolated decidual cell culture 
supernatants 
3) Measure mRNA expression of IL-6 and IL-8 from isolated decidual cell 
populations 
4) Investigate localisation of IL-6, IL-8 and their receptors between normal 
pregnancy and sporadic miscarriage using immunohistochemistry. 
5) Compare IL-6 and IL-8 protein expression by decidual CD14+ and CD56+ cells 
isolated from early normal pregnancy and early sporadic miscarriage using 
ELISA. 
3.3 Experimental design 
3.3.1 Tissues   
Placental bed biopsies were obtained from women undergoing elective TOP in first half 
of pregnancy (refer to section 2.1.3). Freshly obtained tissue from healthy pregnancy 
was snap frozen or formalin fixed and paraffin embedded (refer to section 2.1.8) and 
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used for immunohistochemical analysis (Table 3.1 for sample numbers and Table 3.2 
for primary antibodies use).  
Gestational age matched placental bed biopsies were also used from a former study 
obtained from women undergoing evacuation of retained products of conception 
(ERPC) following sporadic miscarriage (SM) and classified as either early euploid, early 
aneuploid, late euploid or late aneuploid, based on gestational age and cytogenetic 
analysis (Table 3.1) (Ball et al., 2006a, Ball et al., 2006b). All SM placental bed biopsies 
were snap frozen, fixed and cut into 3µm sections as previously described in section 
2.1.8 for immunohistochemical analysis.    
Placental bed biopsies obtained from healthy pregnancy were either snap frozen or 
formalin fixed and paraffin embedded and used for immunohistochemical analysis.  
All samples were subjected to immunohistochemical analysis to identify EVT, SpAs and 
decidual cell leucocytes within the placental bed and IL-6, IL-8 and their receptor 
proteins were identified by positive staining on these cell types. Immunostaining was 
compared between SM tissue and normal pregnancy samples using a scoring method 
outlined in section 3.3.3.   
Decidual tissue was obtained from women undergoing TOP at 8-10 and 12-14 weeks 
gestational age for positive immunomagnetic isolation of CD56+, CD14+, CD10+ and 
CD8+ cells for RT-PCR (T=0) and cell culture supernatants (T=24h; section 2.3.2) in order 
to investigate whether the cell types express IL-6 and IL-8 mRNA and quantify protein 
production by ELISA (sample numbers are listed in Table 3.1). 
Decidual tissue was also obtained from women undergoing ERPC following early 
sporadic miscarriage (section 2.1.4) and used for positive immunoselection of CD56+ 
(section 2.3.2) and CD14+ cells (section 2.3.4) from which cell culture supernatants 
were harvested for analysis of cytokine production to compare levels of IL-6 and IL-8 in 
sporadic miscarriage and normal healthy pregnancy decidua (Table 3.1).   
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Table 3.1 Details of subject groups, sample number sizes and procedures performed in 
Chapter 3 
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3.3.2 Immunolocalisation and specific antibodies used 
For all FFPE placental bed tissue sections immunohistochemical labelling was 
performed as described in section 2.3.1 for the identification of the different cell 
populations including uNK cells, EVT cell populations, spiral artery VSMCs within the 
placental bed using mouse monoclonal antibodies. Details of primary antibodies, 
specificities and pre treatments are given in Table 3.2. Serial sections were then 
immunolabelled with anti-IL-6 and anti-IL-8 antibodies along with antibodies against 
their receptors; gp130, IL-6Rα, CXCR1, CXCR2 (Table 3.2 and 3.3). IL-6Rα, CXCR1 and 
CXCR2 were identified using frozen sections. Frozen sections of placental bed biopsies 
from both normal and miscarriage pregnancy were immunolabelled with antibodies 
detailed in Table 3.3 and immunohistochemistry was performed as described in 
Section 2.3.1. For any given antibody, all tissue sections were immunostained in the 
same staining run to avoid day-day variation. Positive controls were included for each 
antibody in each staining run; negative controls were performed for each sample by 
replacing primary antibody with appropriate non-immune serum.   
 
Table 3.2 Primary antibodies used for immunohistochemistry on FFPE tissue sections 
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Table 3.3 Primary antibodies used for immunohistochemistry on frozen tissue sections 
 
 
3.3.3 Immunohistochemical scoring  
A quickscore was used to assess the immunohistochemical staining taking into account 
proportion and intensity of staining (Schiessl et al., 2009). A 4 point scale was used to 
determine the proportion of positively stained cells; 1<25%, 2= 25-50%, 3=50-75% and 
4>75% and a 3 point scale used for staining intensity; 1= weak staining, 2= moderate 
staining and 3= strong staining. The scores for amount of staining and intensity of 
staining were multiplied together to give a final immune score to a maximum of 12 
(high amounts of very strong staining). For example 50% of cells in the section 
analysed were positively stained and the intensity of that staining was moderate 
therefore, the score would be 6 (3x2).  
3.3.4 ELISA 
Decidual CD56+, CD14+, CD10+ and CD8+ cell culture supernatants (t=24h) isolated from 
normal pregnant decidua (8-10 and 12-14weeks GA) along with total decidual cells 
were subjected to ELISA to measure IL-6 and IL-8 protein concentrations to confirm 
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cytokine production by these cell types are producers of both cytokines and to 
quantify levels at different gestations (section 3.3.1). IL-6 and IL-8 protein levels were 
also measured from CD56+ and CD14+ cell culture supernatants isolated from early 
sporadic miscarriage decidua (≤12 weeks GA) and quantities were compared with 
normal pregnancy.     
All decidual cell culture supernatants were isolated by midimacs positive immune 
selection (sections 2.3.2 and 2.3.4). Cells were checked for purity after isolation by 
preparing cell smears and performing immunocytochemistry (section 2.3.3).  
A top standard of 2000pgml-1 was used for both IL-6 and IL-8 ELISAs (section 2.10) and 
a 7point standard curve was used as a reference (4PL curve).  Sample numbers used 
for ELISAs are indicated in table 3.1 
Briefly, samples were plated in duplicate, diluted by a factor of 2 in reagent diluents 
(see Appendix) and 100µl of sample was added to ELISA plates blocked with the 
appropriate capture antibody and steps were followed according to manufacturer’s 
instructions (see section 2.10). ELISA plates were then read using a plate reader and 
protein concentrations were calculated.  
3.3.5 RT-PCR 
Total RNA was extracted using TRIZOL method (section 2.9.1) from decidual cell 
populations CD56+, CD14+, CD10+ and CD8+ at T=0 isolated from 8-10 weeks gestation 
decidua using immunopositive magnetic selection (n=5 for each cell population). CD56+ 
cells were also isolated at T=0 from 12-14 weeks gestation decidua (n=4). 500ng of 
RNA was reverse transcribed into cDNA using Superscript III (section 2.9.2). 2µl of 
cDNA was used for PCR along with either IL-6, IL-8 or GAPDH primer pairs (IL-6, IL-8 
and GAPDH Assay on demand, Applied Biosystems, USA) and real time RT-PCR was 
performed to 40 cycles (section 2.9.4). Data are presented as the ratio of the amount 
of IL-6/IL-8 to GAPDH.  
To confirm amplicon length some of the IL-6 PCR products from CD56+ cells were 
separated on 1% agarose gel soaked in ethidium bromide and bands were visualised at 
95bp for IL-6cDNA and 250bp for GAPDH cDNA (section 2.9.3 for method).   
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For Laser capture microdissection of placental bed biopsies, they were initially stained 
and prepared (section 2.8). Spiral arteries were identified using immunohistochemistry 
on serial frozen sections (H-Caldesmon and CD31) alongside the prepared sections for 
LCM. The VSMC cell layer of the spiral arteries were the cells of interest and the 
remaining tissue and vessel endothelium were cut away. RNA was then extracted from 
the VSMCs and reverse transcribed (section 2.9.1). Primers for CXCR2, gp130 and IL-
6Rα were used for real time RT PCR. 
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3.4 Results 
3.4.1 Immunohistochemical characterisation of decidual cell populations 
in placental bed biopsies 
The maternal-fetal interface contains numerous different cell populations (Figure 3.3) 
and in order to initially identify the different cell populations within the placental bed 
of early pregnancy FFPE tissue sections were subjected to immunohistochemical 
analysis (Table 3.2).  
Positive cytokeratin-7 staining was observed in all tissue sections stained with the 
antibody. The cytokeratin-7 staining within the placental bed represents glandular 
epithelium and EVT cells; interstitial EVT cells observed embedded in the decidual 
tissue and inner third myometrium (Figure 3.3A); endovascular EVT observed in the 
lumen of spiral arteries (Figure 3.3B) and intramural EVT embedded in the VSMC wall 
of spiral arteries (Figure 3.3C). EVT cells were distinguished by their large appearance 
and unstructured nature embedded throughout the tissue whereas glandular 
epithelium was distinguished by their laminar, structured appearance, which 
surrounded the glandular wall. Positive CD56 staining within the placental bed 
represents uNK cells and these cells were only observed in the decidua and in 
superficial myometrium (Figure 3.3D). Positive CD14 immunostaining represents 
macrophages and dendritic cells within the placental bed (Figure 3.3E) and cells 
immunopositive for CD3 and CD8 (Figure 3.3F and 3.3G) represents T-cells and the 
cytotoxic T cell subset respectively. Uterine spiral arteries were identified in the 
placental bed by their thick muscular vascular wall which is demonstrated by positive 
H-Caldesmon immunostaining (Figure 3.3H) and SpA endothelium is demonstrated by 
CD31 positive immunostaining (Figure 3.3I) which lines the lumen of the arteries.     
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Figure 3.3 Immunohistochemistry demonstrating different cell types within the placental 
bed of first trimester pregnancy 
Representative immunohistochemistry showing the different cell types in the placental bed in 
first trimester pregnancy and how they were identified in FFPE tissue sections. A: positive CK-7 
staining demonstrating iEVT; B: positive CK-7 staining within SpA lumen demonstrating eEVT; 
C: positive CK-7 staining in VSMC wall of SpAs demonstrating inEVT; D: positive CD56 staining 
demonstrating uNK cells; E: positive CD14 staining demonstrating uterine macrophages and 
dendritic cells; F: positive CD3 staining demonstrating T-cells: G: positive CD8 staining 
demonstrating cytotoxic T cell subset; H: positive H-Caldesmon staining demonstrating VSMC 
wall of spiral arteries; I: positive CD31 staining demonstrating endothelium of SpAs (n=10 for 
both 8-10 and 12-14 weeks gestation). Image A, C, D, E, F, G, H, I original magnification x200; 
Image B original magnification x100.    
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3.4.2 Immunohistochemical analysis of expression of IL-6, IL-8 and their 
receptors in normal placental bed  
An immunohistochemical study was performed to investigate whether the cell 
populations within the placental bed of early pregnancies express the cytokine IL-6. IL-
6 receptor expression was also investigated on EVT and IL-6 receptor expression along 
with IL-8 receptor expression was investigated on spiral arteries to investigate whether 
these cytokines have the potential to play a functional role in the SpA transformation/ 
remodelling required for successful pregnancy. 
3.4.2.1 IL-6 immunolocalisation 
IL-6 immunostaining was observed throughout the placental bed and was not defined 
to one particular area. The majority of cells within the placental bed were in proximity 
to IL-6 immunostaining. The proportion of IL-6 staining in decidua was between 50-
75% in all samples and the intensity of IL-6 staining was moderately expressed.  
IL-6 expression was observed on CD56+ immunostained cells in adjacent sections 
(Figure 3.4). CD56 immunopositive uNK cells were abundant in decidua in the placental 
bed at 8-10weeks gestation (Figure 3.4A) and roughly 50% of the CD56+  cells were 
immunostained positive for IL-6 in the near serial sections (Figure 3.4B). 
Representative immunostaining for CD8+ cells and IL-6 expression is shown in Figure 
3.5. CD8 immunopositive T-cells in the placental bed at 8-10 weeks gestation (Figure 
3.5A) were immunopositive for IL-6 in near serial sections (Figure 3.5B).  
IL-6 immunostaining in placental bed was quantified using a quickscore and compared 
between 3 gestational age groups (section 3.3.3) n=5 each gestational age group 
(Figure 3.6). There were no differences observed in the amount of CD56+ (Figure 3.6A), 
CD8+ (Figure 3.6B) and IL-6 positively stained cells in the different gestational age 
groups (n=5 all 3 age groups; 8-10, 12-14, 16-20 weeks gestation).  
In addition to CD56+ and CD8+ cells, IL-6 immuno-positivity was also localised to other 
decidual cells, including stromal cells, glandular epithelial cells and EVT.   
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Figure 3.4 Immunohistochemistry demonstrating IL-6 localisation to uNK cells 
Representative immunostaining of placental bed biopsies demonstrating localisation of IL-6 to 
uNK cells. A: CD56+ cells, indicating uNK cells in a 10 week placental bed biopsy. B: IL-6 positive 
cells localised in proximity of uNK cells in near serial section x400 magnification.   
 
 
Figure 3.5 Immunohistochemistry demonstrating IL-6 localisation to CD8+ T cells 
Representative immunostaining of placental bed biopsies demonstrating localisation of IL-6 to 
T-lymphocytes. A: CD8+ cells, indicating T-lymphocytes in a 10 week placental bed biopsy. B: IL-
6 positive cells localised in proximity of T-cells in near serial section x400 magnification. 
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Figure 3.6 Graphical representation of the amount of CD56+ and CD8+ immunostaining in 
decidua in the first half of pregnancy    
Quickscore assessment of immunostaining (1-12; % of staining x intensity) showing IL-6 
positive staining expressed by A: CD56+ cells in decidua of placental bed biopsies and B: CD8+ T-
cells in decidua of placental bed biopsies at 8-10, 12-14 and 16-20 weeks gestation (n=5 each 
age group). Data are presented as mean ± SEM.      
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3.4.2.2 IL-6 receptor expression on EVT 
IL-6 receptors gp130 and IL-6Rα were both immunolocalised to EVT within the 
placental bed (Figure 3.7) at 8-10, 12-14 and 16-20 weeks gestational age. 
Immunohistochemistry demonstrates cytokeratin-7 immunopositive cells representing 
interstitial EVT cells in placental bed (myometrium and decidua) (Figure 3.7A) near 
serial sections represent positive immunostaining of gp130 expressed by EVT cells 
(Figure 3.7B). Approximately 75% of all EVT cells in each sample observed were 
immunopositive for gp130 receptor.  
EVT cells identified in frozen tissue sections of placental bed biopsies were also 
immunopositive forIL-6Rα (Figure 3.7C). However, the proportion of IL-6Rα 
immunostaining by EVT was not a prevalent as gp130 immunostaining by EVT.       
Quantification of positive gp130 immunostaining on EVT cells in placental bed  
between gestational age groups was assessed using quickscore assessment (Section 
3.3.3) n=5 each gestational age group (Figure 3.8). IL-6Rα was not quantified due to IL-
6Rα antibody being specific for frozen tissue sections only; therefore a qualitative 
assessment was only made.  
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Figure 3.7 Representative immunohistochemistry of IL-6 receptor staining (gp130 and IL-6Rα) 
by EVT cells in a placental bed biopsy 
Representative immunohistochemistry demonstrating EVT cells in an 18 week FFPE placental 
bed biopsy (A) and these cells are immunopositive for gp130 (B) and EVT cells are 
immunopositive for IL-6Rα in frozen tissue section at 19 weeks gestation (C) (n=5 each age 
group). Image of negative control included (non-immune serum) in FFPE placental bed biopsy 
at 16 weeks gestation (D). Magnification x400 for EVT and gp130; x200 magnification for IL-
6Rα; x100 magnification for negative control.   
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Figure 3.8 Graphical representation of the amount of gp130 immunostaining on interstitial 
EVT cells in the first half of pregnancy    
Graph demonstrating immunohistochemistry data showing quickscore assessment of gp130 
positive staining on iEVT cells in the placental bed at 8-10, 12-14 and 16-20 weeks gestation 
(n=5 each age group). Data are presented as mean ± SEM. 
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3.4.2.3 Expression of IL-6 and IL-8 receptors on spiral arteries 
In order to investigate whether IL-6 and IL-8 may play a functional role in the 
remodelling processes of the uterine spiral arteries in the first half of pregnancy, 
cytokine receptor expression was assessed on decidual spiral arteries (SpAs) in 
placental bed of early pregnancy. 
Both of the receptors for IL-6 (IL-6Rα and gp130) were expressed on decidual spiral 
arteries (Figure 3.9). Positive H-Caldesmon immunostaining in frozen tissue sections of 
placental bed biopsies was used to identify VSMCs within the wall of spiral arteries 
(Figure 3.9A) and these muscle cells were immunopositive for IL-6Rα in serial sections 
(Figure 3.9B). Positive immunostaining for myosin heavy chain was used to localise the 
VSMC wall of decidual spiral arteries in FFPE placental bed biopsies (Figure 3.9C). 
Positive staining for gp130 was evident on the luminal endothelium of the SpA in near 
serial sections, although the immunostaining was fairly weak; there were very few 
gp130 immunopositive cells within the VSMCs in the wall of the arteries (Figure 3.9D).     
The receptors for IL-8; CXCR1 and CXCR2 were also expressed on spiral arteries in early 
pregnancy (8-14 weeks GA) shown by immunopositive staining in placental bed 
biopsies (Figure 3.10). Immunostaining for both CXCR1 and CXCR2 was localised to 
iEVT cells (1), SpA VSMCs (2) and endothelial cells of the spiral arteries (3) (CXCR1- 
Figure 3.10B; CXCR2- Figure 3.10C). Immunostaining of both receptors was more 
intense on endothelial cells of the spiral arteries compared to the other cell types 
investigated.       
CXCR1 and CXCR2 immunostaining was also observed by other cells of the placental 
bed, with CXCR1 being very highly expressed by most cells.   
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Figure 3.9 Immunohistochemistry demonstrating IL-6 receptor (gp130 and IL-6Rα) staining 
on decidual spiral arteries in first trimester pregnancy 
Immunohistochemistry demonstrating decidual spiral arteries in early pregnancy (8-14 weeks 
GA) in frozen (A; x200 magnification) and FFPE (C; x100 magnification) placental bed biopsies. 
Serial sections demonstrate positive IL-6Rα expression on VSMC of spiral arteries (B; x200 
magnification) and positive gp130 expression on endothelial cells lining the lumen of SpAs (D; 
x100 magnification).  
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Figure 3.10 Immunohistochemistry demonstrating IL-8 receptor (CXCR1 and CXCR2) staining 
on decidual spiral arteries in first trimester pregnancy 
Immunohistochemistry demonstrating a spiral artery in first trimester pregnancy (A) 1: EVT; 2 
VSMC and 3: endothelial cells. Serial sections representing positive staining (brown) of CXCR1 
and CXCR2 on EVT, the endothelium and VSMC of the spiral artery (B and C, respectively). 
Serial section (A) also represents CK7 immunopositive cells showing EVT.  Original 
magnification x400. Negative control (non-immune serum) image included (D) magnification 
x100. 
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3.4.3 IL-6 and IL-8 protein production by decidual cell populations 
Previous work by De Oliveira et al. (2010) have shown that CD56+ cell culture 
supernatants (T=24h) secrete large amounts of IL-8 with a significant increase at 12-14 
weeks gestation compared with 8-10 weeks gestation (Figure 3.11).  
In this study secretion of IL-8 protein by total decidual cells and other decidual types 
including, CD8+, CD10+ and CD14+ cells was investigated. As well as secretion of IL-6 by 
CD56+ cells including total decidual cells and other decidual cell types at 8-10 and 12-14 
weeks gestation (numbers of samples are indicated in Table 3.1) t=24h.    
3.4.3.1 Secretion by CD56+, CD10+, CD8+ and CD14+ cell culture supernatants 
IL-6 and IL-8 are secreted by all the decidual cell types investigated at both 8-10 and 
12-14 weeks gestation in normal pregnancy (Figure 3.12A and B).  
IL-8 was produced at higher levels within the decidua (Figure 3.12B) than IL-6 protein 
levels (Figure 3.12A). The total non adhered decidual cell population produced 
~10000pgml-1 of IL-8 protein at 8-10 weeks gestation compared with ~6500pgml-1 IL-6 
and at 12-14 weeks gestation there was 10 fold higher levels of IL-8 compared with IL-6 
levels. The majority of IL-8 protein secreted by the total decidual cell populations was 
secreted by the cell types investigated, whereas other cell types within the decidua 
which have not been investigated also secreted IL-6 protein, along with the cell types 
investigated.  
Decidual CD14+ cell culture supernatants (full details of CD14+ supernatant collection is 
reviewed in Chapter 6) expressed the highest amount of IL-6 compared with CD56+, 
CD10+ and CD8+ cell supernatants, although all cell types produced this cytokine 
(Figure 3.12A). In addition, decidual CD14+ and CD8+ cell supernatants secreted the 
highest amounts of IL-8 compared with CD56+ and CD10+ cell supernatants (Figure 
3.12B). 
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Figure 3.11 IL-8 protein secretion by decidual CD56+ and CD8+ cells at 8-10 and 12-14 weeks 
gestation 
Image extracted from De Oliveira et al. (2010) demonstrating IL-8 protein secretion from 
decidual CD56 and CD8 cells. CD56 cells produce more IL-8 at 12-14 weeks gestation compared 
with levels at 8-10 weeks gestation. Data are expressed mean ± SEM (n=10 each GA group).  
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Figure 3.12 IL-6 and IL-8 protein secretion by decidual cells at 8-10 and 12-14 weeks gestation 
Graphical representations of IL-6 (A) and IL-8 (B) protein levels secreted by decidual cells at 8-
10 and 12-14 weeks gestation. Data are presented as mean ± SEM. Data also include total 
decidual cells prior to adherence (non-adherent) and total adhered decidual cells. n=10 
samples per cell type at 8-10 weeks gestation and n=5 samples per cell type at 12-14 weeks 
gestation. All samples were run in triplicate in the ELISA.  
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3.4.3.2 Differences in protein production at 8-10 weeks and 12-14 weeks gestation 
IL-6 protein levels by the total decidual cell fraction appear to be more abundant at 8-
10 weeks gestation compared with 12-14 weeks gestation although this difference was 
not significant (Figure 3.12A). There were no gestational differences in IL-6 protein 
levels secreted by decidual CD14+, CD56+ or CD8+ cells. However, CD10+ stromal cells 
secreted significantly higher levels of IL-6 at 12-14 weeks than at 8-10 weeks gestation 
(P=0.0045).  
IL-8 protein levels secreted by the total decidual cell fraction appear to be higher at 12-
14 weeks gestation than 8-10 weeks gestation, but this was significantly different only 
for the total adhered decidual cell population (P=0.0025; figure 3.12B). There were no 
gestational differences in IL-8 protein levels secreted by CD14+, CD8+ or CD10+ cells. 
However, CD56+ cells isolated from 12-14 weeks gestation secreted increased levels of  
IL-8 than at 8-10 weeks gestation (P=0.0150), in agreement with previously published 
data (De Oliveira et al., 2010).       
I further went on to investigate the production of IL-6 and IL-8 by CD14+ and CD56+ 
cells in miscarriage which is later reviewed in this chapter due to CD14+ cells being the 
largest producer of both cytokines from the decidual cell types investigated and the 
gestational differences observed of cytokine levels produced by CD56+ cells. 
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3.4.4 mRNA expression of IL-6 and IL-8 in decidual cell populations  
To confirm IL-6 and IL-8 production by decidual cell populations CD56+ uNK cells, CD14+ 
macrophages, CD10+ stromal cells and CD8+ cytotoxic T-cells were isolated by positive 
magnetic selection from decidual tissue collected from women undergoing TOP at 8-10 
weeks gestation. Cells were collected immediately following isolation (T=0; n=5 each 
cell type) and used for real time RT-PCR. CD56+ cells isolated from decidua from a 
previous study (De Oliveira et al., 2010) had already shown to express IL-8 mRNA n=10 
(Figure 3.13). 
Each of the cell populations investigated expressed IL-6 and IL-8 mRNA transcripts 
(Figure 3.14A and B). A semi quantitative assessment of delta delta ct values 
demonstrated that CD14+, CD10+ and CD8+ cells express higher levels of IL-8 than IL-6 
(Figure 3.14A and B).  
Fold change values also revealed that CD14+ expressed ~20x more IL-6 than CD8+ cells, 
(Figure 3.14A). CD10+ cells expressed ~ 6x more IL-6 than CD8+cells and CD56+ cells 
expressed ~3x more IL-6 than CD8+ cells (Figure 3.14A).  
Fold change values revealed that CD14+ expressed the highest levels of IL-8 in relation 
to CD8+ T cells: CD14+ cells expressed ~10x more IL-8 than CD8+ cells, and CD10+ cells 
expressed ~5x more IL-8 than CD8+ cells (Figure 3.14B).  
Mean delta CT values are shown for IL-6 and IL-8 in each cell population in Table 3.4.  
PCR gel was performed using total decidual cells and CD56+ cells (T=0) to confirm IL-6 
mRNA expression by in decidua. Transcripts were detected at 95 base pairs which 
indicate IL-6 mRNA is expressed with no difference with GA (Figure 3.15).  
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Figure 3.13 CD56+ IL-8mRNA expression at 8-10 weeks gestation 
Image extracted from De Oliveira et al. (2010) demonstrating CD56+ IL-8 mRNA expression. 
Data are expressed mean ± SEM (n=10 8-10 weeks GA). 
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Figure 3.14 IL-6 and IL-8 mRNA expression by decidual cells at 8-10 weeks gestation 
Graphical representation of fold change of IL-6 (A) and IL-8 (B) delta delta ct values of mRNA 
expression relative to CD8+ decidual cells (initial ct values with reference to GAPDH ct values; 
n=5 each cell type at 8-10weeks GA). 
 
125 
 
Table 3.4 Mean Δct values of IL-6 and IL-8 mRNA expression by decidual cells from 8-10 
weeks gestation 
Mean Δct values of IL-6 and IL-8 mRNA expression in reference to GAPDH in four decidual cell 
populations isolated from 8-10 weeks gestation n=5 each cell type 
 
 
. 
 
 
Figure 3.15 RT-PCR gel illustrating IL-6 mRNA expression by CD56+ cells at 8-10 and 12-14 
weeks gestation 
Representative RT-PCR illustrating IL-6 mRNA expression at 95bp (left) at 8-10 and 12-14 
weeks gestational age (T= total decidual cell isolates; uNK= CD56+ cell isolates). GAPDH mRNA 
expression at 250bp (right) is shown as a loading control for the experiment.  
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3.4.5 Expression of IL-6 and IL-8 receptors by spiral arteries 
To further confirm the immunohistochemistry data of IL-6 and IL-8 receptors 
expression on spiral arteries, IL-6 and IL-8 receptor mRNA expression was investigated 
using laser capture microdissection of spiral artery VSMC cells (endothelium removed) 
from 8-10 week placental bed biopsies (n=5).  
IL-6Rα, gp130 and CXCR2 receptor mRNA was detected in VSMCs of spiral arteries at 8-
10 weeks gestation (Figure 3.16), this further verifies the immunohistochemistry 
results and confirms that gp130 expression is lower on SpA VSMC than IL-6Rα.   
 
Figure 3.16 IL-6R, gp130 and CXCR2 mRNA expression by spiral arteries at 8-10 weeks 
gestation 
Graph representing delta ct values of each receptor gene expressed on SpA VSMCs (8-10 
weeks GA; n=5) from LCM.  
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3.4.6 Immunohistochemical analysis of expression of IL-6, IL-8 and their 
receptors in normal placental bed biopsies from miscarriage; comparison 
with normal early pregnancy 
Placental bed biopsies from women undergoing ERPC and healthy TOP were snap 
frozen, fixed in acetone and immunostained with a collection of antibodies that detect 
IL-6, IL-8 and their receptors (Table 3.3).  
The receptor ligands and cell types assessed are detailed in Table 3.5 and 3.6 and 
representative photomicrographs demonstrate staining patterns shown in figures 3.17 
- 3.19.  
Figure 3.17 demonstrates various cell types in the placental bed and how they were 
identified using immunostaining of serial sections. The immunostaining of the various 
cell types were assessed and compared between normal tissue sections and 
miscarriage tissue sections. 
Interstitial EVT (iEVT), intramural EVT (imEVT) and endovascular EVT (eEVT) were 
identified by positive LP34 staining (Figure 3.17A). Decidual spiral arteries and 
myometrial spiral arteries were both identified by VSMCs positive immunostaining 
with H-Caldesmon (Figure 3.17B and 3.17C respectively).  
IL-6 markers were identified by immunopositive staining of IL-6R on myometrial SpAs 
(Figure 3.18A), gp130 immunostaining was identified on glands and EVT (Figure 3.18B) 
and IL-6 immunostaining was observed on various cell types within the placental bed 
(Figure 3.18C).   
IL-8 markers in placental bed in both miscarriage and normal specimens were 
identified by positive IL-8 immunostaining in placental bed biopsies with intense 
staining on the glandular epithelium and strong staining on SpA endothelium lining the 
lumen and weaker staining on VSMCs of the decidual SpAs (Figure 3.19A), CD13 
expression was identified and localised to VSMCs of SpAs very strongly (Figure 3.19B), 
CXCR2 immunostaining was identified on giant cells and SpA endothelium (Figure 
3.19C) and CXCR1 immunostaining was identified on SpA endothelium amongst most 
cells in the placental bed (Figure 3.19D).   
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Figure 3.17 
Immunohistochemistry 
demonstrating different 
cell types in frozen 
placental bed biopsies  
Immunohistochemistry 
demonstrating different 
cell types in the placental 
bed. A represents 
positive LP34 staining 
demonstrating EVT 
(Magnification x100); B 
represents positive H-
Caldesmon staining in the 
decidua demonstrating 
decidual spiral arteries 
and C represents positive 
H-Caldesmon staining in 
the myometrium 
demonstrating 
myometrial spiral 
arteries. Original 
magnification x200.  
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Figure 3.18 IL-6 and IL-6 
receptor immunostaining 
in placental bed biopsies 
from early sporadic 
miscarriage 
Immunohistochemistry 
demonstrating 
immunostaining for IL-6 
and its receptors in 
placental bed biopsies 
from early sporadic 
miscarriage (SM). Positive 
IL-6R staining (A) 
demonstrating the 
expression of IL-6 receptor 
on myometrial SpAs; 
Positive gp130 expression 
(B) on glands and EVT in 
decidua and positive 
expression of IL-6 (C) on a 
variety of cell types in the 
placental bed including 
endothelium on decidual 
SpAs. Original 
magnification x200.  
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Figure 3.19 IL-8 and IL-8 receptor immunostaining in placental bed biopsies from early 
sporadic miscarriage 
Immunohistochemistry demonstrating IL-8 and it’s receptors in placental bed biopsies from 
early sporadic miscarriage. Positive IL-8 immunostaining (A) demonstrating the expression of 
IL-8 by decidual SpAs and glands; Positive CD13 immunostaining demonstrating the expression 
of amniopeptidase-N (B) on VSMCs of decidual SpAs; Positive CXCR2 immunostaining (C) 
demonstrating IL-8 receptor on giant trophoblast cells and positive CXCR1 immunostaining (D) 
demonstrating IL-8 receptor expressed on a number of cell types within decidua. Original 
magnification x200.  
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Immunoscoring was quantified using quickscore in normal pregnancy and sporadic 
miscarriage (SM) samples. There were no statistical differences between expression of 
IL-6 and IL-8 and their receptors on the different cell types investigated between 
euploid and aneuploid miscarriages, which was also observed in a study by Ball et al. 
(2006b). Therefore, the miscarriage specimens were categorised into early (≤12+6 
weeks gestation) and late (≥13 weeks gestation) giving sample numbers of n=10 of 
each gestational age with respect to the miscarriage samples, data for euploid and 
aneuploid samples combined.  
Tables 3.5 and 3.6 show all cell types and ligands analysed by immune quickscoring 
(n=10 each gestational age for SM and n=5 for each gestational age group for normal 
pregnancy). Lots of cell types and markers were investigated and from this the analysis 
revealed only a few statistical differences were observed between normal pregnancy 
and SM. Analysis from immunoscoring showed that the majority of statistical 
differences between normal pregnancy and SM were observed in the late gestations 
(≥13 weeks) with the majority of differences being increased immunostaining of 
markers in SM compared with normal pregnancy.  
Immunostaining of IL-8 markers; CD13 and CXCR2 were ligands to be significantly 
different on certain cell types between SM and normal pregnancy, immunostaining of 
IL-8 and CXCR1 did not appear to change in miscarriage compared with normal 
specimens. Differences were observed in immunostaining of IL-6 and IL-6Rα in SM and 
normal pregnancy but gp130 immunostaining did not alter.         
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Table 3.5 Immunohistochemisty quickscore assessment of IL-6, IL-8 and their receptors on 
different cell types in early miscarriage 
Table listing immunohistochemistry quickscore assessment of IL-6, IL-8 and their receptors in 
early MC samples (≤12+6 weeks GA; n=10) and early normal pregnancy (8-10 weeks GA; n=5) 
in different cell populations within the placental bed. Data expressed as Mean ± SEM.  
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Table 3.6 Immunohistochemisty quickscore assessment of IL-6, IL-8 and their receptors on 
different cell types in late miscarriage 
Table listing immunohistochemistry quickscore assessment of IL-6, IL-8 and their receptor 
ligands in late MC samples (≥13 weeks GA; n=10) and late normal pregnancy (12-14 weeks GA; 
n=5) in different cell populations within the placental bed. Data expressed as Mean ± SEM.  
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3.4.6.1 Altered immunoexpression of IL-8 markers between normal pregnancy and 
sporadic miscarriage 
 In the early gestational age groups there was more CD13 immunostaining on glandular 
epithelial cells in decidua in normal early pregnancy compared with early SM (P= 
0.0015; Figure 3.20 A-C) and there were no other differences observed in early 
pregnancy. In the late gestational age group, CD13 expression was stronger on 
interstitial EVT (P=0.0343, Figure 3.21) and on myometrial stroma in SM compared 
with normal pregnancy (P=0.0199, Figure 3.22). A decrease in CD13 immunostaining 
was observed in myometrial spiral artery VSMCs in late SM compared with normal 
pregnancy (P=0.0051; Figure 3.23).   
Immunostaining of CXCR1 receptor was not altered in any of the cell types 
investigated, however changes in CXCR2 staining patterns were observed. CXCR2 
immunostaining on the decidual SpA endothelium was stronger and more apparent in 
miscarriage samples compared with normal pregnancy (P=0.0006; Figure 3.24). 
However, this receptor was not altered in any other cell type investigated.  
3.4.6.2 Altered immunoexpression of IL-6 markers between normal pregnancy and 
sporadic miscarriage      
IL-6Rα immunoscoring was increased on glandular epithelium in late SM compared 
with normal pregnancy (P=0.0184; Figure 3.25). However, immunostaining of the 
receptor was not significantly altered in any other cell types investigated. 
In addition to changes in receptor immunostaining, a reduction in IL-6 immunostaining 
was observed on myometrial spiral artery VSMCs in late SM compared with normal 
pregnancy (P=0.0283; figure 3.26) but this difference was not observed on decidual 
artery VSMCs nor any other cell types. However, immunostaining was apparent on 
glandular epithelium in many samples but no differences were observed.  
Immunostaining for gp130 receptor expression was apparent in all specimens 
investigated and staining was very intense on glands and iEVT. However, there were no 
differences in staining patterns between normal pregnancy and miscarriage. 
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Figure 3.20 Differences in CD13+ immunostaining on glandular epithelium in early normal 
pregnancy compared  with early sporadic miscarriage 
Graphical representation of immuno scoring comparison of CD13 immunostaining on glandular 
epithelium in normal pregnancy (n=5) and SM (n=10) early gestation (A). B: 
Immunohistochemistry representing CD13 positive staining on glandular epithelium in normal 
pregnancy and B: represents a loss of staining of CD13 denoted by the arrows. Data are 
presented as mean ± SEM where statistical significance is denoted by P<0.05. Magnification 
x200.  
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Figure 3.21 Differences in CD13+ immunostaining on interstitial EVT in late normal pregnancy 
compared with late sporadic miscarriage 
Graphical representation of immune scoring comparison of CD13 immunostaining on 
interstitial EVT in normal pregnancy (n=5) and SM (n=10) late gestation (A). B: 
Immunohistochemistry representing CD13 positive staining on interstitial EVT in normal 
pregnancy and C: represents CD13 staining on iEVT in SM. Arrows denote the differences in 
CD13 immunostaining of iEVT between normal and MC. Data are presented as mean ± SEM 
where statistical significance is denoted by P<0.05. Magnification x400.  
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Figure 3.22 Differences in CD13+ immunostaining on myometrial stromal cells in late normal 
pregnancy compared with late sporadic miscarriage 
Graphical representation of immunoscoring comparison of CD13 immunostaining on 
myometrial stromal cells in normal pregnancy (n=5) and SM (n=10) late gestation (A). B: 
Immunohistochemistry representing CD13 positive staining on myometrial stromal cells in 
normal pregnancy and C: represents CD13 staining on myometrial stoma  in SM. Data are 
presented as mean ± SEM where statistical significance is denoted by P<0.05. Original 
magnification x400.  
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Figure 3.23 Differences in CD13+ immunostaining on VSMCs of myometrial spiral arteries in 
late normal pregnancy compared with late sporadic miscarriage 
Graphical representation of immuno scoring comparison of CD13 immunostaining on VSMCs of 
myometrial SpAs in normal pregnancy (n=5) and SM (n=10) late gestation (A). B: 
Immunohistochemistry representing CD13 positive staining on myometrial SpA VSMCs in 
normal pregnancy and C: represents CD13 immunostaining on myometrial  SpA VSMCs in SM. 
Arrows denote the difference in staining intensity of CD13 between normal and MC. Data are 
presented as mean ± SEM where statistical significance is denoted by P<0.05. Original 
magnification x200 (B) x400 (C).  
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Figure 3.24 Differences in CXCR2 immunostaining on decidual SpA endothelium in late 
normal pregnancy compared with late sporadic miscarriage 
Graphical representation of immunoscoring comparison of CXCR2 immunostaining on decidual 
SpA endothelium in normal pregnancy (n=5) and SM (n=10) late gestation (A). B: 
Immunohistochemistry representing CXCR2 positive staining on decidual SpA endothelium in 
normal pregnancy and C: represents CXCR2 immunostaining on decidual SpA endothelium in 
SM. Arrows denote the difference in staining intensity of CXCR2 between normal and MC. Data 
are presented as mean ± SEM where statistical significance is denoted by P<0.05. Original 
magnification x200.  
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Figure 3.25 Differences in IL-6Rα immunostaining on glandular epithelium in late normal 
pregnancy compared with late sporadic miscarriage 
Graphical representation of immunoscoring comparison of IL-6Rα immunostaining on 
glandular epithelium in normal pregnancy (n=5) and SM (n=10) late gestation (A). B: 
Immunohistochemistry representing IL-6Rα positive staining on glandular epithelium within 
decidua in normal pregnancy and C: represents IL-6Rα immunostaining on glandular 
epithelium within deciduas in SM. Arrows denote the difference in amount of immunostaining 
of IL-6Rα between normal and MC. Data are presented as mean ± SEM where statistical 
significance is denoted by P<0.05. Original magnification x200. 
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Figure 3.26 Differences in IL-6 immunostaining on VSMCs of myometrial spiral arteries in late 
normal pregnancy compared with late sporadic miscarriage 
Graphical representation of immunoscoring comparison of IL-6 immunostaining on myometrial 
spiral artery VSMCs in normal pregnancy (n=5) and SM (n=10) in late gestation (A). B: 
Immunohistochemistry representing IL-6 positive staining on VSMCs of myometrial spiral 
artery in normal pregnancy and C: represents IL-6 immunostaining on VSMCs of myometrial 
spiral artery in SM. Arrows denote the difference in amount of immunostaining of IL-6 
between normal and MC. Data are presented as mean ± SEM where statistical significance is 
denoted by P<0.05. Original magnification x200. 
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3.4.6.3 IL-6 and IL-8 protein production by decidual CD56+ and CD14+ cell culture 
supernatants isolated from miscarriage tissue; comparison with normal pregnancy 
The cytokine protein analysis of decidual cell populations in normal pregnancy 
revealed that a major producer of IL-6 and IL-8 in early pregnant decidua is CD14+ cells. 
There were also gestational differences in the levels of IL-8 secreted by decidual CD56+ 
cells. 
Therefore it was decided to compare the levels of IL-6 and IL-8 secreted by CD56+ and 
CD14+ cells isolated from SM decidual tissue with levels from healthy decidua obtained 
from pregnancies. Only specimens from ≤12+6 weeks gestation were analysed and 
compared due to difficulties in obtaining late miscarriage tissue (see Chapter 7). 
There was a decrease in secretion of IL-6 protein from both CD14+ and CD56+ cells in 
SM compared with normal early pregnancy (P=0.0469; P=0.0206 respectively; Figure 
3.27A). There was also a dramatic reduction in IL-8 secretion from both CD14+ and 
CD56+ cells in SM compared with normal early pregnancy (CD14+: P<0.0001; CD56+: 
P=0.003; Figure 3.27B).  
Cells isolated from both healthy decidua and SM decidua secreted higher levels of IL-8 
than IL-6.  
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Figure 3.27 IL-6 and IL-8 protein secretion by deciual CD14+ and CD56+ cells in normal 
pregnancy and sporadic miscarriage 
Graphical representation of IL-6 (A) and IL-8 (B) protein levels secreted by decidual CD14+ and 
CD56+ cells in normal healthy pregnancy (n=10) and early SM (n=8) both ≤12+6 weeks gestation. 
Data are presented as mean ± SEM.  
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3.5 Discussion   
Using an immunohistochemical approach this present study provides evidence that IL-
6 and IL-8 are expressed within the placental bed in the first half of normal pregnancy.  
IL-6 and IL-8 immunostaining was immunolocalised to lots of different cell types within 
the decidua including CD56+ cells (uterine natural killer cells) and CD8+ T cells, amongst 
other cell types in early human pregnancy. The immunolocalisation of IL-6 and IL-8 by 
cells of early decidua was further confirmed by in vitro studies demonstrating secretion 
and mRNA expression of these cytokines by cells of the decidua. Receptors for these 
cytokines were also immunolocalised to EVT cells as well mRNA detection by spiral 
arteries.     
The immunolocalisation of IL-6, IL-8 and their receptors were altered on many cells of 
the decidua in miscarriage, in which in vitro studies further confirm altered IL-6 and IL-
8 secretion in miscarriage by uterine CD56+ and CD14+ cells suggesting an importance 
for theses cytokines and decidual cells in the development of successful pregnancy.  
3.5.1 Expression and production of IL-6 and IL-8 by decidual leucocytes  
Decidual cell populations, including stromal cells, macrophages, uterine natural killer 
cells and T cells, all secreted both IL-6 and IL-8. IL-8 was produced in much higher 
concentrations than IL-6. We propose that these various cells within the decidua 
secrete these factors providing a unique immunological balance to facilitate in the 
processes required for successful pregnancy, beginning with implantation through to 
aiding invasion of trophoblast cells through maternal tissues and modulating 
remodelling of spiral arteries. The most abundant source of both IL-6 and IL-8 from the 
decidual cell types that were investigated was CD14+ cells rather than CD56+ cells as 
had originally hypothesised. Although macrophages account for 20% of the leucocyte 
population in the decidua they produce the vast majority of IL-6 and IL-8 in this tissue. 
Low levels of uNK secreted IL-6 and IL-8 compared with total amounts produced within 
the decidua suggest that these cells are secreting growth factors other than IL-6 and IL-
8 such as IFN-γ, TGFB1 and VEGF (Schiessl et al., 2009) which play important roles in 
trophoblast invasion and remodelling of spiral arteries. The immunohistochemistry 
data shows IL-6 positive staining in glandular epithelium in decidua along with strong 
staining of gp130, although this cell type was not investigated in this study. Murine 
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luminal epithelial cells in cultures at estrous has been previously reported to be a 
major source of IL-6 in mouse uterus (Robertson et al., 1992) but this remains to be 
investigated in humans in pregnancy. IL-8 mRNA has also been detected in human 
epithelial cells cultured from human endometrium (Arici et al., 1993) but again there 
remains little investigation into IL-8 expression in pregnancy. However, this does 
suggest that decidual glandular epithelial cells are another potential source of both 
intrauterine IL-6 and IL-8. This evidence adds to the fact that cytokines do not work in 
isolation and lots of cells produce cytokines but a fine complex balance within the 
milieu is required for cytokines to fulfil their functional capabilities.    
Although uNK cells produce a small amount of IL-8 in comparison with other decidual 
cell types, a dramatic increase in IL-8 levels secrete by uNK cells was observed at 12-14 
weeks gestation; which is in concordance with recent data from our laboratory (De 
Oliveira et al., 2010). Other recent reports have demonstarted IL-8 production within 
the decidua from uNK cells (Hanna et al., 2006, Vacca et al., 2008) and decidual 
stromal cells (Engert et al., 2007), although these studies focused on IL-8 production in 
decidua they did not investigate IL-8 production by these cells isolated from first half 
of pregnancy and comparisons with different gestational ages. This evidence of very 
high levels in decidua and increased IL-8 levels at 12-14 weeks gestation suggests a 
functional importance for this cytokine as IL-8 exists in relatively low levels in normal 
adult tissues with levels elevating in oxidative stress and inflammation (Vlahopoulos et 
al., 1999). De Oliveira et al. (2010) have reported a possible involvement in the 
regulation of EVT invasion but a specific function has yet to be elucidated, although 
elevated serum IL-8 has been implicated in preeclampsia (Kauma et al., 2002) and is a 
result of shallow trophoblast invasion, suggesting a main role for IL-8. IL-8 may also 
play a role in SpA remodelling, a possibility investigated in this study in Chapter 5.  
This study has demonstrated that there are differences in the secretion of IL-6 as well 
as IL-8 with gestational age, suggesting an importance for these cytokines in pregnancy 
development processes.  
3.5.2 IL-6 and IL-6 receptors 
IL-6 within the placental bed was immunolocalised to maternal leucocytes and that 
there were no differences in immunostaining throughout gestation up to 20 weeks. 
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However, gestational age changes were observed in IL-6 secretion by CD10+ stromal 
cells and by CD56+ cells along with a total cohort of decidual cells when secretion was 
quantified with ELISA. These data demonstrate that IL-6 is expressed in the decidua in 
early pregnancy with expression remaining constant up to 20 weeks gestation 
suggesting a functional role for this cytokine. IL-6 receptors (IL-6R and gp130) have 
been localised to EVT cells in situ by immunohistochemical staining providing evidence 
that IL-6 has the ability to target these cells and elicit a response which may contribute 
to trophoblast longevity, invasion or cellular events, (see Chapter 4). Expression of 
gp130 mRNA has previously been demonstrated in decidual (Dimitriadis et al., 2000) 
and placental tissues from first and third trimester pregnancies (Lee et al., 2011), 
although IL-6Rα has not been previously investigated; expression of IL-6Rα is required 
to assess and confirm the signalling capabilities of IL-6 as gp130 is a promiscuous 
receptor and can bind to many other ligands such as LIF, oncostatin, CNF and IL-11 
(Bravo and Heath, 2000). IL-6 receptors were also immunolocalised to SpA with IL-6Rα 
staining strongly on myometrial SpA and expression being verified by RT-PCR which 
has yet to be demonstrated in any other study. This study provides evidence that IL-6 
has the ability to bind to VSMC of the decidual SpA and therefore, may play a role in 
SpA transformation events making it an important mediator for successful pregnancy 
development (see Chapter 5 for further study). 
3.5.3 IL-8 and IL-8 receptors 
Previously published data by De Oliveira et al. (2010) demonstrated that intrauterine 
IL-8 is expressed by CD56+ and CD8+ T cells in the placental bed in human pregnancy 
with gestational age differences. This study further verifies this showing that IL-8 is 
immunolocalised to uNK cells, suggesting that these cells are a source of intrauterine 
IL-8. Localisation of IL-8 receptors; CXCR1, CXCR2 and DARC has not previously been 
investigated in human pregnant decidua, although CXCR1 and CXCR2 have been 
indentified in non-pregnant human endometrium (Mulayim et al., 2003) and in 
endometrial carcinoma (Ewington et al., 2012). IL-8 signals via both of the 
transmembrane receptors but each receptor system has different functional responses 
(Rosenkilde and Schwartz, 2004). Signalling through CXCR2 is suggested to mediate 
angiogenic responses (Addison et al., 2000) and this is reflected in mRNA expression on 
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decidual SpA observed from LCM in this study. Using immunohistochemistry data IL-8 
receptors were also localised to EVT, coinciding with reports that IL-8 stimulates EVT 
invasion (De Oliveira et al., 2010).  
CD13 (aminopeptidase N) has been reported to be expressed by decidual stromal cells 
and that its expression by these cells is regulated by oestrogen (Seli et al., 2001). DARC, 
the non-signalling decoy receptor for IL-8, was observed by immunohistochemistry in 
the placental bed of normal pregnancy at 8-10 weeks and 12-14 weeks gestation (n=3 
each gestational age) and expression did not change between the gestational ages. 
Intense DARC staining was observed on EVT; especially on endovascular EVT with 
expression by endothelial cells in the lumen of SpAs and by decidual leucocyte cells 
where staining was very strong and intense. This intense staining was observed in 
areas where CD56+, CD14+ and CD3+ cells were in proximity although this was not 
quantified. However, the immunolocalisation of DARC suggests an active role in the 
placental bed for this receptor and IL-8. DARC immunostaining was not compared in 
MC specimens due to the technical specificity of the DARC antibody used in this study. 
An antibody for use on frozen tissue sections does not exist and is only the one used in 
this study was only effective on FFPE sections, and therefore could not be used on the 
stored frozen MC sections that were used for this study. Immunostaining was 
attempted on frozen sections but with poor results. DARC immunostaining in normal 
pregnancy suggests that this receptor may regulate the amount of IL-8 available within 
the placental bed and decidua in early pregnancy, preventing local levels becoming 
dangerously high which could in turn cause pregnancy complications, as higher levels 
of IL-8 have been reported to increase cellular apoptosis, neutrophil activation and 
endothelial cell damage in pre-eclamptic women, although the source of IL-8 was from 
maternal serum (Laskowska et al., 2007). Localisation of DARC to EVT and SpAs suggest 
that IL-8 may elicit effects on these cells by regulating EVT invasion and playing a role 
in the remodelling of spiral arteries; expression of DARC on these cells may prevent IL-
8 causing aberrant and excessive invasion and SpA remodelling, and thereby 
preventing the cause of pregnancy complications.            
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3.5.4 Receptor expression in miscarriage 
Few reports suggest that IL-6 and IL-8 have an involvement in miscarriage and receptor 
expression of these cytokines has not yet been investigated in miscarriage compared 
with normal pregnancy.  
We hypothesised that IL-8 levels within the decidua would increase in miscarriage; this 
would result in altered receptor expression on target cells. Euploid and aneuploid 
samples from early miscarriage (≤ 12+6 weeks GA) (Ball et al., 2006b) and euploid and 
aneuploid samples from late miscarriage (≥ 13 weeks GA) (Ball et al., 2006a) were 
assessed and analysis revealed there were no differences in immunostaining, so 
therefore decided to combine both euploid and aneuploid samples together as 
discussed in section 3.4.4). CD13+ immunostaining was stronger and more intense on 
interstitial EVT and myometrial stroma in miscarriage ≥ 13 weeks gestational age 
compared with interstitial EVT from normal pregnancy from 12-14 weeks GA. 
Conflicting reports exist on the role of CD13 (aminopeptidase N) and its association 
with IL-8. Reports from 1995 (Kanayama et al., 1995) state that aminopeptidase N was 
found to inactivate IL-8 by degrading it; therefore indicating that IL-8 is a substrate for 
this metalloproteinase. Seli et al. (2001) further concluded that CD13 is a degrading 
enzyme of IL-8 and reported expression in human endometrium, considered to be 
involved in regulating the bioavailability of IL-8. However, in contrast Wulfaenger et al. 
(2008) reported expression of CD13 on human embryonic kidney cells downregulated 
CXCR4 expression and inhibited CXCL12 stimulated migration but did not affect the 
activity of CXCL8 (IL-8). These authors argued that the mononclonal antibody WM15 
(that binds with CD13 and used in the Kanayama study) causes varied results; WM15 
stimulates calcium secretion which leads to phosphorylation of proteins involved in the 
cell signalling cascade which up further upregulates the expression of IL-8 mRNA in 
monocytic cells, so therefore claimed that CD13 had no effect on inactivating IL-8 and 
was a response from using WM15. The increased immunostaining for CD13 observed 
in miscarriage decidual specimens could be a possible explanation for the reduction in 
IL-8. The increase of cell surface CD13 seen on EVT could result in increased 
degradation of uterine IL-8 and this reduction could lead to insufficient invasion of 
trophoblast cells, being a causative factor in spontaneous abortion.  
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CXCR2 immunostaining was also increased on the endothelial cells of decidual spiral 
arteries in MC indicating that the angiogenic properties elicited by IL-8 may be altered 
in MC and contribute to aberrant SpA remodelling.  
Expression of IL-6R was increased in the glandular epithelium of MC compared with 
normal pregnancy but gp130 was not altered. A decrease in IL-6 immunostaining was 
observed in myometrial spiral arteries in late MC compared with normal pregnancy 
suggesting that IL-6 may have some involvement in remodelling of deeper SpAs, 
thereby affecting intervillous blood flow which will further cause oxidative stress and 
may be a causative factor in pathology of MC, coinciding with reports of decreased 
myometrial SpA remodelling in relation to late miscarriage (Ball et al., 2006a).  
A factor to be consider here is that the specimens obtained from normal pregnancy 
were collected throughout the duration of this study, whereas the decidua from 
miscarriage specimens had been collected years before the normal decidua was 
obtained. Therefore, the significant differences observed could have been a 
consequence of the differing timepoints of tissue collection, although the miscarriage 
specimens were stored at -20°C and tissue morphology appeared not to have altered 
when subjected to an H&E stain. Immunostaining of all tissue was performed at the 
same time also to prevent day to day variation in staining. However, it is likely that 
receptor expression would be altered in miscarriage as the data in this study provides 
evidence that the production of intrauterine cytokine levels is reduced compared to 
levels in healthy pregnancies.           
3.5.5 Production of IL-6 and IL-8 in miscarriage 
There are very few reports of IL-6 and IL-8 in miscarriage with the results varying 
significantly. Despite the varying results there is a correlation between altered 
expression and miscarriage. The results from this study support the hypothesis that 
altered cytokine expression is associated with miscarriage but the hypothesis stated 
that the cytokine levels would be increased in MC rather than being decreased.   
 IL-6 and IL-8 production by CD56+ and CD14+ cells isolated from decidua from 
miscarriage was measured and compared with levels from normal pregnant decidua at 
comparable GA and the results were compelling. These decidual cell populations 
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produced significantly less IL-6 and IL-8 in MC compared with normal pregnancy. These 
data contradict findings from Madhappan et al. (2003) who reported higher levels of 
uteroplacental IL-8 in products of conception from women suffering recurrent MC 
compared with normal pregnancy controls. This contradicting data firstly can be 
explained by the source of IL-8, although the source has only been investigated and 
compared using two cell types, the cell types used were specific and both cell 
populations have been linked with successful pregnancy development, with 
macrophages being one of the main producers of IL-8 within the decidua and CD56+ 
cells being the most abundant leucocyte, making this evidence more feasible. Subject 
numbers in the study by Madhappan et al. (2003) may also account for the conflicting 
results; sample numbers were very low and the number of controls did not match that 
of the MC specimen numbers. In addition, the nature of the MC also needs to be taken 
into account. In the present study only specimens from women with sporadic 
miscarriages were examined, whereas Madhappan et al. (2003) investigated IL-8 levels 
in women suffering recurrent miscarriages (RM), a specific group of miscarriages 
where an immune cause is suggested which may differ from sporadic miscarriage and 
this is where the discrepancies may lie.  
There are also conflicting reports of IL-6 in MC. In agreement with the present study 
Jasper et al. (2007) reported a significant reduction in endometrial IL-6 mRNA 
expression in women suffering from recurrent MC, although the source of IL-6 was not 
isolated to a specific cell type in pregnancy. Earlier studies in mouse disagree with both 
Jasper et al. (2007) and data from this study: Zenclussen et al. (2003) reported a 
significant increase in IL-6 at the fetal maternal interface, with increased expression by 
trophoblast cells observed by immunohistochemistry, increased production by 
monocyte cells of decidua and upregulated IL-6mRNA expression in decidual and 
placental tissue at day 18 of gestation which was associated with fetal loss. Also in 
agreement with this data is a report demonstrating increased levels of both IL-8 and IL-
6 in women who had suffered second trimester abortions, although the levels of 
cytokines measured were taken from plasma (Galazios et al., 2011). Elevated levels of 
plasma IL-6 have also been demonstrated in women with euploid miscarriage (Calleja-
Agius et al., 2012). The discrepancies between studies may be due to the difference in 
species, gestational time points and tissues investigated. 
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Since decidual CD14+ cells were the most abundant source of both IL-6 and IL-8 in early 
pregnancy and there was a dramatic reduction of the production/secretion of these 
cytokines in miscarriage subjects, this cell type appears likely to be an important 
mediator of normal pregnancy development as well as the uterine natural killer cells, 
which have been the focus of majority of studies of decidual leucocytes in early 
pregnancy to date. Further studies into mRNA expression in decidual leucocytes in 
particular uterine macrophages and functional studies of these cells are required to 
gain further insight into the mechanism of action of IL-6 and IL-8 in miscarriage and 
how these cytokines contribute to the pathology of sporadic MC. As stated before, the 
local cytokine milieu in uterus in early pregnancy is complex and other factors 
combined with these cytokines are likely to play a role, highlighting the challenge of 
unravelling the complexity of pregnancy complications. IL-8 has been reported to 
increase trophoblast invasion in vitro (De Oliveira et al., 2010) suggesting that it plays a 
role in the regulation of invasion. Reduced decidual IL-8 production could therefore 
result in disruption in this regulation and by reducing trophoblast invasion and this 
could lead to inappropriate increased SpA remodelling altering intervillous blood flow 
which could contribute to MC. Shallow trophoblast invasion and deficient SpA 
remodelling have been associated with numerous pregnancy complications (reviewed 
in chapter 1 and chapter 4). IL-6 could work in a coordinated manner with IL-8 to lead 
to pregnancy loss. Another possible function of these cytokines is that they contribute 
to the recruitment of other leucocytes to sites of SpA remodelling. However, in a large 
immunohistochemical study, Ball et al. (2006b) found no evidence of abnormal SpA 
remodelling and trophoblast invasion in early sporadic MC, indicating that these 
processes do not have an important role in the pathogenesis of early miscarriage. Carp 
(2004) reviewed the importance of cytokines and their involvement in recurrent 
miscarriage, although little evidence exists in humans. The studies that have been 
explored, immune cells and cytokine production in human RM do suggest differences 
in expression compared with healthy individuals; increased CD56+ cells in RM decidua, 
decreased IL-6 production in endometrium and a shift in cytokine production by 
peripheral blood monocytes are all results observed in human RM, although much of 
the evidence is contradictory and variations in data may be indicative of sample type, 
cells investigated and timing of miscarriage and pregnancy. However, the evidence 
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suggests that abnormal expression of immune cells and cytokines contribute to the 
disease but the underlying mechanisms remain unclear. The delicate balance of the 
cytokine milieu in pregnancy and disruptions may lead to altered immune 
surveillance/modulation resulting in increased apoptosis of paternal trophoblast cells 
through HLA interactions with uNK cells and macrophages which may be a possible 
explanation for pregnancy loss and is an area which requires further exploration.  
3.5.6 Overall summary 
This study demonstrates that the decidua produces significant amounts of IL-8 and IL-6 
and that these cytokines are capable of signalling with target cells involved in 
processes of pregnancy. Immune cells are a source of both cytokines but uterine 
macrophages are a major source, suggesting that these cells contribute to successful 
pregnancy. There were dramatic reductions of cytokine production in miscarriage 
inferring that these cytokines contribute to successful pregnancy and therefore an 
importance of IL-6 and IL-8 in pregnancy development. However, this reduction does 
not determine whether the cytokines are dysregulated or simply not being produced; 
these are areas which will require further exploration. If these protein studies of 
miscarriage are confirmed in other studies, with increased knowledge on function and 
the mechanisms involved could be an area for targeted studies that will eventually 
translate this into clinical intervention.      
 
 
Chapter 4 
The effect of interleukin-6 on trophoblast invasion and function 
in early human pregnancy 
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4. The effect of IL-6 on trophoblast invasion and function in 
early human pregnancy 
4.1 Introduction 
Trophoblast differentiation and importance of EVT invasion for successful pregnancy 
has been reviewed in chapter 1. Both interstitial and endovascular EVT invasion is 
tightly coordinated in a spatial and temporal manner and disruptions in this control  
are associated with various pregnancy complications including early and late 
miscarriage (Khong et al., 1987, Hustin et al., 1990, Ball et al., 2006a, Ball et al., 2006b), 
pre-eclampsia (Pijnenborg et al., 1991, Sibai et al., 2005) and fetal growth restriction 
(Khong et al., 1986). In contrast excessive deep EVT invasion is seen in placenta accreta 
(Norwitz, 2006, Rosen, 2008). The association of aberrant invasion with these diverse 
pregnancy disorders highlights the importance of controlled trophoblast invasion for 
successful pregnancy.  
Despite the importance of this regulation, factors that control EVT invasion are poorly 
understood, although it is likely that decidual factors play an important role (Fitzgerald 
et al., 2008). Evidence is accumulating that the factors from decidua including 
cytokines, growth factors and oxygen tension all influence EVT invasion but the 
mechanisms that underpin regulation of the events of invasion remains to be 
elucidated.  Cells within the decidualised endometrium of the uterus in pregnancy are 
believed to be major producers of growth factors and cytokines that are likely to be 
involved in control of EVT invasion (Lala and Chakraborty, 2003, Kharfi et al., 2003, 
Bischof and Irminger-Finger, 2005). Signals from trophoblast cells and maternal 
components in the decidua have been characterised recently (Dimitriadis et al., 2010) 
and it has been postulated that maternal immune cells within the decidua such as uNK 
cells, decidual macrophages and T-lymphocytes secrete many factors that may 
contribute in the regulation of EVT invasion and decidual stromal cells are also likely to 
have a role (Lash et al., 2011).  
In the first half of pregnancy uterine natural killer cells have are the most abundant 
decidual leucocyte population and are in close contact with EVT at the maternal-fetal 
interface. Previous published data from our group have demonstrated that IL-8 
stimulates EVT invasion in vitro (De Oliveira et al., 2010). Decidual cells were found to 
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secrete high levels of IL-8 with uNK cells as a major producer. In addition both CXCR1 
and CXCR2 were localised to EVT in situ (see Chapter 3). These results are consistent 
with previous reports showing that soluble products of isolated uNK cells stimulate 
EVT invasion in a model using primary uNK cells and activated isolated EVT from early 
pregnancy (Hanna et al., 2006, Lash et al., 2010b, De Oliveira et al., 2010). This effect 
was partly dependent on IL-8, as an IL-8 neutralising antibody partially inhibited uNK 
stimulation of EVT invasion.  
This present study has demonstrated that uNK cells, amongst many other cell types in 
the decidua, produce both IL-8 and IL-6 in early pregnancy (Chapter 3). IL-8 has been 
reported to stimulate EVT invasion in vitro (Hanna et al., 2006, De Oliveira et al., 2010), 
but the effect of IL-6 on trophoblast invasion has been sparsely investigated. 
IL-6 has the potential to be an important regulator of EVT invasion since there is 
extensive literature demonstrating that this cytokine is able to increase the 
invasiveness of cancer cells, thus contributing to a variety of malignancies (Nishino et 
al., 1998, Kanazawa et al., 2007, Walter et al., 2009). Despite documentation of the 
presence of IL-6 in the human endometrium and expression by trophoblast 
themselves, little is known about the functional effects of IL-6 on trophoblast, precise 
sites of IL-6 production and mechanisms of IL-6 induced signalling in the trophoblast. 
Chapter 3 includes data of IL-6 localisation and production by maternal cells in 
pregnant decidua, along with evidence of IL-6 receptor expression (IL-6Rα and gp130) 
on decidual cells, but expression by EVT was not investigated. IL-6 signalling pathways 
involve STAT-3 and MAPK signalling pathways (reviewed in chapter 1.4.3) and evidence 
suggests that trophoblast cells mediate through the same pathways, suggesting a role 
for IL-6 in EVT signalling; activation of STATs through receptor mediated signalling  is 
known to up-regulate genes which are involved in proliferation and cell differentiation 
(Corvinus et al., 2003, Fitzgerald et al., 2005) and MAPKs play an important role in the 
cellular processes of migration and invasion in human trophoblast cells (Pollheimer 
and Knofler, 2005). STAT-3 knockout mice studies have also demonstrated embryonic 
lethality (Takeda et al., 1997). 
IL-6 is widely expressed in endometrium at implantation and knockout IL-6-0/IL-6-0 
mouse studies provide evidence that IL-6 plays an important role in implantation and 
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early placental development since the IL-6 KO mice showed a 48% reduction in 
implantation sites that has been linked to decreased fertility (Robertson, 2000). 
Altered levels of IL-6 have also been implicated in human pregnancy disorders 
including pre-eclampsia and miscarriage. Increased levels of placental IL-6 have been 
detected in women suffering pre-eclampsia (Zhao et al., 2008) and Greer et al. (1994) 
reported an increase in IL-6 serum levels in pre-eclamptic women compared with 
normal pregnant women. Sera from women suffering recurrent miscarriage have been 
reported to have increased levels of soluble IL-6 receptor and IL-6 compared with 
controls (Arruvito et al., 2009). In contrast, inadequate IL-6 mRNA production has been 
reported in the endometrium of women suffering recurrent miscarriage (Jasper et al., 
2007). As well as pregnancy pathology, IL-6 has also been implicated in infertility; 
recent data have demonstrated significantly increased serum concentrations of IL-6 in 
infertile compared with fertile women (Demir et al., 2009).  These data suggest a 
possible role of IL-6 in the processes involved in early pregnancy. 
A recent study by Jovanovic et al (Jovanovic and Vicovac, 2009) reported that IL-6 
increased the migration and invasive potential of the EVT immortalised cell line HTR-
8/SVneo in vitro due to the up-regulation of trophoblast integrins α1, α5 and β5  that 
bind to  components of the extracellular matrix. In addition, Dubinsky et al. (2010) 
reported that inhibition of endogenous IL-6 inhibited the migration and invasion of 
JEG-3 cells, indicating that IL-6 has role in the control of trophoblast invasion. 
Our group has already reported stimulation of EVT by IL-8 and that EVT cells expressed 
both receptors for IL-8. In view of abundance of IL-6 in decidua in early pregnancy and 
reports in tumours and trophoblast cell lines, the aim of this part of the study was to 
investigate effect of IL-6 on invasion by primary EVT cells and the HTR-8/SVneo EVT cell 
line.  
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4.2 Aims and Hypotheses 
4.2.1 Hypotheses 
1) IL-6 receptors are expressed by isolated primary EVT cells 
2) IL-6 stimulates EVT invasion and increases their invasive capacity within the 
placental bed 
3)  IL-6 plays a role in the stimulation of trophoblast cellular signalling proteins 
including STAT3 and MAPK. 
4) IL-6 increases EVT secretion of growth factors involved in stimulating EVT cell 
invasion.   
4.2.2 Aims 
In order to test the hypothesis, the specific aims were 
1) To localise cytokine receptor expression by trophoblast cells using 
immunocytochemistry and Western blotting 
2) To measure the effect of varying concentrations of IL-6 on invasiveness by 
invasive potential of 1° EVT and HTR-8/SVneo cell line using a Matrigel invasion 
assay 
3) Measure invasive potential of EVT using first trimester placental chorionic 
villous explants with varying concentrations of IL-6 
4) To further investigate the effect of IL-6 on EVT by measuring stimulation of 
kinase signalling proteins, growth factors and cytokine secretion by EVT after IL-
6 treatment using a kinase-phospho array and FASTQuant multiplex array  
5) To verify the FASTQuant protein data by measurement of mRNA expression 
using Real Time RT-PCR  
 
4.3 Experimental design 
4.3.1 Immunocytochemistry 
Primary EVT cells were isolated from first trimester placenta as previously described 
(section 2.3.5). The HTR-8/SVneo EVT cell line was cultured as described previously 
(section 2.4.1). Cell smears were prepared for immunocytochemistry as described in 
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Chapter 2 (section 2.3.3) and IL-6 receptor protein expression was investigated by 
immunostaining the cell smears with the antibodies shown in Table 4.1. The 
immunostaining was repeated on 3 separate occasions and all smears were subjected 
to LP34 and HLA-G staining as positive controls to identify EVT. Negative controls were 
assessed by omitting primary antibody by replacing with TBS buffer pH 6.5.  
 
Table 4.1 Primary antibodies used for immunocytochemistry (trophoblast cell smears) 
Primary antibodies used for immunocytochemistry 
 
4.3.2 Western blotting of IL-6 receptor proteins and signalling proteins 
IL-6 receptor expression was also investigated by Western blotting. Primary EVT cell 
lysates and cell lysates from HTR-8/SVneo cells were prepared (section 2.4; n=2). 20µg 
protein (determined with a BioRad DC protein assay- section 2.11.2) was subjected to 
SDS polyacrylamide gel electrophoresis using and resolved proteins were transferred 
to Immobilon-P membranes (Millipore, Bedford, MA) and then blocked overnight in 5% 
milk blocking solution (0.05% TBS-Tween20 (TBS-T) and dried non-fat milk) at 4°C 
(section 2.11.3). 
The membranes were probed separately with IL-6Rα antibody and gp130 polyclonal 
antibody (both from Santa Cruz, CA USA; Table 4.2). Protein signal for gp130 receptor 
was not detected in either HTR-8/SVneo cell or primary EVT cell lysates at the correct 
molecular weight (130kDa) using the specific antibody even using a positive control. 
This experiment was repeated on several occasions and different antibody 
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concentrations were used but the result remained negative. Western blotting of IL-6Rα 
was, however successful.  
To assess the effect of IL-6 on STAT and MAPK signalling pathways in EVT cells, isolated 
primary EVT from pregnancies at 8-14 weeks gestation and HTR-8/SVneo cells were 
incubated with 10ngml-1 of IL-6 for 10 minutes at 37°C in 5% CO2. Cells that were not 
exposed to IL-6 were used as controls. Following incubation the cells were lysed in lysis 
buffer-6 (included in the kinase profile kit; R&D systems, Inc. Minneapolis, USA). 20µg 
of each sample was subjected to SDS polyacrylamide gel electrophoresis and resolved 
proteins were transferred onto Immobilon-P membranes (Millipore, Bedford, MA). 
Membranes were probed separately with anti-STAT-3, anti-p-STAT-3 (SantaCruz, CA, 
USA) antibodies and anti-MAPK1/2 and anti-p-MAPK1/2 (Millipore Corp. Temecula, CA, 
USA) antibodies (Table 4.2). All antibodies were subsequently developed using 
chemiluminescence (Thermo Scientific, Rockford, USA) according to manufacturer’s 
instructions and recorded by X-ray Kodak Scientific Imaging film (Sigma Chemical Co.).    
 
Table 4.2 Western blotting conditions and antibodies used 
 
4.3.2 The use of placental villous explants rather than primary EVT cells 
in invasion assays 
Initially in this experiment isolated EVT cells from first trimester placenta (section 
2.3.5) were used in the invasion assays with aim of comparing results with those 
obtained using the trophoblast cell line HTR-8/SVneo cells. Although isolation of EVT 
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cells from first trimester placenta was successful and previous experiments in the 
laboratory had observed EVT invasion using the Matrigel invasion assay (section 2.5), 
invasion of these cells through the 8.0µm pore filters was not observed in these 
studies. It was necessary to see a minimum of 30 invaded EVT cells after the culture 
period but using isolated EVT only very small numbers if any had invaded through the 
growth factor reduced Matrigel onto the underside of the pore membrane filters both 
in controls and all other culture treatments. In addition insufficient cells were isolated 
to perform the number of wells required examine different IL-6 concentrations. We 
investigated different time points of the invasion experiment (12h, 24h, 48h and 72h) 
but failed to detect adequate invasion. The invasion assays using 1˚ EVT were repeated 
on 5 separate occasions and at the same time as those performed with HTR-8/SVneo 
cells (n=3). After isolation of EVT, cell smears were made and characterised for HLA-G 
and cytokeratin-7 expression; thus confirming isolation of EVT. The HTR-8/SVneo cells 
had invaded the pore membrane filters indicating that it was the nature of the EVT 
cells that prevented the invasive potential rather than any problem with the 
experiment design. The lack of invasion by primary EVT cells in this study is therefore 
unexplained; in order to complete the experiments the well described placental 
explants invasion model was used (section 2.3.6 and previously described in Lash et al. 
(2006a)).       
4.3.3 Invasion assays with and without serum 
Fetal calf serum within the media may affect the binding of exogenous IL-6 to EVT; the 
cytokine may bind to components of the serum including oestrogens, insulin and 
testosterone, thus preventing binding to the receptors on EVT thereby blocking the 
possible effects of IL-6 in these cells. 
Using both isolated EVT cells and placental explants I investigated whether this would 
affect binding and cellular invasion by performing invasion assays using 0%, 0.5%, 5% 
and 10% FCS (Sigma) supplemented media +/- 10ngml-1 IL-6. In addition I also set up 
the same experiment with the same FCS concentrations but using charcoal stripped 
FCS (First Link, Birmingham, UK). Each experiment was repeated 3 times. However, 
cellular invasion was only observed using 10% FCS supplemented media; invasion was 
not observed at any other FCS concentration. Low numbers of cells had invaded using 
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10%  charcoal stripped FCS media indicating that components of the normal FCS were 
essential for the invasion of these cells. Therefore, all invasion assays were performed 
in the presence of 10% FCS.  
4.3.4 Invasion assays with addition of sIL-6Rα and IL-6 neutralising 
antibody 
A combination of exogenous IL-6 and sIL-6Rα (both reconstituted in 10nM acetic acid; 
10ngml-1 IL-6 + 20ngml-1 sIL-6Rα; n=5) was used in the invasion assays because of the 
agonist effects of sIL-6Rα; an amplified effect might have been observed rather than 
cytokine alone and this represented a more physiological effect. The role of 
endogenous IL-6 by EVT was investigated by addition of neutralising antibody (rabbit 
anti-human IL-6 1µgml-1).    
4.3.5 Kinase Array  
EVT cell lystates and HTR-8/SVneo cell lystates were prepared (section 2.3.6) after 
treatment with 10ngml-1 recombinant IL-6. A  BioRad DC total protein assay was then 
performed to determine the protein concentration of the cellular extract and EVT 
lysates were pooled to give a total protein concentration of 250µg for each 
experiment. HTR-8/SVneo cells were grown to 100% confluence ~ 1 x 107 cells ml-1 and 
lysed using the lysis buffer provided (see Chapter2, section). 300µg total protein 
concentration was used for each HTR-8/SVneo profile experiment. The array protocol 
was performed as previously described in Chapter 2 (section 2.6). Signals from the X-
ray film were scanned and the images were analysed using Adobe Photoshop software 
package and the images were quantified by using a mean spot pixel density counting 
method. Signal values were exported to Microsoft Excel for analysis. Corresponding 
signals were compared to determine the relative change in phosphorylated kinase 
proteins between untreated and treated cells and between samples. Data from the 
array were normalised to control values to facilitate comparison between each 
experiment (n=3 in both EVT and HTR-8/SVneo lysates). 
4.3.5 FASTQuant® Array 
Isolated EVT cells (8-14 weeks’ gestation; n=4) were cultured on growth factor reduced 
Matrigel® (BD Biosciences) overnight, treated with 10ngml-1 human recombinant IL-6 
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or 10nM acetic acid medium (control) for 24 hours at 37°C, 5% CO2. FAST Quant® 
multiplex arrays (human II, TH1/2 and angiogenesis kits) were used according to 
manufacturer’s instructions (FASTQuant®, GE healthcare; section 2.7) to determine 
whether IL-6 had any effect on EVT secretion of cytokines and angiogenic growth 
factors. The slides were imaged using an Axon GenePix scanner and data analysis was 
performed by the ArrayVision™ FAST® software.              
4.3.6 Statistical analysis 
Data are presented as mean +/- SEM. Data were analysed using StatView software 
package (Abacus Concepts, Inc., Berkley, US). Statistical significance was determined 
using one-way ANOVA, followed by Fisher’s post hoc analysis. Wilcoxon non-
parametric tests were performed for non-normal skewed distribution of data and t-
test was used when only two sets of data were compared and data were normally 
distributed. Differences were considered statistically significant at P < 0.05.  
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4.4 Results 
4.4.1 Expression of IL-6 receptors expressed by trophoblast cells  
To determine whether IL-6 may have an effect on trophoblast invasion, IL-6 receptor 
expression was initially studied to see whether this cytokine had the capability of 
binding with EVT and therefore, elicit an effect. Immunohistochemistry data (Chapter 
3) indicated that EVT in the placental bed in first half of pregnancy (6-20 weeks 
gestation) were immunopositive for both gp130 and IL-6Rα and expression did not 
alter with gestational age. The expression of IL-6 receptors by HTR-8/SVneo cells and 
primary isolated EVT after isolation and culture therefore was investigated.  
Immunocytochemistry of HTR-8/SVneo cells and isolated primary EVT cell smears 
demonstrated that both cell types express the IL-6 receptors, IL-6Rα and gp130 (Figure 
4.1; n=3).  
To further confirm IL-6 receptor protein expression by both trophoblast cell line HTR-
8/SVneo cells and primary EVT cells and confirm IL-6Rα antibody specificity Western 
blot analysis was performed. The 80kDa full length IL-6Rα receptor was expressed in 
both isolated EVT and HTR-8/SVneo cell lysates (Figure 4.2; n=3 both cell types), 
confirming expression of IL-6Rα by trophoblast cells. The house-keeping gene Gβ 
(36kDa) was used as a loading control for the experiment. Gp130 expression was 
undetectable using the antibody used.    
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Figure 4.1 Immunostaining of IL-6 receptors (IL-6Rα and gp130) on primary EVT and HTR-
8/SVneo cells  
Representative immunocytochemistry illustrating expression of IL-6Rα and gp130 by 
trophoblast cells grown in chamber slides showing: A) positive IL-6Rα staining on HTR-8/SVneo 
cells; B) positive gp130 staining on HTR-8/SVneo cells; C) positive IL-6Rα on primary EVT cells; 
D) positive gp130 staining on primary EVT cells. E and F show negative primary antibody 
controls for IL-6Rα and gp130 with HTR-8/SVneo cells. A, B, E and F magnification x200; C and 
D magnification x400.  
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Figure 4.2 Western blot demonstrating expression of IL-6Rα on primary EVT and HTR-
8/SVneo cells 
Representative Western blot showing protein expression of the full length IL-6Rα (80kDa) on 
both HTR-8/SVneo (n=3) and EVT cell isolates taken from 8-14 weeks’ gestation (n=2). The 
bands expressed at 36kDa demonstrate the expression of Gβ as a loading control.  
 
4.4.2 Effect of IL-6 on the invasiveness of trophoblast cells 
IL-6 receptor expression on trophoblast cells in situ and in vitro suggests that this 
cytokine has the ability to bind to these cells and may have a functional role. 
Therefore, the effect of IL-6 on trophoblast invasion was assessed using a Matrigel 
invasion assay. 
Addition of exogenous IL-6 had no effect on the invasiveness of either HTR-8/SVneo 
cells (Figure 4.3A) or primary EVT cells from first trimester (8-10 weeks gestation) 
placental explants (Figure 4.3B). Addition of exogenous sIL-6Rα alone or combined 
with IL-6 also had no effect on the invasiveness of either HTR-8/SVneo cells or 
placental explants, demonstrating that endogenous IL-6 produced by the trophoblast 
cells themselves does not contribute to invasion. Moreover, the presence of IL-6 
neutralising antibody had no effect on EVT cell invasion, suggesting that both 
endogenous IL-6 secreted by EVT cells and exogenous IL-6 plays no part in their 
invasiveness (Figure 4.3B).   
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Figure 4.3 The effect of IL-6 on trophoblast invasion 
A) The effect of exogenous IL-6 and sIL-6Rα on invasion of HTR-8/SVneo cells (n=3); B) the 
effect of exogenous IL-6, sIL-6Rα and IL-6 neutralising antibody on invasion of primary 
extravillous trophoblast cells from isolated villous explants at 8-10 weeks gestational age (n=5) 
in a Matrigel invasion assay. Data are expressed as invasion index normalised to the control for 
each experiment (mean ± SEM).  
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4.4.3 The effect of IL-6 on the stimulation of EVT signalling proteins  
Although IL-6 receptors are expressed by trophoblast cells, IL-6 failed to stimulate 
invasion. Nevertheless, the expression of IL-6 receptors by trophoblast cells indicates a 
potential functional role for this cytokine. In order to investigate the functional 
importance of IL-6 for trophoblast signalling pathways in EVT after stimulation with IL-
6 were investigated. 
4.4.3.1 Western blot of STAT-3 and ERK1/2 
Western blots for STAT-3 and p-STAT-3 were performed on HTR-8SVneo cell line 
lysates. However, there was no signal detected using the p-STAT-3 antibody even with 
the positive controls. A signal was produced for STAT-3 at 92kDa after incubation at 5, 
10 and 30 minutes (Figure 4.4). With regards to MAPK1/2 both EVT isolates and HTR-
8/SVneo cells produced these proteins: 44KDa ERK1 and 42KDa ERK2 (Figure 4.5 top). 
P-MAPK1/2 expression was also demonstrated by Western blot (Figure 4.5 bottom) in 
both HTR-8/SVneo and EVT cells. As the Western blots showed constitutive activation 
of MAPK1/2 signalling proteins in HTR-8/SVneo and EVT cells regardless of IL-6 
treatment and time, we decided to carry out a kinase array to determine which 
signalling proteins were stimulated by IL-6 using 10 minutes as the incubation time 
(section 4.4.4.2). 
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Figure 4.4 Western blot demonstrating the effect of IL-6 on trophoblast STAT-3 cell signalling 
Western blot representing bands at 92kDa demonstrating STAT-3 protein expression in 
untreated and IL-6 treated HTR-8/SVneo cells. The cells were subjected to 10ngml-1 of 
exogenous IL-6 for different incubation times. The positive control used for the experiment 
was HeLa cells stimulated with IFN-γ.  
 
Figure 4.5 Western blot demonstrating the effect of IL-6 on trophoblast cell signalling via 
MAPK pathway 
Western blot representing MAPK1/2 expression (44kDa and 42kDa) in untreated and IL-6 
treated HTR-8/SVneo and EVT cells (upper blot). The lower blot represents the expression of 
stimulated MAPK1/2 (44kDa and 42kDa). 3T3/A31 cell lysate was used as a positive control 
(data not shown). 
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4.4.3.2 Kinase-phospho array  
A kinase array that measures phosphorylation status for 46 kinase proteins involved in 
cellular signalling cascades was performed to determine whether IL-6 signalled in 
trophoblast cells. IL-6 stimulated phosphorylation of 9 of the 46 signalling proteins 
investigated in isolated primary EVT (Figure 4.6; n=3). The proteins that were most 
highly stimulated upon treatment were Src; P=0.01; Jun P=0.01 and STAT-3; P=0.02. IL-
6 significantly decreased stimulation of β-Catenin (P=0.02), STAT1 (P=0.04) and STAT4 
(P=0.002) and increased stimulation of STAT5a (P=0.006) from the 46 different kinase 
proteins in the HTR-8/SVneo cell line (Figure 4.7; n=3). However, signal spot intensity 
was very high in all replicates of the experiment indicating that HTR-8/SVneo cell 
signalling proteins are constitutively stimulated regardless of cytokine treatment. 
When a Bonferroni correction (P<0.001) was performed to take into account the 
multiple comparisons that were performed statistical significance was lost. 
 
Figure 4.6 The effect of IL-6 on EVT kinase signalling proteins 
The effect of IL-6 on stimulation of  46 kinase signalling proteins in isolated primary EVT cells 8-
14 weeks gestation (n=3) Nine signalling proteins in EVT were stimulated with exogenous IL-6 
treatment. A Students paired t-test was performed. * denotes significance between untreated 
and treated cells, (from left to right: P=0.02; P=0.03; P=0.05; P=0.01; P=0.04, P=0.02; P=0.02; 
P=0.04 respectively). 
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Figure 4.7 The effect of IL-6 on HTR-8/SVneo kinase signalling proteins 
The effect of IL-6 on phosphorylation of 46 kinase signalling proteins in HTR-8/SVneo cells 
(n=3). Both untreated and IL-6 treated data were normalised to positive controls. A Students 
paired t-test was performed. Letters A-D denotes significant differences in phosphorylation of 
signalling proteins between treated and untreated cells. A, C and D demonstrates a significant 
decrease in stimulated proteins upon treatment (P=0.02; P=0.04; P=0.002 respectively), 
whereas B denotes a significant increase in protein phosphorylation after IL-6 treatment 
(P=0.006).    
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4.4.4 EVT production of angiogenic growth factors, Th1/Th2 and human 
II cytokines +/- IL-6 
Having established that IL-6 could stimulate phosphorylation of EVT cells, the effect of 
IL-6 on EVT cytokine and angiogenic growth factor production was determined. Levels 
of secreted angiogenic growth factors and cytokines were measured in cell culture 
supernatants of isolated first trimester extravillous trophoblast cells. 
After IL-6 treatment (10ngml-1, 24h) EVT cells secreted similar levels of angiogenic 
growth factors and the majority of the cytokines measured to those detected in 
untreated EVT. Treatment of EVT cells with IL-6 decreased secretion of RANTES 
(Regulated upon Activation, Normal T-cell Expressed and Secreted) (P=0.03, Figure 
4.8A) and there was also a trend towards a reduction in secretion of other proteins 
including angiogenin, Ang-2, PDGF-BB, VEGF-A, ICAM-1, IL-10 and IL-13 (Figure 4.8A).  
Expression of RANTES mRNA was also reduced in EVT cells after treatment with IL-6 
using real time RT-PCR (P=0.05, Figure 4.8B; n=4) further confirming the protein data.   
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Figure 4.8 The effect of IL-6 on EVT protein secretion   
Effect of exogenous IL-6 (10ngml-1) on EVT protein secretion. A illustrates a significant 
reduction in EVT secretion of RANTES after treatment of IL-6, data from Human II FASTQuant 
(n=7).  No significant difference was observed in the levels of EVT secreted proteins between 
untreated and IL-6 treated cells from TH1/2 and angiogenesis FASTQuant assays respectively 
(n=4). Protein levels measured from treated EVT were normalised to untreated control levels 
and data are shown as mean fold change.  A non-parametric Wilcoxon Rank test was 
performed; * denotes significance compared with untreated cells P=0.03. B illustrates a 
significant reduction in RANTES mRNA expression after EVT cells were treated with IL-6. Data 
are normalised to control and are shown as mean fold change of delta-delta CT values. A 
Students paired t-test was performed; * denotes significance P=0.05 n=4.  
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4.5 Discussion 
4.5.1 Expression of IL-6 and IL-8 receptors by EVT cells 
IL-6 along with IL-8 is produced in high amounts within the decidua (reviewed in 
Chapter 3). IL-6 production has also been demonstrated in various choriocarcinoma 
cell lines, including  BeWo, Jar and Jeg-3, as well as the primary extravillous 
trophoblast-like cell line HTR-8/SVneo (Jovanovic and Vicovac, 2009). IL-6 receptor 
expression by trophoblast cells has been identified in primary cytotrophoblast cells and 
HTR-8/SVneo cells (Jovanovic and Vicovac, 2009) but has not been previously explored 
using isolated EVT from first trimester pregnancies. Zhao et al. (2008) investigated the 
expression of both sIL-6Rα and gp130 in villous tissue from both normal and 
preeclampsia placenta from term pregnancies and reported that gp130 expression was 
increased whereas sIL-6Rα was reduced in preeclampsia. These reports led to the 
suggestion that IL-6 may play a functional role for IL-6 in the pathogenesis of this 
disease as well as in normal pregnancy, although this was observed in placental villous 
tissue rather than isolated trophoblast cells. Villous tissue may not be a good tissue 
source for investigating preeclampsia as villous trophoblast cells are not relevant in its 
pathogenesis and is related to invasion by EVT cells.   
We have previously immunolocalised the IL-8 receptors CXCR1 and CXCR2 in first 
trimester EVT (De Oliveira et al., 2010) and CXCR1 has been reported to be expressed 
by EVT (Hanna et al., 2006) and by isolated cytotrophoblast (CTB) cells (Jovanovic et al., 
2010). This present study and studies within our group have confirmed IL-6 and IL-8 
receptor expression by trophoblast cells including isolated EVT both in vitro and in situ 
(Chapter 3) in early pregnancy, suggesting a functional role for both of the cytokines in 
the regulation of EVT invasion or other EVT function. They have the ability to bind and 
communicate with EVT to elicit a response. The signalling of IL-6 in EVT has not been 
investigated by other studies but has been explored in this study (section 4.5.3) EVT 
signalling effects were examined using IL-6 since IL-6 did not stimulate EVT invasion 
but we wanted to investigate other possible functions. IL-8 signalling in EVT was not 
investigated since an increase in EVT invasion was observed when EVT cells were 
treated with IL-8 but remains to be explored.  
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4.5.2 Effect of IL-6 on trophoblast invasion 
It has been proposed that one of the main roles of IL-6 in uteroplacental tissues is 
regulation of trophoblast invasion.  Although IL-6 is widely associated with studies 
involving progression of certain cancers and is known to have an effect on the 
invasiveness of cancer cells, there is limited information on its role in trophoblast 
invasion. Despite the expression of IL-6 receptors by primary isolated EVT and HTR-
8/SVneo cells, neither exogenous nor endogenous IL-6 had any effect on trophoblast 
invasion in this study. Interestingly, the addition of sIL-6Rα with IL-6 did not increase 
the invasiveness of the trophoblast cells, nor did the addition of IL-6 neutralising 
antibody decrease invasion, further suggesting that the functional role of this cytokine 
is not related the regulation of EVT invasion. In contrast, a recent study has reported 
an increase in the invasive potential of first trimester villous cytotrophoblast cells and 
HTR-8/SVneo cells after IL-6 treatment in vitro (Jovanovic and Vicovac, 2009). This 
discrepancy could be explained by the differences in the cell type used; in the present 
study placental villous explants from which EVT are derived were used, whereas 
(Jovanovic and Vicovac, 2009) studied isolated villous cytotrophoblast cells. The 
varying results between the two studies with HTR-8/SVneo cells may be due to their 
differing passage number, which could reflect a change in cellular function. 
Quantification methods also differed between studies; rather than counting selected 
fields of the membrane inserts and including occupied pores within the cell 
quantification as reported by (Jovanovic and Vicovac, 2009), in this study only cells that 
had invaded completely through the pores were included and were quantified in the 
entire membrane. In addition, RNA silencing techniques have been used to inhibit 
expression of IL-6 in JEG-3 choriocarcinoma cells resulting in the inhibition of cellular 
migration and invasion (Dubinsky et al., 2010) suggesting that IL-6 does contribute to 
cell invasion in this cell type. Furthermore, Paiva et al. (2009) reported that IL-11 (a 
member of the IL-6 superfamily) reduced invasion of HTR-8/SVneo cells but, in 
contrast, promoted EVT migration.  
There is increasing evidence that HTR-8/SVneo cells are an imperfect model for 
extravillous trophoblast as they respond differently to altered oxygen concentrations 
compared with primary EVT, and they do not express the specific integrin repertoire 
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and non-classical MHC class I molecules such as HLA-G that are typical of EVT (Kilburn 
et al., 2000) unless cultured on extracellular matrix (Apps et al., 2009, Lash et al., 
2007). Recent data by Bilban et al. (2010) has demonstrated differences in gene 
expression profiles  of integrins, proteases, hormones and growth factors between 
trophoblast cell lines and primary CTB and EVT. Indeed of the cell lines tested, HTR-
8/SVneo cells were most distantly related to primary cells and therefore these cells are 
not an ideal model for extravillous trophoblast.  
The effect of IL-6 on trophoblast invasion using primary EVT isolates or placental 
explants has not been previously reported but the results obtained from this study 
suggest that IL-6 does not play a role in regulating trophoblast invasion in early 
pregnancy; these results are also consistent with preliminary findings from other 
laboratories (Dr M. Knofler, personal communication). In accordance with this reports 
concluded that decidual cells, which we have shown to be producers of IL-6 (Chapter 
3), do not play a major role in regulating CTB invasion in vitro using a decidual/EVT co-
culture method (Cohen and Bischof, 2009). In contrast, CTB cells increased the 
invasiveness of decidual cells by increasing their secretion of MMPs. Recently Lash et 
al. (2010b) demonstrated that uNK cell supernatants from 12-14 weeks gestation 
pregnancies had more effect on the stimulation of EVT invasion compared with 
decidual supernatants from 8-10 weeks gestation. This coincides with findings from 
this study that more IL-6 is produced at 12-14 weeks gestation by uNK cells (Chapter 3) 
and suggests that IL-6 may possibly contribute to the invasive capacity of EVT at later 
gestation. However, EVT are more inherently invasive at 8-10 weeks gestation (Lash et 
al., 2005) and may require external stimuli from decidual components to proceed with 
invasion into the inner third myometrium after 8-10 weeks into later gestation.  
4.5.3 Effect of IL-6 on the stimulation of cellular kinase proteins involved 
in EVT signalling  
Although IL-6 had no effect on trophoblast invasion in the present study, the signalling 
effect of IL-6 on early pregnancy EVT was investigated, an area which has not been 
previously explored. The kinase profile array performed in this study demonstrated 
stimulation of nine signalling pathway kinase proteins in isolated primary EVT by 
exogenous IL-6, but not in the HTR-8/SVneo cell line.  These signalling proteins were 
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constitutively phosphorylated in HTR-8/SVneo cells regardless of IL-6 treatment, 
suggesting constitutive state of activation and providing further evidence that this cell 
line is not an ideal model for EVT.  Indeed, 3 out of the 4 proteins were less 
phosphorylated after treatment of HTR-8/SVneo cells with IL-6. In isolated EVT the 
proteins that were most highly phosphorylated by IL-6 were; Src protein, a proto-
oncogenic tyrosine kinase which is reported to be involved in embryonic development 
and cell growth, STAT-3 a transcriptional activator of transcription of genes involved in 
cellular growth and proliferation and c-Jun an early transcription factor that interacts 
directly with specific target DNA sequences to regulate gene expression. STAT-3 is a 
major downstream protein involved in IL-6 signalling and molecular studies have 
shown that STAT-3 is a contributor to EVT invasive capacities (Fitzgerald et al., 2005). 
However, this provides conflicting evidence to the invasive capacities of IL-6 on EVT as 
no stimulation on EVT invasion was observed with IL-6 in this study and the absence of 
pSTAT protein in EVT after IL-6 treatment also is consistent with this finding, although 
the sensitivity of the kinase array may account for the detection of phosphorylated 
STAT-3. This indicates that signalling between EVT cells and IL-6 is a complex process 
and may include the involvement of other factors to achieve a functional role in EVT 
invasion. STAT-3 signalling is also involved in many cellular events and also plays a part 
in cellular development; IL-6 may help to up-regulate genes involved in trophoblast 
growth or differentiation, although further investigations are required to gain insight 
into the specific role for this cytokine in trophoblast function.  
4.5.4 Effect of IL-6 on the secretion of growth factors and cytokines by 
EVT cells 
Demonstration of IL-6 receptors on EVT and stimulation of signalling proteins in 
primary EVT after IL-6 treatment led to investigation of the effect of IL-6 on EVT 
secretion of angiogenic growth factors and cytokines since IL-6 had no effect on 
trophoblast invasion. Although, the majority of the secreted proteins analysed were 
reduced with IL-6 treatment, this was significant only for RANTES. RANTES (Regulated 
upon Activation, Normal T-cell Expressed, and Secreted) is a chemokine that is 
chemotactic for T-cells, eosinophils and basophils and has an active role in recruiting 
leucocytes to sites of inflammation. EVT cells penetrate the decidualised endometrium 
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and further migrate within the lumen of spiral arteries to remodel the uterine 
vasculature. RANTES has been shown to increase migration of isolated macaque 
trophoblast cells (Thirkill et al., 2005) and also promoted EVT invasion in EVT isolated 
from villous explants cultures in vitro (Fujiwara et al., 2005). Production of RANTES by 
both human primary CTB and EVT was also observed and production increased 
significantly between 8-10 and 12-14 weeks gestational age (Naruse et al., 2010). The 
evidence suggests that EVT RANTES is responsible in mediating trophoblast migration 
and may influence their invasive potential. IL-6 reduced the secretion of EVT RANTES in 
this study suggesting that EVT invasion would have been somewhat inhibited. 
However, this was not observed in this study, although trophoblast secretion of 
RANTES may play a role in mediating trophoblast migration and IL-6 could play a role in 
regulation of this function; a reduction in chemotactic factors may be required to 
support the formation of trophoblast plugs in spiral arteries in the first trimester, thus 
preventing EVT migration and favouring remodelling of the arteries (James et al., 
2012).  
4.5.5 Overall summary   
An extensive literature reflects the importance of IL-6 in human implantation and has 
been implicated pregnancy complications but there is little understanding of the effect 
of IL-6 on trophoblast function in early pregnancy. It has been suggested that IL-6 may 
contribute to trophoblast growth and development by stimulation of trophoblast 
derived human chorionic gonadotrophin (hCG) (Nishino et al., 1990), which is essential 
for the maintenance of pregnancy and may play a role in the differentiation of 
cytotrophoblasts in blastocyst implantation. Indeed (Taniguchi et al., 1992), 
demonstrated that IL-6 enhanced secretion of hCG by Jar, HCCM-5 and BeWo 
choriocarcinoma cell lines. BeWo cells, in common with EVT and CTB, secrete high 
levels of RANTES and IL-1β which in turn increases the secretion of hCG. IL-6 may 
therefore control secretion of these factors by EVT, hence further increasing hCG 
secretion to maintain a healthy pregnancy. However, it should be noted that this has 
not yet been observed using primary EVT. In unpublished data studies (Dr Knofler et al 
personal communication) IL-6 did not cause stimulation of hCG in primary EVT in early 
pregnancy.      
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IL-6 is a pleiotropic cytokine with both pro-inflammatory and anti-inflammatory 
functions; many signalling pathways are affected by IL-6 resulting in a range of 
biological effects. The developmental processes that are essential for successful early 
human pregnancy, including EVT invasion, involve a complex network of multiple 
cytokines and growth factors, with both stimulatory and inhibitory functions. Due to 
the complexity of the cytokine milieu within the decidua it is difficult to determine the 
exact function of this individual cytokine. Furthermore functions of the range of 
different cytokines and growth factors present at the maternal-fetal interface may 
differ with gestational age.  
In summary in the present study using both placental villous explants and a 
trophoblast cell line, HTR-8/SVneo, we have demonstrated that there was no effect of 
IL-6 on trophoblast invasion. Studies and understanding of physiological trophoblast 
invasion remains and the complex array of signalling cascades involved require 
clarification. We have shown that IL-6 signalling effects were able to contribute to the 
stimulation of signalling pathways in isolated EVT cells and affect production of 
cytokines that are involved in migratory function and which may have other roles in 
trophoblast biology such as regulating hCG secretion, EVT differentiation and influence 
EVT dependent SpA remodelling, areas which if altered could contribute to pregnancy 
complications and therefore require further exploration. The current study has 
therefore demonstrated that IL-6 has an effect on EVT, albeit the function remains 
unknown. Nevertheless these data signify a possible important role for IL-6 in early 
human pregnancy which may require both in vivo and in vitro approaches to unravel. 
 
 
Chapter 5 
The effect of interleukins-6 and 8 on the differentiation and 
morphology of vascular smooth muscle cells (VSMCs) in 
chorionic plate arteries (CpA) from term human placenta 
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5. The effect of interleukins-6 and 8 on the differentiation and 
morphology of vascular smooth muscle cells (VSMCs) in 
chorionic plate arteries (CpA) from term human placenta 
5.1 Introduction 
The importance of spiral artery remodelling in early pregnancy development has been 
reviewed in chapter 1. During early pregnancy once implantation has occurred, spiral 
arteries begin to transform from extensively coiled, narrow, thick muscular structures 
into highly dilated vessels ensuring that an adequate supply of blood is delivered to the 
fetus at an optimal pressure to ensure maximal nutrient exchange. This is achieved by 
the loss of their musculoelastic wall which is replaced by fibrinoid material and 
invading extravillous trophoblast (EVT) cells. Failure of remodelling during early 
pregnancy had been implicated in the pathogenesis of preeclampsia (Pijnenborg et al., 
1991), intrauterine growth restriction (IUGR) (Khong et al., 1986) and late miscarriage 
(Ball et al., 2006a). Despite the importance of spiral artery remodelling in early 
pregnancy, the molecular mechanisms which trigger the process remain unclear but it 
is now more evident that there are both EVT-independent and EVT-dependent 
processes.   
The process of spiral artery (SpA) remodelling is a unique process in human vascular 
biology which involves the transient loss of VSMC with complete restoration post 
partum. However, the events of SpA remodelling in early pregnancy are parallel to 
events of angiogenesis which occur during vascular injury or tumourgenesis. The early 
stages of SpA remodelling involve initial disruption of the vascular wall, characterised 
by endothelial cell swelling and loss, vessel dilatation and vascular smooth muscle 
(VSMC) separation and misalignment which occur before the presence of EVT. 
Mechanisms that underlie these processes have yet to be elucidated but VSMC 
migration and de-differentiation are suggested possibilities (Whitley and Cartwright, 
2010, Bulmer et al., 2012). The differentiation of VSMCs is correlated to their 
behaviour and phenotype and they can switch between contractile and synthetic 
stages which makes them unique compared with other muscle cells (Kaplan-
Albuquerque et al., 2005). The VSMCs in an established artery exhibit a contractile 
phenotype expressing proteins such as smooth muscle actin (α-SMA), calponin and 
myosin heavy chain and do not show signs of migration or proliferation (Owens et al., 
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2004). However, extracellular signals can cause the VSMCs to adopt a synthetic 
phenotype resulting in increased migration and proliferation (Wilcox et al., 1997) and 
is associated with a reduction in the expression of contractile proteins (Halka et al., 
2008) which could be evident in remodelling spiral arteries.  
Maternal immune cells such as uNK cells and decidual macrophages have been 
proposed to play a role in the initiation of SpA remodelling (Lash et al., 2006c, Smith et 
al., 2009, Hazan et al., 2010, Robson et al., 2012). Uterine natural killer cells are a rich 
source of many cytokines and angiogenic growth factors and increasing evidence 
suggests a role for these cells in the SpA remodelling that ensures successful 
pregnancy. Studies in mouse pregnancies have demonstrated the importance of uNK 
cells in SpA modification via IFN-γ (Ashkar and Croy, 2001, Zhang et al., 2003). Human 
uNK cells also produce IFN-γ as well as Ang-1, Ang-2 and VEGF-C (Li et al., 2001, Lash et 
al., 2006c) which are all factors involved in vascular modification during angiogenesis 
events (Distler et al., 2003, Ferrara, 2004). Human uNK cell Ang-2 has been reported 
for the first time to be a significant factor in vascular modification using chorionic plate 
arteries (CpA) and non-pregnant myometrial arteries (Robson et al., 2012).     
Uterine macrophages are also observed surrounding SpA undergoing remodelling 
although the function of these cells in SpA remodelling has not been examined 
(Chapter 6). In this study we have demonstrated that both uNK cells and macrophages 
are sources of the cytokines IL-6 and IL-8 (Chapter 3).  IL-6 has been linked to the 
progression of tumour development in many cancers. However, the exact function of 
IL-6 in malignancy has yet been established. Ovarian carcinoma cells have been 
reported to secrete IL-6 which was shown to be a potent pro-angiogenic cytokine 
promoting the progression of the disease by increasing endothelial cell migration and 
therefore increasing vascularisation (Nilsson et al., 2005) as well as regulating the 
migration of VSMCs in rat aortas (Wang et al., 2007). Studies have also shown that 
over expression of IL-8 has been related to tumour progression and metastases 
(Terada et al., 2005, Bai et al., 2005, Reis et al., 2012) with expression shown to 
correlate with angiogenesis of many cancers (Huang et al., 2002, Karashima et al., 
2003). Association of IL-8 with endothelial cells expressing CXCR2 up regulates VEGF 
mRNA resulting in cellular proliferation and migration increasing endothelial cell 
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permeability (Martin et al., 2009). These reports of IL-6 and IL-8 highlight the potential 
of their importance in angiogenesis and raise the possibility of a role for IL-6 and IL-8 in 
the regulation of the initial stages of SpA remodelling.  
Human spiral artery remodelling during early pregnancy has remained difficult to study 
by the lack of an appropriate model. In vivo studies of uterine vascular changes are 
difficult due to the access of early normal pregnancy tissue; there are problems in 
collection of early decidual and placental bed tissue and the microscopic size and 
highly coiled structure of the spiral arteries make them difficult to dissect. Therefore, 
in an effort to address this, the present study used an in vitro vessel model using 5mm 
sections of chorionic plate arteries from term placenta of women undergoing 
Caesarean section in order to investigate the effect of both IL-6 and IL-8 on vascular 
changes relating to pregnancy. Previous investigation using this model within our 
research group has demonstrated that first trimester uNK cell supernatants disrupts 
VSMC organisation, suggesting a role for uNK cell decidual factors including IL-6 and IL-
8. Furthermore effects of uNK cell derived cytokines and angiogenic growth factors 
were similar in CpA and myometrial spiral arteries, suggesting that is readily accessible 
vessel is a valid model for uterine SpA (Robson et al., 2012).    
 
5.2 Aims and Hypotheses 
5.2.1 Hypotheses 
The hypotheses to be tested were:- 
1)  IL-6 and IL-8 receptors are expressed on chorionic plate arteries (CpA) from 
term human placenta 
2)  IL-6 and IL-8 disrupts VSMC organisation of CpA by increasing the separation 
between VSMC layers and increasing rounding of VSMCs within the vessel wall 
– displaying a more synthetic phenotype.    
3)  IL-6 and IL-8 alters the differentiation status of VSMCs in CpA and therefore, 
the cells treated will express markers typical of a synthetic phenotype 
compared with untreated cells that will express markers of a contractile 
phenotype.  
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5.2.2 Aims 
The aims of the study were to:- 
1) Investigate receptor expression using frozen sections of the CpA tissue at T=0 
for immunohistochemical analysis 
2) Investigate the effect of IL-6 and IL-8 on VSMC morphology and differentiation 
in CpA after culture for 5days 
 
5.3 Experimental design  
5.3.1 Chorionic plate artery culture - the in vitro vessel culture model 
Term placentas (37-42 weeks gestation) were obtained from women undergoing 
Caesarean section and the chorionic plate arteries removed and dissected in the 
laboratory (section 2.1.6). Initially, dissected segments were immediately snap frozen 
in isopentane cooled in liquid nitrogen and stored at -80°C until required (section 
2.1.8) and the frozen segments were labelled T=0. The frozen T=0 segments were then 
prepared on glass slides (section 2.3.7) and were immunostained with the muscle 
marker H-Caldesmon, endothelial marker CD34, IL-6 receptors; IL-6Rα and gp130 and 
IL-8 receptors; CXCR1 and CXCR2 (Table 5.1) n=3 to confirm receptor expression by the 
CpA. 
Following confirmation of cytokine receptor expression by immunohistochemistry CpA 
segments that were going to be treated with exogenous IL-6 and IL-8 were prepared 
and the untreated control segments (T=0 days) were immediately fixed in 10% neutral 
buffered formalin.  
 
 
 
 
 
 
183 
 
Table 5.1 Primary antibodies used for immunohistochemistry on both FFPE and frozen tissue 
sections 
Primary antibodies used for immunohistochemistry on both FFPE and frozen tissue sections of 
T=0 and T=5 CpA. 
 
5.3.2 IL-6 and IL-8 treatments 
The dissected segments to be treated with exogenous IL-6 and IL-8 were placed into 
wells of a 48 well culture plate each containing 300µl of differing treatments; control 
RPMI complete medium (RPMI 1640, 10% fetal calf serum, 1% penicillin/streptomycin 
and 1% L-glutamine); 1ngml-1 recombinant IL-6 or IL-8 (Miltenyi), 10ngml-1 
recombinant IL-6 or IL-8, 5ngml-1 recombinant sIL-6Rα (Miltenyi); and 10ngml-1 IL-6 + 
5ngml-1 sIL-6Rα. Each treatment was performed in triplicate (Figure 5.1). The CpA 
segments were cultured at 37°C in 5% CO2 for a total of 5 days. The media was 
refreshed every other day. Previous investigation of this vessel type showed that 5 
days was sufficient culture time and after 5 days loss of the vessel endothelium is 
apparent due to apoptosis. 
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Figure 5.1 Identification of chorionic plate arteries (CpA) from term placenta 
Image showing the chorionic plate of a term placenta and the identification of the chorionic 
arteries which were dissected into segments and cultured for 5 days. 
  
5.3.3 Assessment of VSMC morphological differences 
Following 5 days of incubation, the CpA segments were removed from culture and one 
of each of the segments was placed in 10% neutral buffered formalin (T=5 days). Both 
the T=0 and T=5 day segments were embedded and processed in paraffin wax and cut 
into 3µm sections ready for immunohistochemical analysis.   
To investigate the effect of the cytokines on CpA VSMC morphology the prepared 
sections were immunostained for myosin heavy chain (Table 5.1). The slides were then 
assessed for changes in VSMC rounding, disorganisation of VSMC layers and the 
misalignment of VSMC layers using a four point scale (Figure 5.2).  
In addition to using the four point scale to assess the degree of VSMC rounding, 
separation and disorganisation a generalised quickscore method was also applied; the 
vessels were given a score between 1 and 4; where 1 would score VSMCs having an 
overall contractile appearance (VSMC layers tightly compacted, VSMCs showing a 
spindle shaped appearance and VSMC showing little disorganisation) whereas 4 would 
score VSMC layers having being very separated, VSMCs showing a rounded appearance 
and the cells being highly disorganised.    
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Figure 5.2 Scoring of vascular smooth muscle cell (VSMC) rounding, separation and 
disorganisation 
Immunohistochemical representation of scoring of the changes in vascular smooth muscle cell 
morphology and organisation.  A four point scale (1 <10%, 2= 10-25%, 3= 25-75%, 4= >75%) 
was used to assess the rounding of VSMCs; spindle like and elongated 0% rounding of cells (A) 
to rounded and spherical >75% of the cells (B), the degree of separation of VSMC layers (C-D) 
and the degree of disorganisation of VSMC layers (E-F). Sections were immunostained with 
anti-myosin heavy chain. Magnification x200.  
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5.3.4 Quantification of immunostaining using Adobe Photoshop™ 
In addition to myosin heavy chain immunostaining, tissue sections were also 
immunostained with markers of VSMC differentiation including H-Caldesmon (an 
established smooth muscle marker of muscle differentiation), calponin (an 
intermediate-early differentiation marker) and α-smooth muscle actin (an early 
differentiation marker). One characteristic feature of phenotypically modulated VSMCs 
is that they express markedly lower levels of differentiation markers that the smooth 
muscle cells change from a contractile to a synthetic phenotype.  
The percentage of positive VSMC immunostaining expressed on each of the treated 
CpAs was assessed using a pixel counting method using Adobe Photoshop™ software. 
Microscopic images of the stained vessels were taken using (Nikon 80i microscope and 
NIS Elements software). The images were then uploaded onto Adobe Photoshop™. The 
number of positively immunostained pixels was divided by the total number of pixels 
in the entire image x100 to give a percentage. All sections were blinded.  Following 
assessment the sections were un-blinded and mean values were used in analysis.     
5.3.5 Fetal calf serum concentrations and charcoal stripped serum  
To investigate whether fetal calf serum impaired binding of IL-6 and IL-8 to VSMC in 
CPA, by preventing specific binding to receptors, an additional experiment was 
performed using differing concentrations of fetal calf serum or charcoal-stripped fetal 
calf serum (First Link, Birmingham, UK). Charcoal stripped fetal calf serum is used 
instead of normal fetal calf serum to minimise the level of androgens and hormones 
which may compete with binding to the specific cytokine receptors, may prevent 
cytokines reaching their receptors or may inactivate cell signalling responses, therefore 
affecting the function of the cytokines. Charcoal stripped fetal calf serum is absorbed 
in activated carbon which aids the removal of non-polar compounds such as lipophilic 
material, growth factors, hormones and cytokines which may have impact on research 
results after culture (Herbert et al., 1965, Green, 1987 ). 
Chorionic plate arteries were prepared as described in section 5.3.1.  
Firstly, a time course experiment was performed. Following dissection a T=0 segment 
was immediately fixed in formalin. The remaining CpA segments were cultured in RPMI 
187 
 
medium with or without 10% FCS for 1 day (T=1), 2 days (T=2), 3 days (T=3), 4 days 
(T=4) or a total of 5 days (T=5) (n=3). Following each time point the corresponding 
vessels were fixed in formalin and embedded in paraffin for immunohistochemistry. 
The tissue sections were subjected to a haematoxylin and eosin stain to assess the 
orientation of each vessel and then immunostained for active caspase 3, CD31, myosin 
heavy chain and Ki67 to assess the degree of proliferation and apoptosis of VSMCs and 
endothelial cells (Table 5.1, n=3).  
Following the time course experiment, arteries dissected from term placenta (n=5) 
were cultured with either standard RPMI media containing no FCS, 0.5% or 10% FCS 
versus charcoal stripped FCS supplemented media. CpA sections were cultured in 
media containing 10% of either normal FCS or charcoal stripped FCS with or without 
10ngml-1 IL-6 for 5 days. After 5 days in culture the chorionic arteries were formalin 
fixed and paraffin embedded for immunohistochemistry (as above).  
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5.4 Results 
5.4.1 Immunohistochemical localisation of IL-6 and IL-8 receptors on CpA 
VSMC 
In order to investigate whether IL-6 or IL-8 had any effect on chorionic plate artery 
vascular smooth muscle cell morphology and differentiation, cytokine receptor 
expression was initially investigated to determine whether these cytokines were 
capable of binding to the CpA VSMCs and hence eliciting an effect. 
Positive immunostaining for both IL-6 receptors, sIL-6Rα and gp130, was observed 
(Figure 5.3). Immunostaining for IL-6Rα showed strong expression of the receptor on 
VSMCs of chorionic plate arteries (n=3). Where there were several VSMC layers, IL-6Rα 
immunostaining was abundant and was stronger on VSMCs immediately beneath the 
artery lumen and slight staining was observed on endothelial cells. Gp130 was also 
expressed on VSMCs of CpAs (n=3), but gp130 immunostaining was more intense on 
the endothelial cells of the artery lumen. 
Both receptors for IL-8, CXCR1 and CXCR2, were expressed on chorionic plate arteries 
with positive immunostaining observed on CpA VSMCs (Figure 5.4). CXCR1 
immunostaining showed receptor expression on both CpA VSMCs and endothelial 
cells, with immunostaining being more intense on the endothelium. CXCR2 
immunostaining also showed receptor expression on both VSMCs and endothelial cells 
with intense reactivity on endothelium compared with VSMCs. However, CXCR1 was 
more strongly expressed overall.      
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Figure 5.3 Evidence of IL-6 receptor immunostaining on CpA VSMCs and endothelial cell 
lining 
Representative chorionic plate artery immunostained for CD34 showing endothelial lining; H-
caldesmon showing VSMCs, IL-6Rα and gp130. Magnification x100 (frozen sections).  
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Figure 5.4 Evidence of IL-8 receptor immunostaining on CpA VSMCs and endothelial cell 
lining 
Representative chorionic plate artery immunostained for CD34 showing endothelial lining; H-
caldesmon showing VSMCs, CXCR1 and CXCR2. Magnification x100 (frozen sections).  
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5.4.2 Effect of IL-6 and IL-8 on the morphology of CpA VSMC using 10% 
fetal calf supplemented serum 
Both IL-6 and IL-8 receptors were expressed on VSMC and/or endothelial cells of CpAs 
(section 5.4.1). Therefore, these cytokines have the ability to bind to these cells and 
may have an effect on the vascular changes in these vessels. Changes in CpA 
morphology were assessed on FFPE sections immunostained for myosin heavy chain 
using a four point scoring scale (Figure 5.2), after culture with exogenous IL-6 and IL-8 
in RPMI complete medium (T=5 days). Using this scoring method no morphological 
changes were observed when the arteries were treated with 1ng ml-1 or 10ng ml-1 of 
IL-6 (Figure 5.5; n=6) or IL-8 (Figure 5.6; n=6). 
To validate the four point scoring scale an overall quick score of VSMC rounding, 
separation of VSMC layers and the misalignment of VSMCs was also performed on all 
samples. Individual scores for rounding, separation and misalignment were added 
together and divided by 3 for each vessel. Again using this scoring method neither IL-6 
(Figure 5.5) nor IL-8 (Figure 5.6) had any effect the morphology of CpA VSMC.        
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Figure 5.5 The effect of IL-6 on CpA VSMC morphology 
Graphical representations showing the effect of differing concentrations of exogenous IL-6 on 
the morphological changes of VSMCs of chorionic plate arteries after 5 days of culture. 
Changes were assessed by myosin heavy chain immunohistochemical assessment with control 
treatments using a four point scale (n=6). An overall morphological quick score was also 
assessed. Data are expressed as mean ± SEM.    
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Figure 5.6 The effect of IL-8 on CpA VSMC morphology 
Graphical representations showing the effect of differing concentrations of exogenous IL-8 on 
the morphological changes of VSMCs of chorionic plate arteries after 5 days of culture. 
Changes were assessed by myosin heavy chain immunohistochemical assessment with control 
treatments using a four point scale (n=6). An overall morphological quick score was also 
assessed. Data are expressed as mean ± SEM.    
 
 
 
 
 
 
 
194 
 
5.4.3 Effect of IL-6 and IL-8 on the differentiation of VSMC muscle 
markers using 10% fetal calf supplemented serum  
A characteristic feature of phenotypically modulated VSMCs is that they express 
markedly lower levels of muscle differentiation markers; staining for markers of 
differentiated VSMC should therefore decrease if the vessels are transforming.  
The percentage of positive immunostaining for the muscle differentiation markers 
expressed on the CpA was assessed using an Adobe Photoshop™ pixel counting 
method (section 5.3.4). The percentage of positive immunostaining for different 
muscle markers did not alter after IL-8 treatment compared with media controls 
(Figure 5.8). Similarily, expression of muscle differentiation markers H-caldesmon, 
myosin heavy chain and calponin did not alter in CpA treated with IL-6, sIL-6Rα alone 
and IL-6 + sIL-6Rα combined. However, arteries treated with 10ng ml-1 IL-6, 5ng ml-1 
sIL-6Rα and 10ng ml-1 IL-6 combined with 5ng ml-1 sIL-6Rα showed a significant 
decrease in α-smooth muscle actin expression compared with media control treated 
arteries (Figure 5.7; a: P=0.05; b: P=0.02; c: P=0.03, respectively). 
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Figure 5.7 The effect of IL-6 on CpA VSMC differentiation when cultured with medium 
supplemented with 10% fetal calf serum (FCS) 
Immunostaining for myosin heavy chain on VSMCs of chorionic plate arteries (CpA) from term 
placenta cultured for 5 days with (A): RPMI complete medium control; (B): 1ng ml-1 IL-6; (C): 
10ng ml-1 IL-6; (D): 5ng ml-1 sIL-6Rα; (E): 5ng ml-1 sIL-6Rα + 10ng ml-1 IL-6 combined 
(magnification x40). (F): Graphical representation of the effect of IL-6 on muscle differentiation 
markers (H-caldesmon, myosin heavy chain, α-smooth muscle actin and calponin; n=6). Data 
are expressed by mean ± SEM; a, b, c denotes statistical significance compared with T=5 
control P<0.05 
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Figure 5.8 The effect of IL-8 on CpA VSMC differentiation when cultured with medium 
supplemented with 10% FCS 
Myosin heavy chain immunostaining on VSMCs of chorionic plate arteries (CpA) from term 
placenta cultured for 5 days with (A): RPMI complete medium control; (B): 1ng ml-1 IL-8; (C): 
10ng ml-1 IL-8 (magnification x40). (D): Graphical representation of the effect of IL-8 on muscle 
differentiation markers (H-Caldesmon, myosin heavy chain, α-smooth muscle actin and 
calponin; n=6). Data are expressed as mean ± SEM. 
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5.4.4 Dose response to sera- changes in VSMC morphology and 
degradation of endothelium  
Following 5 days incubation arteries cultured in medium containing no fetal calf serum 
appeared to have lost the luminal endothelium as assessed by immunohistochemistry 
for CD34+ cells compared with vessels treated with 10% FCS supplemented medium, 
regardless of cytokine treatment and there was also more apoptosis evident in the 
endothelium shown by the presence of positive immunostained active caspase 3 
(Figure 5.9). The VSMC layers were more separated and cells in the connective tissue 
surrounding the lumen appeared vacuolated (Figure 5.9). These data suggest that 
substances within the fetal calf serum are important for vascular integrity. This was 
also observed using 0.5% fetal calf serum. VSMC morphology appeared similar using 
the same concentrations of the two different fetal calf sera (normal and charcoal 
stripped) without addition of IL-6. However, CpA cultured in 10ng ml-1 IL-6 with 0.5% 
carbon stripped fetal calf serum showed stronger Ki67 staining and hence more 
proliferation, compared with CpA cultured in normal fetal calf serum. Furthermore, 
arteries treated with 10ng ml-1 IL-6 and 10% charcoal stripped FCS showed differences 
in VSMC morphology from a rounded shape to a spindle shape with separation 
between VSMC layers indicating that the CpA VSMCs were more responsive to IL-6 
compared to when treated with IL-6 cultured in normal FCS (Figure 5.10). No changes 
in apoptosis were observed using the different sera. We therefore, chose to use a 
concentration of 5% charcoal stripped fetal calf supplemented medium for the 
cytokine treatment experiments was sufficient for a morphological change as 0.5% 
charcoal stripped FCS had no effect on IL-6 whereas 10% charcoal stripped FCS did. 
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Figure 5.9 Comparison of culturing CpA in medium supplemented with 10% FCS compared 
with culturing CpA in medium without FCS 
Photomicrograph illustrating immunostaining for CD31, active caspase-3 and myosin heavy 
chain demonstrating: A) The endothelium lining the lumen of term CpA; B) The level of 
apoptosis of the endothelium and C) VSMC layers surrounding the lumen after 5 days 
incubation (T=5). Left hand images represent CpAs cultured with 10% FCS supplemented 
medium and right hand images represent CpAs cultured in medium with no addition of FCS 
n=3. Original magnification x100.  
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Figure 5.10 Comparison of culturing CpA in medium supplemented with 10% FCS compared 
with culturing CpA in medium supplemented with varying concentrations of charcoal 
stripped FCS with addition of IL-6 
Photomicrograph illustrating Ki67 and myosin heavy chain positive immunostaining 
demonstrating: A and B) The degree of cell proliferation of term CpAs cultured in either 
medium containing 10% FCS + 10ng ml-1 IL-6 (A) or cultured in medium containing 0.5% 
charcoal stripped FCS + 10ng ml-1 IL-6 (B); C) VSMC morphology of CpA treated medium 
containing 10% FCS + 10ng ml-1 IL-6; D) CpA treated with medium containing 10% charcoal 
stripped FCS + 10ngml-1 IL-6 after 5 days incubation (T=5, n=3). Original magnification x100.  
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5.4.5 Effect of IL-6 and IL-8 on the morphology of CpA VSMC using 5% 
charcoal stripped fetal calf supplemented serum 
Following the results from the dose response of CpAs to charcoal stripped fetal calf 
serum supplemented medium (section 5.4.4), chorionic plate arteries were cultured 
with exogenous cytokine made up in RPMI media supplemented with 5% charcoal 
stripped FCS (section 5.3.5) and VSMC morphology was assessed using a four point 
scale (Figure 5.2).  
Treatment with IL-6 had no effect on CpA VSMC rounding but did, however, have an 
effect on the separation of VSMC layers and the alignment of VSMCs within the vessel 
(Figure 5.11A). Treatment of CpA with 10ng ml-1IL-6 and 10ng ml-1 IL-6 + 5ng ml-1 sIL-
6Rα significantly increased separation of VSMC layers compared with the 5 day media 
control (P=0.02; P=0.001 respectively). In contrast, only IL-6 + sIL-6Rα affected the 
misalignment of VSMC compared with the 5 day media control (P=0.04; Figure 5.11B).  
Treatment of CpA with IL-8 had no effect on the rounding or separation of VSMC but 
did have a significant effect on the misalignment of VSMCs compared with the 5 day 
media control (P=0.001) (Figure 5.12).  
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A) 
 
 
Figure 5.11 The effect of IL-6 on CpA VSMC morphology when cultured with medium 
supplemented with 5% charcoal stripped FCS 
A) Photomicrogragh illustrating the effect of differing concentrations of exogenous IL-6 on the 
morphology of VSMCs of chorionic plate arteries after 5 days of culture using RPMI medium 
supplemented with 5% charcoal stripped fetal calf serum (cs FCS). Changes were assessed by 
myosin heavy chain positive immunostaining compared with control treatments using a four 
point scale (n=5). Original magnification x200. 
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B) 
 
B) Graphical representation showing the effect of differing concentrations of exogenous IL-6 
on the morphological features of VSMCs of chorionic plate arteries after 5 days of culture using 
RPMI medium supplemented with 5% cs FCS. Changes were assessed by myosin heavy chain 
immunohistochemical assessment with control treatments using a four point scale (n=5). Data 
are expressed as mean ± SEM.  
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Figure 5.12 The effect of IL-8 on CpA VSMC morphology when cultured with medium 
supplemented with 5% charcoal stripped FCS 
Immunohistochemical (A) and graphical (B) representation illustrating the effect of differing 
concentrations of exogenous IL-8 on the morphological features of VSMCs of chorionic plate 
arteries after 5 days of culture using RPMI medium supplemented with 5% cs FCS. Changes 
were assessed by myosin heavy chain immunohistochemical assessment compared control 
treatments using a four point scale (n=5). Data are expressed as mean ± SEM. Original 
magnification x200. 
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5.4.6 Effect of IL-6 and IL-8 on VSMC differentiation markers using 5% 
charcoal stripped fetal calf serum supplemented medium  
The percentage of positive immunostaining for the muscle differentiation markers 
expressed on the CpA was assessed using an Adobe Photoshop™ pixel counting 
method (section 5.3.4).  
The percentage of positive immunostaining of different VSMC markers did not differ 
after IL-6 treatment in 5% charcoal stripped FCS culture medium compared with 
medium controls (Figure 5.13). VSMC differentiation markers, H-caldesmon, myosin 
heavy chain and α-SMA expression did not alter in CpA treated with IL-8, although 
calponin expression increased in CpA VSMCs after treatment with 1ng ml-1 IL-8 
compared with the T5 day medium control (P=0.02; Figure 5.14).  
 
 
Figure 5.13 The effect of IL-6 on CpA VSMC differentiation when cultured with medium 
supplemented with 5% charcoal stripped FCS 
Graphical representation of the effect of IL-6 (in RPMI medium supplemented with 5% cs FCS) 
on VSMC differentiation markers (H-caldesmon, myosin heavy chain, calponin and α-smooth 
muscle actin; n=5). Data are expressed as mean ± SEM.  
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Figure 5.14 The effect of IL-8 on CpA VSMC differentiation when cultured with medium 
supplemented with 5% charcoal stripped FCS 
Graphical representation of the effect of IL-8 (in RPMI medium supplemented with 5% csFCS) 
on VSMC differentiation markers (H-caldesmon, myosin heavy chain, calponin and α-smooth 
muscle actin; n=5). Data are expressed as mean ± SEM. 
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5.5 Discussion 
5.5.1 IL-6 and IL-8 signalling in CpA VSMCs  
The receptors forIL-6 (sIL-6Rα and gp130) and IL-8 (CXCR1 and CXCR2) were expressed 
by chorionic plate arteries of term human placenta. All of the receptors were 
expressed on the VSMCs; IL-6R and CXCR1 were predominantly expressed on VSMCs 
whereas gp130 and CXCR2 were mainly expressed on the vascular endothelium lining 
the lumen.  
Therefore, both IL-6 and IL-8 have the ability to bind to both VSMCs and endothelial 
cells of chorionic plate arteries and elicit a response which may contribute to vascular 
changes within the vessel, hence disrupting integrity and stability of the artery. IL-6 is a 
potent pro-angiogenic cytokine and plays important roles in the progression of tumour 
neovascularisation, wound healing and vasculogenesis in the brain (Fee et al., 2000). 
IL-6 also stimulates circulating blood endothelial progenitor cell proliferation, 
migration and matrigel tube formation in vitro through binding to its receptors: IL-6Rα 
and gp130 (Fan et al., 2008); this could contribute to de novo vessel formation during 
wound healing. 
IL-8 is known to be a potent mediator of angiogenesis. IL-8 signalling has been 
associated with the regulation of endothelial permeability by stimulating the 
phosphorylation of VEGF-R2 in endothelial cells by interaction with both CXCR1 and 
CXCR2 receptors (Petreaca et al., 2007) and more recently it has been found that IL-8 
up regulates VEGF-A mRNA and protein levels in vascular endothelial cells by 
association of IL-8 with CXCR2, which further stimulates VEGF-R2 in an autocrine 
manner (Martin et al., 2009) inducing cellular proliferation, survival and migration of 
vascular endothelial cells. These reports suggest an important role for IL-8 in 
angiogenesis and a possible role for IL-8 in the physiological remodelling events of the 
uterine vasculature in pregnancy. In pathophysiology IL-8 is important for tumour 
formation and growth, and in agreement with reports of an angiogenic role in normal 
physiology many in vitro studies with cancer cell lines and in vivo studies with solid 
cancers have shown that IL-8 corresponds to the angiogenic and tumourgenic potential 
of the progression of cancers (reviewed by (Waugh and Wilson, 2008)) indicating the 
correlation of IL-8 with tumour angiogenesis and disease.  
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5.5.2 Charcoal stripped fetal calf serum vs. Normal fetal calf serum 
In the present study fetal calf serum appears to be an important component of cell 
culture medium for the survival of chorionic plate arteries in vitro. Without it vessel 
integrity rapidly began to show signs of degradation. However, in our initial 
assessment, the effects of particular cytokines on this vessel in vitro were masked by 
the use of fetal calf serum. Different concentrations and types of fetal calf serum were 
therefore assessed. The addition of fetal calf serum provides vital growth factors 
required for cell culture, lowering the FCS concentration in the culture medium used in 
this study or omitting it altogether had a morphological effect on CpA VSMCs; the 
vessel integrity appeared to have been effected as the vessel lumen was highly 
vacuolated and vessel structure overall appeared different. 
Charcoal stripped serum allowed both IL-8 and IL-6 to have an effect on VSMC 
morphology compared with using standard fetal calf serum. An explanation is that the 
stripping of hormones from the serum freed the exogenous cytokines to bind with 
VSMCs and therefore to elicit an effect not seen using standard fetal calf serum. 
5.5.3 Effect of IL-6 on VSMC morphology 
IL-6 was shown to have a significant effect on the separation of vascular smooth 
muscle cell layers and in the misalignment of these cells. IL-6 combined with its soluble 
agonist receptor sIL-6Rα, had the largest effect on VSMC separation and misalignment, 
suggesting that the binding of the cytokine coupled to its receptor elicits a more 
potent cell signalling response resulting in larger changes in the vasculature compared 
with controls, IL-6 or sIL-6Rα alone. This signalling response up-regulates the 
expression of STAT-3, which is known to enhance the transcription of the vascular 
endothelial growth factor (VEGF-A) gene.  In vitro studies using gastric carcinoma 
tissues have shown IL-6 stimulates the production of VEGF-A in a dose/time dependent 
manner and that the JAK/STAT pathway is predominately involved in the transcription 
of VEGF-A in these cells (Huang et al., 2004) contributing to the tumourgenesis and 
progression of this disease. 
Activation of the IL-6 signalling pathways (JAK/STAT and MAPK ERK1/2 pathways) plays 
a crucial role in endothelial proliferation, migration and tubule formation. However, in 
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circulating blood endothelial progenitor cells only a high level of IL-6 induced an 
angiogenic response (Fan et al., 2008). Similarly in the present study lower 
concentrations of IL-6 had little effect on VSMC morphology.      
VEGF-A is one of the most potent angiogenic growth factors involved in vessel 
regrowth and neovasculogenesis. It promotes VSMC and endothelial cell migration, 
tubule formation and increases the permeability of blood vessels (Leung et al., 1989), 
characteristics also involved in successful spiral artery remodelling. Recent studies 
have also demonstrated that gliomas targeted with a combined treatment of anti-
VEGF-A and anti-IL-6 showed markedly reduced growth as they were unable to 
undergo angiogenesis (Saidi et al., 2009), thus suggesting that these factors are 
essential for angiogenesis and that IL-6 stimulates VEGF-A production. IL-6 has the 
capacity to bind to blood vessels in vascularisation and angiogenesis through binding 
with IL-6Rα expressed by endothelial cells and VSMCs, which would potentially 
increase VEGF production resulting in vessel de-stabilisation by the migration of 
VSMCs and making vessels more permeable. In respect to spiral arteries, increased 
vessel permeability would allow the infiltration of essential factors such as leucocytes 
and trophoblast cells which are required for successful remodelling to ensure an 
adequate blood supply to the developing fetus.             
5.5.4 Effect of IL-8 on VSMC morphology 
IL-8 had a significant effect on the organisation of VSMC layers within CpAs but did not 
appear to have any other morphological effects on VSMC. 
IL-8 is a chemotactic cytokine and a potent angiogenic agent as mentioned previously. 
IL-8 has been reported to induce the proliferation and chemotaxis of human umbilical 
vein endothelial cells (HUVECs) (Koch et al., 1992) and to stimulate prostaglandin 
secretion by human aortic and rat aortic VSMCs in vitro resulting in VSMC proliferation 
and migration (Yue et al., 1994). In the present study the observed disorganisation of 
VSMCs in CpA is the effect of IL-8 and the disorganisation may possibly be a sign of 
VSMC migration indicating that IL-8 acts as a chemoattractant for the VSMC. However, 
increased spacing between the VSMC layers was not observed; this may have been 
observed with increased concentrations of IL-8 since the misalignment of cells 
appeared to increase in a dose dependent manner. The results observed using CpAs 
209 
 
indicate that IL-8 has the potential to be major player in vascular changes in a variety 
of different blood vessels, which in turn suggests that physiological alterations of levels 
of IL-8 could also contribute to the pathogenesis of diseases such as atherosclerosis 
and a variety of cancers by aiding tumourgenesis. Together with the data from this 
study and its reported effects in tumourgenesis, uterine IL-8 may have an effect on 
uterine spiral arteries contributing to the vascular remodelling required for successful 
pregnancy. This could be achieved by VSMC and endothelial cell migration allowing the 
invasion of trophoblast cells and deposition of fibrinoid resulting in a low resistance 
high flow vessel. The molecular mechanisms whereby IL-8 achieves this in CpAs remain 
to be explored but IL-8 signalling could up-regulate other angiogenic factors including 
prostaglandins and recruit other cells to the vessel wall which secrete other growth 
factors which may contribute to vascular remodelling.  
Recently, IL-8 has been shown to have a direct effect on EVT invasion (De Oliveira et 
al., 2010) by binding to its receptors expressed by EVT. The binding of IL-8 to EVT may 
also have an indirect effect of spiral artery remodelling by up-regulating the secretion 
of factors by EVT such as TRAIL (TNF-α-related apoptotic induced ligand); this is 
expressed by primary first trimester CTB cultured in vitro and by EVT in situ, and that 
CTB use the TRAIL pathway to induce smooth muscle cell apoptosis (Keogh et al., 2007) 
although there is little evidence of VSMC apoptosis in vivo (Bulmer et al., 2012). 
5.5.5 Effect of IL-6 on VSMC differentiation  
A property of smooth muscle cells is that during injury and remodelling their 
phenotype may alter to a de-differentiated state. A decrease in VSMC differentiation 
marker proteins is a characteristic of vascular changes following injury; changes in 
VSMC differentiation state allow cells to proliferate, migrate and synthesise 
extracellular matrix around them. The transition of VSMCs from a differentiated 
phenotype to a dedifferentiated phenotype assists in the pathogenesis of diseases 
such as atherosclerosis and hypertension (Owens et al., 2004). 
It has been presumed that a reduction in VSMC differentiation markers in 
phenotypically modulated VSMCs in vivo is mediated at transcription level, although 
there is no direct evidence to support this. A recent report provides in vitro evidence 
that micro RNA 145 (miR-145), abundant in vascular walls, is selectively expressed and 
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VSMC differentiation marker genes such as α-SMA, calponin, and myosin heavy chain 
are upregulated by miR-145 and are downregulated by a miR-145 inhibitor (Cheng et 
al., 2009). However more studies are needed to elucidate the genetic factors involved 
and it is likely that changes may be induced post transcriptionally by growth factors 
and cytokines such as IL-6. 
Chorionic plate arteries treated with 10ngml-1 IL-6, 5ngml-1 sIL-6Rα and IL-6 + sIL-6Rα 
combined in media supplemented with 10% FCS showed a significant decrease in α-
SMA expression compared with media controls. This suggests that IL-6 contributes to 
the phenotypic modulation of VSMC and therefore contributes to changes in the vessel 
characteristics as a reduction α-SMA is indicative of differentiated VSMC. However, α-
SMA is a marker of early VSMC differentiation and if IL-6 was mediating de-
differentiation as a feature of remodelling the vasculature, alterations in expression of 
myosin heavy chain and H-caldesmon would have also been expected. Alternatively, IL-
6 could play a role in preventing immature VSMCs from differentiating into mature 
cells; however, vascular smooth muscle differentiation is a complex process and many 
other factors may also be involved. In support of this complexity, the results using 5% 
charcoal stripped supplemented media differed and no loss of α-SMA expression was 
observed after treatment with IL-6. This indicates that components in FCS combined 
with IL-6 have some effect on VSMC differentiation whereas the lack of hormones and 
other factors in charcoal stripped FCS has none suggesting a role for serum proteins in 
the phenotypic modulation of VSMCs.    
5.5.6 Effect of IL-8 on VSMC differentiation 
Vessels treated with IL-8 medium supplemented with 10% FCS showed no significant 
changes in expression of differentiation markers compared with controls. However, 
calponin expression was significantly increased after treatment with 1ngml-1 IL-8 using 
5% charcoal stripped FCS medium, although this was not observed using higher 
concentrations of IL-8. Calponin is an actin and calmodulin binding protein (Takeuchi et 
al., 1991) which is involved in the contractility of smooth muscle cells (Winder et al., 
1993) and accumulates during smooth muscle differentiation (Gimona et al., 1990). 
However, if IL-8 was to cause VSMC differentiation it would be expected that calponin 
expression would increase with increasing concentration. However, low doses of IL-8 
211 
 
may increase calponin expression which binds Ca2+ allowing vascular smooth muscle to 
contract and may contribute to the misalignment of cell layers. However, this 
difference may be a direct result of multiple comparisons but a one way ANOVA with 
post hoc test was used which should correct this.  Multiple comparisons within the 
analysis of data may account for the chance of a significant difference in the data. This 
may be apparent here as no differences in calponin expression were observed when 
CpAs were treated with higher concentrations of IL-8. The underlying mechanisms 
involved require further investigation with correctional statistics like a Bonferroni test.    
5.5.7 Overall summary 
The results from this study have indicated that both IL-6 and IL-8 have the ability to 
bind to blood vessels including chorionic plate arteries from term placenta, by the 
expression of their receptors on VSMC and endothelial cells. This further proposes that 
these cytokines have the ability to bring about vascular changes within this vessel 
which has been confirmed by changes in vessel morphology highlighted with 
immunohistochemistry. The results from this study and the fact that both IL-6 and IL-8 
have potent angiogenic properties both in inflammation and disease suggests that 
these are important mediators of vascular remodelling maybe through the 
mechanisms of VSMC migration and vascular permeability, although, the molecular 
mechanisms need further exploration. This evidence suggests that these cytokines 
have the ability to contribute to spiral artery remodelling in the uterus by these 
proposed mechanisms. However, the limitation to this study is that chorionic arteries 
are derived from the fetus and are not maternal in origin. The vessels were used as an 
easy accessible source of vessels as the dissection of spiral arteries from early pregnant 
decidua and myometrium are very difficult to obtain. The use of non-pregnant 
myometrial vessels as an alternative was a suggestion in this study, but ethical 
approval was not feasible within the timescale. Nevertheless, investigation using 
maternal vessels would be a better model to explore the cytokine effects in relation to 
spiral artery remodelling and have been used in a study by Robson et al. (2012) 
whereby the effect of uNK cell factors on these vessels were investigated. Further 
validation of these results relating to the uterine arteries would have been to treat the 
CpA vessels using isolated CD56+ and CD14+ cell supernatants (known producers of 
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uterine IL-8 and IL-6, see chapter 3)  from first trimester decidua and inhibiting 
endogenous IL-8 and IL-6 to investigate their endogenous effects in this vessel type. 
From the present study it is possible to conclude that IL-6 and IL-8 contribute to 
vascular changes in chorionic plate arteries in vitro indicating that cells of the decidua 
that secrete these factors may play a role in spiral artery remodelling in early 
pregnancy.        
  
 
 
Chapter 6 
The role of decidual leucocytes in spiral artery remodelling 
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6. The role of decidual leucocytes in spiral artery remodelling 
6.1 Introduction 
Changes in vascular smooth muscle cell (VSMC) disorganisation and separation of 
VSMC cell layers in chorionic plate arteries were observed after treatment with 
exogenous IL-6 and IL-8 (reviewed in Chapter 5). This study has demonstrated the 
production of intrauterine IL-6 and IL-8 by various cell types within decidua; 
predominantly by uterine macrophages but uterine natural killer cells, T cells and 
decidual stromal cells are all producers in early pregnancy (reviewed in Chapter 3).The 
data from chapters 3 and 5 combined have led to the hypothesis that decidual 
leucocytes play an important role in spiral artery remodelling in early pregnancy.  
The prevalence and suggested roles of maternal leucocytes during pregnancy has been 
reviewed in Chapter 1. This chapter focuses on the decidual leucocytes; uNK cells, 
macrophages and CD3+ T cells, and their early association with decidual spiral arteries, 
focusing on the possible roles of these leucocytes in the early remodelling events of 
the transformation of spiral arteries in early pregnancy prior to trophoblast invasion. 
Understanding of the complexity of the stages of spiral artery remodelling is ever 
increasing but the cellular and molecular events remain yet to be defined. It is also 
apparent that compromised remodelling may lead to pregnancy complications such as 
pre-eclampsia and fetal growth restriction (IUGR), complications which appear 
clinically in the second trimester of pregnancy. However, it is likely that the aberrant 
processes occurring earlier in pregnancy play a role in complications seen later in 
pregnancy. Brosens et al. (1967) describe a physiological change in early pregnancy 
where spiral arteries transform from narrow, high resistance, low blood flow vessels 
into dilated, low resistance vessels capable of transmitting high blood flow to meet the 
increasingly demanding needs of the developing fetus. The process of delivering high 
volumes, of maternal blood at low resistance to the placental intervillous space is 
critical for successful healthy pregnancy. Remodelling of the arteries involves intricate 
steps from initial endothelial vessel vacuolation to loss of VSMCs and replacement of 
the vessel wall by fibrinoid material and invading extra villous trophoblast (EVT) cells.  
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For many years it was believed that invasive EVT cells were the main mediators of the 
spiral artery remodelling events by invading the vessel walls both interstitially from the 
surrounding decidua and myometrium and by invading the lumen of the arteries by an 
endovascular route (Pijnenborg et al., 1980). Some in vitro studies have suggested that 
EVT cells achieve such vascular destruction by enzymatic activity; they produce MMPs, 
actively cleaving components of the VSMC wall (Isaka et al., 2003, Jones et al., 2006). 
Isolated EVT cells have also been reported to be capable of inducing VSMC apoptosis 
(Harris et al., 2006, Keogh et al., 2007), although, in situ studies by (Bulmer et al., 2012) 
provide no evidence of VSMC apoptosis. Further evidence suggests that spiral artery 
remodelling events occur over many weeks and the initial stages involve mechanisms 
that are independent of trophoblast cell invasion. Prior to interstitial and endovascular 
trophoblast invasion (which occurs around week 8 of gestation) vascular changes that 
are characteristic to early SpA remodelling such as EC vacuolisation and VSMC 
hypertrophy have been observed in the absence of invading EVT (Craven et al., 1998, 
Kam et al., 1999). These trophoblast-independent changes have been described as 
decidualisation-associated vascular remodelling (Pijnenborg et al., 2006b) and it is now 
recognised that the initial stages of vascular remodelling may be regulated by immune 
cells within the decidua (King et al., 1998, Bulmer and Lash, 2005) and Smith et al. 
(2009) have observed high numbers of leucocytes in association with SpAs in the 
absence of EVT and have detected vascular changes in vivo. Uterine natural killer (uNK) 
cells and macrophages were the main leucocyte populations to be observed in 
association with SpAs.  uNK cells produce a range of cytokines and growth factors and 
one cytokine that had been intially suggested to play a role in SpA remodelling was 
IFN-γ from mouse studies (Ashkar and Croy, 2001), more recently human uNK cells 
were found to secrete high levels of IFN-γ (Lash et al., 2006b) which up regulates genes 
involved in smooth muscle cell proliferation and cell adhesion suggesting that these 
cells may be important mediators in the remodelling process. This has been observed 
in mice studies where impaired uNK cells leads to aberrant formation of blood vessels 
via the IFN-γ pathway (Ashkar et al., 2000).  
Smith et al. (2009) have reported high numbers of leucocytes in proximity to 
remodelling spiral arteries in first trimester decidua in the absence of EVT. They have 
also demonstrated the production of MMP-7 and MMP-9 by macrophages and uNK 
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cells within the vascular wall which may contribute to the degradation of the vessel 
wall, thereby affecting vessel integrity; similar changes are seen in tumour 
angiogenesis and metastases in relation to the production of MMP-7 and -9. A recent 
study using a novel placental-decidual co culture model (Hazan et al., 2010) have 
implicated leucocyte derived MMP-2 and MMP-9 in the remodelling events suggesting 
a participation of uNK cells and macrophages in VSMC disruption and clearance. 
However, the exact function of these leucocytes and remodelling events remains 
inconclusive. Elucidating the importance of maternal leucocytes in SpA remodelling will 
help in the understanding of impaired remodelling associated with pregnancy 
complications and may therefore lead to future therapies and prevention.  
The aim of this part of the study was to further determine the association of uNK cells 
and macrophages with decidual SpAs and to investigate the effect of EVT cells on this 
association. This study will also explore ways of obtaining a pure population of 
decidual macrophages to investigate the factors that they secrete which may play an 
important role in spiral artery remodelling. Macrophages are the second most 
abundant leucocyte population within the decidua of early pregnancy and unlike uNK 
cells their numbers remain fairly constant throughout gestation. Decidual 
macrophages express a large variety of cell surface receptors and secrete a variety of 
cytokines suggesting that these cells play a homeostatic role in the decidua and may 
regulate trophoblast function, and unlike uNK cells, macrophages are also present in 
myometrium and SpA transformation extends to the inner myometrium but their role 
in pregnancy remains undefined. The importance of macrophages in successful early 
pregnancy is therefore becoming more apparent hence, the focus on this cell 
population in this study.    
 
6.2 Aims and Hypotheses 
6.2.1 Hypotheses 
1) Decidual leucocytes play a role in the remodelling of the spiral arteries by 
penetrating the muscular wall causing VSMC disruption both in the presence 
and absence of EVT. 
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2) Decidual leucocytes are prevalent in and around the VSMC wall of SpAs in the 
decidua prior to trophoblast invasion. 
3) Decidual leucocyte numbers are higher in the VSMC wall and adventitia of SpA 
at 8-10 weeks gestation compared with numbers at 12-14 weeks gestation 
4) Decidual macrophages produce pro-angiogenic growth factors and cytokines 
that cause disruption of the VSMC wall aiding spiral artery remodelling at both 
8-10 and 12-14 weeks gestation. 
6.2.2 Aims 
1. To assess leucocyte cell numbers in the musculoelastic walls of spiral arteries in 
decidua from placental bed biospsies at 8-10 and 12-14 weeks gestation in the 
presence or absence of EVT 
2. To isolate a pure population of CD14+ cells from first trimester decidua 
3. To investigate which cytokines and growth factors are produced by uterine 
CD14+ cells using a FASTQuant multiplex cytokine array 
 
6.3 Experimental design 
6.3.1 Immunohistochemical labelling of decidual spiral arteries and 
decidual leucocytes  
Placental bed biopsies were obtained from women undergoing elective TOP in early 
pregnancy at 8-10 and 12-14 weeks gestation (section 2.1.3) and tissue was prepared 
for FFPE sections for immunohistochemical analysis (section 2.1.8.3 and section 2.2), 
n=10 each gestational age. Table 6.1 outlines the primary antibodies used, with 
incubation times and pre-treatments, to identify SpA, EVT and decidual leucocytes 
within the spiral artery wall and surrounding areas of decidual spiral arteries at 8-10 
and 12-14 weeks gestation. 
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Table 6.1 Primary antibodies used for immunohistochemistry on FFPE tissue sections 
 
6.3.2 Definition of SpA vessel wall 
The structure of an artery is composed of three distinct layers; the intima, media and 
adventitia. The intima is the inner most layer that is in contact with blood in the lumen 
and includes an endothelial cell layer lining the lumen and an internal layer of elastic 
lamina. The media is the middle layer and consists mainly of compacted smooth 
muscle cells and elastic fibres. The outermost layer is known as the adventitia and is 
composed of fibrous collagen and connective tissue protecting the blood vessel and 
allowing anchorage to surrounding structures.    
The purpose of this part of the study was to assess the number of leucocytes in the 
intima and media of SpAs. Definition of the outer limits (media) of the spiral artery 
musculoelastic wall proved difficult in this study and H-caldesmon staining was not 
sufficient to overcome the problems encountered. Defining the inner and outer limits 
of the vessel was difficult because the wall thickness often varied within any one vessel 
cross section; for example one side of the SpA would have a very thick medial layer, 
whereas the other side of the vessel wall would have lost the VSMC layers, making 
characterisation of the stage of vessel transformation hard to determine. The use of 
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standard histochemical staining techniques helped to overcome this problem and also 
helped to distinguish between arteries and veins.  
6.3.2.1 Orcein and EVG staining techniques 
In order to help to identify and define the limits of SpAs within the placental bed 
biopsies Orcein staining and Elastic Van Gieson staining were also applied to the FFPE 
tissue sections as well as immunohistochemistry for VSMC markers. 
The Orcein staining technique is outlined in the Appendix (see Appendix); this a red-
brown stain that is used to identify elastic layers in connective tissue. Decidual spiral 
arteries are known to lose their elastic lamina during early transformation processes in 
early pregnancy (Figure 6.1B) but deeper sections of SpAs within the myometrium 
appeared to have both internal and external elastic lamina present and intact (Figure 
6.1A).  This staining technique also helped to distinguish arteries from veins within the 
decidua. However, due to the loss of elastic layers in decidual SpAs it was difficult to 
determine vessel wall thickness using the Orcein stain.  
 
Figure 6.1 Orcein staining on placental bed spiral arteries to identify elastic layers 
Image representing spiral arteries stained with Orcein staining technique in both FFPE tissue 
sections of myometrium (A; 8-10 weeks GA) and decidua (B; 8-10 weeks GA) from placental 
bed biopsies. Original magnification x200.   
 
The Elastic Van Geison (EVG) staining technique is an alternative method to identify 
the connective tissue and elastic layers (see Appendix). Elastic layers are stained 
blue/black and muscle layers stain a yellow colour with an orange/red colour 
demonstrating connective tissue, the SpA adventitia. The identification of internal and 
external elastic laminae and adventitial connective tissue helped to identify the inner 
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and outer limits of the VSMC media wall and adventitia of the SpAs (Figure 6.2). This 
staining technique also provided evidence that there is no external elastic lamina 
present in decidual spiral arteries (Figure 6.2). 
 
Figure 6.2 Elastic Van Geison (EVG) on placental bed spiral arteries for identification of 
internal and external elastic laminae and adventitial connective tissue 
Image representing a non-transformed spiral artery. Left image illustrates a decidual SpA 
stained with EVG. Black staining indicates internal elastic lamina, yellowish/purple staining 
indicates muscle layers and reddish colour indicates connective tissue. The right image is a 
serial section of a decidual SpA in the placental bed positive for H-Caldesmon immunostaining 
demonstrating VSMCs (8-10weeks GA). Original magnification x100.    
6.3.3 Assessment of leucocyte cell counts in SpA vessel wall and 
adventitia 
Once a spiral artery was identified microscopically, the thickness of the musculoelastic 
wall and adventitia was determined and serial sections stained with leucocyte markers 
were assessed. Difficulties were encountered when trying to count leucocyte numbers 
within the vessel walls. Initially the sections were double labelled using 
immunohistochemistry with muscle markers and leucocyte markers or counterstained 
with muscle stains. However, this was unsuccessful because the staining with muscle 
markers masked the staining of the leucocyte markers. Therefore, serial sections were 
stained and immunolabelled separately which made it hard to identify exact areas 
within placental bed.  
This problem was overcome by the use of a computer grid graticule applied to 3µm 
serial sections. An image of the area stained on the tissue section was taken using an 
image capture microscope (Nikon Eclipse 80i coupled with a DS-Fil camera) which was 
connected to the computer programme NIS Elements Software. Tissue sections that 
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were immunostained with H-caldesmon were assessed initially. The thickness of the 
spiral artery wall was determined by placing a graticule over the immunostained 
artery. A square of the graticule was placed so that the inner vessel wall (from the 
lumen) to the outer limit of vessel wall would fit the square and the width of the 
square was measured electronically (Figure 6.3).  
 
 
Figure 6.3 The use of a computer graticule in determining SpA vascular wall thickness 
Image taken from computer screen to shown the use of the graticule grid and how VSMC wall 
thickness was determined. The squares on this graticule grid measure 20µm. However, parts of 
the vessel wall exceed this thickness (top of vessel ~60µm), and therefore an average thickness 
was measured for this dedidual SpA. Original magnification x200.  
 
The thickness of the VSMC wall of the artery was assessed by measuring the various 
places within any one vessel and was then given an average thickness measurement. If 
an artery had a wall thickness that exceeded 30µm and the VSMC layers were very 
tightly packed with a swollen endothelium visually present it was characterised as a 
non-transformed vessel that was not going through the remodelling process (Figure 
6.4A). Arteries which had a VSMC wall thickness of 20-30µm and showed slight 
separation of VSMC layers and migration of VSMC layers was characterised as an early 
partially transformed vessel (P1; Figure 6.4B). SpAs that had VSMC walls that were 
10µm or less (one cell layer thick) were classed as late partially transformed vessels 
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(P2; Figure 6.4C) and arteries which had lost their VSMC wall completely  or with one 
or two VSMC remaining were classified as fully transformed vessels (Figure 6.4D).   
Initially difficulties did arise on the classification of vessel thickness and stages of 
transformation. Non-transformed and complete vessels were easy to define but 
intermediate stages were harder to assess. Also vessels that measured 10-20µm thick 
were in between P1 and P2 and had difficulty defining which stage of transformation 
they belonged. We attempted classification of the intermediate partial stages based on 
disorganisation and loss of muscle rather than VSMC thickness. The presence or 
absence of EVT was assessed separately and was not used initially to define 
transformation stage but in difficult specimens the presence of certain EVT 
populations helped on classification.     
Serial tissue sections that were immunostained with leucocyte markers were assessed 
and counted by taking an image of the corresponding SpA, placing the grid graticule 
(measuring the same thickness of the SpA VSMC wall, e.g. 30µm thick) and counting 
the number of leucocytes within that 30µm area starting from the lumen. Cells in the 
adventitia were also counted. Adventitia was identified by EVG staining (section 
6.3.2.1) and the thickness was measured using the computer graticule and was defined 
from the outer limits of the musculoelastic wall to the outer limits of connective tissue 
(where tissue anchored onto decidual tissue). This method was applied to all serial 
sections and all leucocyte markers.         
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Figure 6.4 Identification of SpA vessel classification based on level of vessel transformation 
using immunohistochemistry with anti-H-caldesmon 
Representative immunohistochemistry image demonstrating how SpA vessel classification was 
identified based on vessel transformation in placental bed biopsies. A: Non-transformed; B: P1 
(early) partially transformed; C: P2 (late) partially transformed and D: Fully transformed. All 
tissue is immunostained with H-Caldesmon/PAS demonstrating VSMC wall of decidual SpAs 
with original magnification x100.   
6.3.4 Isolation of decidual CD14+ cell by MidiMacs 
Isolation of a pure, viable source of decidual macrophages from first trimester decidua 
has not been previously described in literature. In this study we wanted to see 
whether it was possible to initially isolate CD14+ cells from early decidual tissue and 
secondly to culture the decidual macrophages to pave the way in allowing to 
investigate their protein secretion and involvement in SpA remodelling.  
Firstly, the proportion of CD14+ cells in digested decidual tissue was investigated. 
Decidual tissue was subjected to enzymatic digestion (section 2.3.1) and incubated in a 
T75 tissue culture flask overnight at 37°C at 5% CO2. Following overnight incubation the 
media was discarded and adhered cells were removed from the tissue culture flask 
using sterile PBS pH7.4 and a cell scraper. The removed cells were then centrifuged at 
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300G for 7mins, resuspended in RPMI complete medium and cell smears prepared 
(section 2.3.3). 
The cell smears were then immunostained using antibodies against CD14, CD56, 
vimentin and LP34 (see Table 6.2). This was repeated 3 times.  
Evaluation of these cell smears revealed that approximately 90% of the adhered cells 
in all 3 samples were positively stained with CD14, all the cells evaluated were 
positively stained with vimentin and none of the cells were CD56 positive or LP34 
positive, indicating that the majority of the adhered decidual cells were a population of 
macrophages/dendritic cells which were mesenchymal in origin.         
6.3.4.1 Preparation of CD14+cell culture supernatants 
The results showed that CD14+ cells are present in adhered cells prepared from early 
pregnancy decidual tissue (8-14 weeks gestational age); the next stage was to isolate 
this population and collect cultured cell supernatants. Initially CD14+ cells were isolated 
from early pregnancy decidua using the standard indirect Midimacs technique (section 
2.3.4) and cell smears were prepared. The CD14+ labelled cell smears were then 
stained with secondary and tertiary antibodies from the Elite ABC kit in order to check 
cell purity, none of the cells were positive for CD14+ protein. This was repeated using 
another 2 decidual samples and results were the same each time.  
Three more early pregnancy decidual samples were digested but for those samples 
isolation of cells was attempted using the Midimacs technique for macrophage 
isolation with labelled anti-CD14 microbeads; cell smears were again prepared to 
check cell purity.  
Cells smears were also immunostained with anti-CD68 as well as checking CD14 purity 
(see Table 6.2). In all of the samples over 95% of the cells were CD68 positive and over 
97% of the cells were CD14 positive. Indicating that this isolation procedure had 
worked and we were able to successfully isolate CD14 cells from early pregnancy 
decidual tissue.      
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6.3.4.2 Characteristion of decidual CD14+ cells 
CD14 cells were isolated from decidual tissue (n=3) and CD14+ cell smears were 
prepared for double labelling with different antibodies (Table 6.2) using the APAAP 
method (see Appendix).  
Frozen sections of decidual tissue from 9 weeks gestation was also immunostained 
with protein markers associated with the phenotype of macrophages (Table 6.2), along 
with the double labelling of these markers in CD14+ labelled cell smears. Frozen 
decidual tissue was used rather than FFPE tissue, to compare with immunostaining in 
cell smears because the antibodies used for cell smears were antibodies which were 
specific to tissue or cells that had not be formalin fixed so decidua that had been 
frozen was used to make ideal comparisons.      
 
Table 6.2 Primary antibodies used in immunocytochemistry of CD14+ cell smears and used 
for immunohistochemistry on frozen decidual tissue sections 
Primary antibodies used in immunocytochemistry (single and double labelling) of cell smears 
and immunohistochemistry of frozen tissue sections. 
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6.3.4.3 Culturing isolated decidual CD14+cells – viability optimisation 
Following isolation of decidual CD14+ cells, isolated fractions were tested for their 
cellular viability using the trypan blue method (section 2.3.3.1) to determine whether 
positive immunomagnetic separation affected cell viability. All samples checked had 
>97% viability of CD14 cells with 95% purity after midimacs with positive selected CD14 
labelled microbeads. However, it was observed that after 24h in culture (in 96 well 
tissue culture plate) following midimacs isolation, cellular viability dramatically 
decreased to less than 20%. 
To overcome this, the culture medium components were altered. The fetal calf serum 
concentration in the culture medium was increased from 10% to 20%. The isolated 
cells were again cultured for 24h at 37°C in 96 well culture plates. The ‘total’ (un 
separated) adhered decidual cell fractions were viable after culture but the CD14 cell 
fraction were all dead when using both 10% and 20% FCS supplemented medium; 
increased FCS concentration therefore did not improve viability. 
The size of the culture plates was also up for debate as macrophages are large cells 
and it was suggested that the wells on a 96 well plate may be too small for the cells, 
causing them to die in culture. Therefore, instead of culturing the cells in 96 well plates 
after isolation the CD14+ cells were cultured in 48 well plates. Although the cells 
appeared less compacted in a 48 well plate, viability was still low after 24h culture. The 
amount of time that the cells were in culture was also reduced from 24h to 12h but 
even after 12h the cells did not survive. It was therefore decided to continue using the 
48 well plates but the culture medium used to culture the cells was changed:  
One well of cells were cultured using DMEM media supplemented using 10% heat 
inactivated FCS (Sigma), another using DMEM media supplemented with 10% FCS that 
had been triple filtered and derived from American fetal bovine blood (ATCC) and 
another using DMEM media supplemented with 10% FCS containing IL-2 and LPS 
(dendritic cell FCS) all with/without the addition of 50ngml-1 granulocyte macrophage 
colony stimulating factor (GM-CSF). This was also run alongside cultures in RPMI 
medium using the same conditions. These experiments were repeated using 3 
different decidual samples.     
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CD14+ cell smears prepared at T=0 were double labelled with the antibodies outlined 
in Table 6.2, using the APAAP method (section 2.2.3). This double labelling was also 
performed on cultured cells (T=24h) by fixing the remaining cells in methanol for ten 
minutes prior to immunostaining.  Once the culture conditions were optimised, cell 
culture supernatant collection began and were harvested and stored at -80°C. 
6.3.5 Measuring secretion of gowth factors by decidual CD14+ cells 
Secretion of growth factors and cytokines by CD14+ cells were measured using the 
CD14+ cell supernatants. Detection of these CD14+ proteins at both 8-10 and 12-14 
weeks gestational age was assessed using ELISA and FASTQuant assays. 
 6.3.5.1 ELISA 
50µl of CD14+ cell supernatant in 50µl reagent diluents (diluted 2 fold) was subjected 
to a sandwich ELISA (section 2.10) and ran in duplicate for detection of PlGF 
(2000pgml-1 top standard) , VEGF-C (6000pgml-1 top standard), TGF-β1 (2000pgml-1 top 
standard)  and Ang-1(10000pgml-1 top standard)  (Duoset R&D systems). An 8 point 
standard curve was used and generated using a computer 4-PL curve fit. The only 
detectable protein in the supernatants was Ang-1; the other proteins were at 
undetectable concentrations by CD14+ cells. N=10 for each age group (8-10 and 12-14 
weeks GA).   
6.3.5.2 Th1/2 and angiogenesis FASTQuant analysis 
Adhered decidual cell supernatants (total adhered cells) and CD14+ cell supernatants 
subjected to FASTQuant assay (section 2.7) to detect angiogenic growth factors and 
cytokines secreted by these cells.  
The angiogenesis kit detects antigens including angiogenin, Ang-2, KGF, PDGF-BB, FGF-
basic, TIMP-1, ICAM-1 and VEGF. There were 24 wells of the angiogenesis FASTQuant 
kit available for this study; a standard curve was made from the standard cocktail 
specific to the angiogenesis kit and added to 8 wells, 8-10 and 12-14 weeks GA total 
adhered decidual cell supernatants (n=3 both gestational age groups) and 8-10 and 12-
14 weeks GA CD14+ cell supernatants (n=5 both gestational age groups) were used for 
the remaining wells.  
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The Th1/2 kit detects antigens including IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IFN-γ 
and TNF-α. There were 32 wells of the human Th1/2 FASTQuant kit available for this 
study; a standard curve was made from the standard cocktail specific to the Th1/2 kit 
and added to 8 wells, 8-10 and 12-14 weeks GA total adhered decidual cell 
supernatants (n=7 8-10 weeks GA and n=5 12-14 weeks GA) and 8-10 and 12-14 weeks 
GA CD14+ cell supernatants (n=7 8-10 weeks GA and n=5 12-14 weeks GA) were used 
for the remaining wells.  
Samples were diluted 2 fold (50µl of each sample was diluted with 50µl of standard 
diluent (0.1% BSA, 0.05% Tween20 in PBS pH7.4) to give a total volume of 100µl). After 
blocking the wells in blocking solution 70µl of each sample and standard was added to 
the corresponding wells and incubated in a moisture sealed bag overnight at room 
temperature and protocol was followed using manufacturer’s guidelines. Antigen 
concentration and detection was visualised using a working solution of SA-Cy™5 
fluorescent reporter and scanned using Genepix scanner (section 2.7.2).      
 
6.4 Results 
6.4.1 Leucocyte cell counts in vessel wall and adventitia of spiral arteries 
in decidua of placental bed biopsies 
In order to initially identify the different cell populations within the placental bed of 
early pregnancy FFPE tissue sections were subjected to immunohistochemical analysis 
(Table 6.1, section 6.3). Sections were immunostained to allow identification of CD3+ T 
cells, CD14+ macrophages and CD56+ uNK cells.  
All three leucocyte populations were identified in the vessel walls and adventitia of 
SpAs at both gestational age groups (8-10 and 12-14 weeks GA) both in the presence 
and absence of EVT (Figure 6.5).  
6.4.1.1 Leucocyte cell counts in vessel wall at 8-10 and 12-14 weeks 
gestational age 
CD14+ leucocytes were observed to be the most prominent leucocyte population 
within the vessel wall of partially transforming and fully transformed decidual SpA at 8-
10 weeks gestational age compared with CD3+ and CD56+ leucocyte populations 
227 
 
(Figure 6.6). A high number of CD3+ and CD14+ leucocytes were observed in non-
transformed vessels with numbers diminishing as the vessels underwent 
transformation. CD56+ cell numbers remained fairly consistent from non-transformed 
to partially transformed vessels but numbers declined in fully transformed vessel walls.   
There were no significant differences observed in the numbers of CD56+ cells in SpA 
VSMC walls throughout each stage of vessel transformation. However, the number of 
CD14+ cells significantly declined from the numbers observed in non-transformed 
vessels to fully transformed vessels (a: P=0.0193) and there were also significantly 
decreased CD14+ cell numbers observed in late partially transformed (P2) SpA 
compared with fully transformed SpA (b: P=0.0155). There was also a dramatic 
reduction in CD3+ cell numbers from non-transformed to early partially transformed 
(P1) SpA, P2 and fully transformed SpA (c ,d, e: P=0.0001). 
 
228 
 
 
Figure 6.5 Immunohistochemistry images representing the different leucocyte cell 
populations in placental bed of early pregnancy 
Immunohistochemical representation of P2 partially remodelled SpA within the placental bed 
at 8-10 weeks GA associated with maternal leucocytes. A: H-Caldesmon/PAS staining 
demonstrating VSMCs; B: Cytokeratin-7/PAS staining demonstrating EVT cells; C: Positive CD56 
staining demonstrating uNK cells; D: Positive CD14 staining demonstrating macrophages; E: 
Positive CD3 staining demonstrating T-cells. Original magnification x200.       
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Figure 6.6 Mean leucocyte cell numbers in SpA vessel wall at each stage of vascular 
transformation at 8-10 weeks gestational age   
Mean numbers of CD56+, CD14+ and CD3+ cells observed within the wall of decidual SpAs at 
four different stages of transformation at 8-10 weeks gestation. Non-transformed (n=3): no 
transformation, thick VSMC layers; P1 (n=8): early partial remodelling of the VSMC, separation 
of VSMC cell layers; P2 (n=17): late partial remodelling of vessel wall, VSMC loss/displacement 
and increased vessel size; Fully-transformed (n=12): complete loss/displacement of VSMC 
layers, no evidence of VSMC. Data are expressed as Mean ± SEM and statistical significance is 
defined P=0.05 using one-way ANOVA with Fishers post hoc analysis.     
 
CD14+ cells were also the most prominent cell type observed in SpA vessel walls at 12-
14 weeks GA, with CD56+ cells being the second most prominent and CD3+ cells were 
observed in low numbers only in partially transformed SpAs at 12-14 weeks GA. The 
highest counts of CD14+ leucocytes were observed in early partially transformed (P1) 
SpA with numbers decreasing with level of transformation (Figure 6.7).  
CD14+ leucocytes were the only cell population observed in the wall of non-
transformed SpA at 12-14 weeks gestation; CD56+ or CD3+ cells were not detected in 
the wall of non-transformed SpA in the samples assessed (Figure 6.7). CD14+ cell 
numbers were increased in vessels showing early partial transformation (P1) compared 
with non-transformed SpA (a: P=0.0409) but numbers significantly decreased later in 
the transformation process with reduction in CD14+ cells in late partially transformed 
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(P2) and fully transformed SpA compared with P1 SpA (b: P=0.0332; c: P=0.0030 
respectively). There were no differences in the number of CD56+ leucocytes observed 
in the vessel wall throughout each stage of transformation, although CD56+ cell 
numbers did slightly decline.  
 
 
Figure 6.7 Mean leucocyte cell numbers in SpA vessel wall at each stage of vascular 
transformation at 12-14 weeks gestational age   
Mean numbers of CD56+, CD14+ and CD3+ cells observed within the wall of decidual SpAs at 
four different stages of transformation at 12-14 weeks gestation. Non-transformed (n=3): no 
transformation, thick VSMC layers; P1 (n=5): early partial remodelling of the VSMC, separation 
of VSMC cell layers; P2 (n=8): late partial remodelling of vessel wall, VSMC loss/displacement 
and increased vessel size; Fully-transformed (n=8): complete loss/displacement of VSMC 
layers, no evidence of VSMC. Data are expressed as Mean ± SEM and statistical significance is 
defined P=0.05 using one-way ANOVA with Fishers post hoc analysis.     
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6.4.1.2 Leucocyte cell counts in adventitia at 8-10 and 12-14 weeks gestational age 
Higher numbers of all the leucocyte populations studied were observed in the 
adventitial layer of SpAs compared with numbers observed in SpA vessel wall at 8-10 
weeks gestation. Leucocytes were clustered around the vessel; CD14+ cell clusters 
appeared to be most striking and again were the most abundant compared with CD56+ 
and CD3+ cell numbers (Figure 6.8). CD14+ and CD3+ cell numbers were highest in non-
transformed vessels and numbers decreased with vessel transformation. Compared 
with non-transformed SpA there were significant decreases in the number of CD14+ 
cells of early partially transformed (P1) SpA (a: P=0.0439) and fully transformed vessels 
(b: P=0.0409). Differences were also observed between the numbers of CD3+ cells 
within the adventitia; CD3+ cell numbers observed in the adventitia decreased 
significantly from non- transformed to early partially transformed (P1) SpA (c: 
P=0.0063), P2 (d: P=0.0032) and fully transformed vessels (e: P=0.0016). Despite 
reducing numbers within the vessel adventitia of CD14+ and CD3+ leucocytes as SpA 
remodelling progresses, CD56+ cell numbers remained consistent at each stage of SpA 
transformation. 
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Figure 6.8 Mean leucocyte cell numbers in SpA vessel adventitia at each stage of vascular 
transformation at 8-10 weeks gestational age   
Mean numbers of CD56+, CD14+ and CD3+ cells observed within adventitia of decidual SpAs at 
four different stages of transformation at 8-10 weeks gestation. Non-transformed (n=3): no 
transformation, thick VSMC layers; P1 (n=8): early partial remodelling of the VSMC, separation 
of VSMC cell layers; P2 (n=17): late partial remodelling of vessel wall, VSMC loss/displacement 
and increased vessel size; Fully-transformed (n=12): complete loss/displacement of VSMC 
layers, no evidence of VSMC. Data are expressed as Mean ± SEM and statistical significance is 
defined P=0.05 using one-way ANOVA with Fishers post hoc analysis.     
 
More leucocytes were observed in the adventitia of spiral arteries at 12-14 weeks 
gestation compared with numbers observed within the vessel walls themselves (Figure 
6.9). CD14+ cells were the most prominent leucocyte population with highest numbers 
observed in the adventitia of non-transformed and early partially transformed (P1) 
SpAs, with numbers decreasing from P1 to P2 (a: P=0.0051) and fully transformed 
vessels (b: P=0.0007). CD56+ cell numbers again remained consistent throughout each 
stage of vessel transformation. Very few CD3+ cells were observed at 12-14 weeks 
gestation both in the vessel walls and adventitia and CD3+ cells were only identified in 
non-transformed and partially transformed vessels, with none detected in fully 
transformed SpA. 
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Figure 6.9 Mean leucocyte cell numbers in SpA vessel adventitia at each stage of vascular 
transformation at 12-14 weeks gestational age   
Mean numbers of CD56+, CD14+ and CD3+ cells observed within adventitia of decidual SpAs at 
four different stages of transformation at 12-14 weeks gestation. Non-transformed (n=3): no 
transformation, thick VSMC layers; P1 (n=5): early partial remodelling of the VSMC, separation 
of VSMC cell layers; P2 (n=8): late partial remodelling of vessel wall, VSMC loss/displacement 
and increased vessel size; Fully-transformed (n=8): complete loss/displacement of VSMC 
layers, no evidence of VSMC. Data are expressed as Mean ± SEM and statistical significance is 
defined P=0.05 using one-way ANOVA with Fishers post hoc analysis.     
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6.4.2 Comparison of leucocyte cell numbers in vessel wall and adventitia 
between 8-10 and 12-14 weeks gestation 
6.4.2.1 Leucocyte cell numbers in vessel wall and adventitia between 8-10 and 12-14 
weeks gestation 
Reduced numbers of all three leucocyte populations were observed in the SpA wall 
and adventitia at 12-14 weeks compared with 8-10 weeks gestation. 
It appeared that there were more CD56+ cells observed in the walls and adventitia of 
SpA at 8-10 weeks compared to 12-14 weeks GA at all stages of vascular 
transformation (Figure 6.10). However, CD56+ cell numbers were only higher in the 
vessel walls of non-transformed vessels at 8-10 weeks gestation compared with cell 
numbers observed in these vessels at 12-14 weeks gestation (Figure 6.10A; P=0.0099) 
and only higher in the adventitia of non-transformed and late partially transformed 
(P2) vessels at 8-10 weeks gestation compared with numbers observed at 12-14 weeks 
gestation (Figure 6.10B: P=0.0523 and P=0.0527 respectively).  
CD14+ cell numbers observed in both the adventitia and SpA wall declined at 12-14 
weeks gestation compared with numbers observed at 8-10 weeks gestation (Figure 
6.11). Non-transformed vessels at 8-10 weeks gestation had the highest number of 
CD14+ cells observed in the walls of the vessels compared with 12-14 weeks gestation 
(Figure 6.11A; P=0.0069) and were also higher in the adventitia (Figure 6.11B; 
P=0.0065). However, early partially transformed vessels appeared to have higher 
numbers of CD14+ cells at 12-14 weeks gestation compared with 8-10 weeks gestation 
SpA but this is not as apparent as vessel transformation increased (Figure 6.11). 
It appeared that there were more CD3+ leucocytes observed in both SpA vessel walls 
and vessel adventitia at 8-10 weeks gestation at each stage of vessel transformation 
compared with 12-14 weeks gestation (Figure 6.12). However, the differences in CD3+ 
cell numbers observed were only significant in the vessel walls of non-transformed SpA 
at 8-10 weeks gestation compared with numbers observed at 12-14 weeks gestation 
(Figure 6.12A; P=0.0023) and in the adventitia of non-transformed SpA and fully 
transformed SpA at 8-10 weeks gestation compared with 12-14 weeks gestation 
(Figure 6.12B; P=0.0040 and P=0.0126 respectively). The number of CD3+ leucocytes 
declined in later stages of transformation, with reduction of CD3+ numbers in both the 
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wall and adventitia of fully transformed vessels compared with non-transformed SpA 
(Figure 6.12).  
 
Figure 6.10 Comparison of CD56+ cell numbers in both SpA vessel wall and SpA adventitia 
between 8-10 weeks and 12-14 weeks gestation 
Graphical representation of CD56+ cell numbers observed in SpA walls (A) and in SpA adventitia 
(B) in placental bed biopsies at both 8-10 (non-transformed n=3, P1 n=8, P2 n=17, fully 
transformed n=12 vessels) and 12-14 (non-transformed n=3, P1 n=5, P2 n=8, fully transformed 
n=8 vessels) weeks gestation. Data are expressed as Mean ± SEM. Significance is denoted by 
P≤0.05. 
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Figure 6.11 Comparison of CD14+ cell numbers in both SpA vessel wall and SpA adventitia 
between 8-10 weeks and 12-14 weeks gestation 
Graphical representation of CD14+ cell numbers observed in SpA walls (A) and in SpA adventitia 
(B) in placental bed biopsies at both 8-10 (non-transformed n=3, P1 n=8, P2 n=17, fully 
transformed n=12 vessels) and 12-14 (non-transformed n=3, P1 n=5, P2 n=8, fully transformed 
n=8 vessels) weeks gestation. Data are expressed as Mean ± SEM n=10. Significance is denoted 
by P≤0.05.  
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Figure 6.12 Comparison of CD3+ T lymphocyte numbers in both SpA vessel wall and SpA 
adventitia between 8-10 weeks and 12-14 weeks gestation 
Graphical representation of CD3+ cell numbers observed in SpA walls (A) and in SpA adventitia 
(B) in placental bed biopsies at both 8-10 (non-transformed n=3, P1 n=8, P2 n=17, fully 
transformed n=12 vessels) and 12-14 (non-transformed n=3, P1 n=5, P2 n=8, fully transformed 
n=8 vessels) weeks gestation. Data are expressed as Mean ± SEM. Significance is denoted by 
P≤0.05. 
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6.4.2.2 Leucocyte cell numbers in vessel wall compared with leucocyte cell numbers in 
adventitia at 8-10 and 12-14 weeks gestation 
 At 8-10 weeks gestation significantly higher numbers of CD56+ cells were present in 
the adventitia at each stage of vascular transformation compared with numbers 
observed within the vessel walls (Figure 6.13A; non-transformed: P=0.0123; P1: 
P=0.0089; P2: P=0.0045; fully transformed: P<0.0001).  
At 12-14 weeks gestation no CD56+ cells were observed in the vessel wall in non-
transformed SpA, but were observed in low numbers at the other stages of 
transformation (Figure 6.13B). There were significantly higher CD56+ cell numbers 
observed in the adventitia at each stage of vessel transformation compared with cell 
numbers observed in the vessel wall at 12-14 weeks gestation (Figure 6.13B; non-
transformed: P=0.0059; P1: P=0.0153; P2: P=0.0213; fully transformed: P=0.0015). 
At both 8-10 weeks and 12-14 weeks gestation there were significantly more CD14+ 
cells observed in the adventitia compared with cell numbers observed in the vessel 
wall (Figure 6.14A and B respectively). CD14+ cells numbers were significantly higher in 
the adventitia in non-transformed (8-10 weeks: P=0.0082; 12-14 weeks: P= 0.0003), P2 
(late partially transformed; 8-10 weeks: P=0.0148; 12-14 weeks: P=0.0428) and fully 
transformed SpA at both gestational ages, with the biggest difference observed in fully 
transformed vessels (8-10 weeks: P=0.0001; 12-14 weeks: P<0.0001). Although, CD14+ 
cell numbers observed in P1 (early partially transformed) vessels at both 8-10 weeks 
and 12-14 weeks gestation appeared to be higher in the adventitia compared to cell 
numbers observed in the vessel wall, the difference was not significant.  
Higher numbers of CD3+ cells were also observed in the adventitia compared with cell 
numbers observed in the vessel wall at both gestational age groups (Figure 6.15). At 8-
10 weeks gestation CD3+ cell numbers were highest in the adventitia in non-
transformed (Figure 6.15A; P=0.0438), P2 (Figure 6.15A; P=0.0048) and fully 
transformed vessels (Figure 6.15A; P=0.0104) compared to cell numbers observed in 
the vessel wall. However, CD3+ cell numbers observed in the adventitia and the vessel 
wall in P1 vessels did not differ.   
There were no CD3+ cells observed in either the vessel wall or adventitia of non-
transformed and fully transformed SpA at 12-14 weeks gestation (Figure 6.15B). There 
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were a few CD3+ cells observed in the partially transformed vessels (P1 and P2) with 
higher cell numbers observed in the adventitia in P2 vessels compared with cell 
numbers observed in the vessel wall (P=0.0214).   
 
Figure 6.13 Comparison between CD56+ cell numbers observed in SpA vessel wall with 
numbers observed in SpA at both 8-10 weeks and 12-14 weeks gestation 
Graphical representation of CD56+ cell numbers in SpA walls compared with numbers 
observed in adventitia in placental bed biopsies at both 8-10 weeks (A) and 12-14 weeks (B) 
gestation (8-10 weeks GA: non-transformed n=3, P1 n=8, P2 n=17, fully transformed n=12 
vessels and 12-14 weeks GA: non-transformed n=3, P1 n=5, P2 n=8, fully transformed n=8 
vessels).  Data are expressed as Mean ± SEM. Significance is denoted by P≤0.05. 
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Figure 6.14 Comparison between CD14+ cell numbers observed in SpA vessel wall with 
numbers observed in SpA at both 8-10 weeks and 12-14 weeks gestation 
Graphical representation of CD14+ cell numbers in SpA walls compared with numbers observed 
in adventitia in placental bed biopsies at both 8-10 weeks (A) and 12-14 weeks (B) gestation (8-
10 weeks GA: non-transformed n=3, P1 n=8, P2 n=17, fully transformed n=12 vessels and 12-14 
weeks GA: non-transformed n=3, P1 n=5, P2 n=8, fully transformed n=8 vessels). Data are 
expressed as Mean ± SEM. Significance is denoted by P≤0.05. 
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Figure 6.15 Comparison between CD3+ T lymphocyte numbers observed in SpA vessel wall 
with numbers observed in SpA at both 8-10 weeks and 12-14 weeks gestation 
Graphical representation of CD3+ cell numbers in SpA walls compared with numbers observed 
in adventitia in placental bed biopsies at both 8-10 weeks (A) and 12-14 weeks (B) gestation (8-
10 weeks GA: non-transformed n=3, P1 n=8, P2 n=17, fully transformed n=12 vessels and 12-14 
weeks GA: non-transformed n=3, P1 n=5, P2 n=8, fully transformed n=8 vessels). Data are 
expressed as Mean ± SEM. Significance is denoted by P≤0.05. 
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In conclusion there were more leucocytes present in association with spiral arteries at 
8-10 weeks gestation compared with 12-14 weeks gestation. In addition, numbers of 
the three leucocyte populations studied were higher in the adventitia (around the 
vessel wall) rather than within the vessel wall itself, with CD14+ cells being the most 
prominent cell population.  
6.4.3 Leucocyte numbers in the presence of EVT cells  
Leucocyte populations were observed clustered around vessels and in the vessel walls 
in both gestational age groups in the absence of EVT. However, the numbers of all the 
leucocyte populations appeared to decline when EVT cells were present.  
All of the non-transformed vessels observed in this study did not contain interstitial 
EVT cells in proximity to the vessels and there were no presence of intramural or 
endovascular EVT in the wall of the non-transformed SpA either, but the non-
transformed SpA were not absent of leucocytes at both GA groups.  
At 8-10 weeks gestation 50% of P1 vessels examined had interstitial EVT cells present, 
25% of P1 vessels also had intramural EVT cells embedded in the vessel wall but none 
of the P1 vessels showed endovascular EVT cells. All of the P2 vessels had interstitial 
EVT cells present, while intramural EVT were observed in 82% and endovascular EVT in 
6%. All of the fully transformed vessels observed contained both interstitial and 
intramural EVT, with 58% of them having endovascular EVT present.     
Of all of the P1 vessels assessed at 12-14 weeks gestation, 40% had associated 
interstitial EVT, while no intramural or endovascular EVT were observed in any of the 
P1 SpAs. All of the P2 vessels analysed had associated interstitial EVT, 75% contained 
intramural EVT and 50% had endovascular EVT present in their lumen. All of the fully 
transformed vessels observed had both interstitial EVT with intramural EVT and 75% 
endovascular EVT.      
Since all non-transformed arteries did not show associated EVT but did show 
leucocytes, whereas all P2 SpAs and fully transformed spiral arteries had EVT in 
associated to them, it was therefore decided to focus on the numbers of leucocytes in 
P1 vessels at both gestations to investigate whether the presence of EVT affected 
leucocyte cell numbers (Figures 6.16-6.18). 
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All three leucocyte numbers were slightly higher in both the adventitia and the wall in 
P1 SpAs when EVT cells were absent (CD56+ Figure 6.16; CD14+ Figure 6.17; CD3+ Figure 
6.18). This difference however, was only statistically significant for the numbers of 
CD3+ leucocytes within the adventitia of P1 SpA, with cell numbers being higher in the 
absence of EVT cells (Figure 6.18; P=0.0312).      
 
Figure 6.16 Mean CD56+ cell numbers in P1 SpA vessel wall and adventitia in both the 
presence and absence of EVT at 8-14 weeks gestation 
Graph illustrating the average number of CD56+ cells observed in VSMC wall of P1 vessels and 
in the adventitia of P1 SpA in both the presence and absence of EVT at 8-14 weeks gestation 
(n=13 vessels assessed). Data expressed as Mean ± SEM.  
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Figure 6.17 Mean CD14+ cell numbers in P1 SpA vessel wall and adventitia in both the 
presence and absence of EVT at 8-14 weeks gestation 
Graph illustrating the average number of CD14+ cells observed in VSMC wall of P1 vessels and 
in the adventitia of P1 SpA in both the presence and absence of EVT at 8-14 weeks gestation 
(n=13 vessels assessed). Data expressed as Mean ± SEM.  
 
Figure 6.18 Mean CD3+ T lymphocyte numbers in P1 SpA vessel wall and adventitia in both 
the presence and absence of EVT at 8-14 weeks gestation 
Graph illustrating the number of CD3+ cells observed in VSMC wall of P1 vessels and in the 
adventitia of P1 SpA in both the presence and absence of EVT at 8-14 weeks gestation (n=13 
vessels assessed). Data are expressed as Mean ± SEM. Significance is denoted by P≤0.05. 
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CD14+ cells also appeared to be clustered around interstitial EVT cells in proximity to 
spiral arteries (Figure 6.19) but this apparent association was not quantified.  
 
Figure 6.19 Immunohistochemistry image showing the relationship between CD14+ cells and 
EVT in early pregnant decidua 
Representative image showing immunostaining in a placental bed biopsy in early pregnant 
decidua. A represents CD14 cells and B represents interstitial EVT cells in proximity to one 
another. Original magnification x100. 
 
6.4.4 Characterisation of pure, viable decidual macrophage population 
The isolation of decidual macrophages was achieved in this study but in standard 
conditions viability decreased after culture (RPMI medium + 10% FCS; section 6.3.4.3). 
Alternative culture conditions were therefore attempted. The average CD14+ cell 
viability for all three decidual samples for each 24h culture treatment is outlined in 
Table 6.3. 
Treatment with DMEM media supplemented with 10% ATCC FCS and without GM-CSF 
addition resulted in 73% of CD14+ cells being viable after24 hours of culture, this 
treatment was therefore used for further cultures. After optimising culture conditions 
we managed to isolate and culture a viable, enriched source of decidual macrophage 
cells. Cell smears prepared at T=0 illustrate key expression markers characteristic of 
macrophages (Figure 6.20). In the samples examined 99% of the cells were 
immunopositive for CD14 protein following immediate isolation. All of the CD14+ cells 
isolated were immunopositive for HLA-DR protein; 90% of the CD14+ cells were 
immunopositive for CD86 protein; 60% of the CD14+ cells examined were 
immunopositive for CD83 protein; 30% of these cells were immunopositive for CD11b; 
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20% of the enriched cells were immunopositive for CD209, whereas only 10% of the 
enriched CD14+ cells were positively stained for Alpha1-Antitrypsin (A1AT).    
 
Table 6.3 CD14+ cell viability with differing culture conditions 
Cell viability in different media conditions used to culture isolated viable decidual CD14+ cells 
(% of viable cells after 24h in culture; n=3). 
 
Cells which were cultured for 24hrs following isolation were also labelled for CD14, 
CD209, CD83 and CD86 and the percentage of positively stained cells compared with 
the T=0 smears. 100% of the cells were CD14 positive, 90% of the cells stained strongly 
positive for CD86, 70-80% of the cells showed positive internalised staining for CD83 
and 20% of cells showed dispersed staining for CD209, suggesting that these cells 
maintain phenotype in 24h culture.  
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Figure 6.20 Double labelled CD14+ cells with varying macrophage markers 
Representative images of decidual CD14+ cell smears following Midimacs cell isolation (T=0). 
CD14 positively labelled cells (brown) were double labelled with various macrophage markers 
(blue) n=3.   
 
To further confirm the expression of the protein markers and to prove that the positive 
immunoreactivity was not a result of the isolation procedure frozen tissue sections of 
first trimester decidua were immunostained. In situ immunostaining (Figure 6.21) 
revealed strong positively stained CD14 cells with strong staining for HLA-DR and CD68. 
Cells in the decidua were positively stained for CD86 but we cannot conclude that 
these cells are CD14+ cells. Immunostaining for MMP-9 and CD83 was confined to the 
walls of spiral arteries. Only a few cells stained positively for CD11b and A1AT was 
undetectable in the decidua.    
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Figure 6.21 Immunostaining of decidual tissue with different macrophage markers 
Immunohistochemistry illustrating immunostaining of decidual tissue with different 
macrophage markers (from left to right: CD14, CD68, HLA-DR, MMP-9, CD86, CD83, CD11b and 
A1AT all x100 magnification). 
 
6.4.5 Growth factor protein production by isolated CD14+ cell 
supernatants from 8-10 and 12-14 weeks gestation 
The data presented from this study provide evidence that CD14+ cells are the most 
prominent leucocyte cell population that are associated with VSMCs within the wall of 
spiral arteries in early pregnancy decidua. Therefore, having isolated an enriched 
population of CD14+ cells from early pregnancy decidua (section 6.3) and optimised 
culture conditions, the cells were cultured for 24h for supernatant collection. Secretion 
of an array of growth factors and cytokines was measured using ELISA and FASTQuant 
and protein levels were compared between the gestational age groups to investigate 
whether decidual macrophages produce growth factors and cytokines which could 
potentially be involved in the remodelling of the spiral arteries in early pregnancy.  
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6.4.5.1 Human Th1/2 growth factors 
Using the Th1/2 FASTQuant multiplex array, it was shown that decidual CD14+ cells 
secreted large quantities of IL-6 (~13000pgml-1), IL-1β (ranging from ~11000-
70000pgml-1) (Figure 6.22A) and TNF-α (ranging from ~1200-5000pgml-1) along with 
substantial quantities of IL-10 (~1000pgml-1 both GA), IL-4 (~1200pgml-1) and IL-13 
(~500pgml-1). However, IL-5 and IL-2 were only detectable at very low levels (Figure 
6.22B). 
 
Figure 6.22 Secretion of Th1/Th2 growth factor proteins secreted by CD14+ cells at both 8-10 
weeks and 12-14 weeks gestation 
Graphical representation demonstrating the Th1/Th2 growth factor proteins secreted by 
isolated decidual CD14+ cells at 8-10 weeks GA (n=7) and at 12-14 weeks GA (n=5). A: 
represents IL-6 and IL-1β protein secretion; B: represents IL-10, IL-2, IL-13, IL-4, IL-5 and TNF-
alpha secretion. Data are expressed as Mean ± SEM.  
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6.4.5.2 Human angiogenic growth factors 
From the proteins measured using the angiogenesis FASTQuant multiplex array (8-10 
weeks GA n=7; 12-14 weeks GA n=5) and Ang-1 ELISA (8-10 weeks GA n=11; 12-14 
weeks GA n=8; duoset, R&D Systems) it was shown that decidual CD14+ cells secreted 
large quantities of Ang-1 and Ang-2 and FGF-basic protein. Angiogenin, VEGF-A and 
KGF were secreted at low levels while PDGF-BB was undetectable (Figure 6.23).  
The concentrations of TGF-β1, PLGF and VEGF-C in CD14+ cell suspension were all 
measured using a Duoset sandwich ELISA (R&D Systems) but these proteins were not 
detected.  
 
Figure 6.23 Secretion of angiogenic growth factor proteins secreted by CD14+ cells at both 8-
10 weeks and 12-14 weeks gestation 
Graphical representation demonstrating angiogenic growth factor proteins secreted by 
isolated decidual CD14+ cells (Angiogenin, KGF, Ang-2, FGF, VEGF-A: 8-10 weeks GA (n=7); 12-
14 weeks GA (n=5) and Ang-1 ELISA: 8-10 weeks GA (n=11); 12-14 weeks GA (n=8)). Data are 
expressed as Mean ± SEM.  
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6.4.5.3 Differences between gestational ages 
There are no significant gestational differences of Th1/2 protein levels, although there 
is a noticeable increase of IL-1β and TNF-α at 12-14 weeks gestation compared with 8-
10 weeks gestation (Figure 6.22). Statistical significance may have not have been 
achieved due to large variation in levels of these cytokines between samples (8-10 
weeks n=7; 12-14 weeks n=5).   
Ang-1, Ang-2 and FGF-basic protein levels differed significantly between the 
gestational age groups (8-10 and 12-14 weeks; Figure 6.23). Ang-2 secretion by CD14+ 
cells was significantly increased at 12-14 weeks compared with levels at 8-10 weeks 
gestation (P=0.0019). In contrast, secretion of Ang-1 and FGF-basic protein by CD14+ 
cells was significantly decreased at 12-14 weeks gestation compared with levels at 8-
10 weeks gestation (P=0.0311; P=0.0477 respectively). 
 
6.5 Discussion  
6.5.1 Leucocyte involvement in spiral artery remodelling 
The remodelling of spiral arteries is a complex series of events that ensures an 
adequate supply of blood and nutrients to the developing fetus to allow successful 
pregnancy. However there is still much debate on the mechanisms that control such 
events due to the difficulty of obtaining appropriate research material from first and 
second trimester pregnancies. Immunohistochemical evidence has shown that EVT 
cells invade both the wall and lumen of spiral arteries, indicating that they have 
relevance in controlling the remodelling events (Pijnenborg et al., 1983). However, 
VSMC swelling, migration and endothelial vacuolation are apparent prior to the 
invasion of trophoblast cells (Smith et al., 2009). 
This study used an immunohistochemical approach to investigate immune cells of the 
decidua and their association and potential involvement in SpA remodelling.  The 
release of soluble products of uNK cells and decidual T cells have been reported 
previously (Lash et al., 2006c, Scaife et al., 2006) but in this study decidual 
macrophages were closely related to spiral arteries, the soluble products of decidual 
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CD14+ cells were also analysed to determine whether they may contribute to the 
remodelling events prior to EVT invasion.  
The three leucocyte populations investigated in this study were all observed to be 
associated with decidual SpAs at 8-10 weeks and 12-14 weeks gestational age using an 
immunohistochemical approach, indicating a potential role in the events of SpA 
remodelling. Data from this study also presents a method for characterising stages of 
vascular remodelling using specialised staining techniques and measurements of 
immunostained SpA VSMC walls.  
There was a large accumulation of leucocytes in proximity to decidual SpAs within 
early placental bed. The highest numbers of leucocytes were observed in vessels that 
had not yet begun the process of remodelling and leucocytes were clustered around 
the vessels. This could be indicative of the leucocytes priming themselves ready for the 
remodelling events or by simply sending signals to EVT cells. Leucocyte numbers did 
decline in early transforming vessels (P1) where they were still present within the 
spiral artery muscular walls and adventitia of the remodelling vessels prior to EVT 
invasion, suggesting an involvement in the separation and/ or loss of VSMC by 
apoptosis or aiding cellular migration or VSMC de-differentiation. P1 vessels observed 
in this study did not have many EVT cells in the vessel wall also suggesting a likely role 
for leucocytes in early stages of remodelling.  These events may be independent or 
may be mediated by invading EVT, by immune cells of the maternal local environment 
or by both mechanisms.   
The infiltration of leucocytes around and into SpA in the early stages of remodelling 
demonstrates that initial transformation of the decidua occurs before EVT involvement 
and provides circumstantial evidence that disruption of SpA VSMC are initially driven 
by factors released by these cells and the process is not initiated by EVT further 
concluding the controversial theory that extravillous trophoblast cells are not 
responsible for early stages of transformation (Pijnenborg et al., 2006b, Smith et al., 
2009). Smith et al. (2009) recently demonstrated that uNK cells and macrophages 
produce MMP-7 and 9 along with reports of production of MMP-2 and -9 by uNK cells 
(Naruse et al., 2009) providing evidence that these cells have the ability to degrade 
vascular extracellular matrix (ECM) and therefore contribute to disruptions in vessel 
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integrity. However, the mechanisms by which the leucocytes may control early 
remodelling events remains poorly understood. The main focus has been on uNK cells 
with production of Ang 1 and vessel destability (Robson et al., 2012) but decidual 
macrophages are equally abundant and therefore have a potential role to play.  
The differences of vessel transformation and leucocyte numbers associated with the 
transforming vessels within the placental bed have not yet been previously 
investigated across gestational age. In this study the number of leucocytes in VSMC 
wall of SpA decreased from 8-10 weeks to 12-14 weeks GA, further suggesting a 
possible role in early vessel transformation before invasion of EVT. Although, leucocyte 
numbers declined in SpAs they were still prevalent in the VSMC wall of SpAs at 12-14 
weeks gestation suggesting a partnership with EVT to achieve full transformation into 
large, conduit vessels lacking medial muscle and elastic ensuring an adequate blood 
supply for successful pregnancy. Leucocyte numbers significantly decreased as vessel 
transformation progressed further indicating a role for EVT in later remodelling stages. 
The localisation of leucocytes in early stages of remodelling suggests a role for the 
immune cells in VSMC cell loss, increased vessel permeability and VSMC in SpA 
undergoing migration, thereby facilitating the infiltration of interstitial EVT into the 
vessel wall and endovascular EVT invasion into the lumen.   
6.5.2 EVT remodelling 
It has been documented in this study (Chapter 4) along with numerous previous 
reports that EVT invasion is controlled by a number of factors including, chemokines, 
cytokines, MMPs and varying oxygen concentrations (Lash et al., 2006a, Naruse et al., 
2010, Dimitriadis et al., 2010). Factors produced by maternal immune cells (including 
uNK cells, macrophages and T cells) are likely to have an influence on the regulation 
and behaviour of invading EVT. They may achieve this level of control either directly 
through molecular interactions with the trophoblast cells or indirectly by the secretion 
of soluble factors. Immunohistochemical evidence show changes in EVT expression cell 
surface markers, particularly adhesion markers, as they near spiral arteries preparing 
the cells for interaction with the VSMCs (Zhou et al., 2003). The interactions with 
maternal leucocytes or their secretory products may affect EVT phenotype to achieve 
this. Alternatively co-culture of EVT cells and uNK cells has been shown to reduce 
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secretion of IL-6, IL-8 and TGF-β1 (Lash et al., 2011); whether inhibiting effects on uNK 
cell secretion or EVT secretion or both is not known but co-culture of these two cell 
types leads to inhibition of secretory products.                 
6.5.3 Mechanisms of leucocyte remodelling  
The focus of this study was to investigate the effect of the most abundant leucocyte 
populations and their relationship with SpAs and their contribution to remodelling 
events. Maternal leucocytes have been proposed to play a role in SpA remodelling but 
the mechanisms remain unclear. A role for uNK cells in spiral artery remodelling has 
been hypothesised (Croy et al., 2003, Lash et al., 2006c, Robson et al., 2012) and has 
been linked with remodelling in mouse (Ashkar and Croy, 2001, Croy et al., 2003) but 
has never been established in humans. The factors produced by uNK cells strongly 
suggest a possible involvement in SpA remodelling, especially a role in initiating the 
remodelling process.  Reports demonstrate that uNK cells are major producer of 
angiogenic growth factors (Li et al., 2001, Lash et al., 2006c, Hanna et al., 2006); they 
have been observed in the walls of remodelling vessels in situ before the invasion of 
EVT (Smith et al., 2009) and uNK cell secretory factors alter vascular integrity of 
chorionic plate arteries (Robson et al., 2012). 
The role of macrophages in SpA remodelling has been proposed due to high numbers 
of macrophages observed in preeclampsia (Reister et al., 1999, Renaud and Graham, 
2008) but this could also be likely of an immune response. CD3+ T cells and their role in 
remodelling has been sparingly investigated, although decreased numbers of CD3+ T 
cells in placental bed biopsies of women suffering preeclampsia has been observed 
compared with numbers in third trimester decidua controls (Williams et al., 2009b), 
indicating an importance for this cell type in pregnancy, perhaps in regulating spiral 
remodelling. The evidence from this study demonstrates a reduction in CD3+ T cells as 
SpA remodelling progresses, suggesting an early involvement prior to trophoblast 
invasion.  
There is increasing evidence, including evidence from this study, that maternal 
leucocytes, in particular uNK cells and macrophages play an important role in spiral 
artery remodelling but the mechanisms remain unclear. Early SpA transformation 
which occurs at 8-10 weeks gestation involves a number of steps including vessel 
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dilation, swollen endothelial cells and the separation of VSMC layers. As gestational 
age increases, the VSMCs begin to de-differentiate and EVT cells displace the muscle 
and elastic arterial media with fibrinoid material which involves the complete loss of 
VSMC and transient loss of endothelium (Pijnenborg et al., 2006b). In this study we 
have observed a reduction in maternal leucocytes as gestational age increases, 
irrespective of the stage of remodelling, indicating that the cells are more than likely to 
play an important role in the early stages of SpA remodelling. This would also be in 
keeping with evidence that uNK cells secrete more Ang-1, Ang-2 and VEGF-C at 8-10 
weeks compared to levels produced at 12 -14 weeks gestation (Lash et al., 2006c); 
these angiogenic growth factors are important in ECM matrix degradation and 
disruption of tight junction proteins between VSMC layers, therefore increasing 
separation and de-differentiation of VSMCs before the infiltration of EVT.    
Macrophages are the second largest leucocyte population in the decidua in early 
pregnancy and have been detected in close contact with invading EVT and express 
receptors that are able to interact with ligands found on trophoblast cells (Bulmer and 
Johnson, 1984, Smith and Kelly, 1988, Reister et al., 2001, Apps et al., 2007). Despite 
their prevalence and close relationship with EVT little attention has been given to the 
role of decidual macrophages in normal pregnancy. Although high numbers of 
macrophages have been observed in early pregnancy their potential involvement in 
SpA remodelling has only been previously described by Smith et al. (2009). Potential 
roles for decidual macrophages in pregnancy have been speculated due to their roles 
in other tissues. Robertson et al. (2003) proposed that during the Th2 cytokine shift 
that monocytes are activated but there is a decrease in the synthesis of pro-
inflammatory cytokines, indicating that the alternatively activated macrophages are 
likely to play an immunosuppressive role in response to fetal antigens and induction of 
tolerance. However, activated macrophages are also adept in tissue remodelling 
observed in other tissues by secretion of proteases, cytokines, growth factors which 
allow tissue remodelling and angiogenesis. In in vivo studies in mouse, activated 
macrophages have been associated with extensive vascularisation and tumour-bearing 
mice with depleted monocytes showed a decrease in tumour vascularisation (Evans, 
1978). In relation to pregnancy, macrophages could control trophoblast invasion by 
secretion of TNF-α (Renaud and Graham, 2008). Therefore, providing circumstantial 
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evidence that macrophages have a possible involvement in SpA remodelling in human 
pregnancy.       
The production of MMPs by uNK cells and macrophages infiltrating remodelling SpAs 
demonstrated by Smith et al. (2009) suggest that these leucocoytes contribute to 
vascular remodelling by influencing VSMC migration although evidence for migrating 
VSMC has not been observed in any other vascular system. 
In the present study CD14+ cell numbers were highest in proximity to the remodelling 
decidual spiral arteries compared to CD56+ and CD3+ T cells at both gestational ages. 
This further led to the hypothesis that these cells may have a strong involvement in 
coordinating the events of SpA transformation and that they may achieve this by 
producing proteins that may play a role in either regulating trophoblast dependent 
mechanisms or by the cells themselves producing factors that regulate angiogenesis. 
The mechanisms that underlie VSMC loss during SpA remodelling events are up for 
much debate. Harris et al. (2006) and Keogh et al. (2007) have demonstrated initiation 
of VSMC apoptosis by trophoblast cells via FAS/FASL and TRAIL pathways in vitro. 
Furthermore, Smith et al. (2009) detected VSMC apoptosis using TUNEL staining in 
decidual SpA undergoing remodelling (in vivo) before infiltration of endovascular EVT. 
However, the degree of VSMC apoptosis was not quantified and TUNEL staining alone 
is not the most reliable marker of apoptosis. The use of an animal based model also 
reported evidence of VSMC apoptosis induced by trophoblast cells (Red-Horse et al., 
2006). In contrast, (Bulmer et al., 2012) did not detect significant VSMC apoptosis in 
partially remodelled SpA with only one apoptosed VSMC detected after assessment of 
294 myometrial and decidual SpAs regardless of EVT influence.  
An alternative explanation proposed for VSMC loss in SpA remodelling is that SpAs 
undergo de-differentiation. Reports in guinea pig have demonstrated that SpA VSMC 
de-differentiate into a non-contractile form which remained associated with the vessel 
until re-muscularising after delivery (Nanaev et al., 2000). However, in humans the 
VSMCs in the vessel wall are completely displaced with fibrinoid material and 
intramural EVT. Recent theories are also emerging that SpA VSMCs detach from the 
vessel and migrate away from the vessel lumen (Whitley and Cartwright, 2010). 
Bulmer et al. (2012) observed in situ migration of VSMCs away from SpAs which were 
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associated with interstitial, intramural or endovascular EVT; VSMC migration was more 
apparent in the presence of EVT. Overall, this is accumulating evidence that indicates a 
role for EVT in the later stages of vascular remodelling and highlights the importance 
of EVT in finalising the remodelling events, whilst maternal leucocytes may play a role 
in initiating the primary stages of SpA remodelling. In this study SpA associated 
leucocytes reduced in number in the later stages of SpA remodelling in the presence of 
intramural and endovascular EVT. Leucocyte products may play a role in VSMC cellular 
migration by the production of angiogenic growth factors such as VEGF-A, -C, Ang-1 
and -2 which are produced by uNK cells and are also produced by decidual CD14+ cells 
shown in this study.  
6.5.4 Role of macrophages in SpA remodelling 
Macrophages are highly versatile cells that adapt to their environment and are capable 
of performing a variety of functions.                   
The overwhelming presence of CD14+ cells in association with the SpA walls observed 
in this study raises the possibility of a role in VSMC loss; this could be by phagocytosis 
or cellular migration through the production of Ang-1 and -2; production of TNF-α and 
IL-1β also may suggest roles in differentiation and apoptosis of VSMC. The differences 
in the secretion of angiogpoeitins between the gestational ages suggest a possible role 
for macrophages in SpA remodelling. Ang-1 protein secretion by CD14+ cells reduced 
significantly as gestation increased while Ang-2 secretion significantly increased with 
gestation. Ang-2 acts as a competitive inhibitor of Ang-1; Ang-2 favouring vessel 
destabilisation allowing angiogenesis and counteracts vessel maturation, whereas Ang-
1 stimulates the formation of new blood vessels. A reduction in the ratio of Ang-1 to 
Ang-2 would therefore favour vessel destabilisation. Thus in early gestation CD14+ cells 
may contribute to vessel stability and then as remodelling is initiated the action of 
macrophage derived Ang-2 facilitates VSMC separation and endothelial cell disruption 
through its anti-angiogenic effects.          
The TNF-α that is secreted by macrophages may also contribute to EVT apoptosis; it 
has been demonstrated that TNF along with IFN-γ increase the expression of pro-
apoptotic factor XAF1 in trophoblast cells initiating the production of caspase-3 
inducing cell death (Abrahams et al., 2004b, Straszewski-Chavez et al., 2004). In 
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complicated pregnancies such as in preeclampsia and spontaneous abortion, 
trophoblast cells undergo abnormal and extensive apoptosis (DiFederico et al., 1999, 
Minas et al., 2007). In addition, Reister et al. (2001) have reported that TNF secreted 
by activated macrophages reduces endovascular EVT invasion by inducing apoptosis 
observed in the uterine wall of preeclamptic women.   
It was also observed in this study that there was a close relationship between EVT and 
CD14+ cells in situ. This interaction is likely to occur through cell surface receptor 
expression; the homodimer HLA-G expressed uniquely by trophoblast cells is 
recognised by LILR (leucocyte immunoglobulin-like receptor) which is expressed by 
macrophages and dendritic cells and LILRB1 and B2 inhibitory receptors have high 
affinity for HLA-G (Shiroishi et al., 2003) indicating a potential role for trophoblast cells 
in controlling the maternal immune response in early pregnancy. It has been suggested 
that HLA-G dimers may act as a pregnancy-specific signal to regulate the maternal 
immune response and interacts with all maternal leucocytes at the maternal-fetal 
interface (Apps et al., 2007). With the marrying receptor repertoire of macrophages 
and EVT through HLA-G/LILRB1 binding this could translate into the release of many 
growth factors and cytokines by both cell populations and therefore, affect the 
processes involved in early pregnancy like SpA remodelling and trophoblast invasion by 
modulating numerous functions. One potential mechanism arising from this 
interaction is for CD14+ cells to phagocytose interstitial EVT cells as it is evident that 
EVT cell numbers decline as gestational age increases and as remodelling progresses 
which is observed in this study. However, further investigation into this hypothesis 
using phagocytosis assays may conclude this role for macrophages.      
6.5.5 Overall summary 
This study has provided circumstantial evidence for a role for maternal leucocytes in 
the early stages of SpA remodelling by their localisation to SpA undergoing early 
remodelling. For the first time an enriched macrophage population was isolated from 
human decidual tissue which remained viable after 24h in culture and produced 
angiogenic growth factors which may be important mediators in the early stages of 
SpA remodelling independent of trophoblast cells.   
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The studies developed along the years have given insight into the regulation of SpA 
remodelling. Further research will finally elucidate the exact roles of EVT dependent 
and independent pathways in SpA remodelling and may give an understanding of the 
mechanisms involved in pathological pregnancies which then can be translated into 
clinical treatment. The interactions between EVT and leucocytes through HLA-G/LILR 
and KIR recepetors (expressed by uNK cells), SpA VSMCs and leucocytes and SpA 
VSMCs with EVT are all basis for future studies. The focus has been on uNK cells but 
macrophages merit further study.  
 
 
 
 
Chapter 7 
Discussion and Future Studies 
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7. Discussion and Future Studies 
7.1 Discussion 
7.1.1 Purpose of study 
Inflammatory cytokines have been implicated in pregnancy function for some time, 
although exact functional roles for these cytokines remain uncertain, due to the 
complexity of the cytokine milieu within the uterine decidua. 
The angiogenic, migratory function of IL-8 and the invasive capacities of IL-6 in diseases 
such as cancer have led to interest in their potential roles in pregnancy, particularly on 
the effects that these cytokines may have on the development of early pregnancy. This 
has led to investigations of the involvement of cytokines in pregnancy complications 
such as pre-eclampsia and sporadic miscarriage, with alterations of these cytokines 
being linked to the pregnancy pathology.  
7.1.2 Cytokine production and localisation  
This is the first study to date that has documented the exact sites of cytokine location 
within the decidual tissues of the first half of human pregnancy and has demonstrated 
receptor expression by specific cells within the decidua, with gestational age 
comparisons. Many studies in the past have focused on maternal serum cytokine levels 
or levels within the amniotic fluid (reviewed in Chapter 1). Levels of intrauterine IL-6 
and IL-8 secretion were quantified by decidual cell populations abundant during 
pregnancy development such as uNK cells, macrophages, T-lymphocytes and decidual 
stromal cells. A gestational age difference in cytokine levels was observed, suggesting a 
functional role either in initiating the remodelling events that occur in the spiral 
arteries in normal pregnancy or in regulating EVT invasion. By gaining a clear 
understanding of the role of these cytokines in normal healthy pregnancy, it will be 
possible to unravel the mechanisms whereby altered levels contribute to pregnancy 
complications. This may in turn lead to targeting therapies and in turn have clinical 
relevance.  
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7.1.3 Functional role of intrauterine IL-6 and IL-8 in EVT invasion 
Uterine natural killer cells and decidual macrophages are sources of uterine IL-6 and IL-
8 in the first half of human pregnancy. This provides evidence that these cytokines are 
involved in important roles in normal pregnancy, although exact in vivo roles still need 
to be clarified. A suggestive role for IL-8 is in the stimulation of EVT invasion; if 
maternal leucocytes such as uNK cells and decidual macrophages fail to secrete 
optimum levels for appropriate regulation of trophoblast invasion into the maternal 
uterine tissues and spiral arteries, aberrant trophoblast invasion could result which 
may be a factor in the aetiology of SM. We have previously demonstrated that uNK cell 
derived IL-8 can stimulate EVT invasion (De Oliveira et al., 2010). However, in the 
current study we did not demonstrate a similar action for IL-6.  
There have been many studies of the regulation of EVT invasion but the in vivo control 
mechanisms still remain to be elucidated due to the complexity of the factors involved 
and the potential interactions between EVT cells and the wide array of cells in the 
decidua. For a number of years it was suggested that cytokines play important roles in 
regulating EVT invasion either by inhibitory or stimulating mechanisms, with data 
providing evidence of TGF-β, IFN-γ, TNF-α, IL-11 and IL-8 involvement, amongst many 
others (Dimitriadis et al., 2005, Hanna et al., 2006, Lash et al., 2006b, Paiva et al., 2009, 
Otun et al., 2011). The effect of IL-6 on EVT invasion has been investigated in a number 
of studies but the use of different immortal trophoblast cell lines, including 
choriocarcinoma cell lines, has produced contradictory results (reviewed in Chapter 4). 
Findings in this study provide further evidence that immortalised EVT-like cell lines are 
an imperfect model for EVT. The present study investigated the effect of IL-6 on EVT 
invasion using placental explants from early human pregnancy and this has yet to be 
investigated by others. The use of primary EVT from early pregnancy placentas would 
have been more desirable to use in this study and would have provided a more pure 
population but after successful isolation the primary cells showed a restrictive invasive 
nature, a feature that has been observed by others previously (personal 
communication Martin Knofler). Although, in the present study IL-6 had no effect on 
EVT invasion from placental explants, IL-6 did significantly alter phosphorylation of 
various EVT signalling proteins in primary EVT cells. The cell signalling pathways are 
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complicated, involving extensive cross talk and it is therefore difficult to determine 
what effect this would have on EVT in vivo. There is some evidence suggesting a role 
for IL-6 in trophoblast differentiation, or perhaps a secondary affect which may in turn 
affect the waves of EVT invasion by other cytokines and growth factors. Since this area 
of research is so complex various different in vitro approaches are emerging; co-
culture models of EVT and decidual cells or placental tissue co-cultured with decidual 
tissue from matched patients have been reported (Hazan et al., 2010, Robson et al., 
2012) and could more closely mimic the environment of the maternal fetal interface, 
providing a clearer insight into how these cells behave by protein and genetic analysis.       
7.1.4 Functional role of intrauterine IL-6 and IL-8 in SpA remodelling 
In this study both IL-6 and IL-8 altered the morphology of VSMCs in CpAs (used as a 
model of spiral artery remodelling) indicating a possible mechanism in the regulation 
of SpA remodelling. Uterine NK cells and decidual macrophages have a very close 
association with SpAs in early pregnancy, providing circumstantial evidence that 
uterine IL-6 and IL-8 could play a role in SpA remodelling events, especially in the early 
events that occur prior to EVT invasion. The findings of expression of receptors for the 
cytokines; IL-6Rα, gp130 and CXCR2, on SpA VSMC in the present study provides 
further evidence for a role for these cytokines in SpA remodelling. These cytokines 
could work together synergistically at sites of spiral artery remodelling along with 
other soluble factors that are also produced by uNK cells and decidual macrophages  
such as VEGF-C, ANG2 and IFN-γ.   
The present study provided circumstantial evidence for a role for uNK and decidual 
macrophages in the early stages of SpA remodelling prior to trophoblast remodelling. 
Previous studies have observed a close relationship between maternal leucocytes and 
decidual spiral arteries undergoing transformation in early pregnancy (Smith et al., 
2009, Harris, 2011). In a more recent study factors secreted by first trimester uNK cells 
facilitate VSMC disruption using ex vivo vessel models (Robson et al., 2012). 
Imunohistochemistry data from the present study provide additional evidence to 
support this hypothesis, since uNK cells and decidual macrophages surround SpA in 
situ in the early stages of remodelling in early pregnancy. This is the first study to 
characterise different stages of SpA remodelling in situ by analysis of VSMC wall 
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thickness, although Smith et al. (2009) investigated leucocyte numbers at different 
remodelling stages, the stages weren’t characterised by muscle thickness. This study 
analysed and compared leucocyte cell numbers associated with transforming SpA at 
each stage of remodelling in the presence and absence of EVT with gestational age 
comparisons.  
The findings from this study and data from previous studies undoubtedly suggest that 
uNK cells play a role in initiating early SpA remodelling events, but less attention has 
been paid to the decidual macrophages. This cell population was dominant in spiral 
arteries in situ, far exceeding the numbers of uNK cells surrounding SpAs. Furthermore 
the present study provides evidence of secretion of high levels of angiogenic factors, 
such as Ang-1 and Ang-2, by decidual macrophages with gestational age differences. 
These results suggest a pivotal role for decidual macrophages in initiating early SpA 
remodelling events; these cells are equipped to induce vascular destabilisation prior to 
EVT invasion, priming the vessels for trophoblast mediated remodelling. Decidual 
macrophages, uNK cells and CD3+ T lymphocyte cell numbers in and around SpAs all 
dramatically reduced as the stage of SpA remodelling progressed with fewer cells 
present at 12-14 weeks GA compared with cell numbers at 8-10 weeks GA; 
demonstrating convincing evidence for a potential role in initiating the early SpA 
remodelling events prior to trophoblast invasion of the vessels. Maternal leucocytes 
may achieve this by cross talk with one another by coordinating themselves spatially. 
Secretion of IL-8 and IL-6 in the decidua may provide the signals for the migration of 
decidual leucocytes to sites of SpA remodelling, or even contribute to the remodelling 
events themselves. Leucocyte secretion of IL-8 and IL-6 may also provide signals for 
invading extravillous trophoblast, so that they locate themselves around and within 
SpA to complete remodelling.  
The mechanisms whereby maternal leucocytes cause VSMC disruption remain to be 
clarified. It has been suggested that macrophages secrete apoptotic factors that kill 
VSMCs in order to destabilise the vessel wall and also to phagocytose the dead cells 
and cellular debris by invading trophoblast (Smith et al., 2009). However, in situ studies 
of placental bed biopsies have found no evidence of VSMC apoptosis but have 
observed VSMC migration away from the SpA lumen (Bulmer et al., 2012); this is 
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another potential mechanism whereby secretion factors produced by maternal 
leucocytes could cause early SpA remodelling changes and could be an explanation for 
their high cell numbers surrounding early transforming arteries. This has recently been 
observed by Robson et al. (2012) where Ang-1, Ang-2 and IFN-gamma (factors secreted 
by both uNK cells and decidual macrophages) all contribute to vascular changes in both 
SpA and CpA.                  
7.1.5 Altered cytokine levels in sporadic miscarriage  
Levels of both cytokines derived from uNK cells and macrophages were dramatically 
reduced in SM compared with healthy pregnancy. The reduction in IL-6 and IL-8 in SM 
may be due to fewer viable leucocyte numbers in SM due to increased apoptosis, 
although cell viability was checked at the end of the cell culture period, so this is 
possible but not likely in this study. Alternatively reduction in cytokine levels could be a 
result of impaired signalling within the uterine environment resulting in down-
regulation of cytokine synthesis at either pre transcriptional stages or post 
translational stages. 
 A decrease in IL-6 and IL-8 receptors was also observed in SM indicating that cells in 
the decidua associated with SM have decreased capacity to interact with these 
cytokines; this may be a response to reduced cytokine production. However, as for all 
studies of miscarriage samples altered levels of these cytokines may be an effect of the 
condition and not the cause, although none of the SM samples in this study showed 
evidence of acute infection, therefore the results observed were not likely to be cause 
of infection. Although this study did not elucidate specific mechanisms of IL-6 and IL-8 
in SM, the reduction in their receptor expression and secretion levels by uterine cells in 
SM strongly implies that IL-6 and IL-8 are important in early pregnancy. Their 
functional role may be regulating early events of spiral artery remodelling and this is a 
potential area for further study that may have future clinical relevance.           
Investigation of normal and pathological early pregnancy development in humans is 
difficult since it is impossible to investigate the role of specific cells/factors in vivo. 
Isolating and culturing primary cells and cell lines in a monolayer destroys three 
dimensional interactions and the association of the extracellular matrix with 
neighbouring cells, potentially affecting cell behaviour. However, the use of placental 
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explants and Matrigel™ in the present study has partly overcome such problems, and 
the data are supported with in situ immunohistochemistry data in placental bed 
biopsies. Many in vitro, ex vivo and in situ models have provided great insights into the 
processes of pregnancy development and advances such as uterine artery Doppler 
ultrasound screening of spiral arteries is a useful tool for measuring artery resistance 
which can be used as a predictive measure of pregnancy outcome. A problem that 
cannot be overcome in using human early pregnancy tissue is that it is not known 
whether the pregnancy would have continued to term and whether those pregnancies 
would have developed clinical complications in later pregnancy including SM tissue 
where some samples collected may have had underlying causes and may lead to 
recurrent miscarriages.        
7.1.6 Conclusion 
The present study provides convincing evidence for the importance of maternal 
leucocytes in early pregnancy and that their secretory factors, including IL-8 and IL-6, 
have major roles in pregnancy processes with altered levels potentially contributing to 
pregnancy failure. The functional mechanisms, however, remain unclear; this is due at 
least in part to cytokine redundancy, pleiotrophy and the complexity of their 
interactions with one another as they may promote or inhibit actions of other factors. 
The large cytokine milieu at the maternal fetal interface suggests a large network of 
cross-talk between factors and that cytokines do not work alone in regulating the 
uterine environment.  
 
7.2 Future Studies 
7.2.1 Further investigation into functional roles of intrauterine IL-6 and 
IL-8  
Although this study has defined some functions of IL-6 and IL-8 such as involvement in 
VSMC disruption and stimulation of EVT invasion, the effects observed in this study 
have raised more questions. The localisation and production of IL-6 and IL-8 by four 
decidual cell populations has been demonstrated in the first half of pregnancy, the 
total cohort of decidual cells produced large amounts of each cytokine, exceeding the 
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amounts by the individual cell populations investigated, suggesting that other cell 
types that were not studied are main producers of IL-6 and IL-8, which was not 
expected as the initial focus of this study was on uNK cells, but this demonstrates that 
other cell types are equally or not more important. Therefore, in further studies it 
would be important to isolate more decidual cell populations such as glandular 
epithelial cells to analyse their secretion of these cytokines. Immunohistochemistry 
data revealed intense staining for both IL-6 and IL-8 along with strong staining for 
gp130 on uterine glands, suggesting that this cell population are producers of these 
cytokines. Recent evidence has suggested that EVT invade uterine glands in early 
pregnancy (Moser et al., 2010) and this could raise the possibility of roles for these 
cytokines in regulating endoglandular EVT invasion. 
Further investigation is required to determine the effect of IL-6 on trophoblast 
function as the present study demonstrated that IL-6 stimulated many proteins 
involved in the EVT signalling pathways and reduced EVT secretion of RANTES, 
although no effect on EVT invasiveness was observed. Furture investigation could gain 
insight to the alternative effects IL-6 has on EVT migration and EVT hCG secretion; the 
differentiation of trophoblast cells from cyototrophoblasts into invading extravillous 
trophoblasts or invading EVT into non invasive giant cells. It would be interesting to 
see whether decidual CD14+ supernatants, cultured with isolated primary EVT from the 
same patient, had a similar effect and whether using neutralising antibodies against IL-
6 would abrogate the effect. Although previous studies from our group (unpublished 
data) observed no evidence of IL-6 treatment on EVT apoptosis using M30 protein 
detection by Western blotting, this still could be an area for further clarification using 
immunocytochemistry, immunofluorescence and Western blot analysis for different 
apoptotic markers. EVT migration assays would be a further area to research also, 
given that production of RANTES by EVT was reduced after IL-6 treatment. In addition 
the effects of IL-8 on EVT signalling and secretion should be investigated to elucidate 
the mechanisms whereby IL-8 stimulates EVT invasion. Regulatory proteins may then 
be targeted for therapies in disorders where excessive EVT invasion is apparent; this 
could potentially be a cause of placenta accreta, although the decidua is absent in 
placenta accreta making it difficult to assess the extent of EVT invasion. The exact 
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mechanism for pathogenesis of the disease is currently unknown and is a major 
pregnancy complication, recently reviewed by Garmi and Salim (2012).   
Observations of disruptions of CpA VSMC after cytokine treatment indicated a 
potential role for these cytokines in SpA remodelling. The effect of these cytokines on 
VSMCs can be further studied by treating primary vascular smooth muscle cells lines 
such as primary human aorta cells and measuring the protease activity and secretion 
of angiogenic proteins. Non-pregnant myometrial arteries are another possible source 
of a more directly relevant tissue and it would be good to investigate the effect of IL-6 
and IL-8 on this vasculature and compare this with the effect observed with CpAs. It is 
accepted that CpAs are not a perfect model for SpAs as they differ in arterial 
composition compared with myometrial arteries, but endometrial arteries may differ 
in composition to myometrial arteries and the process of SpA remodelling may be very 
different in the decidua and myometrium. Chorionic plate artery vessels are, however, 
readily accessible and easy to dissect compared with myometrial and decidual SpAs. 
Recently it has been reported that both first trimester EVT and uNK cell conditioned 
medium disrupted VSMC morphology and disorganisation in both CpAs and 
myometrial arteries dissected from non-pregnant hysterectomy specimens (Robson et 
al., 2012). Potential soluble mediators of this effect were studies including Ang-1, Ang-
2, IFN-γ and VEGF-C. However, other uNK and EVT cell derived factors including IL-8 
and IL-6 may contribute to VSMC disruption; evidence from a recent study has 
demonstrated that both uNK and EVT cells produce a variety of other cytokines and 
angiogenic growth factors that are potentially involved in SpA remodelling (Lash et al., 
2010a). This could be achieved by culturing CpAs and myometrial arteries with uNK cell 
supernatants as well as CD14+ supernatants with neutralising antibodies against IL-6 
and IL-8. Comparison of VSMC disruption in CpAs and non-pregnant myometrial 
arteries cultured with uNK cell and CD14+ cell supernatants isolated from early SM 
decidua compared with supernatants from healthy pregnant decidua would be an 
interesting area to research; the hypothesis would be that VSMC disruption would be 
reduced in SM due to less IL-6 and IL-8 being produced by uNK and CD14+ cells 
compared with these cells in normal pregnancy. This could also be coupled with 
Doppler measurements; levels of IL-6 and IL-8 could be measured in decidual 
supernatants in pregnancies which have had Doppler measurements taken. Abnormal 
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Doppler versus normal Doppler can be compared with decidual cytokine levels; blood 
vessel changes observed may be related to differences in decidual IL-6 and IL-8 levels, 
an area which has yet to be studied.    
7.2.2 Further investigation into the role of maternal leucocytes   
Further studies into association of maternal leucocytes and remodelling of spiral 
arteries in the myometrium are required to assess whether they play a role in initiating 
remodelling events deeper in the placental bed. Uterine NK cells are only present in 
decidua (Bulmer and Lash, 2005), and so it would be interesting to investigate 
macrophage and T lymphocyte cell numbers in the myometrium and their involvement 
in remodelling myometrial SpA. These cells could potentially provide signals to recruit 
invading EVT from the decidua or eEVT in the second wave of deeper EVT invasion to 
modify the SpAs deeper in the uterine tissues. Spiral artery invasion in the 
myometrium has been observed where uNK cells are absent, therefore other 
leucocytes may have role; this has been originally hypothesised but never proven 
(Pijnenborg et al., 2006b).  
7.2.3 Limitations of tissue collection 
Normal early pregnancy tissue was readily obtainable; a limitation of the present study 
was the difficulty in obtaining SM tissue, due to restricted availability, especially in 
obtaining late (≥13 weeks gestational age) SM tissue. Due to the difficulties 
encountered only early (≤ 12+6 weeks gestational age) SM decidua was collected. Many 
early miscarriages are now managed medically with misoprostol treatment and this 
limited the number of miscarriage cases that were available as hormone treatment 
could potentially alter cytokine levels. This study would have benefited from studies on 
late miscarriage tissue but late miscarriage samples are less common and may be 
associated with abnormal SpA remodelling (Ball et al., 2006a). Emotional issues of 
collecting samples from women suffering miscarriage may have also contributed to the 
limited availability of samples as many women were too upset to approach for 
consent. Therefore if there was more time to collect the tissue then cytokine levels 
from later SM decidua would have been compared to cytokine levels with those in 
early SM decidua and also levels from chromosomally normal (euploid) and abnormal 
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(aneuploid) miscarriages would have been investigated. Although 
immunohistochemistry data in this study observed no differences in staining patterns 
which is confirmed by reports demonstrating that decidual defects are similar in both 
euploid and aneuploid miscarriages (Brosens et al., 1978, Ball et al., 2006a, Ball et al., 
2006b) and leucocyte numbers do not significantly differ between them (Williams et 
al., 2009b) but it would be worthwhile to compare cytokine secretion levels in both 
miscarriages as this has yet to investigated.      
7.2.4 Overall summary 
In summary, in the present study IL-6, IL-8 and their receptors were localised in the 
decidua of early human pregnancy and it was shown that cells such as uNK cells, 
uterine macrophages, T-lymphocytes and stromal cells are producers of both cytokines 
at the fetal maternal interface. The present study also demonstrated gestational age 
differences in cytokine production by particular decidual cell populations, suggesting 
different roles and importance at different stages of early pregnancy. From the cells 
studied, uterine macrophages are the most abundant source of IL-6 and IL-8 although 
they are the second most abundant leucocyte in the decidua in early pregnancy. A 
possible role for this cell population is to mediate VSMC and endothelial cell changes in 
early stages of SpA remodelling may be through the localised production of both IL-6 
and IL-8. Further evidence for this is demonstration that receptors for both IL-6 and IL-
8 on SpA endothelium and VSMCs have altered expression in SM. Both cytokines play 
roles in regulating trophoblast biology suggesting further involvement in pregnancy 
processes. 
The importance of IL-6 and IL-8 in early human pregnancy is apparent from the 
evidence in the present study and is further supported by reduced cytokine expression 
in SM; this warrants further investigations in order to clarify specific roles for both 
cytokines in these crucial processes. Further studies of the mechanisms that underlie 
the functional effects of these cytokines are required. Functional studies with a cohort 
of decidual cytokines should be also investigated due to the large and complex 
cytokine milieu at the maternal fetal interface which may alter with gestational age, 
potentially even from one week to the next; there is a wide array of cytokines and 
growth factors which may have synergistic or antagonising effects on each other and 
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therefore affect the outcome of such processes in vivo. Mouse cytokine gene knockout 
studies would be one approach to achieve this by investigating how this impacts upon 
mouse reproduction reviewed by Ingman and Jones (2008). Better understanding of 
the roles of these cytokines in healthy pregnancy thereby creating a clearer picture in 
vivo will allow better understanding of their roles in pathology pregnancy and may 
eventually lead to targeted therapies of clinical importance.         
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Appendix 
Materials and solutions 
All chemicals were obtained from Sigma Chemical Company Ltd., Poole, Dorset, UK 
except where otherwise stated. 
Cell culture reagents: 
Complete medium (RPMI 1640) 
RPMI 1640 medium 
10% fetal calf serum (FCS; heat inactivated)  
0.4mM/ml L-glutamine 
5U/ml Penicillin  
0.05mg/ml Streptomycin 
All components mixed together at room temperature and stored at 4°C 
Complete medium (DMEM-F12) 
Dulbecco’s modified eagle medium nutrient mixture:F-12 HAM [1:1 ratio] 
10% FCS (heat inactivated)  
0.4mM/ml L-glutamine 
5U/ml Penicillin  
0.05mg/ml Streptomycin 
All components mixed together at room temperature and stored at 4°C 
Incomplete medium (RPMI 1640) 
RPMI 1640 medium 
0.4mM/ml L-glutamine 
5U/ml Penicillin  
0.05mg/ml Streptomycin 
All components mixed together at room temperature and stored at 4°C 
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Charcoal stripped medium (0.5, 5 or 10%) 
RPMI 1640 medium 
0.5, 5 or 10% charcoal stripped FCS 
0.4mM/ml L-glutamine 
5U/ml Penicillin  
0.05mg/ml Streptomycin 
All components mixed together at room temperature and stored at 4°C 
Complete medium for CD14+ cells 
Dulbecco’s modified eagle medium 
10% FCS (ATCC; Manassas, VA, USA)   
0.4mM/ml L-glutamine 
5U/ml Penicillin  
0.05mg/ml Streptomycin 
All components mixed together at room temperature and stored at 4°C 
MidiMACS buffer 
0.19g EDTA 
0.5g bovine serum albumin (BSA) 
100ml PBS 
Adjusted to pH7.4 
Filtered through a sterile 0.2µm syringe filter (Nalgene) and stored at 4°C. 
 
General laboratory reagents and buffers: 
Sterile phosphate buffered saline (PBS) 
1 phosphate buffered saline tablet dissolved in 200ml distilled H2O, to obtain 
0.01M phosphate buffer, 0.0027M potassium chloride and 0.137M sodium 
chloride adjusted to pH7.4.  The mixture was filtered through a sterile 0.2µm 
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syringe filter (Nalgene Thermo Scientific; Germany) then autoclaved and stored 
at 4°C. 
0.1M Tris buffered saline (TBS) 
10L distilled H20 
80g sodium chloride 
6.05g Tris (hydroxymethyl) methyl amine 
38ml 1N hydrochloric acid 
Sodium chloride and Tris were dissolved overnight and adjusted to pH7.6 
before use. 
Citrate buffer 
2.1g citric acid monohydrate 
13ml 2M NaOH  
900ml distilled water 
Dissolved overnight and adjusted to pH6.0 before use.  
Ethylenediaminetetraacetic acid (EDTA) buffer 
2.26g EDTA 
5L distilled water 
Adjusted to pH8.0 
Trypsin working solution 
Trypsin solution (0.5%) 
 0.05g trypsin 
10ml distilled water 
Dissolved and stored at -20°C 
Calcium chloride solution (1%) 
0.1g calcium chloride  
10ml distilled water 
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Dissolved and stored at -20°C 
1ml of trypsin solution and 1ml calcium chloride solution added to 8ml of 
water, adjusted to pH 7.8 with 1N NaOH. 
Sections were immersed in warmed trypsin working solution at 37°C waterbath 
and incubated for 20 minutes and then placed in distilled water. Slides were 
then added to TBS (room temperature).   
Tris acetate TEA buffer (50x stock solution) 
242g Tris base dissolved in 250ml deionised water 
57.1ml acetic acid 
100ml EDTA (pH 8.0) 
Adjusted to make the final volume of 1L pH 8.5 
The working solution of 1x TAE buffer is made by diluting the stock solution by 50x in 
deionised water. 
Dimethyl sulfoxide (DMSO) freezing mix 
20% DMSO 
80% FCS 
Aliquoted into 1ml aliquots in cryovials and stored at -20°C until required.  
Histochemical Stains and solutions: 
Mayer’s haematoxylin 
2g haematoxylin (Raymond A Lamb, London, UK) 
100g potassium alum (BDH, Poole, UK) 
0.4g sodium iodate 
2L distilled water 
Dissolved at room temperature overnight. Then added:- 
100g chloral hydrate (BDH) 
2g citric acid 
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All components were brought to the boil and left overnight. Filtered before use. 
Eosin  
11.25g eosin (Raymond A Lamb) 
5.0g erythrosin (Raymond A Lamb) 
2.0g phloxine (Raymond A Lamb) 
200ml 95% ethanol 
800ml tap water 
All components were dissolved together at room temperature. 
Scott’s tap water substitute 
17.5g sodium bicarbonate (BDH) 
100g magnesium sulphate (BDH) 
5L distilled water 
A few crystals of thymol 
All components were dissolved together at room temperature. 
Preparation of APES coated slides 
4ml APES solution (3-aminopropyltriethoxysilane) 
1L acetone  
1L 99% industrial methylated spirits  
Washed glass slides in a dilute detergent and rinsed in water several times. The 
slides were then immersed into distilled water followed by washes in 99% 
industrial methylated spirits. The slides were air dried at room temperature 
before coating with the APES solution. The slides were then immersed into 
acetone, acetone and APES solution (196ml acetone and 4ml APES solution), 
acetone only and distilled water. Once again, the slides were air dried at room 
temperature overnight and stored at 4°C until required.   
Elastic Van Gieson staining 
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This stain is used to visualise elastin and mast cell granules; elastic tissue- 
appears blue/black. The Van Gieson counterstain is used to visualise connective 
tissue within the slides; collagen stains red.   
Miller’s elastin 
2g victoria blue 
2g new fuchsin 
2g crsyal violet 
Dissolved the dyes in 400ml distilled water then added:- 
8g resorcin 
2g dextrin 
100ml 30% aqueous ferric nitrate 
The mixture was boiled for 5 minutes and filtered. The precipitate was re-
dissolved in 400ml of 95% alcohol and boiled for 20 minutes. The mixtures was 
cooled and filtered before topping up with 95% alcohol to make 400ml. 4ml of 
concentrated hydrochloric acid was then added. 
Van Gieson’s counterstain 
15ml 1% aqueous acid fuchsin 
50ml saturated picric acid 
50ml distilled water   
The sections were immersed in running tap water and sections were then 
oxidised in potassium permanganate solution for 5 minutes. The slides were 
rinsed in water before being decolourised with oxalic acid (approximately 1 
minute) rinsed in water and then rinsed in 95% alcohol. The slides were then 
placed in a coplin jar containing Miller’s elastin stain and incubated for 2 hours 
at room temperature. The slides were then washed in 95% alcohol to remove 
excess stain and differentiated microscopically using alcohol until elastic fibres 
appeared blue/black. Once differentiated Van Gieson’s counterstain was 
applied to the stained sections for 3 minutes followed by a rinse in 95% alcohol 
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and dehydration in absolute alcohol. The slides were then cleared in xylene and 
mounted using DPX synthetic resin.   
Periodic Acid Schiff (PAS) staining 
50ml 50% Periodic acid solution 
2450ml Distilled water 
(To make 1% periodic acid solution) 
Schiffs reagent obtained from Sigma (S-5133) store at 4°C 
Following immunohistochemistry the sections were rinsed thoroughly in tap 
water. Each section was then incubated for 5 minutes in 1% periodic acid and 
rinsed with distilled water. Sections were then incubated for 8 minutes in 
Schiffs reagent. The slides were then immersed in running tap water for 12 
minutes to further develop the PAS stain. The slides were then counterstained 
in Mayer’s haematoxylin, dehydrated in ascending concentrations of alcohol, 
cleared in xylene and mounted with DPX synthetic resin.      
Orcein staining (Shikata technique) 
1g Shikata orcein 
100ml 70% alcohol 
1ml concentrated hydrochloric acid 
Sections were rinsed in tap water and treated with acidified potassium 
permanganate solution for 3 minutes. Slides were washed in water then 
decolourised with 1% oxalic acid, washed in water then immersed into the 
Shikata stain for 90 minutes at room temperature. Following staining the slides 
were rinsed in water, dehydrated in alcohol, cleared in xylene and mounted 
with DPX synthetic resin.   
Immunohistochemistry staining kits: 
Vectastain Elite mouse IgG ABC kit (Vector Laboratories Ltd, Peterborough, UK); 
avidin-biotin peroxidase complex method 
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Blocking serum: 15µl Vectastain normal horse serum diluted in 1ml 0.1M Tris 
buffered saline (TBS) 
Secondary antibody: 15µl normal horse serum and 5µl Vectastain biotinylated 
anti-mouse IgG antibody in 1ml TBS 
Tertiary antibody: 20µl Vectastain A and 20µl Vectastain B, diluted in 1ml TBS  
Vectastain Elite rabbit IgG ABC kit (Vector Laboratories Ltd.); avidin-biotin peroxidase 
complex method 
Blocking serum: 15µl Vectastain normal goat serum diluted in 1ml TBS 
Secondary antibody: 15µl normal goat serum and 5µl Vectastain biotinylated 
anti-rabbit IgG antibody in 1ml TBS 
Tertiary antibody: 20µl Vectastain A and 20µl Vectastain B, diluted in 1ml TBS  
Vectastain Elite goat IgG ABC kit (Vector Laboratories Ltd.); avidin-biotin peroxidase 
complex method 
Blocking serum: 15µl Vectastain normal rabbit serum diluted in 1ml TBS 
Secondary antibody: 15µl normal rabbit serum and 5µl Vectastain biotinylated 
anti-goat IgG antibody in 1ml TBS 
Tertiary antibody: 20µl Vectastain A and 20µl Vectastain B, diluted in 1ml TBS  
ImPRESS kit mouse/rabbit Ig (MP-7500) (Vector Laboratories Ltd, California, USA); 
polymerised reporter enzyme staining system 
Blocking serum: normal horse serum (2.5%) 
Universal peroxidase: anti-mouse/rabbit Ig 
APAAP double labelling reagents 
Blocking serum: normal rabbit serum (from Vectastain Elite goat IgG ABC kit)  
Secondary antibody: Rabbit anti-mouse IgG (Z259; Dako UK Ltd, Cambride, UK) 
1:100 TBS pH7.6 
Tertiary antibody: Alkaline phosphatase anti-phosphatase (APAAP) complex 
antibody (D651; Dako) 1:50 in TBS pH7.6  
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Chromogens used for development of immunostaining: 
3,3’- Diaminobenzidine tetrachloride (DAB) 
One DAB tablet (Sigma) was added to 0.2ml 1% aqueous H2O2 (Sigma) in 10mls 
TBS pH7.6 and left to dissolve. This solution was then filtered and applied to 
the sections for approximately 2-3 minutes. The colour reaction was ended by 
placing slides in running tap water for 5 minutes. 
Vector NovaRed Substrate kit (SK-4800; Vector laboratories) 
To 5ml distilled water add:- 
3 drops of reagent 1, mix well 
2 drops of reagent 2, mix well 
2 drops of reagent 3, mix well 
2 drops of hydrogen peroxide, mix well  
This mix was applied to the slides for approximately 5 minutes and the reaction was 
ended by placing the slides in running tap water. 
Alkaline phosphatase substrate kit III (SK-5300; Vector laboratories) 
To 5ml of TBS pH8.2 add:- 
2 drops reagent 1, mix well 
2 drops reagent 2, mix well 
2 drops reagent 3, mix well  
The mixture was immediately applied to the slides and developed in the dark 
for between 5-20 minutes.  Following this the slides were washed in running 
tap water to end the reaction. 
Western Blotting solutions:  
HEPES Protein Extraction Buffer 
20mM HEPES buffer, pH7.4 
150mM NaCl 
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2mM CaCl2 
10mM CHAPS 
1% protease inhibitor cocktail (to be added just before homogenising/lysing) 
The buffer was kept ice cold prior to homogenisation/lysis. Tissue was homogenised or 
cells were lysed in the buffer and the lysates were microfuged for 10 minutes at full 
speed (14.1rcf (relative centrifugal force)).  
2x Separating buffer 
0.75mM Tris 
0.2% SDS 
100ml deionised H2O  
pH 8.8 
2x Stacking buffer 
0.25mM Tris 
0.2% SDS 
100ml ddH2O 
pH 6.8 
Separating gel 
Acrylamide (40%) 
5ml 2x separating buffer 
ddH2O 
20µl of temed* 
100µl of 10% APS (ammonium persulfate; 50mg in 500µl of ddH2O)* 
*Temed and APS were added just before gel casting. The gel was loaded onto the glass 
plate apparatus, topping the gel with isopropanol to prevent air bubbles. The gel was 
allowed to polymerise for 45 minutes. 
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The size of the separating gel could be adjusted using different volumes of acrylamide 
to water:  
7.5% gel= 2ml acrylamide: 3ml water 
10% gel= 2.7ml acrylamide: 3ml water 
12.5% gel= 3.3ml acrylamide: 1.7ml water 
Stacking gel 
1ml acrylamide 
2.5ml 2x stacking buffer  
1.5ml ddH2O 
10µl temed* 
50µl APS* 
*Temed and APS were added just before gel casting. The isopropanol layer was poured 
off and gel was added to set the separating gel. Combs were placed in the stacking gel 
before casting. The gel was allowed to polymerise for 45 minutes and the combs were 
then removed. 
5x electrode buffer 
Tris-base 15g/L  or  Tris-HCL 19.5g/L 
Glycine 72g/L 
SDS 5g/L 
1L ddH2O 
pH 8.3 
To make 1x electrode buffer 200mls of 5x buffer was added to 800ml deionised H2O. 
Transfer buffer 
Tris-HCL 3.93g/L 
Glycine 14.26g/L 
Methanol 200ml/L 
311 
 
pH8.3 
The buffer was stored at 4°C prior to transblotting. 
Protein loading buffer (2x Laemmli buffer) - reducing conditions 
Reducing conditions = disrupts the tertiary structure of the proteins by breaking the 
disulphide bridges (S-S) into sulphydryl (SH-SH) groups allowing the proteins to 
separate by molecular weight (kDa).  
4% Sodium dodecyl sulphate (SDS) 
10% 2-mercaptoethanol 
20% glycerol 
0.004% bromophenol blue 
0.125M Tris-HCL 
pH 6.8 
The samples were boiled for 5 minutes at 95-100°C for denaturing of protein. If 
detecting epiptope on native protein SDS was omitted and the sample was not boiled. 
If detecting oxidised proteins (non-reducing conditions) 2-mercaptoethanol was 
omitted. 5µl of dye was added to each sample. 
Blocking buffer (10%) 
5g of non-fat dried powdered milk  
50ml 1xTBS/PBS-T (TBS/PBS + 0.05% Tween20) 
Milk was dissolved in TBS/PBS-T and stored at 4°C 
 
FastQuant Array:  
Human Th1/Th2 kit 
Detects IL-6, IL-1β, IL-12, IL-13, IL-4, IFN-γ, IL-5 and TNF-α proteins. 
Human II kit 
Detects IL-8, GM-CSF, IL-10, IL-1β, IL-12p70, IL-2, MCP-1, IL-4, RANTES and IL-6 
proteins. 
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Human Angiogenesis kit 
Detects Angiogenin, Angopoietin-2, KGF, PDGF-BB, FGF-basic, TIMP-1, ICAM-1, and 
VEGF growth factors. 
Each kit contains 4 slides, each with 16 3D nitrocellulose arrays with anti cytokine 
monoclonal antibodies arrayed in triplicate.   
Solutions 
Standard dileunt: 0.1% BSA, 0.05% Tween 20 in PBS pH7.4 
1x blocking buffer (6mls provided) 
10x wash solution (125mls provided) - for 1x wash buffer added 50ml of 10x washing 
solution to 450mls dH20.  
600µl biotinylated antibody solution in 0.5mgml-1 BSA, 1X TBS – diluted 500µl of 
antibody cocktail solution with 4500µl of 1x wash buffer. 
Stock SA-Cy5 solution (GE healthcare): 1mg of lyophilised SA-Cy5 fluorescent reporter 
– added 1ml of dH20 and dispensed 5µl aliquots and stored at -20°C until required.    
Working SA-Cy5 solution: added 1µl of SA-Cy5 stock solution to 7999µl of 1x wash 
buffer and protected from light. 
Three 25µl vials of recombinant antigen cocktail in 1mgml-1 BSA, PBS (20µl of 
recombinant antigen cocktail was added to 280µl of diluents to make standard A, then 
an 8 point standard curve was prepared).  
 
Publications 
1. Effects of interleukin-6 on extravillous trophoblast invasion in early human 
pregnancy H Champion Molecular Human Reproduction 2012 (Champion et al., 
2012) 
 
 
